data_2pcf_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2pcf _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.503 2.187 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.83 108.21 5.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.276 -0.89 . . . . 0.0 109.469 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 t -103.82 125.91 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.405 -0.809 . . . . 0.0 109.47 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.5 mt -113.08 105.4 13.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 109.319 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.666 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.48 140.94 58.04 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.334 -0.854 . . . . 0.0 109.421 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.57 137.72 1.59 Allowed Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.53 -118.79 0.38 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -127.76 7.05 6.95 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -145.69 -41.83 0.22 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.287 -1.125 . . . . 0.0 109.57 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.3 45.59 0.04 OUTLIER Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.464 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -102.72 97.67 7.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.373 -1.075 . . . . 0.0 109.253 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.5 mt -77.72 94.19 4.41 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.378 -0.826 . . . . 0.0 109.415 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.84 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.65 139.31 4.49 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.324 -0.86 . . . . 0.0 109.7 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.474 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 37.2 m-85 -67.36 127.74 33.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.285 -0.884 . . . . 0.0 109.094 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.509 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.43 103.44 20.02 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.25 -0.906 . . . . 0.0 109.593 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.73 170.91 65.53 Favored 'Cis proline' 0 C--N 1.312 -1.373 0 C-N-CA 123.454 -1.478 . . . . 0.0 110.646 -0.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.434 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.28 12.39 48.09 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -167.11 111.14 0.72 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.371 -1.076 . . . . 0.0 109.125 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.0 p90 -132.2 169.68 16.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.358 -0.839 . . . . 0.0 109.709 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.89 130.24 53.2 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.384 -0.823 . . . . 0.0 109.45 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.48 -170.8 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.314 -0.867 . . . . 0.0 109.456 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.92 179.12 6.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.29 -0.881 . . . . 0.0 109.504 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.7 t -72.09 108.81 5.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.332 -0.855 . . . . 0.0 109.401 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.29 -17.02 5.65 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -82.09 172.55 13.08 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.366 -1.079 . . . . 0.0 109.493 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -129.06 134.96 48.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.633 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.536 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.7 149.52 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 t -133.44 145.72 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 109.939 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.479 ' HB3' HD12 ' A' ' 5' ' ' LEU . 51.3 m-85 -133.09 79.94 1.86 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.456 -0.777 . . . . 0.0 108.927 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 29.6 mttt -81.81 124.23 29.48 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.26 -0.9 . . . . 0.0 109.783 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 26.8 p-10 -95.14 130.23 41.93 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.311 -0.868 . . . . 0.0 109.425 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -104.51 -67.9 0.88 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -0.851 . . . . 0.0 109.593 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.86 152.42 48.53 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.329 -0.857 . . . . 0.0 109.568 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.28 21.45 35.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.511 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.8 p90 -64.34 163.03 28.1 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.354 -1.086 . . . . 0.0 109.585 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.511 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.3 Cg_endo -79.5 155.49 89.55 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.421 -1.491 . . . . 0.0 110.726 -0.038 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.666 ' HB3' HD21 ' A' ' 5' ' ' LEU . 27.3 m-70 -126.62 40.99 3.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.413 -0.805 . . . . 0.0 109.222 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -68.2 128.3 36.05 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.249 -0.907 . . . . 0.0 109.369 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -100.23 153.17 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.33 -0.856 . . . . 0.0 109.841 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.479 HG11 ' H ' ' A' ' 57' ' ' MET . 9.7 m -140.7 123.0 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.418 -0.801 . . . . 0.0 109.217 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.52 133.42 45.8 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.291 -0.88 . . . . 0.0 109.571 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.421 ' HB2' ' HE1' ' A' ' 83' ' ' TYR . 0.7 OUTLIER -96.29 160.15 14.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.36 -0.838 . . . . 0.0 109.571 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.525 ' HA ' HD13 ' A' ' 46' ' ' ILE . 6.7 tp10 -100.39 44.84 1.0 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.37 -0.831 . . . . 0.0 109.429 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.29 -23.8 6.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.304 -0.872 . . . . 0.0 109.373 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -125.59 25.76 6.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 0.0 109.471 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.548 HG22 ' HD2' ' A' ' 47' ' ' PRO . 55.8 mt -90.09 141.15 27.64 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.314 -0.866 . . . . 0.0 108.988 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.548 ' HD2' HG22 ' A' ' 46' ' ' ILE . 33.7 Cg_endo -75.62 -62.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.68 2.253 . . . . 0.0 111.023 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.0 t -87.05 -178.94 6.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.151 -0.968 . . . . 0.0 109.549 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.522 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -75.25 -101.68 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.522 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.67 157.56 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.517 -0.99 . . . . 0.0 109.867 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.852 ' HA ' ' HZ2' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -88.83 154.84 19.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.267 -0.896 . . . . 0.0 109.632 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.46 ' H ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.77 -27.27 40.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.419 -0.8 . . . . 0.0 109.532 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.96 -17.02 62.68 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.378 -0.827 . . . . 0.0 109.854 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.0 tptt -77.12 -31.24 55.64 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.299 -0.875 . . . . 0.0 109.699 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -113.02 4.97 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.196 -0.94 . . . . 0.0 109.935 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 66.3 m -108.52 177.81 4.68 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.479 ' H ' HG11 ' A' ' 40' ' ' VAL . 28.3 mtp -98.78 164.07 12.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -98.55 -168.47 1.65 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.395 -0.816 . . . . 0.0 109.563 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.514 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.4 OUTLIER -88.64 -27.58 21.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.383 -0.823 . . . . 0.0 109.816 -179.817 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . 0.472 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.6 OUTLIER -81.12 -33.36 33.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.233 -0.917 . . . . 0.0 109.703 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -91.38 90.63 7.78 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.286 -0.884 . . . . 0.0 109.443 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.543 HD12 HD23 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -115.98 145.83 42.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.355 -0.841 . . . . 0.0 109.444 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.695 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.1 mp -92.93 80.59 4.61 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.831 . . . . 0.0 109.149 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.489 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.8 OUTLIER -102.09 -17.67 15.93 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.344 -0.847 . . . . 0.0 109.812 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.34 145.46 30.05 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.256 -0.903 . . . . 0.0 109.781 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.33 83.46 2.14 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.736 2.291 . . . . 0.0 110.274 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.5 -26.18 0.3 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.695 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -68.47 148.82 50.06 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.348 -1.09 . . . . 0.0 109.42 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -136.15 146.25 46.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.876 . . . . 0.0 109.85 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -109.18 109.08 19.95 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.35 -0.844 . . . . 0.0 109.011 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.19 133.87 43.95 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.662 -179.72 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.419 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.8 OUTLIER -122.76 115.74 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -0.785 . . . . 0.0 109.243 179.871 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.69 102.95 14.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.31 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -100.0 143.07 30.63 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.69 -26.36 3.83 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.347 -0.846 . . . . 0.0 109.744 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.19 152.15 45.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.213 -0.929 . . . . 0.0 109.666 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.7 mttt -99.11 121.61 41.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.369 -0.832 . . . . 0.0 109.556 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.496 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.61 -171.18 42.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -113.26 114.73 27.11 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.328 -1.101 . . . . 0.0 109.512 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -93.1 177.79 5.95 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.376 -0.828 . . . . 0.0 109.176 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.52 97.56 2.65 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.155 -0.966 . . . . 0.0 109.887 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -100.66 159.16 15.4 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.421 ' HE1' ' HB2' ' A' ' 42' ' ' ASP . 40.0 p90 -149.13 155.65 41.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 110.16 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.9 t -67.82 111.77 4.5 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.654 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.718 0 O-C-N 121.402 -0.811 . . . . 0.0 110.215 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.84 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.8 ptm . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.531 0.682 . . . . 0.0 109.377 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.7 m -145.91 153.12 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.269 -0.894 . . . . 0.0 109.425 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.19 178.79 18.11 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -149.39 139.85 22.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.276 -1.131 . . . . 0.0 109.701 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.3 t -94.63 109.66 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.325 -0.86 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -94.05 68.3 3.74 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.257 -0.902 . . . . 0.0 109.254 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.1 p -80.23 139.77 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.34 -0.85 . . . . 0.0 109.623 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.58 179.948 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . 0.543 HD23 HD12 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.654 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.514 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.511 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.852 ' HZ2' ' HA ' ' A' ' 51' ' ' ASP . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.502 2.14 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.28 107.79 5.08 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.305 -0.872 . . . . 0.0 109.506 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 15.2 t -102.65 125.25 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 0.0 109.398 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 22.3 mt -111.36 103.27 11.63 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.399 -0.813 . . . . 0.0 109.347 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.609 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -65.6 139.09 58.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.375 -0.828 . . . . 0.0 109.415 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.447 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.71 136.79 1.82 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.01 -118.46 0.33 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -128.74 5.12 6.56 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -143.21 -41.38 0.3 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.366 -1.079 . . . . 0.0 109.62 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.27 46.13 0.04 OUTLIER Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.447 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.5 t -103.83 93.5 4.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.365 -1.079 . . . . 0.0 109.374 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 mt -75.67 91.79 2.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 109.414 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.856 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.07 141.71 8.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.331 -0.856 . . . . 0.0 109.637 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.469 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 36.8 m-85 -68.84 128.45 36.71 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.401 -0.812 . . . . 0.0 109.217 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.95 103.02 17.28 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.889 . . . . 0.0 109.637 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.71 171.2 64.36 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.482 . . . . 0.0 110.687 -0.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -104.97 10.32 47.97 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -164.88 113.26 1.05 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.351 -1.088 . . . . 0.0 109.135 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -133.87 170.58 15.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 109.641 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.4 m -122.58 131.34 53.78 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.352 -0.842 . . . . 0.0 109.474 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -133.25 -171.93 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.384 -0.823 . . . . 0.0 109.468 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.02 178.29 7.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.0 t -72.07 111.93 7.72 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.275 -0.89 . . . . 0.0 109.405 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.32 -17.52 7.0 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -81.42 167.4 19.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.317 -1.108 . . . . 0.0 109.496 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -124.09 131.17 53.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.594 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.489 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -95.66 151.08 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 108.986 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 t -133.42 146.74 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.176 -0.953 . . . . 0.0 110.007 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.467 ' HB3' HD12 ' A' ' 5' ' ' LEU . 54.7 m-85 -132.65 77.35 1.74 Allowed 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 29.4 mttt -78.92 134.01 36.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.912 . . . . 0.0 109.786 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.428 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.4 p-10 -106.04 137.58 43.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.278 -0.889 . . . . 0.0 109.415 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -112.64 -70.46 0.81 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.352 -0.842 . . . . 0.0 109.672 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -121.09 149.97 41.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 109.578 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.91 23.22 36.11 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.49 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 4.0 p90 -67.82 162.45 58.28 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.441 -1.035 . . . . 0.0 109.525 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.52 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 35.9 Cg_endo -79.26 158.19 90.57 Favored 'Cis proline' 0 C--N 1.313 -1.31 0 C-N-CA 123.395 -1.502 . . . . 0.0 110.806 0.052 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.609 ' HB3' HD21 ' A' ' 5' ' ' LEU . 25.1 m-70 -126.17 39.77 3.87 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.43 -0.794 . . . . 0.0 109.269 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.8 p-10 -66.06 130.47 43.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.159 -0.963 . . . . 0.0 109.273 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -105.17 157.69 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 0.0 109.923 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.431 HG11 ' H ' ' A' ' 57' ' ' MET . 4.8 m -141.65 130.87 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.469 -0.77 . . . . 0.0 109.307 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -78.0 136.24 37.92 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.475 ' O ' HG13 ' A' ' 46' ' ' ILE . 0.6 OUTLIER -104.56 157.93 16.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.41 -0.806 . . . . 0.0 109.322 179.734 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.507 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 10.5 tp10 -94.47 17.38 13.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.333 -0.854 . . . . 0.0 109.671 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.6 -19.78 32.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 109.455 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -136.89 36.4 2.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.35 -0.844 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.602 HG22 ' HD2' ' A' ' 47' ' ' PRO . 22.1 mt -99.32 142.47 24.67 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.086 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.602 ' HD2' HG22 ' A' ' 46' ' ' ILE . 34.3 Cg_endo -76.03 -66.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 122.665 2.244 . . . . 0.0 111.125 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 t -84.39 -178.77 7.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.213 -0.929 . . . . 0.0 109.679 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.457 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.36 -100.76 0.14 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.457 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.61 152.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.511 -0.993 . . . . 0.0 109.79 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.788 ' HA ' ' HZ2' ' B' ' 187' ' ' LYS . 0.6 OUTLIER -80.68 152.93 28.18 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.211 -0.931 . . . . 0.0 109.597 -179.869 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.503 ' N ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.93 -25.31 40.55 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.349 -0.844 . . . . 0.0 109.593 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -74.89 -16.93 60.65 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.32 -0.862 . . . . 0.0 109.794 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.4 tptt -76.29 -32.48 58.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.334 -0.854 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.1 pt -107.54 -3.32 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.28 -0.887 . . . . 0.0 109.89 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 58.8 m -99.79 177.3 5.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.227 -0.92 . . . . 0.0 109.3 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.431 ' H ' HG11 ' A' ' 40' ' ' VAL . 8.4 mtp -92.48 155.94 17.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.269 -0.894 . . . . 0.0 109.595 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.21 -163.19 0.8 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.352 -0.842 . . . . 0.0 109.512 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.504 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -96.4 -31.35 12.89 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.348 -0.845 . . . . 0.0 110.003 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -80.62 -30.78 36.73 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.305 -0.872 . . . . 0.0 109.797 -179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -89.08 100.69 13.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.304 -0.873 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.579 HD12 HD23 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -124.5 145.21 49.68 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.473 -0.767 . . . . 0.0 109.488 -179.935 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.672 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 4.2 mp -91.03 68.57 6.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.392 -0.817 . . . . 0.0 109.16 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -24.69 20.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.351 -0.843 . . . . 0.0 109.949 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.87 146.17 38.24 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.218 -0.926 . . . . 0.0 109.738 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.34 79.25 3.22 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.755 2.303 . . . . 0.0 110.252 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.09 -24.92 0.19 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.672 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.1 tp10 -68.31 148.6 50.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.444 -1.033 . . . . 0.0 109.347 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.7 p -136.09 145.81 46.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 109.867 -179.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 23.3 t80 -107.06 107.78 18.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.35 -0.844 . . . . 0.0 109.144 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.85 131.25 45.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 109.566 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.98 114.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.363 -0.836 . . . . 0.0 109.3 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.7 m -86.66 101.65 13.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.342 -0.849 . . . . 0.0 109.254 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -98.63 142.15 30.56 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.371 -0.83 . . . . 0.0 109.57 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.5 p -123.3 -24.68 4.6 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.699 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.36 153.99 42.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.288 -0.883 . . . . 0.0 109.622 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.3 mttt -101.16 125.38 47.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.529 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.99 -166.88 37.77 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -117.44 112.65 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.298 -1.119 . . . . 0.0 109.527 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -91.21 176.83 6.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.338 -0.851 . . . . 0.0 109.178 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.4 99.31 3.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.199 -0.938 . . . . 0.0 109.866 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -103.48 164.04 11.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.361 -0.837 . . . . 0.0 108.868 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -153.02 155.78 37.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.168 -0.957 . . . . 0.0 109.812 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.68 108.1 2.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.424 -0.797 . . . . 0.0 109.119 179.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.768 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.48 -0.763 . . . . 0.0 109.924 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.856 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.4 m -143.06 165.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.271 -0.893 . . . . 0.0 109.615 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -144.14 177.76 22.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -150.14 139.03 20.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.261 -1.141 . . . . 0.0 109.839 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.8 t -94.64 115.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.401 -0.812 . . . . 0.0 109.507 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -98.21 67.2 1.85 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.253 -0.905 . . . . 0.0 109.122 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.79 141.85 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.39 -0.819 . . . . 0.0 109.643 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.581 179.939 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . 0.579 HD23 HD12 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.768 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . 0.443 ' HB3' ' HG ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.504 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.511 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.788 ' HZ2' ' HA ' ' A' ' 51' ' ' ASP . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 N--CA 1.502 2.143 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.3 109.86 4.94 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.303 -0.873 . . . . 0.0 109.417 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.5 t -104.52 120.53 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.328 -0.858 . . . . 0.0 109.559 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 24.6 mt -106.73 101.36 10.81 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -0.838 . . . . 0.0 109.287 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.656 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.2 mp -64.42 141.21 58.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 109.432 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.18 138.36 1.56 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.74 -115.28 0.33 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -132.12 6.37 5.38 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.6 -41.34 0.22 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.346 -1.091 . . . . 0.0 109.596 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.22 45.45 0.04 OUTLIER Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.411 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.3 t -105.65 98.0 7.76 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.308 -1.113 . . . . 0.0 109.304 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.728 HD12 HG23 ' B' ' 3' ' ' ILE . 9.0 mt -78.79 101.12 7.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.324 -0.86 . . . . 0.0 109.487 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.691 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -169.58 136.24 1.63 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 109.661 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.459 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 39.6 m-85 -65.9 126.5 28.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 109.124 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.496 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -126.83 103.14 24.36 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.262 -0.898 . . . . 0.0 109.573 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.496 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.72 169.33 70.86 Favored 'Cis proline' 0 C--N 1.312 -1.356 0 C-N-CA 123.459 -1.475 . . . . 0.0 110.67 -0.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.442 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.2 12.28 51.89 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -166.98 105.63 0.58 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.393 -1.063 . . . . 0.0 109.009 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -126.77 167.67 15.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.707 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.5 128.39 53.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.345 -0.847 . . . . 0.0 109.393 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -130.43 -171.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.35 -0.844 . . . . 0.0 109.519 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.15 179.38 6.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.312 -0.868 . . . . 0.0 109.451 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.19 108.78 5.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.297 -0.877 . . . . 0.0 109.385 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.47 -17.26 5.58 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -81.84 171.41 14.53 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.31 -1.112 . . . . 0.0 109.434 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -128.27 133.39 48.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.288 -0.883 . . . . 0.0 109.702 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -94.45 146.56 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.442 -0.786 . . . . 0.0 109.071 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -129.57 145.48 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.19 -0.944 . . . . 0.0 109.818 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.526 ' HB3' HD12 ' A' ' 5' ' ' LEU . 46.5 m-85 -133.01 82.04 1.97 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.469 -0.769 . . . . 0.0 109.03 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.7 mttt -83.34 126.57 32.84 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.201 -0.937 . . . . 0.0 109.752 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.461 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.9 p-10 -98.85 127.8 44.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.259 -0.901 . . . . 0.0 109.481 179.752 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -104.65 -65.74 1.01 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 109.54 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -129.71 144.1 51.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.338 -0.851 . . . . 0.0 109.517 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.43 22.53 16.46 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.545 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -66.78 163.98 37.94 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.362 -1.081 . . . . 0.0 109.486 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.619 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.4 Cg_endo -80.4 152.14 83.09 Favored 'Cis proline' 0 C--N 1.312 -1.36 0 C-N-CA 123.389 -1.504 . . . . 0.0 110.858 -0.062 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.656 ' HB3' HD21 ' A' ' 5' ' ' LEU . 27.4 m-70 -118.26 40.35 3.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.347 -0.846 . . . . 0.0 109.222 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.2 p-10 -65.64 120.29 12.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.311 -0.868 . . . . 0.0 109.34 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.7 m -96.35 148.8 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.335 -0.853 . . . . 0.0 109.9 -179.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.482 HG23 ' HB3' ' B' ' 63' ' ' ASN . 7.7 m -134.82 119.79 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.43 -0.794 . . . . 0.0 109.048 179.769 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 15.0 m-85 -67.78 131.92 46.46 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.287 -0.883 . . . . 0.0 109.968 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.448 ' HB2' ' HE2' ' A' ' 83' ' ' TYR . 1.4 t0 -93.79 158.08 15.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.384 -0.822 . . . . 0.0 109.43 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.712 ' OE1' ' HE2' ' B' ' 187' ' ' LYS . 2.8 tp10 -100.55 17.82 20.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.844 . . . . 0.0 109.631 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -92.3 -18.04 23.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.148 -0.97 . . . . 0.0 109.483 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -130.64 26.21 5.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.226 -0.922 . . . . 0.0 109.629 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.618 HG22 ' HD2' ' A' ' 47' ' ' PRO . 19.0 mt -91.06 142.65 27.54 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.258 -0.901 . . . . 0.0 109.182 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.618 ' HD2' HG22 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -75.96 -65.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.704 2.27 . . . . 0.0 111.171 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.442 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.7 t -81.84 -177.61 6.64 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.189 -0.944 . . . . 0.0 109.692 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.491 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.9 -107.61 0.14 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.491 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.5 156.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.969 . . . . 0.0 109.856 179.926 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.72 160.8 14.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.419 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -80.55 -24.13 39.46 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.307 -0.871 . . . . 0.0 109.613 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -66.27 -19.16 65.74 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.227 -0.921 . . . . 0.0 109.951 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -80.57 -30.88 36.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.236 -0.915 . . . . 0.0 109.682 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.1 pt -117.17 23.26 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 109.84 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.419 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 45.0 m -127.72 171.28 11.85 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.478 ' H ' HG11 ' A' ' 40' ' ' VAL . 27.0 mtp -96.78 162.86 13.24 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.356 -0.84 . . . . 0.0 109.638 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.1 t -102.0 -171.2 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.349 -0.844 . . . . 0.0 109.746 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -84.64 -24.76 28.92 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.373 -0.829 . . . . 0.0 109.817 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -82.2 -32.42 29.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.254 -0.904 . . . . 0.0 109.705 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -95.23 90.02 5.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.83 146.29 42.11 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.42 -0.8 . . . . 0.0 109.388 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.652 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.6 mp -93.28 76.01 4.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.387 -0.821 . . . . 0.0 109.357 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.513 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.7 OUTLIER -98.04 -0.82 43.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.339 -0.851 . . . . 0.0 109.944 -179.721 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -107.19 143.85 27.97 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.174 -0.954 . . . . 0.0 109.711 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.42 84.7 1.91 Allowed 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.704 2.27 . . . . 0.0 110.296 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.22 -25.43 0.47 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.652 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -69.2 149.72 48.27 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.339 -1.095 . . . . 0.0 109.428 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 37.1 p -136.55 145.44 45.01 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.266 -0.896 . . . . 0.0 109.797 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -108.68 109.67 20.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.352 -0.842 . . . . 0.0 109.034 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.95 134.25 44.22 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.258 -0.901 . . . . 0.0 109.762 -179.722 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.427 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.8 OUTLIER -123.14 115.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.374 -0.829 . . . . 0.0 109.211 179.851 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.49 104.18 15.71 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.281 -0.887 . . . . 0.0 109.343 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -101.4 142.75 32.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.384 -0.822 . . . . 0.0 109.547 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.8 p -124.66 -25.99 3.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.436 -0.79 . . . . 0.0 109.737 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 152.7 45.1 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.247 -0.908 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -99.61 124.39 44.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 109.514 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.465 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 164.13 -168.55 38.63 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.3 m -115.3 118.72 34.07 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.313 -1.11 . . . . 0.0 109.528 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -96.63 179.13 5.1 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.349 -0.845 . . . . 0.0 109.149 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.79 96.99 2.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.193 -0.942 . . . . 0.0 109.835 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -100.43 153.52 19.28 Favored 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.448 ' HE2' ' HB2' ' A' ' 42' ' ' ASP . 35.5 p90 -143.46 155.97 44.51 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.081 -1.012 . . . . 0.0 110.34 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 8.6 t -68.55 114.02 6.58 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.499 ' O ' ' HB1' ' B' ' 62' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.809 0 O-C-N 121.252 -0.905 . . . . 0.0 109.992 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.758 ' CG ' ' O ' ' A' ' 92' ' ' MET . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 121.576 0.703 . . . . 0.0 109.515 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 17.4 m -146.63 148.61 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.381 -0.825 . . . . 0.0 109.211 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.32 179.88 16.69 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.3 ptmt -149.44 139.56 22.14 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.444 -1.033 . . . . 0.0 109.6 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.1 t -93.44 109.33 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.374 -0.829 . . . . 0.0 109.536 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -93.88 68.1 3.82 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.275 -0.891 . . . . 0.0 109.169 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.3 p -79.77 141.23 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.309 -0.869 . . . . 0.0 109.535 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.636 -179.998 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . 0.728 HG23 HD12 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.499 ' HB1' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . 0.482 ' HB3' HG23 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.511 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.712 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.43 108.32 4.8 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 0.0 109.427 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 t -103.73 125.0 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.869 . . . . 0.0 109.497 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 19.8 mt -111.98 104.06 12.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.357 -0.839 . . . . 0.0 109.299 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.686 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.0 OUTLIER -65.62 139.42 58.42 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.834 . . . . 0.0 109.445 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.484 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.57 136.47 1.72 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.01 -117.07 0.23 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -129.86 7.39 6.13 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.38 -41.11 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.332 -1.099 . . . . 0.0 109.59 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.89 47.64 0.04 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.484 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -104.92 97.93 7.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.347 -1.09 . . . . 0.0 109.373 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.7 mt -77.42 94.21 4.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.34 -0.85 . . . . 0.0 109.403 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.848 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.86 139.4 4.35 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.366 -0.834 . . . . 0.0 109.744 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.481 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 37.2 m-85 -67.51 128.06 35.02 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.406 -0.809 . . . . 0.0 109.072 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.463 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.66 103.17 19.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.234 -0.916 . . . . 0.0 109.572 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.3 Cg_endo -79.74 170.79 65.88 Favored 'Cis proline' 0 C--N 1.313 -1.333 0 C-N-CA 123.41 -1.496 . . . . 0.0 110.646 -0.269 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.427 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.33 12.49 47.92 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -166.9 110.08 0.71 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.338 -1.095 . . . . 0.0 109.086 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -131.3 169.45 15.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.678 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.5 m -121.91 130.35 53.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.345 -0.847 . . . . 0.0 109.498 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.49 -170.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.398 -0.814 . . . . 0.0 109.453 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.08 179.15 6.67 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.8 t -72.12 109.14 5.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.289 -0.882 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.72 -17.04 5.81 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.1 171.22 14.59 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.339 -1.095 . . . . 0.0 109.467 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.69 134.7 49.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.272 -0.892 . . . . 0.0 109.646 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.82 149.91 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.416 -0.803 . . . . 0.0 109.058 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.34 145.95 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.209 -0.932 . . . . 0.0 109.949 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.476 ' HB3' HD12 ' A' ' 5' ' ' LEU . 52.0 m-85 -133.41 79.99 1.86 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 108.95 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -81.36 125.74 30.75 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.242 -0.911 . . . . 0.0 109.758 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 26.6 p-10 -97.11 125.99 41.97 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.304 -0.873 . . . . 0.0 109.52 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -101.21 -65.46 0.97 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.33 -0.857 . . . . 0.0 109.544 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.17 148.28 52.7 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.54 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.04 21.1 26.3 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.508 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.9 p90 -64.86 163.23 30.54 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.324 -1.104 . . . . 0.0 109.676 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.548 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -79.75 153.65 87.17 Favored 'Cis proline' 0 C--N 1.312 -1.363 0 C-N-CA 123.367 -1.514 . . . . 0.0 110.68 -0.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.686 ' HB3' HD21 ' A' ' 5' ' ' LEU . 34.4 m-70 -123.9 39.0 4.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.405 -0.81 . . . . 0.0 109.269 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -66.0 126.0 27.2 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.272 -0.892 . . . . 0.0 109.367 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -97.89 149.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.884 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.401 HG11 ' H ' ' A' ' 57' ' ' MET . 6.4 m -136.61 119.88 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.504 -0.747 . . . . 0.0 108.999 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -68.62 133.17 48.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.232 -0.918 . . . . 0.0 109.692 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.21 159.99 14.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.37 -0.831 . . . . 0.0 109.371 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.56 ' HA ' HD11 ' A' ' 46' ' ' ILE . 4.9 tp10 -100.78 31.94 3.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.4 -0.812 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.15 -18.66 13.95 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -130.67 24.93 5.07 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.345 -0.847 . . . . 0.0 109.56 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.582 HG22 ' HD2' ' A' ' 47' ' ' PRO . 35.8 mt -89.36 141.82 29.26 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.324 -0.86 . . . . 0.0 109.119 179.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.582 ' HD2' HG22 ' A' ' 46' ' ' ILE . 33.8 Cg_endo -75.69 -63.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.733 2.289 . . . . 0.0 111.103 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.412 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.9 t -84.81 -177.95 6.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.177 -0.952 . . . . 0.0 109.588 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.504 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.41 -105.47 0.13 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.504 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.24 156.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.53 -0.982 . . . . 0.0 109.835 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.76 158.2 16.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.307 -0.871 . . . . 0.0 109.581 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.46 -24.25 39.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.334 -0.854 . . . . 0.0 109.558 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.31 -15.94 62.94 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.38 -0.825 . . . . 0.0 109.853 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.2 tptt -81.3 -31.17 33.69 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.283 -0.886 . . . . 0.0 109.697 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.5 pt -113.23 7.55 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 67.5 m -111.74 173.92 6.12 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.194 -0.942 . . . . 0.0 109.419 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.401 ' H ' HG11 ' A' ' 40' ' ' VAL . 19.8 mtp -93.63 161.29 14.41 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 109.624 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.8 -167.25 1.56 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.341 -0.849 . . . . 0.0 109.681 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.406 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.8 OUTLIER -90.18 -28.66 18.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.339 -0.851 . . . . 0.0 109.976 -179.666 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . 0.406 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -80.28 -30.38 38.33 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.253 -0.905 . . . . 0.0 109.859 -179.734 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -95.0 91.5 6.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.213 -0.93 . . . . 0.0 109.575 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.6 142.98 46.0 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.406 -0.809 . . . . 0.0 109.296 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.709 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.8 mp -89.14 80.57 6.92 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.3 -0.875 . . . . 0.0 109.133 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.45 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 2.0 t30 -100.4 -22.9 14.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.91 145.46 36.63 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 109.905 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.59 81.6 2.62 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.801 2.334 . . . . 0.0 110.275 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 -25.74 0.24 Allowed Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.709 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.59 149.18 50.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.331 -1.1 . . . . 0.0 109.441 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -135.79 145.98 47.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 109.878 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.7 t80 -109.09 108.94 19.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.343 -0.848 . . . . 0.0 109.045 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.528 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.0 133.83 43.81 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.314 -0.866 . . . . 0.0 109.703 -179.697 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.411 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.7 OUTLIER -122.76 115.22 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.42 -0.8 . . . . 0.0 109.239 179.911 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.24 102.04 13.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.296 -0.878 . . . . 0.0 109.279 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.1 142.98 29.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.347 -0.845 . . . . 0.0 109.559 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.56 -26.31 3.88 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.335 -0.853 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 151.8 46.47 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.328 -0.858 . . . . 0.0 109.615 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.3 mttt -98.81 122.55 42.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.376 -0.828 . . . . 0.0 109.594 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.491 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.64 -171.42 41.55 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -112.97 114.4 26.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.319 -1.106 . . . . 0.0 109.494 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -92.73 176.89 6.27 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.303 -0.873 . . . . 0.0 109.123 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.43 93.9 2.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.117 -0.99 . . . . 0.0 109.86 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -97.36 155.94 16.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.331 -0.856 . . . . 0.0 108.806 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 41.4 p90 -145.84 155.32 42.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.041 -1.037 . . . . 0.0 110.207 -179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.7 t -67.69 107.2 2.47 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.587 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.803 0 O-C-N 121.395 -0.816 . . . . 0.0 109.975 -179.674 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.848 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.4 ptm . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.559 0.695 . . . . 0.0 109.481 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 28.9 m -146.72 150.08 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.0 178.17 17.93 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.7 ptmt -149.03 138.93 22.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.35 -1.088 . . . . 0.0 109.696 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 33.0 t -93.98 110.12 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.343 -0.848 . . . . 0.0 109.533 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.18 67.53 3.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.303 -0.873 . . . . 0.0 109.297 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.0 p -79.46 140.0 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.4 -0.812 . . . . 0.0 109.55 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.549 179.994 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.587 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.511 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.502 ' HD3' ' HG2' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.2 p . . . . . 0 N--CA 1.502 2.162 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.85 106.64 4.87 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.895 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.9 t -102.33 126.35 56.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 17.8 mt -114.0 106.29 14.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.382 -0.823 . . . . 0.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.656 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.65 136.85 56.18 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.39 -0.819 . . . . 0.0 109.419 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.492 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 81.2 135.44 1.75 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.88 -119.42 0.26 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.88 -0.69 9.03 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -134.82 -41.11 0.76 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.364 -1.08 . . . . 0.0 109.549 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.925 ' O ' ' NE2' ' B' ' 7' ' ' GLN . . . 169.57 42.93 0.03 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.492 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.2 t -94.6 93.47 7.6 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.274 -1.133 . . . . 0.0 109.324 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -73.75 92.26 1.99 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.286 -0.884 . . . . 0.0 109.491 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.819 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.43 141.96 3.77 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.334 -0.854 . . . . 0.0 109.6 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -68.12 127.87 34.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.378 -0.826 . . . . 0.0 109.197 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.406 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.4 mp -129.35 104.18 17.9 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 109.591 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.406 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.55 170.43 67.65 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.389 -1.505 . . . . 0.0 110.66 -0.272 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.401 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.65 10.47 49.34 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -165.05 111.65 0.97 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.316 -1.108 . . . . 0.0 109.131 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -132.29 169.38 16.55 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.388 -0.82 . . . . 0.0 109.59 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.07 130.16 53.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.344 -0.848 . . . . 0.0 109.423 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.6 m -132.92 -171.58 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.369 -0.832 . . . . 0.0 109.487 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.99 178.52 7.06 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.4 t -71.9 109.94 6.08 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.296 -0.878 . . . . 0.0 109.326 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.54 -17.29 5.85 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.04 173.4 12.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.39 -1.065 . . . . 0.0 109.453 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -129.73 134.67 47.76 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.284 -0.885 . . . . 0.0 109.675 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.539 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.46 149.39 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.407 -0.808 . . . . 0.0 109.046 179.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 t -133.25 145.6 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.179 -0.951 . . . . 0.0 109.992 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.515 ' HB3' HD12 ' A' ' 5' ' ' LEU . 54.0 m-85 -132.89 77.89 1.76 Allowed 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 mttt -79.38 124.66 28.64 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.191 -0.943 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.42 ' HA ' ' HB2' ' A' ' 5' ' ' LEU . 24.0 p-10 -96.75 120.82 37.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.319 -0.863 . . . . 0.0 109.451 179.69 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -93.99 -65.56 0.98 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 109.677 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.14 150.46 52.14 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.351 -0.843 . . . . 0.0 109.643 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 17.08 37.78 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.521 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 5.1 p90 -63.27 162.93 20.74 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.334 -1.098 . . . . 0.0 109.601 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.579 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.2 Cg_endo -79.11 150.9 86.53 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.483 . . . . 0.0 110.848 0.123 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.656 ' HB3' HD21 ' A' ' 5' ' ' LEU . 37.0 m-70 -124.04 42.39 3.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.39 -0.819 . . . . 0.0 109.41 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -66.24 126.4 28.58 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.168 -0.958 . . . . 0.0 109.333 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.5 m -96.53 150.57 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.283 -0.886 . . . . 0.0 109.75 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.487 HG11 ' H ' ' A' ' 57' ' ' MET . 10.2 m -138.99 121.51 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.438 -0.789 . . . . 0.0 109.302 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -71.07 127.8 33.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.24 -0.913 . . . . 0.0 109.41 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.26 163.98 18.32 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.238 -0.914 . . . . 0.0 109.624 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -101.49 25.58 8.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.408 -0.807 . . . . 0.0 109.527 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.46 -18.69 14.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.565 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -130.13 59.64 1.63 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.183 -0.948 . . . . 0.0 109.708 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.526 HG22 ' HD2' ' A' ' 47' ' ' PRO . 76.9 mt -119.82 140.3 29.4 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.267 -0.896 . . . . 0.0 109.089 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.526 ' HD2' HG22 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -76.05 -62.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 122.697 2.265 . . . . 0.0 110.968 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.4 t -88.92 -172.91 3.88 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.185 -0.947 . . . . 0.0 109.581 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.459 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.81 -112.29 0.14 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.459 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.8 154.95 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.495 -1.003 . . . . 0.0 109.792 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -95.35 168.05 10.96 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.28 -0.888 . . . . 0.0 109.661 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -85.03 -20.94 29.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.35 -0.844 . . . . 0.0 109.669 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -69.76 -12.34 61.56 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.213 -0.93 . . . . 0.0 109.982 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -88.88 -27.49 20.98 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.211 -0.931 . . . . 0.0 109.829 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.7 pt -117.96 12.21 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.195 -0.94 . . . . 0.0 110.078 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 74.7 m -117.08 175.31 5.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.159 -0.963 . . . . 0.0 109.45 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.487 ' H ' HG11 ' A' ' 40' ' ' VAL . 31.5 mtp -99.78 164.64 11.95 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.368 -0.833 . . . . 0.0 109.522 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.7 -170.83 1.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.324 -0.86 . . . . 0.0 109.745 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.507 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.6 OUTLIER -87.71 -25.97 23.19 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.374 -0.828 . . . . 0.0 109.794 -179.84 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . 0.443 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 1.5 mp0 -82.38 -32.08 29.39 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.525 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -95.0 89.56 5.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.277 -0.889 . . . . 0.0 109.217 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.91 144.74 43.64 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.352 -0.843 . . . . 0.0 109.622 -179.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.663 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.0 mp -86.94 79.44 8.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.415 -0.803 . . . . 0.0 109.155 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.431 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.4 t30 -100.26 -4.64 28.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.304 -0.872 . . . . 0.0 110.01 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -103.46 143.55 26.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.21 79.94 3.02 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.711 2.274 . . . . 0.0 110.242 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.2 -25.41 0.26 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.663 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.51 149.46 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.371 -1.076 . . . . 0.0 109.403 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 29.6 p -135.91 145.68 46.54 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.925 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 33.5 t80 -108.53 108.55 19.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.539 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -99.76 134.22 42.97 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.338 -0.851 . . . . 0.0 109.723 -179.627 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.42 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.6 OUTLIER -122.93 113.92 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.38 -0.825 . . . . 0.0 109.319 179.85 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -84.63 102.31 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.253 -0.904 . . . . 0.0 109.291 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.64 142.17 31.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.1 p -123.92 -25.66 4.2 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.356 -0.84 . . . . 0.0 109.718 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.0 151.66 46.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.293 -0.879 . . . . 0.0 109.708 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -98.68 120.84 39.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.398 -0.814 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.401 ' H ' HG11 ' A' ' 98' ' ' VAL . . . 168.42 -171.82 42.75 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.4 m -113.56 114.14 26.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.274 -1.133 . . . . 0.0 109.493 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.17 179.02 5.55 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.366 -0.834 . . . . 0.0 109.095 179.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.78 101.46 3.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 109.8 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -102.91 163.28 12.3 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.7 p90 -155.17 154.32 32.1 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.078 -1.014 . . . . 0.0 110.158 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 35.2 t -66.43 110.08 2.98 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.898 ' O ' ' HB2' ' B' ' 62' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.686 0 O-C-N 121.451 -0.78 . . . . 0.0 110.247 -179.369 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.819 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.8 m -142.74 167.6 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -0.867 . . . . 0.0 109.629 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -147.8 -177.95 22.62 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.1 ptmt -152.36 142.02 21.85 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.122 . . . . 0.0 109.848 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 27.1 t -97.5 112.02 28.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.36 -0.838 . . . . 0.0 109.371 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -95.95 68.89 2.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.203 -0.936 . . . . 0.0 109.175 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.401 HG11 ' H ' ' A' ' 78' ' ' GLY . 4.4 p -81.01 139.52 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.33 -0.856 . . . . 0.0 109.591 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.604 -179.974 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.925 ' NE2' ' O ' ' A' ' 10' ' ' GLY . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.898 ' HB2' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . 0.447 ' HB3' ' OG ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.507 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.511 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.171 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.6 108.97 4.61 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.0 t -104.08 120.37 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.315 -0.866 . . . . 0.0 109.474 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 21.2 mt -107.58 101.68 10.99 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.338 -0.851 . . . . 0.0 109.321 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.68 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -64.44 141.93 58.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.381 -0.824 . . . . 0.0 109.512 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.466 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.17 135.16 1.09 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.01 -116.79 0.19 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -130.45 7.64 5.93 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.61 -41.02 0.22 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.334 -1.097 . . . . 0.0 109.586 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.46 48.19 0.04 OUTLIER Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.466 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.8 t -105.67 99.33 8.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.339 -1.095 . . . . 0.0 109.322 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 11.1 mt -78.32 96.07 5.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.37 -0.831 . . . . 0.0 109.404 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.849 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.23 138.1 3.07 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.342 -0.849 . . . . 0.0 109.728 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 36.8 m-85 -66.68 127.71 33.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.357 -0.839 . . . . 0.0 109.031 179.635 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -128.12 103.12 20.94 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.293 -0.879 . . . . 0.0 109.573 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.61 170.43 67.46 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.394 -1.503 . . . . 0.0 110.666 -0.348 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.431 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.22 12.7 48.43 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -167.03 108.6 0.66 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.331 -1.1 . . . . 0.0 109.076 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -130.02 169.49 15.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.393 -0.817 . . . . 0.0 109.666 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 m -121.97 129.65 52.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.332 -0.855 . . . . 0.0 109.438 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.77 -170.17 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.38 -0.825 . . . . 0.0 109.482 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.55 179.11 6.75 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.305 -0.872 . . . . 0.0 109.473 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.09 108.83 5.5 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.27 -17.38 5.62 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -81.8 171.61 14.32 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.345 -1.091 . . . . 0.0 109.468 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -127.97 134.25 49.26 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.285 -0.884 . . . . 0.0 109.665 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.53 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.0 149.04 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.437 -0.789 . . . . 0.0 109.042 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 t -132.4 145.71 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.193 -0.942 . . . . 0.0 109.896 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.512 ' HB3' HD12 ' A' ' 5' ' ' LEU . 49.9 m-85 -133.32 80.38 1.88 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.424 -0.797 . . . . 0.0 109.016 179.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.9 mttt -81.55 126.78 32.12 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.223 -0.923 . . . . 0.0 109.729 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.451 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 26.9 p-10 -98.07 126.22 43.41 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.333 -0.855 . . . . 0.0 109.484 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.99 -65.72 0.97 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.856 . . . . 0.0 109.522 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.33 146.91 52.49 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.344 -0.848 . . . . 0.0 109.544 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.05 20.95 26.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.563 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.7 p90 -64.24 164.8 16.38 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.363 -1.08 . . . . 0.0 109.634 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.606 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -80.03 153.54 85.99 Favored 'Cis proline' 0 C--N 1.313 -1.338 0 C-N-CA 123.378 -1.509 . . . . 0.0 110.606 -0.246 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.68 ' HB3' HD21 ' A' ' 5' ' ' LEU . 32.2 m-70 -121.1 37.96 4.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.217 179.564 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 15.7 p-10 -65.1 121.64 15.19 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.318 -0.864 . . . . 0.0 109.304 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -94.83 148.43 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.28 -0.888 . . . . 0.0 109.846 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.77 117.49 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.482 -0.761 . . . . 0.0 109.01 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -66.38 133.25 50.09 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.322 -0.861 . . . . 0.0 109.82 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -94.96 159.15 15.16 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.389 -0.819 . . . . 0.0 109.361 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.569 ' HA ' HD11 ' A' ' 46' ' ' ILE . 3.9 tp10 -100.55 24.71 8.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 109.591 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.97 -16.69 17.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -131.42 27.21 4.76 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.285 -0.884 . . . . 0.0 109.539 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.597 HG22 ' HD2' ' A' ' 47' ' ' PRO . 28.2 mt -92.15 142.18 25.96 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.301 -0.874 . . . . 0.0 109.055 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.597 ' HD2' HG22 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.67 -63.9 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.713 2.276 . . . . 0.0 111.101 -179.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.422 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.8 t -84.15 -176.85 6.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.162 -0.961 . . . . 0.0 109.563 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.486 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.66 -107.59 0.14 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.486 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.41 155.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.494 -1.004 . . . . 0.0 109.841 179.886 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.2 161.55 15.02 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.251 -0.906 . . . . 0.0 109.636 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.12 -22.16 36.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 0.0 109.644 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.78 -13.83 62.2 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.295 -0.878 . . . . 0.0 109.846 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -85.15 -29.86 24.44 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.247 -0.908 . . . . 0.0 109.679 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -114.54 8.2 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.17 -0.956 . . . . 0.0 110.021 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.8 m -113.47 172.93 6.67 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.168 -0.957 . . . . 0.0 109.408 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.8 mtp -92.52 160.91 14.83 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.317 -0.864 . . . . 0.0 109.56 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -95.14 -167.36 1.61 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.42 -0.8 . . . . 0.0 109.545 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.424 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.7 OUTLIER -90.94 -25.67 19.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.288 -0.883 . . . . 0.0 109.785 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . 0.424 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -82.07 -30.41 31.33 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.739 -179.81 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -95.99 93.64 7.12 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.197 -0.94 . . . . 0.0 109.605 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.95 143.1 46.1 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.401 -0.812 . . . . 0.0 109.332 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.705 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.9 mp -89.28 80.52 6.84 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.346 -0.846 . . . . 0.0 109.18 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.455 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.8 t30 -100.09 -21.17 15.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 -179.647 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -88.53 144.82 34.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.175 -0.953 . . . . 0.0 109.864 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.45 81.62 2.6 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.754 2.303 . . . . 0.0 110.276 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.53 -25.6 0.25 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.705 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.58 149.43 50.12 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.419 -1.048 . . . . 0.0 109.408 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.9 p -135.81 145.39 46.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.251 -0.906 . . . . 0.0 109.864 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -108.84 109.22 20.28 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.453 -0.779 . . . . 0.0 109.008 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.29 134.3 43.43 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.343 -0.848 . . . . 0.0 109.726 -179.695 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.414 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.7 OUTLIER -122.94 115.44 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.407 -0.808 . . . . 0.0 109.243 179.852 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -86.3 102.21 13.78 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.252 -0.905 . . . . 0.0 109.31 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.3 143.0 30.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.855 . . . . 0.0 109.606 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.3 p -124.63 -26.61 3.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.39 47.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.264 -0.898 . . . . 0.0 109.682 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -98.41 122.43 41.58 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.427 -0.795 . . . . 0.0 109.529 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.473 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.9 -170.92 41.58 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -113.68 114.1 25.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -1.157 . . . . 0.0 109.513 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -92.31 177.87 6.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.419 -0.801 . . . . 0.0 109.118 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.21 93.65 2.12 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.213 -0.93 . . . . 0.0 109.85 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.7 p90 -96.99 154.5 17.26 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 108.791 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -144.49 157.05 44.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.134 -0.979 . . . . 0.0 110.174 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 10.1 t -67.83 114.77 6.68 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.767 0 O-C-N 121.348 -0.845 . . . . 0.0 110.036 -179.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.849 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 1.3 ptm . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 121.563 0.697 . . . . 0.0 109.325 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 28.0 m -146.8 148.41 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.351 -0.843 . . . . 0.0 109.405 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.431 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -129.45 178.69 17.23 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -148.86 138.51 21.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.123 . . . . 0.0 109.636 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.8 t -93.21 110.07 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.08 67.22 3.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.248 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.6 p -79.25 139.59 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.333 -0.854 . . . . 0.0 109.6 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.577 179.936 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.644 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.511 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.53 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 N--CA 1.503 2.188 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.82 107.97 4.88 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.307 -0.871 . . . . 0.0 109.408 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.9 t -102.98 124.01 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.363 -0.835 . . . . 0.0 109.451 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 21.8 mt -110.26 101.88 10.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.361 -0.837 . . . . 0.0 109.383 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.679 HD21 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.24 133.08 50.7 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.335 -0.853 . . . . 0.0 109.388 -179.99 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 84.69 133.01 2.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.72 -118.15 0.15 Allowed Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.62 -1.89 6.95 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -132.93 -40.34 0.94 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.129 . . . . 0.0 109.592 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.802 ' HA3' HD12 ' B' ' 3' ' ' ILE . . . 168.31 46.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.507 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.7 t -99.19 94.56 6.56 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.356 -1.085 . . . . 0.0 109.338 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.5 mt -75.18 89.7 2.53 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.343 -0.848 . . . . 0.0 109.471 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.856 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.51 142.03 7.93 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.295 -0.878 . . . . 0.0 109.674 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.511 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 38.1 m-85 -68.15 128.26 35.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -0.849 . . . . 0.0 109.159 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.411 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.54 102.31 18.33 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 109.604 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.74 171.6 62.44 Favored 'Cis proline' 0 C--N 1.312 -1.351 0 C-N-CA 123.428 -1.488 . . . . 0.0 110.714 -0.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.404 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.42 10.77 46.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -165.15 110.46 0.91 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.328 -1.101 . . . . 0.0 109.078 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -131.2 167.75 18.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.639 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.9 m -120.43 129.84 54.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.327 -0.858 . . . . 0.0 109.471 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 98' ' ' VAL . 3.0 m -131.94 -172.85 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.369 -0.832 . . . . 0.0 109.545 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.68 178.55 6.95 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 109.482 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.7 t -72.17 111.47 7.42 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.333 -0.854 . . . . 0.0 109.428 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.77 -16.38 6.94 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -82.57 167.11 18.64 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.395 -1.062 . . . . 0.0 109.488 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -123.92 133.14 53.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.64 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.3 mp -97.36 151.03 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.438 -0.789 . . . . 0.0 109.042 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.4 t -133.7 145.22 33.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 109.967 -179.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.471 ' HB3' HD12 ' A' ' 5' ' ' LEU . 54.6 m-85 -130.92 77.43 1.78 Allowed 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -77.07 132.61 39.0 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.272 -0.892 . . . . 0.0 109.842 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 20.6 p-10 -105.72 122.22 45.62 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.52 -67.18 0.87 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.281 -0.887 . . . . 0.0 109.588 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -125.44 149.99 47.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.326 -0.858 . . . . 0.0 109.525 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.33 11.02 61.55 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.652 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 3.0 p90 -61.76 165.99 6.75 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 121.399 -1.059 . . . . 0.0 109.543 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.591 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.2 Cg_endo -78.84 151.64 88.39 Favored 'Cis proline' 0 C--N 1.313 -1.292 0 C-N-CA 123.329 -1.53 . . . . 0.0 110.506 -0.016 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.679 ' HB3' HD21 ' A' ' 5' ' ' LEU . 50.6 m-70 -122.78 44.78 2.55 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.384 -0.823 . . . . 0.0 109.365 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -68.57 123.15 20.05 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.196 -0.94 . . . . 0.0 109.199 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.07 155.7 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.245 -0.909 . . . . 0.0 109.992 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.421 HG11 ' H ' ' A' ' 57' ' ' MET . 3.6 m -141.33 118.8 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.418 -0.801 . . . . 0.0 109.201 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -69.31 130.57 42.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 109.663 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.11 159.39 15.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.355 -0.841 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.519 ' HA ' HD11 ' A' ' 46' ' ' ILE . 4.5 tp10 -99.02 34.46 2.11 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.313 -0.867 . . . . 0.0 109.491 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -108.38 -22.09 12.47 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -0.899 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -128.5 32.78 4.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.738 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.575 HG22 ' HD2' ' A' ' 47' ' ' PRO . 49.0 mt -95.35 141.44 23.22 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.24 -0.913 . . . . 0.0 109.188 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.575 ' HD2' HG22 ' A' ' 46' ' ' ILE . 34.4 Cg_endo -76.46 -59.6 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.723 2.282 . . . . 0.0 111.038 -179.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.403 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.5 t -87.65 -176.26 5.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.932 . . . . 0.0 109.683 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.496 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -78.26 -107.01 0.19 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.496 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.45 156.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.513 -0.992 . . . . 0.0 109.773 179.896 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.89 160.75 16.29 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 0.0 109.637 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.26 -18.18 40.02 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.872 . . . . 0.0 109.729 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -77.15 -9.42 58.74 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.222 -0.924 . . . . 0.0 109.851 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.0 tptp -87.75 -27.18 22.51 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.279 -0.888 . . . . 0.0 109.715 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.6 pt -113.68 -5.1 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.212 -0.93 . . . . 0.0 109.976 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.2 m -98.99 175.29 5.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.168 -0.957 . . . . 0.0 109.473 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.421 ' H ' HG11 ' A' ' 40' ' ' VAL . 16.5 mtp -93.24 157.26 16.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.819 . . . . 0.0 109.563 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -88.35 -160.13 0.61 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.467 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.828 ' OE1' ' HE2' ' B' ' 65' ' ' LYS . 8.8 pm0 -98.24 -29.21 13.32 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.296 -0.877 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . 0.501 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.7 -30.33 36.38 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.302 -0.874 . . . . 0.0 109.737 -179.873 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -92.16 95.42 9.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.335 -0.853 . . . . 0.0 109.48 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.694 HD12 HD23 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -116.7 141.61 47.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.424 -0.797 . . . . 0.0 109.34 -179.986 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.646 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.0 OUTLIER -90.52 80.14 6.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.338 -0.851 . . . . 0.0 109.14 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -102.7 -41.05 6.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.324 -0.86 . . . . 0.0 109.8 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.49 145.63 98.4 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.326 -0.859 . . . . 0.0 109.979 -179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.75 78.09 3.67 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.771 2.314 . . . . 0.0 110.219 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 165.38 -24.79 0.16 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.646 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.2 tp10 -67.84 148.11 51.62 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.365 -1.08 . . . . 0.0 109.339 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 41.1 p -136.74 143.27 43.2 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 109.899 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -105.28 107.15 17.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.348 -0.845 . . . . 0.0 109.094 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.47 131.07 45.02 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 109.62 -179.744 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -121.08 112.44 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.424 -0.798 . . . . 0.0 109.206 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.8 m -83.66 104.04 13.45 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 109.297 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -100.92 141.26 34.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.362 -0.836 . . . . 0.0 109.557 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.9 p -123.14 -24.73 4.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.19 153.42 43.72 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.274 -0.891 . . . . 0.0 109.642 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.8 mttt -100.67 124.07 45.75 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.309 -0.869 . . . . 0.0 109.548 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.428 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 165.71 -168.53 39.64 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.8 m -116.86 110.82 18.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.332 -1.099 . . . . 0.0 109.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -89.35 176.09 7.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.8 92.51 2.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.169 -0.957 . . . . 0.0 109.918 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.41 ' HE1' ' CE2' ' A' ' 14' ' ' PHE . 47.9 p90 -97.54 154.6 17.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.337 -0.852 . . . . 0.0 108.738 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 41.6 p90 -143.79 154.61 43.6 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 109.987 -179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 49.6 t -65.9 106.91 1.68 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.502 -0.749 . . . . 0.0 109.024 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.866 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.494 1.725 0 O-C-N 121.49 -0.756 . . . . 0.0 110.089 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.856 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.009 -0.738 . . . . 0.0 109.009 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.0 m -144.97 146.79 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.362 -0.836 . . . . 0.0 109.607 -179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -124.7 176.32 17.04 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.81 136.2 20.29 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.263 -1.139 . . . . 0.0 109.816 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.5 t -91.49 109.96 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.344 -0.847 . . . . 0.0 109.476 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -94.79 66.75 3.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.204 -0.935 . . . . 0.0 109.104 179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 7.0 p -79.21 141.24 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.307 -0.87 . . . . 0.0 109.62 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.2 p30 . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.566 179.946 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . 0.802 HD12 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . 0.694 HD23 HD12 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.866 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . 0.413 ' HB3' ' OG ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.828 ' HE2' ' OE1' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.511 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.4 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.38 107.99 4.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.8 t -102.9 125.46 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.364 -0.835 . . . . 0.0 109.504 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 25.0 mt -111.13 100.52 9.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.387 -0.82 . . . . 0.0 109.299 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.702 HD21 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.01 128.57 36.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.373 -0.83 . . . . 0.0 109.388 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 88.71 134.0 4.79 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -77.58 -124.62 0.28 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.26 -13.52 8.25 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -118.74 -37.39 3.27 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.322 -1.104 . . . . 0.0 109.615 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.946 ' HA3' HD12 ' B' ' 3' ' ' ILE . . . 160.61 45.9 0.02 OUTLIER Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.499 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.8 t -94.64 98.47 10.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.288 -1.125 . . . . 0.0 109.301 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 mt -73.83 91.92 2.0 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.298 -0.876 . . . . 0.0 109.485 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.887 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.2 137.53 5.21 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.358 -0.839 . . . . 0.0 109.617 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.555 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 35.4 m-85 -65.71 126.58 28.88 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.383 -0.823 . . . . 0.0 109.054 179.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -127.9 102.28 22.29 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.248 -0.907 . . . . 0.0 109.607 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.78 170.47 66.89 Favored 'Cis proline' 0 C--N 1.313 -1.317 0 C-N-CA 123.45 -1.479 . . . . 0.0 110.679 -0.271 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.412 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.41 12.45 47.57 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -166.49 105.92 0.64 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.406 -1.055 . . . . 0.0 109.043 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -127.45 167.25 16.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.307 -0.87 . . . . 0.0 109.695 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.64 128.55 53.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 109.404 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.0 m -130.44 -171.52 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.388 -0.82 . . . . 0.0 109.532 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.31 179.01 6.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.329 -0.857 . . . . 0.0 109.442 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -72.3 110.52 6.78 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.238 -0.914 . . . . 0.0 109.417 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.62 -16.91 6.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -82.1 165.71 20.35 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.34 -1.094 . . . . 0.0 109.472 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -122.61 132.11 54.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.337 -0.852 . . . . 0.0 109.636 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.31 151.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 109.045 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -133.5 146.28 32.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.217 -0.927 . . . . 0.0 109.934 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.447 ' HB3' HD12 ' A' ' 5' ' ' LEU . 52.1 m-85 -132.5 80.05 1.88 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.3 mttt -80.45 131.79 35.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.333 -0.855 . . . . 0.0 109.716 -179.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.2 p-10 -105.25 119.57 39.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.282 -0.886 . . . . 0.0 109.493 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -98.19 -67.83 0.83 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.343 -0.848 . . . . 0.0 109.573 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -124.68 149.85 46.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.33 -0.856 . . . . 0.0 109.49 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 92.13 12.71 58.51 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.642 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 4.9 p90 -61.5 163.97 10.35 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.405 -1.056 . . . . 0.0 109.542 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.548 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.2 Cg_endo -79.1 157.28 91.4 Favored 'Cis proline' 0 C--N 1.313 -1.322 0 C-N-CA 123.322 -1.532 . . . . 0.0 110.481 -0.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.702 ' HB3' HD21 ' A' ' 5' ' ' LEU . 43.9 m-70 -127.97 39.75 3.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.385 -0.822 . . . . 0.0 109.33 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -65.19 120.64 13.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.334 -0.854 . . . . 0.0 109.267 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -93.0 151.45 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.305 -0.872 . . . . 0.0 109.823 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.506 HG11 ' H ' ' A' ' 57' ' ' MET . 10.2 m -137.99 121.71 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.109 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -70.26 132.11 45.22 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.258 -0.901 . . . . 0.0 109.709 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.45 157.86 15.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.294 -0.879 . . . . 0.0 109.53 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.539 ' HA ' HD11 ' A' ' 46' ' ' ILE . 6.0 tp10 -98.02 47.04 1.01 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.294 -0.879 . . . . 0.0 109.45 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.56 -26.77 5.67 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.286 -0.884 . . . . 0.0 109.38 179.727 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -124.25 25.25 7.83 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.342 -0.849 . . . . 0.0 109.61 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.567 HG22 ' HD2' ' A' ' 47' ' ' PRO . 58.0 mt -87.87 141.36 31.54 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.254 -0.904 . . . . 0.0 109.155 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.567 ' HD2' HG22 ' A' ' 46' ' ' ILE . 34.0 Cg_endo -76.23 -60.71 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.738 2.292 . . . . 0.0 110.999 -179.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.8 t -87.57 -178.3 6.08 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.211 -0.931 . . . . 0.0 109.642 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.521 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.6 -103.39 0.14 Allowed Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.521 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.92 157.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.523 -0.987 . . . . 0.0 109.899 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.471 ' HA ' ' HZ2' ' B' ' 187' ' ' LYS . 0.6 OUTLIER -89.23 156.42 18.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.263 -0.898 . . . . 0.0 109.624 -179.904 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.63 -24.41 39.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.321 -0.862 . . . . 0.0 109.677 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -72.82 -15.22 61.63 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 109.777 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -79.43 -31.62 42.63 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.303 -0.873 . . . . 0.0 109.735 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.0 pt -111.07 0.44 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.272 -0.892 . . . . 0.0 109.879 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 62.4 m -104.02 177.93 4.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.506 ' H ' HG11 ' A' ' 40' ' ' VAL . 22.7 mtp -98.67 159.07 15.21 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.289 -0.882 . . . . 0.0 109.523 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.73 -166.43 1.58 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.354 -0.841 . . . . 0.0 109.552 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.516 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -91.43 -28.06 17.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.354 -0.841 . . . . 0.0 109.92 -179.807 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . 0.435 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.5 OUTLIER -80.93 -31.25 35.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.88 . . . . 0.0 109.775 -179.851 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -91.23 97.37 11.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.337 -0.852 . . . . 0.0 109.483 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.532 HD12 HD23 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -120.15 145.49 46.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.38 -0.825 . . . . 0.0 109.363 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.656 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.0 mp -93.31 75.31 4.56 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.415 -0.803 . . . . 0.0 109.185 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -96.04 -35.45 11.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.292 -0.88 . . . . 0.0 109.749 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -73.21 143.84 83.82 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.308 -0.87 . . . . 0.0 109.808 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.56 80.06 3.03 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.777 2.318 . . . . 0.0 110.215 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 163.84 -24.95 0.19 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.656 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.55 149.33 50.27 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.387 -1.066 . . . . 0.0 109.387 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 36.2 p -136.4 144.22 44.4 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.2 t80 -106.73 108.72 20.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.384 -0.823 . . . . 0.0 109.07 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.446 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.06 132.28 45.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.322 -0.861 . . . . 0.0 109.685 -179.742 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -122.1 112.85 36.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.418 -0.801 . . . . 0.0 109.263 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.6 m -84.2 102.0 12.29 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.291 -0.88 . . . . 0.0 109.326 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -98.46 142.45 30.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.33 -0.856 . . . . 0.0 109.531 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.3 p -123.9 -25.92 4.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.351 -0.843 . . . . 0.0 109.714 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.46 152.27 45.63 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 109.669 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -99.43 123.1 43.41 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.418 -0.801 . . . . 0.0 109.605 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.481 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.68 -171.67 41.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 4.0 m -113.3 111.01 21.3 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.298 -1.119 . . . . 0.0 109.401 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -89.57 175.44 7.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.362 -0.837 . . . . 0.0 109.171 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.7 88.58 1.77 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.223 -0.923 . . . . 0.0 109.861 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.445 ' HE1' ' CE2' ' A' ' 14' ' ' PHE . 48.3 p90 -93.23 146.5 23.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.249 -0.907 . . . . 0.0 108.802 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -133.41 153.03 51.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.863 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 42.5 t -65.68 109.2 2.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.542 -0.724 . . . . 0.0 109.246 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.823 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.5 OUTLIER . . . . . 0 N--CA 1.495 1.787 0 O-C-N 121.471 -0.768 . . . . 0.0 109.812 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.887 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.359 0.6 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.3 m -149.57 134.49 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.299 -0.876 . . . . 0.0 109.31 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -115.17 174.98 15.64 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -147.65 135.3 20.94 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.13 . . . . 0.0 109.614 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 34.9 t -89.33 109.87 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.97 65.87 2.97 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 109.174 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.7 p -78.32 140.47 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.369 -0.832 . . . . 0.0 109.575 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.586 179.982 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . 0.946 HD12 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.415 ' NE2' ' O ' ' A' ' 10' ' ' GLY . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . 0.532 HD23 HD12 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.823 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.516 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.511 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 0.471 ' HZ2' ' HA ' ' A' ' 51' ' ' ASP . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.9 p . . . . . 0 N--CA 1.503 2.195 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.56 108.91 5.18 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.235 -0.915 . . . . 0.0 109.46 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 15.8 t -104.35 120.65 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.34 -0.85 . . . . 0.0 109.446 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 19.0 mt -107.63 102.59 11.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.389 -0.82 . . . . 0.0 109.342 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.64 HD21 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.09 141.62 58.66 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.326 -0.859 . . . . 0.0 109.415 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.09 136.48 1.23 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.64 -121.35 0.46 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -125.48 5.12 8.13 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.03 -42.61 0.27 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.315 -1.109 . . . . 0.0 109.601 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.97 42.41 0.05 OUTLIER Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.475 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 1.7 t -97.71 96.91 8.57 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.311 -1.111 . . . . 0.0 109.295 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.1 mt -80.03 90.95 5.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.377 -0.827 . . . . 0.0 109.451 -179.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.84 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.61 142.58 6.67 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.338 -0.851 . . . . 0.0 109.781 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.522 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 33.5 m-85 -67.62 128.06 35.06 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.418 -0.801 . . . . 0.0 109.082 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.463 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.11 102.76 18.71 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.612 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.75 171.18 64.32 Favored 'Cis proline' 0 C--N 1.312 -1.359 0 C-N-CA 123.43 -1.487 . . . . 0.0 110.648 -0.248 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.448 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -106.17 14.64 43.96 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -169.1 110.54 0.49 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.393 -1.063 . . . . 0.0 109.051 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -132.22 170.19 15.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.34 -0.85 . . . . 0.0 109.67 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.3 m -122.69 130.95 53.54 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 109.443 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -132.96 -169.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.354 -0.841 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.49 178.93 6.86 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.283 -0.885 . . . . 0.0 109.455 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.0 t -71.98 109.42 5.79 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.349 -0.844 . . . . 0.0 109.385 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.43 -17.03 5.9 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -81.91 171.4 14.5 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -1.095 . . . . 0.0 109.479 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.86 133.93 49.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.268 -0.895 . . . . 0.0 109.642 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.532 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -95.9 150.72 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.379 -0.825 . . . . 0.0 109.035 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -134.34 146.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 109.949 -179.561 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.476 ' HB3' HD12 ' A' ' 5' ' ' LEU . 56.8 m-85 -133.72 80.21 1.86 Allowed 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.6 mttt -81.11 123.86 28.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.229 -0.919 . . . . 0.0 109.825 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -94.46 126.73 39.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.334 -0.854 . . . . 0.0 109.388 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -102.93 -63.7 1.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.847 . . . . 0.0 109.566 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -134.33 148.04 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.344 -0.848 . . . . 0.0 109.561 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 14.96 45.74 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 1.034 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 0.2 OUTLIER -62.86 166.15 8.38 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.44 -1.036 . . . . 0.0 109.542 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.541 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 35.6 Cg_endo -78.06 145.32 78.13 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.679 0.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.64 ' HB3' HD21 ' A' ' 5' ' ' LEU . 34.7 m-70 -115.58 32.7 5.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -58.23 119.38 6.78 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.269 -0.894 . . . . 0.0 109.361 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -93.32 157.23 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.358 -0.839 . . . . 0.0 110.026 -179.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 6.5 m -139.79 119.98 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.397 -0.814 . . . . 0.0 109.194 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -67.19 116.74 8.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.397 -0.814 . . . . 0.0 109.927 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.422 ' O ' HG13 ' A' ' 46' ' ' ILE . 1.3 t70 -81.41 149.62 28.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.29 -0.881 . . . . 0.0 109.523 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 1.284 ' CB ' ' HE2' ' B' ' 187' ' ' LYS . 1.0 OUTLIER -96.79 6.44 48.66 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.267 -0.896 . . . . 0.0 109.918 179.909 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.43 -19.7 57.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.183 -0.948 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -131.49 38.44 3.6 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.384 -0.823 . . . . 0.0 109.515 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.672 HD11 ' HG3' ' A' ' 43' ' ' GLU . 8.1 mt -98.96 143.97 27.35 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.254 -0.904 . . . . 0.0 109.25 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.622 ' HD2' HG22 ' A' ' 46' ' ' ILE . 33.9 Cg_endo -76.02 -63.99 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.786 2.324 . . . . 0.0 111.068 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.406 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.8 t -83.4 -176.45 6.32 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.177 -0.952 . . . . 0.0 109.686 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.535 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -78.37 -105.63 0.2 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.535 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.65 160.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.56 -0.964 . . . . 0.0 109.861 179.811 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -99.45 162.61 12.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.256 -0.903 . . . . 0.0 109.547 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.433 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -81.78 -17.23 48.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.33 -0.856 . . . . 0.0 109.73 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.62 -2.3 28.64 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.217 -0.927 . . . . 0.0 109.898 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -101.5 -25.57 13.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.235 -0.915 . . . . 0.0 109.649 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.3 pt -119.0 6.67 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.198 -0.939 . . . . 0.0 110.114 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 69.0 m -113.05 171.18 7.7 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.108 -0.995 . . . . 0.0 109.366 179.746 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.6 mtp -88.79 152.12 21.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.323 -0.86 . . . . 0.0 109.571 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.2 t -89.82 -154.67 0.33 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.43 -0.794 . . . . 0.0 109.498 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' B' ' 66' ' ' LYS . 3.2 pt-20 -101.83 -33.55 9.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.259 -0.9 . . . . 0.0 109.888 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.86 -29.69 63.4 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.874 . . . . 0.0 109.829 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -96.88 87.26 4.23 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.262 -0.899 . . . . 0.0 109.672 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.05 139.75 43.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.374 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.667 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.7 mp -89.75 84.52 6.29 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.558 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.4 OUTLIER -111.44 -4.47 14.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.272 -0.892 . . . . 0.0 109.824 -179.763 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -101.38 146.71 32.67 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 109.689 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -77.11 78.47 3.44 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.795 2.33 . . . . 0.0 110.225 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.94 -23.88 0.29 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.667 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -68.2 147.16 52.64 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.322 -1.105 . . . . 0.0 109.442 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.0 p -136.36 147.32 47.31 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.247 -0.908 . . . . 0.0 109.828 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.6 t80 -110.24 109.27 19.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.81 . . . . 0.0 109.019 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.23 133.86 44.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 -179.673 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.418 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.7 OUTLIER -123.05 116.58 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.384 -0.823 . . . . 0.0 109.242 179.807 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -87.14 102.48 14.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.287 -0.883 . . . . 0.0 109.355 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.76 142.95 30.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.343 -0.848 . . . . 0.0 109.584 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.7 p -124.46 -27.04 3.8 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.374 -0.829 . . . . 0.0 109.786 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.67 152.08 46.21 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.216 -0.927 . . . . 0.0 109.696 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -99.18 125.13 44.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.375 -0.828 . . . . 0.0 109.557 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.424 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.71 -165.88 37.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.2 m -118.28 120.05 36.5 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.317 -1.108 . . . . 0.0 109.524 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -97.08 178.15 5.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.421 -0.799 . . . . 0.0 109.085 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -147.54 88.36 1.7 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.114 -0.992 . . . . 0.0 109.891 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -93.65 161.22 14.43 Favored 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.4 ' HB2' HG11 ' A' ' 93' ' ' VAL . 44.7 p90 -155.15 152.96 30.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.038 -1.039 . . . . 0.0 110.339 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 51.6 t -64.31 114.08 4.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.612 -0.68 . . . . 0.0 109.233 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 1.261 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 5.6 t . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.407 -0.808 . . . . 0.0 110.107 -179.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.84 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.8 ptm . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.505 0.669 . . . . 0.0 109.26 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.4 HG11 ' HB2' ' A' ' 83' ' ' TYR . 35.1 m -143.88 153.22 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.46 176.45 19.87 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.04 138.11 22.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.316 -1.108 . . . . 0.0 109.74 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 45.7 t -93.25 108.67 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.361 -0.837 . . . . 0.0 109.473 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -92.35 67.3 4.83 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.263 -0.898 . . . . 0.0 109.162 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.7 p -78.7 139.71 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.378 -0.826 . . . . 0.0 109.607 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.563 179.937 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 1.261 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . 0.986 HD21 ' CB ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . 0.513 ' O ' ' CB ' ' A' ' 59' ' ' GLU . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 1.034 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.511 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . 1.284 ' HE2' ' CB ' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.141 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.76 108.29 4.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.9 t -103.55 121.12 54.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.469 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 20.1 mt -108.24 101.87 11.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.355 -0.841 . . . . 0.0 109.275 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.71 HD21 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.74 137.11 57.6 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.352 -0.843 . . . . 0.0 109.398 -179.956 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.533 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 83.0 135.37 2.42 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.07 -119.13 0.26 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.27 4.17 7.75 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -141.3 -41.28 0.38 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.311 -1.111 . . . . 0.0 109.592 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.808 ' HA3' HD12 ' B' ' 3' ' ' ILE . . . 171.03 43.66 0.03 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.533 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.3 t -97.4 99.39 10.82 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.344 -1.092 . . . . 0.0 109.273 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.6 mt -79.67 93.35 5.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.884 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -166.59 139.11 3.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 109.792 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.519 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 36.5 m-85 -65.9 127.05 30.5 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.42 -0.8 . . . . 0.0 108.98 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 1.6 mp -127.86 102.84 21.82 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 109.641 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -79.73 170.22 67.83 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 123.452 -1.478 . . . . 0.0 110.651 -0.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.438 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.47 13.28 47.4 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -167.56 107.62 0.58 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.415 -1.05 . . . . 0.0 108.991 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -129.37 169.13 15.28 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.355 -0.84 . . . . 0.0 109.661 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.8 m -121.77 129.19 52.49 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.417 -0.802 . . . . 0.0 109.434 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.36 -170.11 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.61 179.15 6.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.329 -0.857 . . . . 0.0 109.476 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -71.96 108.39 5.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.7 -17.23 5.53 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -81.97 172.17 13.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.318 -1.107 . . . . 0.0 109.516 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -128.52 134.9 48.79 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.314 -0.866 . . . . 0.0 109.662 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.54 149.3 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.473 -0.767 . . . . 0.0 109.047 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -133.29 145.54 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.913 . . . . 0.0 109.952 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.498 ' HB3' HD12 ' A' ' 5' ' ' LEU . 50.8 m-85 -132.96 80.29 1.88 Allowed 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.9 mttt -80.88 124.31 29.0 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.165 -0.959 . . . . 0.0 109.767 -179.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.6 p-10 -96.63 116.96 29.98 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.269 -0.894 . . . . 0.0 109.441 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -94.39 -69.21 0.76 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.536 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.11 151.17 49.51 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.358 -0.839 . . . . 0.0 109.473 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 94.1 10.16 58.79 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.798 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 2.1 p90 -57.94 166.18 2.13 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.34 -1.094 . . . . 0.0 109.421 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.581 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.2 Cg_endo -78.95 150.01 85.55 Favored 'Cis proline' 0 C--N 1.312 -1.355 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.536 -0.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.71 ' HB3' HD21 ' A' ' 5' ' ' LEU . 45.1 m-70 -121.72 45.24 2.36 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.339 -0.851 . . . . 0.0 109.25 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.9 p-10 -70.48 119.05 14.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.229 -0.919 . . . . 0.0 109.304 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -92.27 152.5 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.392 -0.818 . . . . 0.0 109.964 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.553 HG23 ' HB3' ' B' ' 63' ' ' ASN . 6.8 m -140.52 119.27 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 109.033 179.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -67.48 132.38 47.49 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.22 -0.925 . . . . 0.0 109.771 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -94.15 159.33 15.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.394 -0.816 . . . . 0.0 109.465 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.526 ' HA ' HD11 ' A' ' 46' ' ' ILE . 4.4 tp10 -99.82 24.81 7.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.312 -0.867 . . . . 0.0 109.573 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.02 -17.33 16.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.186 -0.946 . . . . 0.0 109.489 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -131.72 36.72 3.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.268 -0.895 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . 0.583 HG22 ' HD2' ' A' ' 47' ' ' PRO . 33.4 mt -100.43 141.93 23.64 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.333 -0.855 . . . . 0.0 108.988 179.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.583 ' HD2' HG22 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.55 -63.6 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.696 2.264 . . . . 0.0 111.151 -179.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . 0.412 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.7 t -85.48 -175.14 5.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.169 -0.957 . . . . 0.0 109.641 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.489 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.89 -108.18 0.14 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.489 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.44 155.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.494 -1.003 . . . . 0.0 109.796 179.895 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.98 162.21 14.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.297 -0.877 . . . . 0.0 109.583 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.48 -21.88 35.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.387 -0.82 . . . . 0.0 109.671 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -71.27 -12.53 61.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.273 -0.892 . . . . 0.0 109.927 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -86.68 -27.68 23.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.285 -0.884 . . . . 0.0 109.749 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.1 pt -116.72 6.32 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.235 -0.916 . . . . 0.0 110.045 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -110.77 174.55 5.81 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.174 -0.954 . . . . 0.0 109.348 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' MET . . . . . 0.469 ' H ' HG11 ' A' ' 40' ' ' VAL . 27.6 mtp -95.6 160.58 14.43 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.382 -0.824 . . . . 0.0 109.498 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -95.63 -170.86 2.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.358 -0.839 . . . . 0.0 109.563 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.487 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.5 OUTLIER -87.48 -26.19 23.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.301 -0.874 . . . . 0.0 109.865 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . 0.487 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.39 -35.42 35.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.284 -0.885 . . . . 0.0 109.643 -179.865 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.58 92.81 8.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.428 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . 0.741 HD13 HD23 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -114.82 141.36 48.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 109.462 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.673 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.3 mp -89.48 87.45 7.07 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.423 -0.798 . . . . 0.0 109.179 179.783 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.432 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.6 OUTLIER -108.52 -32.8 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.33 -0.856 . . . . 0.0 109.765 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.44 144.83 81.62 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.226 -0.921 . . . . 0.0 109.837 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.39 80.28 2.95 Favored 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.733 2.289 . . . . 0.0 110.25 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.51 -25.15 0.22 Allowed Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.673 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -67.36 148.72 51.26 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.364 -1.08 . . . . 0.0 109.448 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 32.0 p -136.36 144.21 44.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.915 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -107.73 109.17 20.69 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.35 -0.844 . . . . 0.0 108.998 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' LYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.49 134.44 43.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.343 -0.848 . . . . 0.0 109.743 -179.729 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.402 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.7 OUTLIER -123.25 114.73 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.405 -0.809 . . . . 0.0 109.242 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -85.46 102.35 13.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.301 -0.875 . . . . 0.0 109.301 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.54 142.99 30.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.4 p -124.6 -26.8 3.79 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.372 -0.83 . . . . 0.0 109.818 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.03 47.81 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.272 -0.893 . . . . 0.0 109.683 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -97.99 121.33 39.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.373 -0.829 . . . . 0.0 109.52 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.445 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.93 -171.91 42.49 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -112.93 115.01 27.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.311 -1.111 . . . . 0.0 109.487 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 46.3 m-85 -93.32 178.61 5.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.351 -0.843 . . . . 0.0 109.093 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.59 93.27 2.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.984 . . . . 0.0 109.912 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -97.12 155.62 16.74 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -145.0 153.18 41.22 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.041 -1.037 . . . . 0.0 110.272 -179.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.0 t -68.65 106.81 2.74 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.821 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.747 0 O-C-N 121.414 -0.804 . . . . 0.0 110.109 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' MET . . . . . 0.884 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.6 ptm . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.473 0.654 . . . . 0.0 109.305 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.6 m -145.57 138.4 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.295 -0.878 . . . . 0.0 109.485 -179.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -118.79 177.42 16.41 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -148.25 137.43 21.96 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -1.145 . . . . 0.0 109.675 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 30.8 t -91.91 108.13 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.293 -0.879 . . . . 0.0 109.503 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -92.99 66.76 4.21 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.302 -0.874 . . . . 0.0 109.256 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.402 HG11 ' H ' ' A' ' 78' ' ' GLY . 3.3 p -78.96 138.94 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.341 -0.849 . . . . 0.0 109.56 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.592 179.922 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 3' ' ' ILE . . . . . 0.808 HD12 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 61' ' ' LEU . . . . . 0.741 HD23 HD13 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 62' ' ' ALA . . . . . 0.821 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 63' ' ' ASN . . . . . 0.553 ' HB3' HG23 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 70' ' ' ASN . . . . . . . . . . . . . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 117' ' ' PRO . . . . . 0.798 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 156' ' ' ARG . . . . . 0.511 ' NH2' ' HB2' ' B' ' 168' ' ' ASN . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.503 2.187 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.83 108.21 5.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.276 -0.89 . . . . 0.0 109.469 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 t -103.82 125.91 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.405 -0.809 . . . . 0.0 109.47 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 18.5 mt -113.08 105.4 13.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 109.319 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.666 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.48 140.94 58.04 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.334 -0.854 . . . . 0.0 109.421 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.57 137.72 1.59 Allowed Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.53 -118.79 0.38 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -127.76 7.05 6.95 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -145.69 -41.83 0.22 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.287 -1.125 . . . . 0.0 109.57 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.3 45.59 0.04 OUTLIER Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.464 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -102.72 97.67 7.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.373 -1.075 . . . . 0.0 109.253 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.5 mt -77.72 94.19 4.41 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.378 -0.826 . . . . 0.0 109.415 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.84 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.65 139.31 4.49 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.324 -0.86 . . . . 0.0 109.7 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.474 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 37.2 m-85 -67.36 127.74 33.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.285 -0.884 . . . . 0.0 109.094 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.509 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.43 103.44 20.02 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.25 -0.906 . . . . 0.0 109.593 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.73 170.91 65.53 Favored 'Cis proline' 0 C--N 1.312 -1.373 0 C-N-CA 123.454 -1.478 . . . . 0.0 110.646 -0.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.434 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.28 12.39 48.09 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -167.11 111.14 0.72 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.371 -1.076 . . . . 0.0 109.125 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.0 p90 -132.2 169.68 16.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.358 -0.839 . . . . 0.0 109.709 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.89 130.24 53.2 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.384 -0.823 . . . . 0.0 109.45 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.48 -170.8 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.314 -0.867 . . . . 0.0 109.456 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.92 179.12 6.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.29 -0.881 . . . . 0.0 109.504 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.7 t -72.09 108.81 5.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.332 -0.855 . . . . 0.0 109.401 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.29 -17.02 5.65 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -82.09 172.55 13.08 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.366 -1.079 . . . . 0.0 109.493 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -129.06 134.96 48.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.633 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.536 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.7 149.52 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 t -133.44 145.72 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 109.939 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.479 ' HB3' HD12 ' A' ' 5' ' ' LEU . 51.3 m-85 -133.09 79.94 1.86 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.456 -0.777 . . . . 0.0 108.927 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 29.6 mttt -81.81 124.23 29.48 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.26 -0.9 . . . . 0.0 109.783 -179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 26.8 p-10 -95.14 130.23 41.93 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.311 -0.868 . . . . 0.0 109.425 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -104.51 -67.9 0.88 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -0.851 . . . . 0.0 109.593 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.86 152.42 48.53 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.329 -0.857 . . . . 0.0 109.568 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.28 21.45 35.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.511 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.8 p90 -64.34 163.03 28.1 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.354 -1.086 . . . . 0.0 109.585 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.511 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.3 Cg_endo -79.5 155.49 89.55 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.421 -1.491 . . . . 0.0 110.726 -0.038 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.666 ' HB3' HD21 ' A' ' 5' ' ' LEU . 27.3 m-70 -126.62 40.99 3.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.413 -0.805 . . . . 0.0 109.222 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.471 ' OD1' ' HD3' ' A' ' 86' ' ' PRO . 11.4 p-10 -68.2 128.3 36.05 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.249 -0.907 . . . . 0.0 109.369 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -100.23 153.17 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.33 -0.856 . . . . 0.0 109.841 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.479 HG11 ' H ' ' A' ' 57' ' ' MET . 9.7 m -140.7 123.0 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.418 -0.801 . . . . 0.0 109.217 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.52 133.42 45.8 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.291 -0.88 . . . . 0.0 109.571 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.421 ' HB2' ' HE1' ' A' ' 83' ' ' TYR . 0.7 OUTLIER -96.29 160.15 14.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.36 -0.838 . . . . 0.0 109.571 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.525 ' HA ' HD13 ' A' ' 46' ' ' ILE . 6.7 tp10 -100.39 44.84 1.0 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.37 -0.831 . . . . 0.0 109.429 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.29 -23.8 6.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.304 -0.872 . . . . 0.0 109.373 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -125.59 25.76 6.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 0.0 109.471 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.548 HG22 ' HD2' ' A' ' 47' ' ' PRO . 55.8 mt -90.09 141.15 27.64 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.314 -0.866 . . . . 0.0 108.988 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.548 ' HD2' HG22 ' A' ' 46' ' ' ILE . 33.7 Cg_endo -75.62 -62.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.68 2.253 . . . . 0.0 111.023 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.0 t -87.05 -178.94 6.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.151 -0.968 . . . . 0.0 109.549 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.522 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -75.25 -101.68 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.522 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.67 157.56 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.517 -0.99 . . . . 0.0 109.867 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.852 ' HA ' ' HZ2' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -88.83 154.84 19.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.267 -0.896 . . . . 0.0 109.632 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.46 ' H ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.77 -27.27 40.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.419 -0.8 . . . . 0.0 109.532 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.96 -17.02 62.68 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.378 -0.827 . . . . 0.0 109.854 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.0 tptt -77.12 -31.24 55.64 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.299 -0.875 . . . . 0.0 109.699 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -113.02 4.97 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.196 -0.94 . . . . 0.0 109.935 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 66.3 m -108.52 177.81 4.68 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.479 ' H ' HG11 ' A' ' 40' ' ' VAL . 28.3 mtp -98.78 164.07 12.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -98.55 -168.47 1.65 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.395 -0.816 . . . . 0.0 109.563 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.514 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.4 OUTLIER -88.64 -27.58 21.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.383 -0.823 . . . . 0.0 109.816 -179.817 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.472 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.6 OUTLIER -81.12 -33.36 33.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.233 -0.917 . . . . 0.0 109.703 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -91.38 90.63 7.78 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.286 -0.884 . . . . 0.0 109.443 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.543 HD12 HD23 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -115.98 145.83 42.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.355 -0.841 . . . . 0.0 109.444 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.695 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.1 mp -92.93 80.59 4.61 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.831 . . . . 0.0 109.149 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.489 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.8 OUTLIER -102.09 -17.67 15.93 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.344 -0.847 . . . . 0.0 109.812 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.34 145.46 30.05 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.256 -0.903 . . . . 0.0 109.781 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.33 83.46 2.14 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.736 2.291 . . . . 0.0 110.274 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.5 -26.18 0.3 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.695 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -68.47 148.82 50.06 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.348 -1.09 . . . . 0.0 109.42 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -136.15 146.25 46.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.876 . . . . 0.0 109.85 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -109.18 109.08 19.95 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.35 -0.844 . . . . 0.0 109.011 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.19 133.87 43.95 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.662 -179.72 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.419 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.8 OUTLIER -122.76 115.74 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -0.785 . . . . 0.0 109.243 179.871 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.69 102.95 14.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.31 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -100.0 143.07 30.63 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.69 -26.36 3.83 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.347 -0.846 . . . . 0.0 109.744 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.19 152.15 45.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.213 -0.929 . . . . 0.0 109.666 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.7 mttt -99.11 121.61 41.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.369 -0.832 . . . . 0.0 109.556 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.496 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.61 -171.18 42.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -113.26 114.73 27.11 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.328 -1.101 . . . . 0.0 109.512 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -93.1 177.79 5.95 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.376 -0.828 . . . . 0.0 109.176 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.52 97.56 2.65 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.155 -0.966 . . . . 0.0 109.887 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -100.66 159.16 15.4 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.421 ' HE1' ' HB2' ' A' ' 42' ' ' ASP . 40.0 p90 -149.13 155.65 41.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 110.16 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.9 t -67.82 111.77 4.5 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.654 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.4 OUTLIER -53.19 -52.41 66.12 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.402 -0.811 . . . . 0.0 110.215 -179.42 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.755 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 33.5 Cg_endo -74.98 21.93 0.42 Allowed 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.288 1.992 . . . . 0.0 111.012 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.755 ' CD2' ' O ' ' A' ' 86' ' ' PRO . 8.8 m170 -173.33 49.18 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.382 -0.824 . . . . 0.0 109.413 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.511 ' H ' ' HG3' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -78.08 -41.54 35.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.085 -1.009 . . . . 0.0 109.137 179.869 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.84 -7.31 84.21 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -67.53 -60.79 2.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.331 -1.099 . . . . 0.0 109.379 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 145.44 1.37 0.76 Allowed Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.872 -1.156 . . . . 0.0 110.373 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.84 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.8 ptm -98.23 103.82 15.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.13 -1.217 . . . . 0.0 109.377 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.7 m -145.91 153.12 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.269 -0.894 . . . . 0.0 109.425 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.19 178.79 18.11 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -149.39 139.85 22.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.276 -1.131 . . . . 0.0 109.701 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.3 t -94.63 109.66 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.325 -0.86 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -94.05 68.3 3.74 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.257 -0.902 . . . . 0.0 109.254 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.1 p -80.23 139.77 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.34 -0.85 . . . . 0.0 109.623 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.58 179.948 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . 0.543 HD23 HD12 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.654 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.514 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.879 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.664 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.852 ' HZ2' ' HA ' ' A' ' 51' ' ' ASP . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 251' ' ' HEC . . . . . 0.879 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.502 2.14 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.28 107.79 5.08 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.305 -0.872 . . . . 0.0 109.506 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 15.2 t -102.65 125.25 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 0.0 109.398 -179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 22.3 mt -111.36 103.27 11.63 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.399 -0.813 . . . . 0.0 109.347 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.609 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -65.6 139.09 58.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.375 -0.828 . . . . 0.0 109.415 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.447 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.71 136.79 1.82 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.01 -118.46 0.33 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -128.74 5.12 6.56 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -143.21 -41.38 0.3 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.366 -1.079 . . . . 0.0 109.62 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.27 46.13 0.04 OUTLIER Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.447 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.5 t -103.83 93.5 4.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.365 -1.079 . . . . 0.0 109.374 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 mt -75.67 91.79 2.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 109.414 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.856 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.07 141.71 8.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.331 -0.856 . . . . 0.0 109.637 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.469 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 36.8 m-85 -68.84 128.45 36.71 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.401 -0.812 . . . . 0.0 109.217 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.95 103.02 17.28 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.889 . . . . 0.0 109.637 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.71 171.2 64.36 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.482 . . . . 0.0 110.687 -0.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -104.97 10.32 47.97 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -164.88 113.26 1.05 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.351 -1.088 . . . . 0.0 109.135 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -133.87 170.58 15.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 109.641 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.4 m -122.58 131.34 53.78 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.352 -0.842 . . . . 0.0 109.474 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -133.25 -171.93 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.384 -0.823 . . . . 0.0 109.468 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.02 178.29 7.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.0 t -72.07 111.93 7.72 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.275 -0.89 . . . . 0.0 109.405 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.32 -17.52 7.0 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -81.42 167.4 19.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.317 -1.108 . . . . 0.0 109.496 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -124.09 131.17 53.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.594 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.489 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -95.66 151.08 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 108.986 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 t -133.42 146.74 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.176 -0.953 . . . . 0.0 110.007 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.467 ' HB3' HD12 ' A' ' 5' ' ' LEU . 54.7 m-85 -132.65 77.35 1.74 Allowed 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 29.4 mttt -78.92 134.01 36.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.912 . . . . 0.0 109.786 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.428 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.4 p-10 -106.04 137.58 43.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.278 -0.889 . . . . 0.0 109.415 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -112.64 -70.46 0.81 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.352 -0.842 . . . . 0.0 109.672 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -121.09 149.97 41.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 109.578 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.91 23.22 36.11 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.49 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 4.0 p90 -67.82 162.45 58.28 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.441 -1.035 . . . . 0.0 109.525 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.52 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 35.9 Cg_endo -79.26 158.19 90.57 Favored 'Cis proline' 0 C--N 1.313 -1.31 0 C-N-CA 123.395 -1.502 . . . . 0.0 110.806 0.052 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.609 ' HB3' HD21 ' A' ' 5' ' ' LEU . 25.1 m-70 -126.17 39.77 3.87 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.43 -0.794 . . . . 0.0 109.269 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.461 ' OD1' ' HG3' ' A' ' 86' ' ' PRO . 10.8 p-10 -66.06 130.47 43.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.159 -0.963 . . . . 0.0 109.273 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -105.17 157.69 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 0.0 109.923 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.431 HG11 ' H ' ' A' ' 57' ' ' MET . 4.8 m -141.65 130.87 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.469 -0.77 . . . . 0.0 109.307 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -78.0 136.24 37.92 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.475 ' O ' HG13 ' A' ' 46' ' ' ILE . 0.6 OUTLIER -104.56 157.93 16.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.41 -0.806 . . . . 0.0 109.322 179.734 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.507 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 10.5 tp10 -94.47 17.38 13.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.333 -0.854 . . . . 0.0 109.671 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.6 -19.78 32.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 109.455 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -136.89 36.4 2.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.35 -0.844 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.602 HG22 ' HD2' ' A' ' 47' ' ' PRO . 22.1 mt -99.32 142.47 24.67 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.086 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.602 ' HD2' HG22 ' A' ' 46' ' ' ILE . 34.3 Cg_endo -76.03 -66.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 122.665 2.244 . . . . 0.0 111.125 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.9 t -84.39 -178.77 7.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.213 -0.929 . . . . 0.0 109.679 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.457 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.36 -100.76 0.14 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.457 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.61 152.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.511 -0.993 . . . . 0.0 109.79 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.788 ' HA ' ' HZ2' ' B' ' 187' ' ' LYS . 0.6 OUTLIER -80.68 152.93 28.18 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.211 -0.931 . . . . 0.0 109.597 -179.869 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.503 ' N ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.93 -25.31 40.55 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.349 -0.844 . . . . 0.0 109.593 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -74.89 -16.93 60.65 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.32 -0.862 . . . . 0.0 109.794 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.4 tptt -76.29 -32.48 58.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.334 -0.854 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.1 pt -107.54 -3.32 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.28 -0.887 . . . . 0.0 109.89 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 58.8 m -99.79 177.3 5.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.227 -0.92 . . . . 0.0 109.3 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.431 ' H ' HG11 ' A' ' 40' ' ' VAL . 8.4 mtp -92.48 155.94 17.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.269 -0.894 . . . . 0.0 109.595 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.21 -163.19 0.8 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.352 -0.842 . . . . 0.0 109.512 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.504 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -96.4 -31.35 12.89 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.348 -0.845 . . . . 0.0 110.003 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -80.62 -30.78 36.73 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.305 -0.872 . . . . 0.0 109.797 -179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -89.08 100.69 13.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.304 -0.873 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.579 HD12 HD23 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -124.5 145.21 49.68 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.473 -0.767 . . . . 0.0 109.488 -179.935 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.672 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 4.2 mp -91.03 68.57 6.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.392 -0.817 . . . . 0.0 109.16 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -24.69 20.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.351 -0.843 . . . . 0.0 109.949 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.87 146.17 38.24 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.218 -0.926 . . . . 0.0 109.738 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.34 79.25 3.22 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.755 2.303 . . . . 0.0 110.252 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.09 -24.92 0.19 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.672 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.1 tp10 -68.31 148.6 50.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.444 -1.033 . . . . 0.0 109.347 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.7 p -136.09 145.81 46.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 109.867 -179.567 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 23.3 t80 -107.06 107.78 18.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.35 -0.844 . . . . 0.0 109.144 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.489 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.85 131.25 45.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 109.566 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.98 114.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.363 -0.836 . . . . 0.0 109.3 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.7 m -86.66 101.65 13.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.342 -0.849 . . . . 0.0 109.254 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -98.63 142.15 30.56 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.371 -0.83 . . . . 0.0 109.57 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.5 p -123.3 -24.68 4.6 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.699 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.36 153.99 42.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.288 -0.883 . . . . 0.0 109.622 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.3 mttt -101.16 125.38 47.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.529 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.99 -166.88 37.77 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -117.44 112.65 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.298 -1.119 . . . . 0.0 109.527 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -91.21 176.83 6.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.338 -0.851 . . . . 0.0 109.178 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.4 99.31 3.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.199 -0.938 . . . . 0.0 109.866 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -103.48 164.04 11.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.361 -0.837 . . . . 0.0 108.868 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -153.02 155.78 37.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.168 -0.957 . . . . 0.0 109.812 -179.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.68 108.1 2.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.424 -0.797 . . . . 0.0 109.119 179.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.768 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.6 OUTLIER -51.44 -53.31 51.06 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.48 -0.763 . . . . 0.0 109.924 -179.89 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.728 ' HA ' ' CGD' ' B' ' 251' ' ' HEC . 32.4 Cg_endo -74.04 34.68 0.37 Allowed 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.209 1.939 . . . . 0.0 110.733 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.708 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 7.9 m170 174.12 34.61 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.59 -0.694 . . . . 0.0 109.187 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.75 -33.21 73.51 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.254 -0.904 . . . . 0.0 109.571 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.43 ' HA3' ' CD2' ' B' ' 160' ' ' TYR . . . -92.22 -10.08 61.31 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -67.65 -72.57 0.17 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.391 -1.064 . . . . 0.0 109.406 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.24 29.53 0.03 OUTLIER Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.838 -1.173 . . . . 0.0 110.426 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.856 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm -126.39 104.69 8.31 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.157 -1.202 . . . . 0.0 109.07 179.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.4 m -143.06 165.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.271 -0.893 . . . . 0.0 109.615 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -144.14 177.76 22.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -150.14 139.03 20.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.261 -1.141 . . . . 0.0 109.839 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.8 t -94.64 115.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.401 -0.812 . . . . 0.0 109.507 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -98.21 67.2 1.85 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.253 -0.905 . . . . 0.0 109.122 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.79 141.85 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.39 -0.819 . . . . 0.0 109.643 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.581 179.939 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . 0.579 HD23 HD12 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.768 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . 0.443 ' HB3' ' HG ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.504 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.879 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.664 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.788 ' HZ2' ' HA ' ' A' ' 51' ' ' ASP . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 251' ' ' HEC . . . . . 0.879 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 N--CA 1.502 2.143 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.3 109.86 4.94 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.303 -0.873 . . . . 0.0 109.417 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.5 t -104.52 120.53 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.328 -0.858 . . . . 0.0 109.559 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 24.6 mt -106.73 101.36 10.81 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -0.838 . . . . 0.0 109.287 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.656 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.2 mp -64.42 141.21 58.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 109.432 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.411 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.18 138.36 1.56 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.74 -115.28 0.33 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -132.12 6.37 5.38 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.6 -41.34 0.22 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.346 -1.091 . . . . 0.0 109.596 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.22 45.45 0.04 OUTLIER Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.411 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.3 t -105.65 98.0 7.76 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.308 -1.113 . . . . 0.0 109.304 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.728 HD12 HG23 ' B' ' 3' ' ' ILE . 9.0 mt -78.79 101.12 7.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.324 -0.86 . . . . 0.0 109.487 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.691 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -169.58 136.24 1.63 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 109.661 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.459 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 39.6 m-85 -65.9 126.5 28.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 109.124 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.496 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -126.83 103.14 24.36 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.262 -0.898 . . . . 0.0 109.573 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.496 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.72 169.33 70.86 Favored 'Cis proline' 0 C--N 1.312 -1.356 0 C-N-CA 123.459 -1.475 . . . . 0.0 110.67 -0.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.442 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.2 12.28 51.89 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -166.98 105.63 0.58 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.393 -1.063 . . . . 0.0 109.009 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -126.77 167.67 15.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.707 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.5 128.39 53.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.345 -0.847 . . . . 0.0 109.393 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -130.43 -171.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.35 -0.844 . . . . 0.0 109.519 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.15 179.38 6.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.312 -0.868 . . . . 0.0 109.451 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.19 108.78 5.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.297 -0.877 . . . . 0.0 109.385 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.47 -17.26 5.58 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -81.84 171.41 14.53 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.31 -1.112 . . . . 0.0 109.434 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -128.27 133.39 48.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.288 -0.883 . . . . 0.0 109.702 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -94.45 146.56 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.442 -0.786 . . . . 0.0 109.071 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -129.57 145.48 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.19 -0.944 . . . . 0.0 109.818 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.526 ' HB3' HD12 ' A' ' 5' ' ' LEU . 46.5 m-85 -133.01 82.04 1.97 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.469 -0.769 . . . . 0.0 109.03 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.7 mttt -83.34 126.57 32.84 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.201 -0.937 . . . . 0.0 109.752 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.461 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.9 p-10 -98.85 127.8 44.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.259 -0.901 . . . . 0.0 109.481 179.752 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -104.65 -65.74 1.01 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 109.54 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -129.71 144.1 51.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.338 -0.851 . . . . 0.0 109.517 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.43 22.53 16.46 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.545 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 3.3 p90 -66.78 163.98 37.94 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.362 -1.081 . . . . 0.0 109.486 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.619 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.4 Cg_endo -80.4 152.14 83.09 Favored 'Cis proline' 0 C--N 1.312 -1.36 0 C-N-CA 123.389 -1.504 . . . . 0.0 110.858 -0.062 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.656 ' HB3' HD21 ' A' ' 5' ' ' LEU . 27.4 m-70 -118.26 40.35 3.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.347 -0.846 . . . . 0.0 109.222 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.2 p-10 -65.64 120.29 12.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.311 -0.868 . . . . 0.0 109.34 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.7 m -96.35 148.8 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.335 -0.853 . . . . 0.0 109.9 -179.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.482 HG23 ' HB3' ' B' ' 63' ' ' ASN . 7.7 m -134.82 119.79 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.43 -0.794 . . . . 0.0 109.048 179.769 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 15.0 m-85 -67.78 131.92 46.46 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.287 -0.883 . . . . 0.0 109.968 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.448 ' HB2' ' HE2' ' A' ' 83' ' ' TYR . 1.4 t0 -93.79 158.08 15.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.384 -0.822 . . . . 0.0 109.43 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.712 ' OE1' ' HE2' ' B' ' 187' ' ' LYS . 2.8 tp10 -100.55 17.82 20.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.844 . . . . 0.0 109.631 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -92.3 -18.04 23.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.148 -0.97 . . . . 0.0 109.483 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -130.64 26.21 5.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.226 -0.922 . . . . 0.0 109.629 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.618 HG22 ' HD2' ' A' ' 47' ' ' PRO . 19.0 mt -91.06 142.65 27.54 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.258 -0.901 . . . . 0.0 109.182 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.618 ' HD2' HG22 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -75.96 -65.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.704 2.27 . . . . 0.0 111.171 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.442 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.7 t -81.84 -177.61 6.64 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.189 -0.944 . . . . 0.0 109.692 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.491 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.9 -107.61 0.14 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.491 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.5 156.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.969 . . . . 0.0 109.856 179.926 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.72 160.8 14.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.419 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -80.55 -24.13 39.46 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.307 -0.871 . . . . 0.0 109.613 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -66.27 -19.16 65.74 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.227 -0.921 . . . . 0.0 109.951 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -80.57 -30.88 36.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.236 -0.915 . . . . 0.0 109.682 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.1 pt -117.17 23.26 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 109.84 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.419 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 45.0 m -127.72 171.28 11.85 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.478 ' H ' HG11 ' A' ' 40' ' ' VAL . 27.0 mtp -96.78 162.86 13.24 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.356 -0.84 . . . . 0.0 109.638 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.1 t -102.0 -171.2 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.349 -0.844 . . . . 0.0 109.746 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -84.64 -24.76 28.92 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.373 -0.829 . . . . 0.0 109.817 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -82.2 -32.42 29.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.254 -0.904 . . . . 0.0 109.705 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -95.23 90.02 5.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.83 146.29 42.11 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.42 -0.8 . . . . 0.0 109.388 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.652 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.6 mp -93.28 76.01 4.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.387 -0.821 . . . . 0.0 109.357 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.513 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.7 OUTLIER -98.04 -0.82 43.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.339 -0.851 . . . . 0.0 109.944 -179.721 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -107.19 143.85 27.97 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.174 -0.954 . . . . 0.0 109.711 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.42 84.7 1.91 Allowed 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.704 2.27 . . . . 0.0 110.296 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.22 -25.43 0.47 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.652 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -69.2 149.72 48.27 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.339 -1.095 . . . . 0.0 109.428 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 37.1 p -136.55 145.44 45.01 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.266 -0.896 . . . . 0.0 109.797 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -108.68 109.67 20.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.352 -0.842 . . . . 0.0 109.034 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.95 134.25 44.22 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.258 -0.901 . . . . 0.0 109.762 -179.722 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.427 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.8 OUTLIER -123.14 115.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.374 -0.829 . . . . 0.0 109.211 179.851 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.49 104.18 15.71 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.281 -0.887 . . . . 0.0 109.343 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -101.4 142.75 32.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.384 -0.822 . . . . 0.0 109.547 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.8 p -124.66 -25.99 3.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.436 -0.79 . . . . 0.0 109.737 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 152.7 45.1 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.247 -0.908 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -99.61 124.39 44.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 109.514 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.465 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 164.13 -168.55 38.63 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.3 m -115.3 118.72 34.07 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.313 -1.11 . . . . 0.0 109.528 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -96.63 179.13 5.1 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.349 -0.845 . . . . 0.0 109.149 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.79 96.99 2.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.193 -0.942 . . . . 0.0 109.835 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -100.43 153.52 19.28 Favored 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.576 ' CD1' ' HB3' ' A' ' 88' ' ' GLN . 35.5 p90 -143.46 155.97 44.51 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.081 -1.012 . . . . 0.0 110.34 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.428 ' HB3' ' O ' ' A' ' 87' ' ' HIS . 8.6 t -68.55 114.02 6.58 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.459 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.591 ' N ' ' HD2' ' A' ' 86' ' ' PRO . 0.3 OUTLIER -51.28 -50.53 75.42 Favored Pre-proline 0 N--CA 1.495 1.809 0 O-C-N 121.252 -0.905 . . . . 0.0 109.992 -179.481 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.691 ' O ' ' HE2' ' B' ' 1' ' ' TYR . 33.0 Cg_endo -75.16 -19.4 17.54 Favored 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.23 1.953 . . . . 0.0 110.937 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.747 ' NE2' ' CD2' ' B' ' 1' ' ' TYR . 43.7 m170 -137.22 65.37 1.5 Allowed 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.051 -1.03 . . . . 0.0 110.159 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 1.168 ' OE1' ' OH ' ' B' ' 160' ' ' TYR . 0.0 OUTLIER -105.71 -22.06 13.04 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.059 -1.026 . . . . 0.0 109.219 179.502 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.69 -4.23 62.12 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.904 ' HB3' ' HZ ' ' B' ' 4' ' ' PHE . . . -84.47 -55.98 3.86 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.406 -1.055 . . . . 0.0 109.4 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.3 -15.08 0.48 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.758 ' CG ' ' O ' ' A' ' 92' ' ' MET . 0.5 OUTLIER -77.18 94.98 4.18 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.169 -1.195 . . . . 0.0 109.515 -179.781 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 17.4 m -146.63 148.61 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.381 -0.825 . . . . 0.0 109.211 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.32 179.88 16.69 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.3 ptmt -149.44 139.56 22.14 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.444 -1.033 . . . . 0.0 109.6 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.1 t -93.44 109.33 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.374 -0.829 . . . . 0.0 109.536 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -93.88 68.1 3.82 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.275 -0.891 . . . . 0.0 109.169 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.3 p -79.77 141.23 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.309 -0.869 . . . . 0.0 109.535 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.636 -179.998 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.747 ' CD2' ' NE2' ' A' ' 87' ' ' HIS . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . 0.728 HG23 HD12 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.904 ' HZ ' ' HB3' ' A' ' 90' ' ' ALA . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.499 ' HB1' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . 0.482 ' HB3' HG23 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.879 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.664 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 1.168 ' OH ' ' OE1' ' A' ' 88' ' ' GLN . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.712 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 251' ' ' HEC . . . . . 0.879 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.43 108.32 4.8 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 0.0 109.427 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 t -103.73 125.0 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.869 . . . . 0.0 109.497 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 19.8 mt -111.98 104.06 12.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.357 -0.839 . . . . 0.0 109.299 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.686 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.0 OUTLIER -65.62 139.42 58.42 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.834 . . . . 0.0 109.445 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.484 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.57 136.47 1.72 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.01 -117.07 0.23 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -129.86 7.39 6.13 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.38 -41.11 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.332 -1.099 . . . . 0.0 109.59 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.89 47.64 0.04 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.484 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -104.92 97.93 7.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.347 -1.09 . . . . 0.0 109.373 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.7 mt -77.42 94.21 4.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.34 -0.85 . . . . 0.0 109.403 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.848 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.86 139.4 4.35 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.366 -0.834 . . . . 0.0 109.744 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.481 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 37.2 m-85 -67.51 128.06 35.02 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.406 -0.809 . . . . 0.0 109.072 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.463 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.66 103.17 19.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.234 -0.916 . . . . 0.0 109.572 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.3 Cg_endo -79.74 170.79 65.88 Favored 'Cis proline' 0 C--N 1.313 -1.333 0 C-N-CA 123.41 -1.496 . . . . 0.0 110.646 -0.269 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.427 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.33 12.49 47.92 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -166.9 110.08 0.71 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.338 -1.095 . . . . 0.0 109.086 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -131.3 169.45 15.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.678 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.5 m -121.91 130.35 53.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.345 -0.847 . . . . 0.0 109.498 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.49 -170.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.398 -0.814 . . . . 0.0 109.453 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.08 179.15 6.67 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.8 t -72.12 109.14 5.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.289 -0.882 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.72 -17.04 5.81 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.1 171.22 14.59 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.339 -1.095 . . . . 0.0 109.467 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.69 134.7 49.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.272 -0.892 . . . . 0.0 109.646 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.82 149.91 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.416 -0.803 . . . . 0.0 109.058 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.34 145.95 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.209 -0.932 . . . . 0.0 109.949 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.476 ' HB3' HD12 ' A' ' 5' ' ' LEU . 52.0 m-85 -133.41 79.99 1.86 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 108.95 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -81.36 125.74 30.75 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.242 -0.911 . . . . 0.0 109.758 -179.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 26.6 p-10 -97.11 125.99 41.97 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.304 -0.873 . . . . 0.0 109.52 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -101.21 -65.46 0.97 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.33 -0.857 . . . . 0.0 109.544 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.17 148.28 52.7 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.54 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.04 21.1 26.3 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.508 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.9 p90 -64.86 163.23 30.54 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.324 -1.104 . . . . 0.0 109.676 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.548 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -79.75 153.65 87.17 Favored 'Cis proline' 0 C--N 1.312 -1.363 0 C-N-CA 123.367 -1.514 . . . . 0.0 110.68 -0.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.686 ' HB3' HD21 ' A' ' 5' ' ' LEU . 34.4 m-70 -123.9 39.0 4.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.405 -0.81 . . . . 0.0 109.269 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -66.0 126.0 27.2 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.272 -0.892 . . . . 0.0 109.367 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -97.89 149.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.884 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.401 HG11 ' H ' ' A' ' 57' ' ' MET . 6.4 m -136.61 119.88 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.504 -0.747 . . . . 0.0 108.999 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -68.62 133.17 48.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.232 -0.918 . . . . 0.0 109.692 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.21 159.99 14.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.37 -0.831 . . . . 0.0 109.371 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.56 ' HA ' HD11 ' A' ' 46' ' ' ILE . 4.9 tp10 -100.78 31.94 3.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.4 -0.812 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.15 -18.66 13.95 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -130.67 24.93 5.07 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.345 -0.847 . . . . 0.0 109.56 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.582 HG22 ' HD2' ' A' ' 47' ' ' PRO . 35.8 mt -89.36 141.82 29.26 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.324 -0.86 . . . . 0.0 109.119 179.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.582 ' HD2' HG22 ' A' ' 46' ' ' ILE . 33.8 Cg_endo -75.69 -63.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.733 2.289 . . . . 0.0 111.103 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.412 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.9 t -84.81 -177.95 6.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.177 -0.952 . . . . 0.0 109.588 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.504 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.41 -105.47 0.13 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.504 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.24 156.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.53 -0.982 . . . . 0.0 109.835 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.76 158.2 16.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.307 -0.871 . . . . 0.0 109.581 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.46 -24.25 39.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.334 -0.854 . . . . 0.0 109.558 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.31 -15.94 62.94 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.38 -0.825 . . . . 0.0 109.853 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.2 tptt -81.3 -31.17 33.69 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.283 -0.886 . . . . 0.0 109.697 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.5 pt -113.23 7.55 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 67.5 m -111.74 173.92 6.12 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.194 -0.942 . . . . 0.0 109.419 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.401 ' H ' HG11 ' A' ' 40' ' ' VAL . 19.8 mtp -93.63 161.29 14.41 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 109.624 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.8 -167.25 1.56 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.341 -0.849 . . . . 0.0 109.681 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.406 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.8 OUTLIER -90.18 -28.66 18.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.339 -0.851 . . . . 0.0 109.976 -179.666 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.406 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -80.28 -30.38 38.33 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.253 -0.905 . . . . 0.0 109.859 -179.734 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -95.0 91.5 6.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.213 -0.93 . . . . 0.0 109.575 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.6 142.98 46.0 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.406 -0.809 . . . . 0.0 109.296 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.709 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.8 mp -89.14 80.57 6.92 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.3 -0.875 . . . . 0.0 109.133 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.45 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 2.0 t30 -100.4 -22.9 14.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.91 145.46 36.63 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 109.905 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.59 81.6 2.62 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.801 2.334 . . . . 0.0 110.275 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 -25.74 0.24 Allowed Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.709 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.59 149.18 50.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.331 -1.1 . . . . 0.0 109.441 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -135.79 145.98 47.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 109.878 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.7 t80 -109.09 108.94 19.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.343 -0.848 . . . . 0.0 109.045 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.528 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.0 133.83 43.81 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.314 -0.866 . . . . 0.0 109.703 -179.697 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.411 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.7 OUTLIER -122.76 115.22 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.42 -0.8 . . . . 0.0 109.239 179.911 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.24 102.04 13.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.296 -0.878 . . . . 0.0 109.279 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.1 142.98 29.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.347 -0.845 . . . . 0.0 109.559 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.56 -26.31 3.88 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.335 -0.853 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 151.8 46.47 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.328 -0.858 . . . . 0.0 109.615 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.3 mttt -98.81 122.55 42.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.376 -0.828 . . . . 0.0 109.594 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.491 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.64 -171.42 41.55 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -112.97 114.4 26.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.319 -1.106 . . . . 0.0 109.494 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -92.73 176.89 6.27 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.303 -0.873 . . . . 0.0 109.123 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.43 93.9 2.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.117 -0.99 . . . . 0.0 109.86 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -97.36 155.94 16.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.331 -0.856 . . . . 0.0 108.806 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 41.4 p90 -145.84 155.32 42.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.041 -1.037 . . . . 0.0 110.207 -179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.404 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 36.7 t -67.69 107.2 2.47 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.587 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -49.48 -52.42 49.99 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.395 -0.816 . . . . 0.0 109.975 -179.674 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.749 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 34.6 Cg_endo -76.25 31.67 0.4 Allowed 'Trans proline' 0 C--N 1.311 -1.413 0 C-N-CA 122.298 1.999 . . . . 0.0 110.761 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.749 ' CD2' ' O ' ' A' ' 86' ' ' PRO . 8.9 m170 175.77 49.79 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.433 -0.792 . . . . 0.0 109.316 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.442 ' H ' ' HG3' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -81.35 -41.53 21.87 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.019 -1.05 . . . . 0.0 109.281 179.967 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.432 ' O ' ' OD1' ' B' ' 162' ' ' ASP . . . -81.88 -10.53 83.95 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.24 -64.13 0.92 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.277 -1.131 . . . . 0.0 109.425 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 149.53 -1.0 0.49 Allowed Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.915 -1.136 . . . . 0.0 110.337 179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.848 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.4 ptm -94.42 103.79 15.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.087 -1.243 . . . . 0.0 109.481 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 28.9 m -146.72 150.08 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.0 178.17 17.93 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.7 ptmt -149.03 138.93 22.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.35 -1.088 . . . . 0.0 109.696 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 33.0 t -93.98 110.12 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.343 -0.848 . . . . 0.0 109.533 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.18 67.53 3.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.303 -0.873 . . . . 0.0 109.297 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.0 p -79.46 140.0 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.4 -0.812 . . . . 0.0 109.55 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.549 179.994 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.587 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.879 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.664 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 89' ' ' GLY . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.502 ' HD3' ' HG2' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 251' ' ' HEC . . . . . 0.879 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.2 p . . . . . 0 N--CA 1.502 2.162 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.85 106.64 4.87 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.895 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.9 t -102.33 126.35 56.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 17.8 mt -114.0 106.29 14.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.382 -0.823 . . . . 0.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.656 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.65 136.85 56.18 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.39 -0.819 . . . . 0.0 109.419 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.492 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 81.2 135.44 1.75 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.88 -119.42 0.26 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.88 -0.69 9.03 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -134.82 -41.11 0.76 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.364 -1.08 . . . . 0.0 109.549 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.925 ' O ' ' NE2' ' B' ' 7' ' ' GLN . . . 169.57 42.93 0.03 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.492 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.2 t -94.6 93.47 7.6 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.274 -1.133 . . . . 0.0 109.324 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -73.75 92.26 1.99 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.286 -0.884 . . . . 0.0 109.491 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.819 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.43 141.96 3.77 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.334 -0.854 . . . . 0.0 109.6 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 43.0 m-85 -68.12 127.87 34.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.378 -0.826 . . . . 0.0 109.197 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.406 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.4 mp -129.35 104.18 17.9 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 109.591 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.406 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.55 170.43 67.65 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.389 -1.505 . . . . 0.0 110.66 -0.272 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.401 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.65 10.47 49.34 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -165.05 111.65 0.97 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.316 -1.108 . . . . 0.0 109.131 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -132.29 169.38 16.55 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.388 -0.82 . . . . 0.0 109.59 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.07 130.16 53.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.344 -0.848 . . . . 0.0 109.423 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.6 m -132.92 -171.58 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.369 -0.832 . . . . 0.0 109.487 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.99 178.52 7.06 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.4 t -71.9 109.94 6.08 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.296 -0.878 . . . . 0.0 109.326 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.54 -17.29 5.85 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.04 173.4 12.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.39 -1.065 . . . . 0.0 109.453 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -129.73 134.67 47.76 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.284 -0.885 . . . . 0.0 109.675 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.539 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.46 149.39 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.407 -0.808 . . . . 0.0 109.046 179.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 t -133.25 145.6 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.179 -0.951 . . . . 0.0 109.992 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.515 ' HB3' HD12 ' A' ' 5' ' ' LEU . 54.0 m-85 -132.89 77.89 1.76 Allowed 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 mttt -79.38 124.66 28.64 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.191 -0.943 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.42 ' HA ' ' HB2' ' A' ' 5' ' ' LEU . 24.0 p-10 -96.75 120.82 37.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.319 -0.863 . . . . 0.0 109.451 179.69 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -93.99 -65.56 0.98 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 109.677 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.14 150.46 52.14 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.351 -0.843 . . . . 0.0 109.643 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 17.08 37.78 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.521 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 5.1 p90 -63.27 162.93 20.74 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.334 -1.098 . . . . 0.0 109.601 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.579 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.2 Cg_endo -79.11 150.9 86.53 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.483 . . . . 0.0 110.848 0.123 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.656 ' HB3' HD21 ' A' ' 5' ' ' LEU . 37.0 m-70 -124.04 42.39 3.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.39 -0.819 . . . . 0.0 109.41 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.494 ' OD1' ' HD3' ' A' ' 86' ' ' PRO . 8.8 p-10 -66.24 126.4 28.58 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.168 -0.958 . . . . 0.0 109.333 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.5 m -96.53 150.57 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.283 -0.886 . . . . 0.0 109.75 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.487 HG11 ' H ' ' A' ' 57' ' ' MET . 10.2 m -138.99 121.51 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.438 -0.789 . . . . 0.0 109.302 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -71.07 127.8 33.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.24 -0.913 . . . . 0.0 109.41 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.26 163.98 18.32 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.238 -0.914 . . . . 0.0 109.624 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -101.49 25.58 8.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.408 -0.807 . . . . 0.0 109.527 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.46 -18.69 14.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.565 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -130.13 59.64 1.63 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.183 -0.948 . . . . 0.0 109.708 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.526 HG22 ' HD2' ' A' ' 47' ' ' PRO . 76.9 mt -119.82 140.3 29.4 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.267 -0.896 . . . . 0.0 109.089 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.526 ' HD2' HG22 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -76.05 -62.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 122.697 2.265 . . . . 0.0 110.968 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.4 t -88.92 -172.91 3.88 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.185 -0.947 . . . . 0.0 109.581 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.459 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.81 -112.29 0.14 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.459 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.8 154.95 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.495 -1.003 . . . . 0.0 109.792 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -95.35 168.05 10.96 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.28 -0.888 . . . . 0.0 109.661 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -85.03 -20.94 29.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.35 -0.844 . . . . 0.0 109.669 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -69.76 -12.34 61.56 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.213 -0.93 . . . . 0.0 109.982 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -88.88 -27.49 20.98 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.211 -0.931 . . . . 0.0 109.829 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.7 pt -117.96 12.21 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.195 -0.94 . . . . 0.0 110.078 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 74.7 m -117.08 175.31 5.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.159 -0.963 . . . . 0.0 109.45 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.487 ' H ' HG11 ' A' ' 40' ' ' VAL . 31.5 mtp -99.78 164.64 11.95 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.368 -0.833 . . . . 0.0 109.522 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.7 -170.83 1.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.324 -0.86 . . . . 0.0 109.745 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.507 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.6 OUTLIER -87.71 -25.97 23.19 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.374 -0.828 . . . . 0.0 109.794 -179.84 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.443 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 1.5 mp0 -82.38 -32.08 29.39 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.525 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -95.0 89.56 5.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.277 -0.889 . . . . 0.0 109.217 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.91 144.74 43.64 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.352 -0.843 . . . . 0.0 109.622 -179.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.663 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.0 mp -86.94 79.44 8.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.415 -0.803 . . . . 0.0 109.155 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.431 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.4 t30 -100.26 -4.64 28.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.304 -0.872 . . . . 0.0 110.01 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -103.46 143.55 26.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.21 79.94 3.02 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.711 2.274 . . . . 0.0 110.242 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.2 -25.41 0.26 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.663 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.51 149.46 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.371 -1.076 . . . . 0.0 109.403 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 29.6 p -135.91 145.68 46.54 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.925 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 33.5 t80 -108.53 108.55 19.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.539 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -99.76 134.22 42.97 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.338 -0.851 . . . . 0.0 109.723 -179.627 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.42 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.6 OUTLIER -122.93 113.92 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.38 -0.825 . . . . 0.0 109.319 179.85 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -84.63 102.31 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.253 -0.904 . . . . 0.0 109.291 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.64 142.17 31.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.1 p -123.92 -25.66 4.2 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.356 -0.84 . . . . 0.0 109.718 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.0 151.66 46.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.293 -0.879 . . . . 0.0 109.708 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -98.68 120.84 39.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.398 -0.814 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.401 ' H ' HG11 ' A' ' 98' ' ' VAL . . . 168.42 -171.82 42.75 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.4 m -113.56 114.14 26.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.274 -1.133 . . . . 0.0 109.493 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.17 179.02 5.55 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.366 -0.834 . . . . 0.0 109.095 179.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.78 101.46 3.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 109.8 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -102.91 163.28 12.3 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 43.7 p90 -155.17 154.32 32.1 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.078 -1.014 . . . . 0.0 110.158 -179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 35.2 t -66.43 110.08 2.98 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.898 ' O ' ' HB2' ' B' ' 62' ' ' ALA . 0.1 OUTLIER -52.47 -55.52 31.33 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.451 -0.78 . . . . 0.0 110.247 -179.369 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.639 ' O ' ' CG ' ' A' ' 87' ' ' HIS . 35.0 Cg_endo -76.38 41.42 0.87 Allowed 'Trans proline' 0 C--N 1.314 -1.268 0 C-N-CA 122.393 2.062 . . . . 0.0 110.947 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.639 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 3.7 m170 174.67 32.45 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.453 -0.779 . . . . 0.0 109.351 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.521 ' H ' ' HG3' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -71.27 -25.72 62.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.312 -0.867 . . . . 0.0 109.24 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.88 -11.54 57.66 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -71.91 -75.51 0.13 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.358 -1.084 . . . . 0.0 109.319 179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 154.51 41.0 0.02 OUTLIER Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.7 -1.238 . . . . 0.0 110.452 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.819 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm -132.45 102.38 5.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.198 -1.177 . . . . 0.0 108.956 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.8 m -142.74 167.6 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -0.867 . . . . 0.0 109.629 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -147.8 -177.95 22.62 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.1 ptmt -152.36 142.02 21.85 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.122 . . . . 0.0 109.848 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 27.1 t -97.5 112.02 28.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.36 -0.838 . . . . 0.0 109.371 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -95.95 68.89 2.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.203 -0.936 . . . . 0.0 109.175 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.401 HG11 ' H ' ' A' ' 78' ' ' GLY . 4.4 p -81.01 139.52 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.33 -0.856 . . . . 0.0 109.591 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.604 -179.974 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.925 ' NE2' ' O ' ' A' ' 10' ' ' GLY . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.898 ' HB2' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . 0.447 ' HB3' ' OG ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.507 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.879 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.664 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 251' ' ' HEC . . . . . 0.879 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.171 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.6 108.97 4.61 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.0 t -104.08 120.37 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.315 -0.866 . . . . 0.0 109.474 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 21.2 mt -107.58 101.68 10.99 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.338 -0.851 . . . . 0.0 109.321 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.68 HD21 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -64.44 141.93 58.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.381 -0.824 . . . . 0.0 109.512 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.466 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.17 135.16 1.09 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.01 -116.79 0.19 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -130.45 7.64 5.93 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.61 -41.02 0.22 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.334 -1.097 . . . . 0.0 109.586 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.46 48.19 0.04 OUTLIER Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.466 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.8 t -105.67 99.33 8.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.339 -1.095 . . . . 0.0 109.322 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 11.1 mt -78.32 96.07 5.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.37 -0.831 . . . . 0.0 109.404 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.849 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.23 138.1 3.07 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.342 -0.849 . . . . 0.0 109.728 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.467 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 36.8 m-85 -66.68 127.71 33.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.357 -0.839 . . . . 0.0 109.031 179.635 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -128.12 103.12 20.94 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.293 -0.879 . . . . 0.0 109.573 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.61 170.43 67.46 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.394 -1.503 . . . . 0.0 110.666 -0.348 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.431 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.22 12.7 48.43 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -167.03 108.6 0.66 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.331 -1.1 . . . . 0.0 109.076 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -130.02 169.49 15.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.393 -0.817 . . . . 0.0 109.666 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 m -121.97 129.65 52.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.332 -0.855 . . . . 0.0 109.438 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.77 -170.17 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.38 -0.825 . . . . 0.0 109.482 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.55 179.11 6.75 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.305 -0.872 . . . . 0.0 109.473 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.09 108.83 5.5 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.27 -17.38 5.62 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -81.8 171.61 14.32 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.345 -1.091 . . . . 0.0 109.468 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -127.97 134.25 49.26 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.285 -0.884 . . . . 0.0 109.665 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.53 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.0 149.04 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.437 -0.789 . . . . 0.0 109.042 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 t -132.4 145.71 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.193 -0.942 . . . . 0.0 109.896 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.512 ' HB3' HD12 ' A' ' 5' ' ' LEU . 49.9 m-85 -133.32 80.38 1.88 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.424 -0.797 . . . . 0.0 109.016 179.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.9 mttt -81.55 126.78 32.12 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.223 -0.923 . . . . 0.0 109.729 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.451 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 26.9 p-10 -98.07 126.22 43.41 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.333 -0.855 . . . . 0.0 109.484 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.99 -65.72 0.97 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.856 . . . . 0.0 109.522 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.33 146.91 52.49 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.344 -0.848 . . . . 0.0 109.544 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.05 20.95 26.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.563 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.7 p90 -64.24 164.8 16.38 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.363 -1.08 . . . . 0.0 109.634 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.606 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -80.03 153.54 85.99 Favored 'Cis proline' 0 C--N 1.313 -1.338 0 C-N-CA 123.378 -1.509 . . . . 0.0 110.606 -0.246 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.68 ' HB3' HD21 ' A' ' 5' ' ' LEU . 32.2 m-70 -121.1 37.96 4.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.217 179.564 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 15.7 p-10 -65.1 121.64 15.19 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.318 -0.864 . . . . 0.0 109.304 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -94.83 148.43 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.28 -0.888 . . . . 0.0 109.846 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.77 117.49 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.482 -0.761 . . . . 0.0 109.01 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -66.38 133.25 50.09 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.322 -0.861 . . . . 0.0 109.82 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -94.96 159.15 15.16 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.389 -0.819 . . . . 0.0 109.361 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.569 ' HA ' HD11 ' A' ' 46' ' ' ILE . 3.9 tp10 -100.55 24.71 8.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 109.591 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.97 -16.69 17.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -131.42 27.21 4.76 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.285 -0.884 . . . . 0.0 109.539 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.597 HG22 ' HD2' ' A' ' 47' ' ' PRO . 28.2 mt -92.15 142.18 25.96 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.301 -0.874 . . . . 0.0 109.055 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.597 ' HD2' HG22 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.67 -63.9 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.713 2.276 . . . . 0.0 111.101 -179.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.422 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.8 t -84.15 -176.85 6.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.162 -0.961 . . . . 0.0 109.563 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.486 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.66 -107.59 0.14 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.486 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.41 155.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.494 -1.004 . . . . 0.0 109.841 179.886 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.2 161.55 15.02 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.251 -0.906 . . . . 0.0 109.636 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.12 -22.16 36.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 0.0 109.644 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.78 -13.83 62.2 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.295 -0.878 . . . . 0.0 109.846 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -85.15 -29.86 24.44 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.247 -0.908 . . . . 0.0 109.679 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -114.54 8.2 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.17 -0.956 . . . . 0.0 110.021 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.8 m -113.47 172.93 6.67 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.168 -0.957 . . . . 0.0 109.408 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.8 mtp -92.52 160.91 14.83 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.317 -0.864 . . . . 0.0 109.56 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -95.14 -167.36 1.61 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.42 -0.8 . . . . 0.0 109.545 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.424 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.7 OUTLIER -90.94 -25.67 19.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.288 -0.883 . . . . 0.0 109.785 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.424 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -82.07 -30.41 31.33 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.739 -179.81 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -95.99 93.64 7.12 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.197 -0.94 . . . . 0.0 109.605 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.95 143.1 46.1 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.401 -0.812 . . . . 0.0 109.332 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.705 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.9 mp -89.28 80.52 6.84 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.346 -0.846 . . . . 0.0 109.18 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.455 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.8 t30 -100.09 -21.17 15.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 -179.647 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -88.53 144.82 34.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.175 -0.953 . . . . 0.0 109.864 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.45 81.62 2.6 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.754 2.303 . . . . 0.0 110.276 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.53 -25.6 0.25 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.705 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.58 149.43 50.12 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.419 -1.048 . . . . 0.0 109.408 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.9 p -135.81 145.39 46.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.251 -0.906 . . . . 0.0 109.864 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -108.84 109.22 20.28 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.453 -0.779 . . . . 0.0 109.008 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.29 134.3 43.43 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.343 -0.848 . . . . 0.0 109.726 -179.695 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.414 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.7 OUTLIER -122.94 115.44 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.407 -0.808 . . . . 0.0 109.243 179.852 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -86.3 102.21 13.78 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.252 -0.905 . . . . 0.0 109.31 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.3 143.0 30.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.855 . . . . 0.0 109.606 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.3 p -124.63 -26.61 3.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.39 47.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.264 -0.898 . . . . 0.0 109.682 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -98.41 122.43 41.58 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.427 -0.795 . . . . 0.0 109.529 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.473 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.9 -170.92 41.58 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -113.68 114.1 25.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -1.157 . . . . 0.0 109.513 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -92.31 177.87 6.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.419 -0.801 . . . . 0.0 109.118 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.21 93.65 2.12 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.213 -0.93 . . . . 0.0 109.85 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.7 p90 -96.99 154.5 17.26 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 108.791 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -144.49 157.05 44.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.134 -0.979 . . . . 0.0 110.174 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 10.1 t -67.83 114.77 6.68 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER -54.87 -50.21 87.41 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.348 -0.845 . . . . 0.0 110.036 -179.562 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.614 ' HD2' ' N ' ' A' ' 85' ' ' SER . 32.9 Cg_endo -74.13 -8.28 20.82 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.187 1.925 . . . . 0.0 111.004 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.595 ' NE2' ' CD2' ' B' ' 1' ' ' TYR . 29.4 m170 -146.69 67.62 1.17 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.095 -1.003 . . . . 0.0 109.701 179.568 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.655 ' OE1' ' OH ' ' B' ' 160' ' ' TYR . 0.0 OUTLIER -98.62 -37.0 9.7 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.064 -1.023 . . . . 0.0 109.009 179.581 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.57 -9.88 80.58 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . 0.578 ' HB3' ' HZ ' ' B' ' 4' ' ' PHE . . . -71.54 -63.4 1.13 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.285 -1.126 . . . . 0.0 109.441 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 153.01 2.47 0.17 Allowed Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.86 -1.162 . . . . 0.0 110.45 179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.849 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 1.3 ptm -96.35 100.87 12.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.13 -1.218 . . . . 0.0 109.325 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 28.0 m -146.8 148.41 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.351 -0.843 . . . . 0.0 109.405 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.431 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -129.45 178.69 17.23 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -148.86 138.51 21.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.123 . . . . 0.0 109.636 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.8 t -93.21 110.07 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.08 67.22 3.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.248 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.6 p -79.25 139.59 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.333 -0.854 . . . . 0.0 109.6 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.577 179.936 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.644 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.879 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.664 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.53 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 251' ' ' HEC . . . . . 0.879 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 N--CA 1.503 2.188 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.82 107.97 4.88 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.307 -0.871 . . . . 0.0 109.408 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.9 t -102.98 124.01 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.363 -0.835 . . . . 0.0 109.451 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 21.8 mt -110.26 101.88 10.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.361 -0.837 . . . . 0.0 109.383 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.679 HD21 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.24 133.08 50.7 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.335 -0.853 . . . . 0.0 109.388 -179.99 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 84.69 133.01 2.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.72 -118.15 0.15 Allowed Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.62 -1.89 6.95 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -132.93 -40.34 0.94 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.129 . . . . 0.0 109.592 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.802 ' HA3' HD12 ' B' ' 3' ' ' ILE . . . 168.31 46.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.507 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.7 t -99.19 94.56 6.56 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.356 -1.085 . . . . 0.0 109.338 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.5 mt -75.18 89.7 2.53 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.343 -0.848 . . . . 0.0 109.471 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.856 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.51 142.03 7.93 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.295 -0.878 . . . . 0.0 109.674 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.511 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 38.1 m-85 -68.15 128.26 35.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -0.849 . . . . 0.0 109.159 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.411 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.54 102.31 18.33 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 109.604 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.411 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.74 171.6 62.44 Favored 'Cis proline' 0 C--N 1.312 -1.351 0 C-N-CA 123.428 -1.488 . . . . 0.0 110.714 -0.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.404 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.42 10.77 46.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -165.15 110.46 0.91 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.328 -1.101 . . . . 0.0 109.078 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -131.2 167.75 18.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.639 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.9 m -120.43 129.84 54.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.327 -0.858 . . . . 0.0 109.471 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 98' ' ' VAL . 3.0 m -131.94 -172.85 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.369 -0.832 . . . . 0.0 109.545 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.68 178.55 6.95 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 109.482 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.7 t -72.17 111.47 7.42 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.333 -0.854 . . . . 0.0 109.428 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.77 -16.38 6.94 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -82.57 167.11 18.64 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.395 -1.062 . . . . 0.0 109.488 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -123.92 133.14 53.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.64 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.3 mp -97.36 151.03 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.438 -0.789 . . . . 0.0 109.042 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.4 t -133.7 145.22 33.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 109.967 -179.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.471 ' HB3' HD12 ' A' ' 5' ' ' LEU . 54.6 m-85 -130.92 77.43 1.78 Allowed 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 27.3 mttt -77.07 132.61 39.0 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.272 -0.892 . . . . 0.0 109.842 -179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 20.6 p-10 -105.72 122.22 45.62 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.52 -67.18 0.87 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.281 -0.887 . . . . 0.0 109.588 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -125.44 149.99 47.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.326 -0.858 . . . . 0.0 109.525 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.33 11.02 61.55 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.652 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 3.0 p90 -61.76 165.99 6.75 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 121.399 -1.059 . . . . 0.0 109.543 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.591 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.2 Cg_endo -78.84 151.64 88.39 Favored 'Cis proline' 0 C--N 1.313 -1.292 0 C-N-CA 123.329 -1.53 . . . . 0.0 110.506 -0.016 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.679 ' HB3' HD21 ' A' ' 5' ' ' LEU . 50.6 m-70 -122.78 44.78 2.55 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.384 -0.823 . . . . 0.0 109.365 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.504 ' OD1' ' HG3' ' A' ' 86' ' ' PRO . 9.7 p-10 -68.57 123.15 20.05 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.196 -0.94 . . . . 0.0 109.199 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.07 155.7 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.245 -0.909 . . . . 0.0 109.992 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.421 HG11 ' H ' ' A' ' 57' ' ' MET . 3.6 m -141.33 118.8 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.418 -0.801 . . . . 0.0 109.201 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -69.31 130.57 42.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 109.663 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.11 159.39 15.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.355 -0.841 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.519 ' HA ' HD11 ' A' ' 46' ' ' ILE . 4.5 tp10 -99.02 34.46 2.11 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.313 -0.867 . . . . 0.0 109.491 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -108.38 -22.09 12.47 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -0.899 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -128.5 32.78 4.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.738 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.575 HG22 ' HD2' ' A' ' 47' ' ' PRO . 49.0 mt -95.35 141.44 23.22 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.24 -0.913 . . . . 0.0 109.188 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.575 ' HD2' HG22 ' A' ' 46' ' ' ILE . 34.4 Cg_endo -76.46 -59.6 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.723 2.282 . . . . 0.0 111.038 -179.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.403 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.5 t -87.65 -176.26 5.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.932 . . . . 0.0 109.683 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.496 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -78.26 -107.01 0.19 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.496 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.45 156.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.513 -0.992 . . . . 0.0 109.773 179.896 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.89 160.75 16.29 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 0.0 109.637 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.26 -18.18 40.02 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.872 . . . . 0.0 109.729 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -77.15 -9.42 58.74 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.222 -0.924 . . . . 0.0 109.851 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.0 tptp -87.75 -27.18 22.51 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.279 -0.888 . . . . 0.0 109.715 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.6 pt -113.68 -5.1 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.212 -0.93 . . . . 0.0 109.976 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.2 m -98.99 175.29 5.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.168 -0.957 . . . . 0.0 109.473 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.421 ' H ' HG11 ' A' ' 40' ' ' VAL . 16.5 mtp -93.24 157.26 16.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.819 . . . . 0.0 109.563 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -88.35 -160.13 0.61 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.467 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.828 ' OE1' ' HE2' ' B' ' 65' ' ' LYS . 8.8 pm0 -98.24 -29.21 13.32 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.296 -0.877 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.501 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.7 -30.33 36.38 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.302 -0.874 . . . . 0.0 109.737 -179.873 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -92.16 95.42 9.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.335 -0.853 . . . . 0.0 109.48 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.694 HD12 HD23 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -116.7 141.61 47.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.424 -0.797 . . . . 0.0 109.34 -179.986 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.646 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.0 OUTLIER -90.52 80.14 6.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.338 -0.851 . . . . 0.0 109.14 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -102.7 -41.05 6.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.324 -0.86 . . . . 0.0 109.8 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.49 145.63 98.4 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.326 -0.859 . . . . 0.0 109.979 -179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.75 78.09 3.67 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.771 2.314 . . . . 0.0 110.219 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 165.38 -24.79 0.16 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.646 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.2 tp10 -67.84 148.11 51.62 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.365 -1.08 . . . . 0.0 109.339 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 41.1 p -136.74 143.27 43.2 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 109.899 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -105.28 107.15 17.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.348 -0.845 . . . . 0.0 109.094 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.47 131.07 45.02 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 109.62 -179.744 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -121.08 112.44 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.424 -0.798 . . . . 0.0 109.206 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.8 m -83.66 104.04 13.45 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 109.297 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -100.92 141.26 34.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.362 -0.836 . . . . 0.0 109.557 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.9 p -123.14 -24.73 4.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.19 153.42 43.72 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.274 -0.891 . . . . 0.0 109.642 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.8 mttt -100.67 124.07 45.75 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.309 -0.869 . . . . 0.0 109.548 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.428 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 165.71 -168.53 39.64 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.8 m -116.86 110.82 18.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.332 -1.099 . . . . 0.0 109.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -89.35 176.09 7.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.8 92.51 2.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.169 -0.957 . . . . 0.0 109.918 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.41 ' HE1' ' CE2' ' A' ' 14' ' ' PHE . 47.9 p90 -97.54 154.6 17.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.337 -0.852 . . . . 0.0 108.738 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 41.6 p90 -143.79 154.61 43.6 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 109.987 -179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 49.6 t -65.9 106.91 1.68 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.502 -0.749 . . . . 0.0 109.024 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.866 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -49.33 -55.36 22.24 Favored Pre-proline 0 N--CA 1.494 1.725 0 O-C-N 121.49 -0.756 . . . . 0.0 110.089 -179.553 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.696 ' O ' ' CG ' ' A' ' 87' ' ' HIS . 33.4 Cg_endo -74.08 41.66 0.68 Allowed 'Trans proline' 0 C--N 1.312 -1.346 0 C-N-CA 122.142 1.895 . . . . 0.0 110.783 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.696 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 4.3 m170 170.91 33.91 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.61 -0.681 . . . . 0.0 109.197 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.48 -31.24 70.37 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.269 -0.894 . . . . 0.0 109.391 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -95.72 -4.03 60.66 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.8 -74.42 0.18 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.325 -1.103 . . . . 0.0 109.375 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.2 38.32 0.02 OUTLIER Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.896 -1.145 . . . . 0.0 110.345 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.856 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm -135.47 105.75 6.36 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.224 -1.162 . . . . 0.0 109.009 179.456 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.0 m -144.97 146.79 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.362 -0.836 . . . . 0.0 109.607 -179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -124.7 176.32 17.04 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.81 136.2 20.29 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.263 -1.139 . . . . 0.0 109.816 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.5 t -91.49 109.96 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.344 -0.847 . . . . 0.0 109.476 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -94.79 66.75 3.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.204 -0.935 . . . . 0.0 109.104 179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.4 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 7.0 p -79.21 141.24 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.307 -0.87 . . . . 0.0 109.62 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.2 p30 . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.566 179.946 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . 0.802 HD12 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . 0.694 HD23 HD12 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.866 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . 0.413 ' HB3' ' OG ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.828 ' HE2' ' OE1' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.879 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.664 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 251' ' ' HEC . . . . . 0.879 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.4 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.38 107.99 4.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.8 t -102.9 125.46 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.364 -0.835 . . . . 0.0 109.504 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 25.0 mt -111.13 100.52 9.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.387 -0.82 . . . . 0.0 109.299 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.702 HD21 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.01 128.57 36.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.373 -0.83 . . . . 0.0 109.388 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 88.71 134.0 4.79 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -77.58 -124.62 0.28 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.26 -13.52 8.25 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -118.74 -37.39 3.27 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.322 -1.104 . . . . 0.0 109.615 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.946 ' HA3' HD12 ' B' ' 3' ' ' ILE . . . 160.61 45.9 0.02 OUTLIER Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.499 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.8 t -94.64 98.47 10.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.288 -1.125 . . . . 0.0 109.301 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.6 mt -73.83 91.92 2.0 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.298 -0.876 . . . . 0.0 109.485 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.887 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.2 137.53 5.21 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.358 -0.839 . . . . 0.0 109.617 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.555 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 35.4 m-85 -65.71 126.58 28.88 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.383 -0.823 . . . . 0.0 109.054 179.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -127.9 102.28 22.29 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.248 -0.907 . . . . 0.0 109.607 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.78 170.47 66.89 Favored 'Cis proline' 0 C--N 1.313 -1.317 0 C-N-CA 123.45 -1.479 . . . . 0.0 110.679 -0.271 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.412 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.41 12.45 47.57 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -166.49 105.92 0.64 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.406 -1.055 . . . . 0.0 109.043 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -127.45 167.25 16.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.307 -0.87 . . . . 0.0 109.695 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.64 128.55 53.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 109.404 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 3.0 m -130.44 -171.52 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.388 -0.82 . . . . 0.0 109.532 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.31 179.01 6.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.329 -0.857 . . . . 0.0 109.442 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -72.3 110.52 6.78 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.238 -0.914 . . . . 0.0 109.417 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.62 -16.91 6.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -82.1 165.71 20.35 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.34 -1.094 . . . . 0.0 109.472 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -122.61 132.11 54.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.337 -0.852 . . . . 0.0 109.636 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.31 151.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 109.045 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -133.5 146.28 32.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.217 -0.927 . . . . 0.0 109.934 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.447 ' HB3' HD12 ' A' ' 5' ' ' LEU . 52.1 m-85 -132.5 80.05 1.88 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.3 mttt -80.45 131.79 35.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.333 -0.855 . . . . 0.0 109.716 -179.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.2 p-10 -105.25 119.57 39.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.282 -0.886 . . . . 0.0 109.493 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -98.19 -67.83 0.83 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.343 -0.848 . . . . 0.0 109.573 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -124.68 149.85 46.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.33 -0.856 . . . . 0.0 109.49 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 92.13 12.71 58.51 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.642 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 4.9 p90 -61.5 163.97 10.35 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.405 -1.056 . . . . 0.0 109.542 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.548 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.2 Cg_endo -79.1 157.28 91.4 Favored 'Cis proline' 0 C--N 1.313 -1.322 0 C-N-CA 123.322 -1.532 . . . . 0.0 110.481 -0.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.702 ' HB3' HD21 ' A' ' 5' ' ' LEU . 43.9 m-70 -127.97 39.75 3.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.385 -0.822 . . . . 0.0 109.33 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -65.19 120.64 13.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.334 -0.854 . . . . 0.0 109.267 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -93.0 151.45 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.305 -0.872 . . . . 0.0 109.823 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.506 HG11 ' H ' ' A' ' 57' ' ' MET . 10.2 m -137.99 121.71 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.109 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -70.26 132.11 45.22 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.258 -0.901 . . . . 0.0 109.709 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.45 157.86 15.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.294 -0.879 . . . . 0.0 109.53 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.539 ' HA ' HD11 ' A' ' 46' ' ' ILE . 6.0 tp10 -98.02 47.04 1.01 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.294 -0.879 . . . . 0.0 109.45 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.56 -26.77 5.67 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.286 -0.884 . . . . 0.0 109.38 179.727 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -124.25 25.25 7.83 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.342 -0.849 . . . . 0.0 109.61 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.567 HG22 ' HD2' ' A' ' 47' ' ' PRO . 58.0 mt -87.87 141.36 31.54 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.254 -0.904 . . . . 0.0 109.155 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.567 ' HD2' HG22 ' A' ' 46' ' ' ILE . 34.0 Cg_endo -76.23 -60.71 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.738 2.292 . . . . 0.0 110.999 -179.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.8 t -87.57 -178.3 6.08 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.211 -0.931 . . . . 0.0 109.642 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.521 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.6 -103.39 0.14 Allowed Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.521 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.92 157.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.523 -0.987 . . . . 0.0 109.899 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.471 ' HA ' ' HZ2' ' B' ' 187' ' ' LYS . 0.6 OUTLIER -89.23 156.42 18.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.263 -0.898 . . . . 0.0 109.624 -179.904 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.63 -24.41 39.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.321 -0.862 . . . . 0.0 109.677 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -72.82 -15.22 61.63 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 109.777 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -79.43 -31.62 42.63 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.303 -0.873 . . . . 0.0 109.735 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.0 pt -111.07 0.44 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.272 -0.892 . . . . 0.0 109.879 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 62.4 m -104.02 177.93 4.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.506 ' H ' HG11 ' A' ' 40' ' ' VAL . 22.7 mtp -98.67 159.07 15.21 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.289 -0.882 . . . . 0.0 109.523 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.73 -166.43 1.58 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.354 -0.841 . . . . 0.0 109.552 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.516 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -91.43 -28.06 17.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.354 -0.841 . . . . 0.0 109.92 -179.807 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.435 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.5 OUTLIER -80.93 -31.25 35.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.88 . . . . 0.0 109.775 -179.851 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -91.23 97.37 11.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.337 -0.852 . . . . 0.0 109.483 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.532 HD12 HD23 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -120.15 145.49 46.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.38 -0.825 . . . . 0.0 109.363 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.656 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.0 mp -93.31 75.31 4.56 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.415 -0.803 . . . . 0.0 109.185 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -96.04 -35.45 11.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.292 -0.88 . . . . 0.0 109.749 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -73.21 143.84 83.82 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.308 -0.87 . . . . 0.0 109.808 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.56 80.06 3.03 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.777 2.318 . . . . 0.0 110.215 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 163.84 -24.95 0.19 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.656 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.55 149.33 50.27 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.387 -1.066 . . . . 0.0 109.387 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 36.2 p -136.4 144.22 44.4 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.2 t80 -106.73 108.72 20.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.384 -0.823 . . . . 0.0 109.07 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.446 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.06 132.28 45.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.322 -0.861 . . . . 0.0 109.685 -179.742 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -122.1 112.85 36.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.418 -0.801 . . . . 0.0 109.263 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.6 m -84.2 102.0 12.29 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.291 -0.88 . . . . 0.0 109.326 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -98.46 142.45 30.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.33 -0.856 . . . . 0.0 109.531 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.3 p -123.9 -25.92 4.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.351 -0.843 . . . . 0.0 109.714 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.46 152.27 45.63 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 109.669 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -99.43 123.1 43.41 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.418 -0.801 . . . . 0.0 109.605 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.481 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.68 -171.67 41.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 4.0 m -113.3 111.01 21.3 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.298 -1.119 . . . . 0.0 109.401 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -89.57 175.44 7.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.362 -0.837 . . . . 0.0 109.171 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.7 88.58 1.77 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.223 -0.923 . . . . 0.0 109.861 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.445 ' HE1' ' CE2' ' A' ' 14' ' ' PHE . 48.3 p90 -93.23 146.5 23.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.249 -0.907 . . . . 0.0 108.802 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -133.41 153.03 51.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.863 -179.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 42.5 t -65.68 109.2 2.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.542 -0.724 . . . . 0.0 109.246 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.823 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.5 OUTLIER -49.49 -54.37 31.31 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.471 -0.768 . . . . 0.0 109.812 -179.8 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.74 ' O ' ' CG ' ' A' ' 87' ' ' HIS . 32.7 Cg_endo -74.36 33.13 0.35 Allowed 'Trans proline' 0 C--N 1.312 -1.346 0 C-N-CA 122.105 1.87 . . . . 0.0 110.503 179.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.74 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 9.9 m170 174.04 49.89 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 179.523 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.501 ' H ' ' HG3' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -74.15 -52.55 12.17 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.202 -0.936 . . . . 0.0 109.161 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.11 1.1 89.27 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -68.4 -61.98 1.59 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.267 -1.137 . . . . 0.0 109.348 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 151.79 -15.61 0.81 Allowed Glycine 0 N--CA 1.493 2.485 0 C-N-CA 119.839 -1.172 . . . . 0.0 110.241 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.887 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm -88.08 109.8 20.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.158 -1.201 . . . . 0.0 109.719 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.3 m -149.57 134.49 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.299 -0.876 . . . . 0.0 109.31 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -115.17 174.98 15.64 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -147.65 135.3 20.94 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.13 . . . . 0.0 109.614 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 34.9 t -89.33 109.87 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.97 65.87 2.97 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 109.174 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.7 p -78.32 140.47 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.369 -0.832 . . . . 0.0 109.575 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.586 179.982 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . 0.946 HD12 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.415 ' NE2' ' O ' ' A' ' 10' ' ' GLY . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . 0.532 HD23 HD12 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.823 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.516 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.879 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.717 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.664 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 0.471 ' HZ2' ' HA ' ' A' ' 51' ' ' ASP . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 251' ' ' HEC . . . . . 0.879 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.9 p . . . . . 0 N--CA 1.503 2.195 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.56 108.91 5.18 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.235 -0.915 . . . . 0.0 109.46 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 15.8 t -104.35 120.65 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.34 -0.85 . . . . 0.0 109.446 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 19.0 mt -107.63 102.59 11.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.389 -0.82 . . . . 0.0 109.342 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.64 HD21 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.09 141.62 58.66 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.326 -0.859 . . . . 0.0 109.415 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.09 136.48 1.23 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.64 -121.35 0.46 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -125.48 5.12 8.13 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.03 -42.61 0.27 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.315 -1.109 . . . . 0.0 109.601 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.97 42.41 0.05 OUTLIER Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.475 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 1.7 t -97.71 96.91 8.57 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.311 -1.111 . . . . 0.0 109.295 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.1 mt -80.03 90.95 5.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.377 -0.827 . . . . 0.0 109.451 -179.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.84 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.61 142.58 6.67 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.338 -0.851 . . . . 0.0 109.781 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.522 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 33.5 m-85 -67.62 128.06 35.06 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.418 -0.801 . . . . 0.0 109.082 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.463 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.11 102.76 18.71 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.612 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.75 171.18 64.32 Favored 'Cis proline' 0 C--N 1.312 -1.359 0 C-N-CA 123.43 -1.487 . . . . 0.0 110.648 -0.248 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.448 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -106.17 14.64 43.96 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -169.1 110.54 0.49 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.393 -1.063 . . . . 0.0 109.051 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -132.22 170.19 15.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.34 -0.85 . . . . 0.0 109.67 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.3 m -122.69 130.95 53.54 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 109.443 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -132.96 -169.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.354 -0.841 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.49 178.93 6.86 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.283 -0.885 . . . . 0.0 109.455 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.0 t -71.98 109.42 5.79 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.349 -0.844 . . . . 0.0 109.385 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.43 -17.03 5.9 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -81.91 171.4 14.5 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -1.095 . . . . 0.0 109.479 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.86 133.93 49.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.268 -0.895 . . . . 0.0 109.642 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.532 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -95.9 150.72 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.379 -0.825 . . . . 0.0 109.035 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -134.34 146.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 109.949 -179.561 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.476 ' HB3' HD12 ' A' ' 5' ' ' LEU . 56.8 m-85 -133.72 80.21 1.86 Allowed 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.6 mttt -81.11 123.86 28.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.229 -0.919 . . . . 0.0 109.825 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -94.46 126.73 39.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.334 -0.854 . . . . 0.0 109.388 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -102.93 -63.7 1.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.847 . . . . 0.0 109.566 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -134.33 148.04 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.344 -0.848 . . . . 0.0 109.561 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 14.96 45.74 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 1.034 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 0.2 OUTLIER -62.86 166.15 8.38 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.44 -1.036 . . . . 0.0 109.542 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.67 ' O ' ' HG2' ' A' ' 86' ' ' PRO . 35.6 Cg_endo -78.06 145.32 78.13 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.679 0.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.64 ' HB3' HD21 ' A' ' 5' ' ' LEU . 34.7 m-70 -115.58 32.7 5.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -58.23 119.38 6.78 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.269 -0.894 . . . . 0.0 109.361 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -93.32 157.23 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.358 -0.839 . . . . 0.0 110.026 -179.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 6.5 m -139.79 119.98 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.397 -0.814 . . . . 0.0 109.194 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -67.19 116.74 8.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.397 -0.814 . . . . 0.0 109.927 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.422 ' O ' HG13 ' A' ' 46' ' ' ILE . 1.3 t70 -81.41 149.62 28.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.29 -0.881 . . . . 0.0 109.523 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 1.284 ' CB ' ' HE2' ' B' ' 187' ' ' LYS . 1.0 OUTLIER -96.79 6.44 48.66 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.267 -0.896 . . . . 0.0 109.918 179.909 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.43 -19.7 57.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.183 -0.948 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -131.49 38.44 3.6 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.384 -0.823 . . . . 0.0 109.515 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.672 HD11 ' HG3' ' A' ' 43' ' ' GLU . 8.1 mt -98.96 143.97 27.35 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.254 -0.904 . . . . 0.0 109.25 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.622 ' HD2' HG22 ' A' ' 46' ' ' ILE . 33.9 Cg_endo -76.02 -63.99 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.786 2.324 . . . . 0.0 111.068 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.406 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.8 t -83.4 -176.45 6.32 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.177 -0.952 . . . . 0.0 109.686 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.535 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -78.37 -105.63 0.2 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.535 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.65 160.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.56 -0.964 . . . . 0.0 109.861 179.811 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -99.45 162.61 12.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.256 -0.903 . . . . 0.0 109.547 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.433 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -81.78 -17.23 48.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.33 -0.856 . . . . 0.0 109.73 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.62 -2.3 28.64 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.217 -0.927 . . . . 0.0 109.898 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -101.5 -25.57 13.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.235 -0.915 . . . . 0.0 109.649 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.3 pt -119.0 6.67 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.198 -0.939 . . . . 0.0 110.114 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 69.0 m -113.05 171.18 7.7 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.108 -0.995 . . . . 0.0 109.366 179.746 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.6 mtp -88.79 152.12 21.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.323 -0.86 . . . . 0.0 109.571 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.2 t -89.82 -154.67 0.33 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.43 -0.794 . . . . 0.0 109.498 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' B' ' 66' ' ' LYS . 3.2 pt-20 -101.83 -33.55 9.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.259 -0.9 . . . . 0.0 109.888 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.86 -29.69 63.4 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.874 . . . . 0.0 109.829 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -96.88 87.26 4.23 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.262 -0.899 . . . . 0.0 109.672 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.05 139.75 43.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.374 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.667 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.7 mp -89.75 84.52 6.29 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.558 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.4 OUTLIER -111.44 -4.47 14.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.272 -0.892 . . . . 0.0 109.824 -179.763 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -101.38 146.71 32.67 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 109.689 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -77.11 78.47 3.44 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.795 2.33 . . . . 0.0 110.225 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.94 -23.88 0.29 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.667 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -68.2 147.16 52.64 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.322 -1.105 . . . . 0.0 109.442 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.0 p -136.36 147.32 47.31 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.247 -0.908 . . . . 0.0 109.828 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.6 t80 -110.24 109.27 19.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.81 . . . . 0.0 109.019 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.23 133.86 44.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 -179.673 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.418 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.7 OUTLIER -123.05 116.58 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.384 -0.823 . . . . 0.0 109.242 179.807 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -87.14 102.48 14.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.287 -0.883 . . . . 0.0 109.355 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.76 142.95 30.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.343 -0.848 . . . . 0.0 109.584 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.7 p -124.46 -27.04 3.8 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.374 -0.829 . . . . 0.0 109.786 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.67 152.08 46.21 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.216 -0.927 . . . . 0.0 109.696 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -99.18 125.13 44.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.375 -0.828 . . . . 0.0 109.557 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.424 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.71 -165.88 37.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.2 m -118.28 120.05 36.5 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.317 -1.108 . . . . 0.0 109.524 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -97.08 178.15 5.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.421 -0.799 . . . . 0.0 109.085 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -147.54 88.36 1.7 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.114 -0.992 . . . . 0.0 109.891 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -93.65 161.22 14.43 Favored 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.4 ' HB2' HG11 ' A' ' 93' ' ' VAL . 44.7 p90 -155.15 152.96 30.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.038 -1.039 . . . . 0.0 110.339 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 51.6 t -64.31 114.08 4.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.612 -0.68 . . . . 0.0 109.233 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 1.261 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 5.6 t -49.99 -63.08 1.96 Allowed Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.407 -0.808 . . . . 0.0 110.107 -179.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.871 ' HD3' ' HB3' ' A' ' 85' ' ' SER . 36.1 Cg_endo -76.7 62.16 7.13 Favored 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 122.284 1.989 . . . . 0.0 110.767 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.773 ' NE2' ' CE2' ' B' ' 1' ' ' TYR . 4.4 m170 159.03 25.91 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.537 -0.727 . . . . 0.0 109.531 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -71.06 -24.42 62.33 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.133 -0.979 . . . . 0.0 108.906 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.86 -13.14 55.68 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -69.92 -71.27 0.24 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.408 -1.054 . . . . 0.0 109.263 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 152.97 36.24 0.03 OUTLIER Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.82 -1.181 . . . . 0.0 110.491 179.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.84 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.8 ptm -127.88 102.51 6.8 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -1.197 . . . . 0.0 109.26 179.473 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.4 HG11 ' HB2' ' A' ' 83' ' ' TYR . 35.1 m -143.88 153.22 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.46 176.45 19.87 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.04 138.11 22.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.316 -1.108 . . . . 0.0 109.74 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 45.7 t -93.25 108.67 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.361 -0.837 . . . . 0.0 109.473 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -92.35 67.3 4.83 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.263 -0.898 . . . . 0.0 109.162 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.7 p -78.7 139.71 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.378 -0.826 . . . . 0.0 109.607 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.563 179.937 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.773 ' CE2' ' NE2' ' A' ' 87' ' ' HIS . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 1.261 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . 0.986 HD21 ' CB ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . 0.513 ' O ' ' CB ' ' A' ' 59' ' ' GLU . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.879 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 1.034 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.664 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . 1.284 ' HE2' ' CB ' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 251' ' ' HEC . . . . . 0.879 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.141 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.76 108.29 4.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.9 t -103.55 121.12 54.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.469 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 20.1 mt -108.24 101.87 11.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.355 -0.841 . . . . 0.0 109.275 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.71 HD21 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.74 137.11 57.6 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.352 -0.843 . . . . 0.0 109.398 -179.956 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.533 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 83.0 135.37 2.42 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.07 -119.13 0.26 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.27 4.17 7.75 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -141.3 -41.28 0.38 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.311 -1.111 . . . . 0.0 109.592 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.808 ' HA3' HD12 ' B' ' 3' ' ' ILE . . . 171.03 43.66 0.03 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.533 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.3 t -97.4 99.39 10.82 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.344 -1.092 . . . . 0.0 109.273 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.6 mt -79.67 93.35 5.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.884 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -166.59 139.11 3.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 109.792 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.519 ' CE1' ' HG3' ' A' ' 92' ' ' MET . 36.5 m-85 -65.9 127.05 30.5 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.42 -0.8 . . . . 0.0 108.98 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 1.6 mp -127.86 102.84 21.82 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 109.641 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -79.73 170.22 67.83 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 123.452 -1.478 . . . . 0.0 110.651 -0.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.438 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.47 13.28 47.4 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -167.56 107.62 0.58 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.415 -1.05 . . . . 0.0 108.991 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -129.37 169.13 15.28 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.355 -0.84 . . . . 0.0 109.661 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.8 m -121.77 129.19 52.49 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.417 -0.802 . . . . 0.0 109.434 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.36 -170.11 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.61 179.15 6.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.329 -0.857 . . . . 0.0 109.476 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -71.96 108.39 5.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.7 -17.23 5.53 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -81.97 172.17 13.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.318 -1.107 . . . . 0.0 109.516 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -128.52 134.9 48.79 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.314 -0.866 . . . . 0.0 109.662 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.54 149.3 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.473 -0.767 . . . . 0.0 109.047 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -133.29 145.54 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.913 . . . . 0.0 109.952 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.498 ' HB3' HD12 ' A' ' 5' ' ' LEU . 50.8 m-85 -132.96 80.29 1.88 Allowed 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 26.9 mttt -80.88 124.31 29.0 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.165 -0.959 . . . . 0.0 109.767 -179.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.6 p-10 -96.63 116.96 29.98 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.269 -0.894 . . . . 0.0 109.441 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -94.39 -69.21 0.76 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.536 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.11 151.17 49.51 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.358 -0.839 . . . . 0.0 109.473 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 94.1 10.16 58.79 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.798 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 2.1 p90 -57.94 166.18 2.13 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.34 -1.094 . . . . 0.0 109.421 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.585 ' O ' ' HG2' ' A' ' 86' ' ' PRO . 36.2 Cg_endo -78.95 150.01 85.55 Favored 'Cis proline' 0 C--N 1.312 -1.355 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.536 -0.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.71 ' HB3' HD21 ' A' ' 5' ' ' LEU . 45.1 m-70 -121.72 45.24 2.36 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.339 -0.851 . . . . 0.0 109.25 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.451 ' OD1' ' HD3' ' A' ' 86' ' ' PRO . 10.9 p-10 -70.48 119.05 14.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.229 -0.919 . . . . 0.0 109.304 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -92.27 152.5 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.392 -0.818 . . . . 0.0 109.964 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.553 HG23 ' HB3' ' B' ' 63' ' ' ASN . 6.8 m -140.52 119.27 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 109.033 179.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -67.48 132.38 47.49 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.22 -0.925 . . . . 0.0 109.771 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -94.15 159.33 15.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.394 -0.816 . . . . 0.0 109.465 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.526 ' HA ' HD11 ' A' ' 46' ' ' ILE . 4.4 tp10 -99.82 24.81 7.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.312 -0.867 . . . . 0.0 109.573 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.02 -17.33 16.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.186 -0.946 . . . . 0.0 109.489 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -131.72 36.72 3.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.268 -0.895 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . 0.583 HG22 ' HD2' ' A' ' 47' ' ' PRO . 33.4 mt -100.43 141.93 23.64 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.333 -0.855 . . . . 0.0 108.988 179.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.583 ' HD2' HG22 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.55 -63.6 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.696 2.264 . . . . 0.0 111.151 -179.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.412 ' O ' HG21 ' A' ' 46' ' ' ILE . 1.7 t -85.48 -175.14 5.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.169 -0.957 . . . . 0.0 109.641 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.489 ' O ' HG11 ' A' ' 50' ' ' VAL . . . -76.89 -108.18 0.14 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.489 HG11 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.44 155.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.494 -1.003 . . . . 0.0 109.796 179.895 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.98 162.21 14.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.297 -0.877 . . . . 0.0 109.583 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.48 -21.88 35.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.387 -0.82 . . . . 0.0 109.671 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -71.27 -12.53 61.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.273 -0.892 . . . . 0.0 109.927 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -86.68 -27.68 23.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.285 -0.884 . . . . 0.0 109.749 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.1 pt -116.72 6.32 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.235 -0.916 . . . . 0.0 110.045 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -110.77 174.55 5.81 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.174 -0.954 . . . . 0.0 109.348 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' MET . . . . . 0.469 ' H ' HG11 ' A' ' 40' ' ' VAL . 27.6 mtp -95.6 160.58 14.43 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.382 -0.824 . . . . 0.0 109.498 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -95.63 -170.86 2.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.358 -0.839 . . . . 0.0 109.563 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.487 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.5 OUTLIER -87.48 -26.19 23.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.301 -0.874 . . . . 0.0 109.865 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.487 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.39 -35.42 35.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.284 -0.885 . . . . 0.0 109.643 -179.865 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.58 92.81 8.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.428 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . 0.741 HD13 HD23 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -114.82 141.36 48.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 109.462 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.673 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.3 mp -89.48 87.45 7.07 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.423 -0.798 . . . . 0.0 109.179 179.783 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.432 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.6 OUTLIER -108.52 -32.8 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.33 -0.856 . . . . 0.0 109.765 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.44 144.83 81.62 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.226 -0.921 . . . . 0.0 109.837 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.39 80.28 2.95 Favored 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.733 2.289 . . . . 0.0 110.25 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.51 -25.15 0.22 Allowed Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.673 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -67.36 148.72 51.26 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.364 -1.08 . . . . 0.0 109.448 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 32.0 p -136.36 144.21 44.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.915 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -107.73 109.17 20.69 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.35 -0.844 . . . . 0.0 108.998 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.49 134.44 43.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.343 -0.848 . . . . 0.0 109.743 -179.729 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.402 ' O ' HD11 ' A' ' 27' ' ' ILE . 0.7 OUTLIER -123.25 114.73 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.405 -0.809 . . . . 0.0 109.242 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -85.46 102.35 13.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.301 -0.875 . . . . 0.0 109.301 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.54 142.99 30.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.4 p -124.6 -26.8 3.79 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.372 -0.83 . . . . 0.0 109.818 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.03 47.81 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.272 -0.893 . . . . 0.0 109.683 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -97.99 121.33 39.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.373 -0.829 . . . . 0.0 109.52 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.445 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.93 -171.91 42.49 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -112.93 115.01 27.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.311 -1.111 . . . . 0.0 109.487 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 46.3 m-85 -93.32 178.61 5.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.351 -0.843 . . . . 0.0 109.093 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.59 93.27 2.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.984 . . . . 0.0 109.912 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -97.12 155.62 16.74 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -145.0 153.18 41.22 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.041 -1.037 . . . . 0.0 110.272 -179.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' CYS . . . . . 0.405 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 52.0 t -68.65 106.81 2.74 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.821 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER -47.55 -55.09 18.02 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.414 -0.804 . . . . 0.0 110.109 -179.599 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.759 ' O ' ' CG ' ' A' ' 87' ' ' HIS . 34.3 Cg_endo -75.46 42.39 0.9 Allowed 'Trans proline' 0 C--N 1.313 -1.318 0 C-N-CA 122.273 1.982 . . . . 0.0 110.643 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.759 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 6.9 m170 168.15 29.98 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.608 -0.683 . . . . 0.0 109.331 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.3 -31.93 70.74 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.235 -0.916 . . . . 0.0 109.225 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.02 -4.67 64.69 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.294 -1.523 . . . . 0.0 109.294 179.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.85 -69.7 0.42 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.43 -1.041 . . . . 0.0 109.273 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.37 21.77 0.03 OUTLIER Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.581 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' MET . . . . . 0.884 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.6 ptm -118.25 104.01 10.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.099 -1.236 . . . . 0.0 109.305 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.6 m -145.57 138.4 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.295 -0.878 . . . . 0.0 109.485 -179.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -118.79 177.42 16.41 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -148.25 137.43 21.96 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -1.145 . . . . 0.0 109.675 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 30.8 t -91.91 108.13 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.293 -0.879 . . . . 0.0 109.503 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -92.99 66.76 4.21 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.302 -0.874 . . . . 0.0 109.256 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.402 HG11 ' H ' ' A' ' 78' ' ' GLY . 3.3 p -78.96 138.94 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.341 -0.849 . . . . 0.0 109.56 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.592 179.922 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' TYR . . . . . 0.717 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' PRO . . . . . 0.58 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' ILE . . . . . 0.808 HD12 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' TYR . . . . . . . . . . . . . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' ILE . . . . . . . . . . . . . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' VAL . . . . . . . . . . . . . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' CYS . . . . . 0.464 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' LYS . . . . . 0.609 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' PRO . . . . . 0.525 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' VAL . . . . . 0.401 HG21 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ASP . . . . . 0.432 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.405 HG22 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' GLU . . . . . 0.488 ' CB ' HG11 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' VAL . . . . . 0.596 HG23 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . 0.596 ' HD2' HG23 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.664 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 41' ' ' PRO . . . . . 0.664 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 43' ' ' THR . . . . . . . . . . . . . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 45' ' ' PHE . . . . . 0.836 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 48' ' ' VAL . . . . . 0.488 HG11 ' CB ' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.464 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 51' ' ' ILE . . . . . 0.476 HG22 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 52' ' ' PRO . . . . . 0.525 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 56' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 57' ' ' LEU . . . . . . . . . . . . . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 59' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 60' ' ' VAL . . . . . 0.439 ' CG2' ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 61' ' ' LEU . . . . . 0.741 HD23 HD13 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 62' ' ' ALA . . . . . 0.821 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 63' ' ' ASN . . . . . 0.553 ' HB3' HG23 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 64' ' ' GLY . . . . . . . . . . . . . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.418 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 66' ' ' LYS . . . . . 0.4 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 70' ' ' ASN . . . . . 0.879 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 71' ' ' VAL . . . . . 0.402 ' CG1' HD11 ' B' ' 51' ' ' ILE . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 74' ' ' VAL . . . . . . . . . . . . . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . 0.436 HD21 HD12 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . 0.418 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 77' ' ' LEU . . . . . 0.795 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 78' ' ' PRO . . . . . 0.795 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 81' ' ' PHE . . . . . 0.69 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 85' ' ' PRO . . . . . 0.471 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 89' ' ' ILE . . . . . 0.471 HG13 ' O ' ' B' ' 85' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 93' ' ' MET . . . . . 0.472 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 96' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 100' ' ' LEU . . . . . 0.4 ' HB3' HD13 ' B' ' 115' ' ' ILE . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 105' ' ' TYR . . . . . . . . . . . . . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 109' ' ' LYS . . . . . . . . . . . . . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 112' ' ' ILE . . . . . . . . . . . . . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD13 ' HB3' ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 117' ' ' PRO . . . . . 0.798 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 118' ' ' VAL . . . . . 0.469 ' HB ' ' HD2' ' B' ' 119' ' ' PRO . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 119' ' ' PRO . . . . . 0.469 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 122' ' ' LYS . . . . . 0.45 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 123' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 130' ' ' ILE . . . . . 0.836 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 133' ' ' PRO . . . . . 0.492 ' HG2' HG13 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 135' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 137' ' ' THR . . . . . 0.449 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 141' ' ' VAL . . . . . 0.492 HG13 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 143' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 144' ' ' LEU . . . . . 0.592 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 146' ' ' TYR . . . . . 0.431 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 147' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 149' ' ' TYR . . . . . 0.418 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 151' ' ' GLY . . . . . . . . . . . . . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 153' ' ' ASN . . . . . 0.492 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 154' ' ' ARG . . . . . 0.848 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 156' ' ' ARG . . . . . 0.664 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 158' ' ' GLN . . . . . 0.469 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 160' ' ' TYR . . . . . 0.919 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 161' ' ' PRO . . . . . 0.919 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 168' ' ' ASN . . . . . 0.511 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 170' ' ' VAL . . . . . . . . . . . . . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 171' ' ' TYR . . . . . 0.403 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 173' ' ' ALA . . . . . . . . . . . . . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 175' ' ' ALA . . . . . . . . . . . . . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 179' ' ' ILE . . . . . . . . . . . . . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 182' ' ' ILE . . . . . . . . . . . . . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 184' ' ' ARG . . . . . 0.406 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 190' ' ' TYR . . . . . 0.406 ' HE1' ' HG2' ' B' ' 184' ' ' ARG . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 194' ' ' ILE . . . . . 0.711 ' HB ' HG22 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 203' ' ' VAL . . . . . 0.711 HG22 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 207' ' ' ILE . . . . . 0.519 HD12 HD21 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 208' ' ' PRO . . . . . 0.515 ' HD2' HG21 ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 209' ' ' ARG . . . . . . . . . . . . . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 211' ' ' LEU . . . . . 0.469 HD21 ' OG1' ' B' ' 228' ' ' THR . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 212' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 213' ' ' LEU . . . . . 0.667 ' HA ' ' HA ' ' B' ' 228' ' ' THR . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 214' ' ' LEU . . . . . . . . . . . . . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 215' ' ' VAL . . . . . . . . . . . . . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 217' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 219' ' ' GLU . . . . . . . . . . . . . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 221' ' ' ILE . . . . . 0.419 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 225' ' ' GLN . . . . . 0.612 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 226' ' ' PRO . . . . . 0.612 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 227' ' ' LEU . . . . . . . . . . . . . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 228' ' ' THR . . . . . 0.667 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 229' ' ' SER . . . . . 0.531 ' O ' ' HD3' ' B' ' 231' ' ' PRO . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 230' ' ' ASN . . . . . . . . . . . . . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 231' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 233' ' ' VAL . . . . . . . . . . . . . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 235' ' ' GLY . . . . . 0.588 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 236' ' ' PHE . . . . . 0.492 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 237' ' ' GLY . . . . . 0.401 ' HA3' HG21 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 238' ' ' GLN . . . . . . . . . . . . . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 247' ' ' ASP . . . . . 0.427 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 248' ' ' PRO . . . . . 0.403 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 251' ' ' HEC . . . . . 0.879 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.503 2.187 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.83 108.21 5.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.276 -0.89 . . . . 0.0 109.469 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.604 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.7 t -103.82 125.91 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.405 -0.809 . . . . 0.0 109.47 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.421 HD23 ' HB2' ' A' ' 30' ' ' LYS . 18.5 mt -113.08 105.4 13.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 109.319 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.832 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.48 140.94 58.04 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.334 -0.854 . . . . 0.0 109.421 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.57 137.72 1.59 Allowed Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.53 -118.79 0.38 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -127.76 7.05 6.95 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -145.69 -41.83 0.22 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.287 -1.125 . . . . 0.0 109.57 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.3 45.59 0.04 OUTLIER Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.458 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -102.72 97.67 7.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.373 -1.075 . . . . 0.0 109.253 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.55 HD11 HG21 ' B' ' 3' ' ' ILE . 7.5 mt -77.72 94.19 4.41 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.378 -0.826 . . . . 0.0 109.415 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.869 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.65 139.31 4.49 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.324 -0.86 . . . . 0.0 109.7 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.604 ' HD2' HG11 ' A' ' 3' ' ' VAL . 37.2 m-85 -67.36 127.74 33.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.285 -0.884 . . . . 0.0 109.094 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.529 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.43 103.44 20.02 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.25 -0.906 . . . . 0.0 109.593 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.73 170.91 65.53 Favored 'Cis proline' 0 C--N 1.312 -1.373 0 C-N-CA 123.454 -1.478 . . . . 0.0 110.646 -0.274 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.452 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.28 12.39 48.09 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -167.11 111.14 0.72 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.371 -1.076 . . . . 0.0 109.125 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.0 p90 -132.2 169.68 16.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.358 -0.839 . . . . 0.0 109.709 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.89 130.24 53.2 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.384 -0.823 . . . . 0.0 109.45 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.48 -170.8 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.314 -0.867 . . . . 0.0 109.456 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.92 179.12 6.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.29 -0.881 . . . . 0.0 109.504 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.7 t -72.09 108.81 5.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.332 -0.855 . . . . 0.0 109.401 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.29 -17.02 5.65 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -82.09 172.55 13.08 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.366 -1.079 . . . . 0.0 109.493 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -129.06 134.96 48.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.633 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.542 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.7 149.52 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 t -133.44 145.72 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 109.939 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.647 ' HB3' HD11 ' A' ' 5' ' ' LEU . 51.3 m-85 -133.09 79.94 1.86 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.456 -0.777 . . . . 0.0 108.927 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.421 ' HB2' HD23 ' A' ' 4' ' ' LEU . 29.6 mttt -81.81 124.23 29.48 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.26 -0.9 . . . . 0.0 109.783 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 26.8 p-10 -95.14 130.23 41.93 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.311 -0.868 . . . . 0.0 109.425 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -104.51 -67.9 0.88 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -0.851 . . . . 0.0 109.593 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.86 152.42 48.53 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.329 -0.857 . . . . 0.0 109.568 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.28 21.45 35.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.526 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 2.8 p90 -64.34 163.03 28.1 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.354 -1.086 . . . . 0.0 109.585 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -79.5 155.49 89.55 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.421 -1.491 . . . . 0.0 110.726 -0.038 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.832 ' HB3' HD22 ' A' ' 5' ' ' LEU . 27.3 m-70 -126.62 40.99 3.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.413 -0.805 . . . . 0.0 109.222 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -68.2 128.3 36.05 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.249 -0.907 . . . . 0.0 109.369 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -100.23 153.17 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.33 -0.856 . . . . 0.0 109.841 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.491 HG12 ' H ' ' A' ' 57' ' ' MET . 9.7 m -140.7 123.0 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.418 -0.801 . . . . 0.0 109.217 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.52 133.42 45.8 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.291 -0.88 . . . . 0.0 109.571 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.409 ' HB2' ' HE1' ' A' ' 83' ' ' TYR . 0.7 OUTLIER -96.29 160.15 14.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.36 -0.838 . . . . 0.0 109.571 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.536 ' HA ' HD12 ' A' ' 46' ' ' ILE . 6.7 tp10 -100.39 44.84 1.0 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.37 -0.831 . . . . 0.0 109.429 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.29 -23.8 6.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.304 -0.872 . . . . 0.0 109.373 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -125.59 25.76 6.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 0.0 109.471 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.715 HG23 ' HD2' ' A' ' 47' ' ' PRO . 55.8 mt -90.09 141.15 27.64 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.314 -0.866 . . . . 0.0 108.988 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.715 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.7 Cg_endo -75.62 -62.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.68 2.253 . . . . 0.0 111.023 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.529 ' O ' HG22 ' A' ' 46' ' ' ILE . 2.0 t -87.05 -178.94 6.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.151 -0.968 . . . . 0.0 109.549 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.545 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -75.25 -101.68 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.67 157.56 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.517 -0.99 . . . . 0.0 109.867 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.478 ' HA ' ' NZ ' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -88.83 154.84 19.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.267 -0.896 . . . . 0.0 109.632 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.505 ' H ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.77 -27.27 40.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.419 -0.8 . . . . 0.0 109.532 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.96 -17.02 62.68 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.378 -0.827 . . . . 0.0 109.854 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.0 tptt -77.12 -31.24 55.64 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.299 -0.875 . . . . 0.0 109.699 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -113.02 4.97 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.196 -0.94 . . . . 0.0 109.935 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 66.3 m -108.52 177.81 4.68 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.491 ' H ' HG12 ' A' ' 40' ' ' VAL . 28.3 mtp -98.78 164.07 12.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -98.55 -168.47 1.65 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.395 -0.816 . . . . 0.0 109.563 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.527 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.4 OUTLIER -88.64 -27.58 21.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.383 -0.823 . . . . 0.0 109.816 -179.817 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.479 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.6 OUTLIER -81.12 -33.36 33.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.233 -0.917 . . . . 0.0 109.703 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -91.38 90.63 7.78 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.286 -0.884 . . . . 0.0 109.443 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.639 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -115.98 145.83 42.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.355 -0.841 . . . . 0.0 109.444 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.707 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.1 mp -92.93 80.59 4.61 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.831 . . . . 0.0 109.149 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.517 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.8 OUTLIER -102.09 -17.67 15.93 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.344 -0.847 . . . . 0.0 109.812 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.34 145.46 30.05 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.256 -0.903 . . . . 0.0 109.781 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.33 83.46 2.14 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.736 2.291 . . . . 0.0 110.274 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.5 -26.18 0.3 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.707 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -68.47 148.82 50.06 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.348 -1.09 . . . . 0.0 109.42 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -136.15 146.25 46.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.876 . . . . 0.0 109.85 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -109.18 109.08 19.95 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.35 -0.844 . . . . 0.0 109.011 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.542 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.19 133.87 43.95 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.662 -179.72 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -122.76 115.74 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -0.785 . . . . 0.0 109.243 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.69 102.95 14.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.31 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -100.0 143.07 30.63 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.69 -26.36 3.83 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.347 -0.846 . . . . 0.0 109.744 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.19 152.15 45.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.213 -0.929 . . . . 0.0 109.666 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.7 mttt -99.11 121.61 41.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.369 -0.832 . . . . 0.0 109.556 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.504 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.61 -171.18 42.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -113.26 114.73 27.11 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.328 -1.101 . . . . 0.0 109.512 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -93.1 177.79 5.95 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.376 -0.828 . . . . 0.0 109.176 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.52 97.56 2.65 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.155 -0.966 . . . . 0.0 109.887 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -100.66 159.16 15.4 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.533 ' HB2' HG12 ' A' ' 93' ' ' VAL . 40.0 p90 -149.13 155.65 41.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 110.16 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.9 t -67.82 111.77 4.5 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.654 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.718 0 O-C-N 121.402 -0.811 . . . . 0.0 110.215 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.869 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.8 ptm . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.531 0.682 . . . . 0.0 109.377 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.533 HG12 ' HB2' ' A' ' 83' ' ' TYR . 27.7 m -145.91 153.12 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.269 -0.894 . . . . 0.0 109.425 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.19 178.79 18.11 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -149.39 139.85 22.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.276 -1.131 . . . . 0.0 109.701 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.3 t -94.63 109.66 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.325 -0.86 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -94.05 68.3 3.74 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.257 -0.902 . . . . 0.0 109.254 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.1 p -80.23 139.77 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.34 -0.85 . . . . 0.0 109.623 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.58 179.948 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.55 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 001 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 61' ' ' LEU . . . . . 0.639 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.654 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.527 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.505 ' HE2' ' H ' ' A' ' 52' ' ' ALA . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.502 2.14 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.28 107.79 5.08 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.305 -0.872 . . . . 0.0 109.506 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.627 HG11 ' HD2' ' A' ' 14' ' ' PHE . 15.2 t -102.65 125.25 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 0.0 109.398 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.479 HD23 ' HB2' ' A' ' 30' ' ' LYS . 22.3 mt -111.36 103.27 11.63 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.399 -0.813 . . . . 0.0 109.347 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.767 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -65.6 139.09 58.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.375 -0.828 . . . . 0.0 109.415 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.71 136.79 1.82 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.01 -118.46 0.33 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -128.74 5.12 6.56 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -143.21 -41.38 0.3 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.366 -1.079 . . . . 0.0 109.62 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.27 46.13 0.04 OUTLIER Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.438 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.5 t -103.83 93.5 4.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.365 -1.079 . . . . 0.0 109.374 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 mt -75.67 91.79 2.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 109.414 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.879 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.07 141.71 8.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.331 -0.856 . . . . 0.0 109.637 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.627 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.8 m-85 -68.84 128.45 36.71 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.401 -0.812 . . . . 0.0 109.217 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.95 103.02 17.28 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.889 . . . . 0.0 109.637 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.71 171.2 64.36 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.482 . . . . 0.0 110.687 -0.235 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.414 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.97 10.32 47.97 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -164.88 113.26 1.05 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.351 -1.088 . . . . 0.0 109.135 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -133.87 170.58 15.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 109.641 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.4 m -122.58 131.34 53.78 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.352 -0.842 . . . . 0.0 109.474 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -133.25 -171.93 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.384 -0.823 . . . . 0.0 109.468 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.02 178.29 7.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.0 t -72.07 111.93 7.72 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.275 -0.89 . . . . 0.0 109.405 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.32 -17.52 7.0 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -81.42 167.4 19.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.317 -1.108 . . . . 0.0 109.496 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -124.09 131.17 53.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.594 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -95.66 151.08 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 108.986 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 t -133.42 146.74 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.176 -0.953 . . . . 0.0 110.007 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.603 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.7 m-85 -132.65 77.35 1.74 Allowed 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.479 ' HB2' HD23 ' A' ' 4' ' ' LEU . 29.4 mttt -78.92 134.01 36.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.912 . . . . 0.0 109.786 -179.606 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.472 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.4 p-10 -106.04 137.58 43.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.278 -0.889 . . . . 0.0 109.415 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -112.64 -70.46 0.81 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.352 -0.842 . . . . 0.0 109.672 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -121.09 149.97 41.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 109.578 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.91 23.22 36.11 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.469 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 4.0 p90 -67.82 162.45 58.28 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.441 -1.035 . . . . 0.0 109.525 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.526 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 35.9 Cg_endo -79.26 158.19 90.57 Favored 'Cis proline' 0 C--N 1.313 -1.31 0 C-N-CA 123.395 -1.502 . . . . 0.0 110.806 0.052 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.767 ' HB3' HD22 ' A' ' 5' ' ' LEU . 25.1 m-70 -126.17 39.77 3.87 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.43 -0.794 . . . . 0.0 109.269 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.8 p-10 -66.06 130.47 43.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.159 -0.963 . . . . 0.0 109.273 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -105.17 157.69 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 0.0 109.923 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.698 HG11 ' HB3' ' B' ' 63' ' ' ASN . 4.8 m -141.65 130.87 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.469 -0.77 . . . . 0.0 109.307 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -78.0 136.24 37.92 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.478 ' O ' HG13 ' A' ' 46' ' ' ILE . 0.6 OUTLIER -104.56 157.93 16.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.41 -0.806 . . . . 0.0 109.322 179.734 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.51 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 10.5 tp10 -94.47 17.38 13.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.333 -0.854 . . . . 0.0 109.671 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.6 -19.78 32.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 109.455 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -136.89 36.4 2.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.35 -0.844 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.74 HG23 ' HD2' ' A' ' 47' ' ' PRO . 22.1 mt -99.32 142.47 24.67 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.086 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.74 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.3 Cg_endo -76.03 -66.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 122.665 2.244 . . . . 0.0 111.125 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.521 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.9 t -84.39 -178.77 7.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.213 -0.929 . . . . 0.0 109.679 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.465 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.36 -100.76 0.14 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.465 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.61 152.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.511 -0.993 . . . . 0.0 109.79 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.504 ' HA ' ' NZ ' ' B' ' 187' ' ' LYS . 0.6 OUTLIER -80.68 152.93 28.18 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.211 -0.931 . . . . 0.0 109.597 -179.869 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.524 ' N ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.93 -25.31 40.55 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.349 -0.844 . . . . 0.0 109.593 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -74.89 -16.93 60.65 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.32 -0.862 . . . . 0.0 109.794 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.4 tptt -76.29 -32.48 58.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.334 -0.854 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.1 pt -107.54 -3.32 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.28 -0.887 . . . . 0.0 109.89 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 58.8 m -99.79 177.3 5.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.227 -0.92 . . . . 0.0 109.3 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.617 ' H ' HG12 ' A' ' 40' ' ' VAL . 8.4 mtp -92.48 155.94 17.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.269 -0.894 . . . . 0.0 109.595 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.21 -163.19 0.8 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.352 -0.842 . . . . 0.0 109.512 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.519 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -96.4 -31.35 12.89 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.348 -0.845 . . . . 0.0 110.003 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.403 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.62 -30.78 36.73 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.305 -0.872 . . . . 0.0 109.797 -179.734 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -89.08 100.69 13.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.304 -0.873 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.715 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -124.5 145.21 49.68 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.473 -0.767 . . . . 0.0 109.488 -179.935 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 4.2 mp -91.03 68.57 6.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.392 -0.817 . . . . 0.0 109.16 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -24.69 20.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.351 -0.843 . . . . 0.0 109.949 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.87 146.17 38.24 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.218 -0.926 . . . . 0.0 109.738 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.34 79.25 3.22 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.755 2.303 . . . . 0.0 110.252 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.09 -24.92 0.19 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.1 tp10 -68.31 148.6 50.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.444 -1.033 . . . . 0.0 109.347 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.7 p -136.09 145.81 46.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 109.867 -179.567 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 23.3 t80 -107.06 107.78 18.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.35 -0.844 . . . . 0.0 109.144 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.85 131.25 45.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 109.566 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.98 114.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.363 -0.836 . . . . 0.0 109.3 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.7 m -86.66 101.65 13.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.342 -0.849 . . . . 0.0 109.254 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -98.63 142.15 30.56 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.371 -0.83 . . . . 0.0 109.57 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.5 p -123.3 -24.68 4.6 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.699 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.36 153.99 42.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.288 -0.883 . . . . 0.0 109.622 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.3 mttt -101.16 125.38 47.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.533 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.99 -166.88 37.77 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -117.44 112.65 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.298 -1.119 . . . . 0.0 109.527 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -91.21 176.83 6.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.338 -0.851 . . . . 0.0 109.178 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.4 99.31 3.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.199 -0.938 . . . . 0.0 109.866 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.434 ' CE2' HG23 ' A' ' 96' ' ' VAL . 44.9 p90 -103.48 164.04 11.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.361 -0.837 . . . . 0.0 108.868 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.644 ' HB2' HG12 ' A' ' 93' ' ' VAL . 34.7 p90 -153.02 155.78 37.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.168 -0.957 . . . . 0.0 109.812 -179.649 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.68 108.1 2.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.424 -0.797 . . . . 0.0 109.119 179.604 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.842 ' HB3' ' HB3' ' B' ' 62' ' ' ALA . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.48 -0.763 . . . . 0.0 109.924 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.879 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.644 HG12 ' HB2' ' A' ' 83' ' ' TYR . 32.4 m -143.06 165.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.271 -0.893 . . . . 0.0 109.615 -179.534 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.414 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -144.14 177.76 22.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -150.14 139.03 20.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.261 -1.141 . . . . 0.0 109.839 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.434 HG23 ' CE2' ' A' ' 82' ' ' PHE . 40.8 t -94.64 115.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.401 -0.812 . . . . 0.0 109.507 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -98.21 67.2 1.85 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.253 -0.905 . . . . 0.0 109.122 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.79 141.85 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.39 -0.819 . . . . 0.0 109.643 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.581 179.939 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 002 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 61' ' ' LEU . . . . . 0.715 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.842 ' HB3' ' HB3' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.698 ' HB3' HG11 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.519 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.524 ' HE2' ' N ' ' A' ' 52' ' ' ALA . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 N--CA 1.502 2.143 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.3 109.86 4.94 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.303 -0.873 . . . . 0.0 109.417 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.645 HG11 ' HD2' ' A' ' 14' ' ' PHE . 11.5 t -104.52 120.53 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.328 -0.858 . . . . 0.0 109.559 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.485 HD23 ' HB2' ' A' ' 30' ' ' LYS . 24.6 mt -106.73 101.36 10.81 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -0.838 . . . . 0.0 109.287 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.829 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.2 mp -64.42 141.21 58.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 109.432 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.18 138.36 1.56 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.74 -115.28 0.33 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -132.12 6.37 5.38 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.6 -41.34 0.22 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.346 -1.091 . . . . 0.0 109.596 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.22 45.45 0.04 OUTLIER Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.403 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.3 t -105.65 98.0 7.76 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.308 -1.113 . . . . 0.0 109.304 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.018 HD11 HG21 ' B' ' 3' ' ' ILE . 9.0 mt -78.79 101.12 7.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.324 -0.86 . . . . 0.0 109.487 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.692 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -169.58 136.24 1.63 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 109.661 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.645 ' HD2' HG11 ' A' ' 3' ' ' VAL . 39.6 m-85 -65.9 126.5 28.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 109.124 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.513 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -126.83 103.14 24.36 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.262 -0.898 . . . . 0.0 109.573 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.513 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.72 169.33 70.86 Favored 'Cis proline' 0 C--N 1.312 -1.356 0 C-N-CA 123.459 -1.475 . . . . 0.0 110.67 -0.224 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.458 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.2 12.28 51.89 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -166.98 105.63 0.58 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.393 -1.063 . . . . 0.0 109.009 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -126.77 167.67 15.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.707 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.5 128.39 53.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.345 -0.847 . . . . 0.0 109.393 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -130.43 -171.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.35 -0.844 . . . . 0.0 109.519 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.15 179.38 6.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.312 -0.868 . . . . 0.0 109.451 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.19 108.78 5.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.297 -0.877 . . . . 0.0 109.385 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.47 -17.26 5.58 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -81.84 171.41 14.53 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.31 -1.112 . . . . 0.0 109.434 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -128.27 133.39 48.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.288 -0.883 . . . . 0.0 109.702 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -94.45 146.56 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.442 -0.786 . . . . 0.0 109.071 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -129.57 145.48 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.19 -0.944 . . . . 0.0 109.818 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.631 ' HB3' HD11 ' A' ' 5' ' ' LEU . 46.5 m-85 -133.01 82.04 1.97 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.469 -0.769 . . . . 0.0 109.03 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.485 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.7 mttt -83.34 126.57 32.84 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.201 -0.937 . . . . 0.0 109.752 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.498 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.9 p-10 -98.85 127.8 44.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.259 -0.901 . . . . 0.0 109.481 179.752 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -104.65 -65.74 1.01 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 109.54 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -129.71 144.1 51.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.338 -0.851 . . . . 0.0 109.517 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.43 22.53 16.46 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.54 ' HB2' ' HA ' ' A' ' 64' ' ' ASN . 3.3 p90 -66.78 163.98 37.94 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.362 -1.081 . . . . 0.0 109.486 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.63 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.4 Cg_endo -80.4 152.14 83.09 Favored 'Cis proline' 0 C--N 1.312 -1.36 0 C-N-CA 123.389 -1.504 . . . . 0.0 110.858 -0.062 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.829 ' HB3' HD22 ' A' ' 5' ' ' LEU . 27.4 m-70 -118.26 40.35 3.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.347 -0.846 . . . . 0.0 109.222 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.2 p-10 -65.64 120.29 12.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.311 -0.868 . . . . 0.0 109.34 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.7 m -96.35 148.8 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.335 -0.853 . . . . 0.0 109.9 -179.376 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' B' ' 63' ' ' ASN . 7.7 m -134.82 119.79 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.43 -0.794 . . . . 0.0 109.048 179.769 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 15.0 m-85 -67.78 131.92 46.46 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.287 -0.883 . . . . 0.0 109.968 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.44 ' HB2' ' HE2' ' A' ' 83' ' ' TYR . 1.4 t0 -93.79 158.08 15.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.384 -0.822 . . . . 0.0 109.43 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.71 ' OE1' ' HE2' ' B' ' 187' ' ' LYS . 2.8 tp10 -100.55 17.82 20.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.844 . . . . 0.0 109.631 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -92.3 -18.04 23.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.148 -0.97 . . . . 0.0 109.483 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -130.64 26.21 5.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.226 -0.922 . . . . 0.0 109.629 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.738 HG23 ' HD2' ' A' ' 47' ' ' PRO . 19.0 mt -91.06 142.65 27.54 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.258 -0.901 . . . . 0.0 109.182 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.738 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -75.96 -65.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.704 2.27 . . . . 0.0 111.171 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.541 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.7 t -81.84 -177.61 6.64 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.189 -0.944 . . . . 0.0 109.692 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.505 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.9 -107.61 0.14 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.505 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.5 156.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.969 . . . . 0.0 109.856 179.926 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.72 160.8 14.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.401 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -80.55 -24.13 39.46 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.307 -0.871 . . . . 0.0 109.613 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -66.27 -19.16 65.74 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.227 -0.921 . . . . 0.0 109.951 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -80.57 -30.88 36.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.236 -0.915 . . . . 0.0 109.682 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.1 pt -117.17 23.26 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 109.84 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.401 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 45.0 m -127.72 171.28 11.85 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.472 ' H ' HG12 ' A' ' 40' ' ' VAL . 27.0 mtp -96.78 162.86 13.24 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.356 -0.84 . . . . 0.0 109.638 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.1 t -102.0 -171.2 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.349 -0.844 . . . . 0.0 109.746 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -84.64 -24.76 28.92 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.373 -0.829 . . . . 0.0 109.817 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -82.2 -32.42 29.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.254 -0.904 . . . . 0.0 109.705 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -95.23 90.02 5.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.83 146.29 42.11 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.42 -0.8 . . . . 0.0 109.388 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.664 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.6 mp -93.28 76.01 4.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.387 -0.821 . . . . 0.0 109.357 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.54 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.7 OUTLIER -98.04 -0.82 43.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.339 -0.851 . . . . 0.0 109.944 -179.721 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -107.19 143.85 27.97 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.174 -0.954 . . . . 0.0 109.711 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.42 84.7 1.91 Allowed 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.704 2.27 . . . . 0.0 110.296 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.22 -25.43 0.47 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.664 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -69.2 149.72 48.27 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.339 -1.095 . . . . 0.0 109.428 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 37.1 p -136.55 145.44 45.01 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.266 -0.896 . . . . 0.0 109.797 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -108.68 109.67 20.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.352 -0.842 . . . . 0.0 109.034 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.95 134.25 44.22 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.258 -0.901 . . . . 0.0 109.762 -179.722 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -123.14 115.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.374 -0.829 . . . . 0.0 109.211 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.49 104.18 15.71 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.281 -0.887 . . . . 0.0 109.343 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -101.4 142.75 32.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.384 -0.822 . . . . 0.0 109.547 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.8 p -124.66 -25.99 3.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.436 -0.79 . . . . 0.0 109.737 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 152.7 45.1 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.247 -0.908 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -99.61 124.39 44.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 109.514 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.465 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 164.13 -168.55 38.63 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.3 m -115.3 118.72 34.07 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.313 -1.11 . . . . 0.0 109.528 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -96.63 179.13 5.1 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.349 -0.845 . . . . 0.0 109.149 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.79 96.99 2.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.193 -0.942 . . . . 0.0 109.835 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -100.43 153.52 19.28 Favored 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.44 ' HE2' ' HB2' ' A' ' 42' ' ' ASP . 35.5 p90 -143.46 155.97 44.51 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.081 -1.012 . . . . 0.0 110.34 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 8.6 t -68.55 114.02 6.58 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.459 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.481 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.809 0 O-C-N 121.252 -0.905 . . . . 0.0 109.992 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.758 ' CG ' ' O ' ' A' ' 92' ' ' MET . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 121.576 0.703 . . . . 0.0 109.515 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.42 HG12 ' HB2' ' A' ' 83' ' ' TYR . 17.4 m -146.63 148.61 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.381 -0.825 . . . . 0.0 109.211 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.32 179.88 16.69 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.3 ptmt -149.44 139.56 22.14 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.444 -1.033 . . . . 0.0 109.6 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.1 t -93.44 109.33 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.374 -0.829 . . . . 0.0 109.536 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -93.88 68.1 3.82 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.275 -0.891 . . . . 0.0 109.169 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.3 p -79.77 141.23 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.309 -0.869 . . . . 0.0 109.535 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.636 -179.998 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 1.018 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 003 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.523 ' HB2' ' NH1' ' B' ' 156' ' ' ARG . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.537 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.71 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.43 108.32 4.8 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 0.0 109.427 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.608 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.7 t -103.73 125.0 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.869 . . . . 0.0 109.497 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.413 HD23 ' HB2' ' A' ' 30' ' ' LYS . 19.8 mt -111.98 104.06 12.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.357 -0.839 . . . . 0.0 109.299 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.873 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.0 OUTLIER -65.62 139.42 58.42 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.834 . . . . 0.0 109.445 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.479 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.57 136.47 1.72 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.01 -117.07 0.23 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -129.86 7.39 6.13 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.38 -41.11 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.332 -1.099 . . . . 0.0 109.59 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.89 47.64 0.04 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.479 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -104.92 97.93 7.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.347 -1.09 . . . . 0.0 109.373 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.434 HD11 HG21 ' B' ' 3' ' ' ILE . 8.7 mt -77.42 94.21 4.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.34 -0.85 . . . . 0.0 109.403 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.878 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.86 139.4 4.35 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.366 -0.834 . . . . 0.0 109.744 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.608 ' HD2' HG11 ' A' ' 3' ' ' VAL . 37.2 m-85 -67.51 128.06 35.02 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.406 -0.809 . . . . 0.0 109.072 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.463 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.66 103.17 19.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.234 -0.916 . . . . 0.0 109.572 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.3 Cg_endo -79.74 170.79 65.88 Favored 'Cis proline' 0 C--N 1.313 -1.333 0 C-N-CA 123.41 -1.496 . . . . 0.0 110.646 -0.269 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.443 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.33 12.49 47.92 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -166.9 110.08 0.71 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.338 -1.095 . . . . 0.0 109.086 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -131.3 169.45 15.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.678 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.5 m -121.91 130.35 53.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.345 -0.847 . . . . 0.0 109.498 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.49 -170.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.398 -0.814 . . . . 0.0 109.453 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.08 179.15 6.67 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.8 t -72.12 109.14 5.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.289 -0.882 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.72 -17.04 5.81 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.1 171.22 14.59 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.339 -1.095 . . . . 0.0 109.467 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.69 134.7 49.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.272 -0.892 . . . . 0.0 109.646 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.82 149.91 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.416 -0.803 . . . . 0.0 109.058 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.34 145.95 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.209 -0.932 . . . . 0.0 109.949 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.647 ' HB3' HD11 ' A' ' 5' ' ' LEU . 52.0 m-85 -133.41 79.99 1.86 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 108.95 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.413 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.3 mttt -81.36 125.74 30.75 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.242 -0.911 . . . . 0.0 109.758 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.435 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 26.6 p-10 -97.11 125.99 41.97 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.304 -0.873 . . . . 0.0 109.52 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -101.21 -65.46 0.97 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.33 -0.857 . . . . 0.0 109.544 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.17 148.28 52.7 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.54 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.04 21.1 26.3 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.49 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.9 p90 -64.86 163.23 30.54 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.324 -1.104 . . . . 0.0 109.676 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.564 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -79.75 153.65 87.17 Favored 'Cis proline' 0 C--N 1.312 -1.363 0 C-N-CA 123.367 -1.514 . . . . 0.0 110.68 -0.162 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.873 ' HB3' HD22 ' A' ' 5' ' ' LEU . 34.4 m-70 -123.9 39.0 4.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.405 -0.81 . . . . 0.0 109.269 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -66.0 126.0 27.2 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.272 -0.892 . . . . 0.0 109.367 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -97.89 149.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.884 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.409 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.4 m -136.61 119.88 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.504 -0.747 . . . . 0.0 108.999 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -68.62 133.17 48.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.232 -0.918 . . . . 0.0 109.692 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.21 159.99 14.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.37 -0.831 . . . . 0.0 109.371 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.579 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.9 tp10 -100.78 31.94 3.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.4 -0.812 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.15 -18.66 13.95 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -130.67 24.93 5.07 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.345 -0.847 . . . . 0.0 109.56 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.736 HG23 ' HD2' ' A' ' 47' ' ' PRO . 35.8 mt -89.36 141.82 29.26 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.324 -0.86 . . . . 0.0 109.119 179.683 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.736 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.8 Cg_endo -75.69 -63.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.733 2.289 . . . . 0.0 111.103 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.543 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.9 t -84.81 -177.95 6.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.177 -0.952 . . . . 0.0 109.588 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.517 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.41 -105.47 0.13 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.517 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.24 156.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.53 -0.982 . . . . 0.0 109.835 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.76 158.2 16.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.307 -0.871 . . . . 0.0 109.581 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.46 -24.25 39.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.334 -0.854 . . . . 0.0 109.558 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.31 -15.94 62.94 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.38 -0.825 . . . . 0.0 109.853 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.2 tptt -81.3 -31.17 33.69 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.283 -0.886 . . . . 0.0 109.697 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.5 pt -113.23 7.55 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 67.5 m -111.74 173.92 6.12 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.194 -0.942 . . . . 0.0 109.419 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.4 ' H ' HG12 ' A' ' 40' ' ' VAL . 19.8 mtp -93.63 161.29 14.41 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 109.624 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.8 -167.25 1.56 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.341 -0.849 . . . . 0.0 109.681 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.412 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.8 OUTLIER -90.18 -28.66 18.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.339 -0.851 . . . . 0.0 109.976 -179.666 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.412 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -80.28 -30.38 38.33 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.253 -0.905 . . . . 0.0 109.859 -179.734 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -95.0 91.5 6.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.213 -0.93 . . . . 0.0 109.575 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.403 HD11 HD21 ' B' ' 61' ' ' LEU . 0.2 OUTLIER -115.6 142.98 46.0 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.406 -0.809 . . . . 0.0 109.296 179.914 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.719 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.8 mp -89.14 80.57 6.92 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.3 -0.875 . . . . 0.0 109.133 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.476 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 2.0 t30 -100.4 -22.9 14.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.91 145.46 36.63 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 109.905 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.59 81.6 2.62 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.801 2.334 . . . . 0.0 110.275 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 -25.74 0.24 Allowed Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.719 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.59 149.18 50.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.331 -1.1 . . . . 0.0 109.441 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -135.79 145.98 47.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 109.878 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.7 t80 -109.09 108.94 19.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.343 -0.848 . . . . 0.0 109.045 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.0 133.83 43.81 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.314 -0.866 . . . . 0.0 109.703 -179.697 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.76 115.22 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.42 -0.8 . . . . 0.0 109.239 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.24 102.04 13.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.296 -0.878 . . . . 0.0 109.279 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.1 142.98 29.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.347 -0.845 . . . . 0.0 109.559 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.56 -26.31 3.88 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.335 -0.853 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 151.8 46.47 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.328 -0.858 . . . . 0.0 109.615 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.3 mttt -98.81 122.55 42.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.376 -0.828 . . . . 0.0 109.594 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.5 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.64 -171.42 41.55 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -112.97 114.4 26.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.319 -1.106 . . . . 0.0 109.494 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -92.73 176.89 6.27 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.303 -0.873 . . . . 0.0 109.123 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.43 93.9 2.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.117 -0.99 . . . . 0.0 109.86 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -97.36 155.94 16.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.331 -0.856 . . . . 0.0 108.806 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.542 ' HB2' HG12 ' A' ' 93' ' ' VAL . 41.4 p90 -145.84 155.32 42.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.041 -1.037 . . . . 0.0 110.207 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.7 t -67.69 107.2 2.47 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.587 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.803 0 O-C-N 121.395 -0.816 . . . . 0.0 109.975 -179.674 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.878 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.4 ptm . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.559 0.695 . . . . 0.0 109.481 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.542 HG12 ' HB2' ' A' ' 83' ' ' TYR . 28.9 m -146.72 150.08 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.443 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.0 178.17 17.93 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.7 ptmt -149.03 138.93 22.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.35 -1.088 . . . . 0.0 109.696 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 33.0 t -93.98 110.12 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.343 -0.848 . . . . 0.0 109.533 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.18 67.53 3.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.303 -0.873 . . . . 0.0 109.297 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.0 p -79.46 140.0 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.4 -0.812 . . . . 0.0 109.55 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.549 179.994 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.434 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 004 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 61' ' ' LEU . . . . . 0.403 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.587 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.409 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.493 ' HD3' ' HG2' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.2 p . . . . . 0 N--CA 1.502 2.162 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.85 106.64 4.87 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.895 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.565 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.9 t -102.33 126.35 56.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 17.8 mt -114.0 106.29 14.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.382 -0.823 . . . . 0.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.829 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.65 136.85 56.18 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.39 -0.819 . . . . 0.0 109.419 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.484 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 81.2 135.44 1.75 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.88 -119.42 0.26 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.88 -0.69 9.03 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -134.82 -41.11 0.76 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.364 -1.08 . . . . 0.0 109.549 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.925 ' O ' ' NE2' ' B' ' 7' ' ' GLN . . . 169.57 42.93 0.03 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.484 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.2 t -94.6 93.47 7.6 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.274 -1.133 . . . . 0.0 109.324 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -73.75 92.26 1.99 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.286 -0.884 . . . . 0.0 109.491 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.844 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.43 141.96 3.77 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.334 -0.854 . . . . 0.0 109.6 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.565 ' HD2' HG11 ' A' ' 3' ' ' VAL . 43.0 m-85 -68.12 127.87 34.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.378 -0.826 . . . . 0.0 109.197 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.4 mp -129.35 104.18 17.9 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 109.591 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.55 170.43 67.65 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.389 -1.505 . . . . 0.0 110.66 -0.272 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.42 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.65 10.47 49.34 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -165.05 111.65 0.97 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.316 -1.108 . . . . 0.0 109.131 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -132.29 169.38 16.55 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.388 -0.82 . . . . 0.0 109.59 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.07 130.16 53.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.344 -0.848 . . . . 0.0 109.423 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.6 m -132.92 -171.58 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.369 -0.832 . . . . 0.0 109.487 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.99 178.52 7.06 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.4 t -71.9 109.94 6.08 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.296 -0.878 . . . . 0.0 109.326 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.54 -17.29 5.85 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.04 173.4 12.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.39 -1.065 . . . . 0.0 109.453 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -129.73 134.67 47.76 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.284 -0.885 . . . . 0.0 109.675 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.546 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.46 149.39 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.407 -0.808 . . . . 0.0 109.046 179.7 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 t -133.25 145.6 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.179 -0.951 . . . . 0.0 109.992 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.635 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.0 m-85 -132.89 77.89 1.76 Allowed 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 mttt -79.38 124.66 28.64 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.191 -0.943 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.429 ' HA ' ' HB2' ' A' ' 5' ' ' LEU . 24.0 p-10 -96.75 120.82 37.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.319 -0.863 . . . . 0.0 109.451 179.69 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -93.99 -65.56 0.98 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 109.677 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.14 150.46 52.14 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.351 -0.843 . . . . 0.0 109.643 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 17.08 37.78 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.512 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 5.1 p90 -63.27 162.93 20.74 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.334 -1.098 . . . . 0.0 109.601 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.59 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.2 Cg_endo -79.11 150.9 86.53 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.483 . . . . 0.0 110.848 0.123 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.829 ' HB3' HD22 ' A' ' 5' ' ' LEU . 37.0 m-70 -124.04 42.39 3.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.39 -0.819 . . . . 0.0 109.41 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -66.24 126.4 28.58 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.168 -0.958 . . . . 0.0 109.333 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.5 m -96.53 150.57 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.283 -0.886 . . . . 0.0 109.75 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.484 HG12 ' H ' ' A' ' 57' ' ' MET . 10.2 m -138.99 121.51 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.438 -0.789 . . . . 0.0 109.302 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -71.07 127.8 33.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.24 -0.913 . . . . 0.0 109.41 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.26 163.98 18.32 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.238 -0.914 . . . . 0.0 109.624 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.503 ' HA ' HD12 ' A' ' 46' ' ' ILE . 1.3 tp10 -101.49 25.58 8.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.408 -0.807 . . . . 0.0 109.527 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.46 -18.69 14.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.565 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -130.13 59.64 1.63 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.183 -0.948 . . . . 0.0 109.708 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.679 HG23 ' HD2' ' A' ' 47' ' ' PRO . 76.9 mt -119.82 140.3 29.4 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.267 -0.896 . . . . 0.0 109.089 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.679 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -76.05 -62.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 122.697 2.265 . . . . 0.0 110.968 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.469 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.4 t -88.92 -172.91 3.88 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.185 -0.947 . . . . 0.0 109.581 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.477 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.81 -112.29 0.14 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.477 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.8 154.95 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.495 -1.003 . . . . 0.0 109.792 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -95.35 168.05 10.96 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.28 -0.888 . . . . 0.0 109.661 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -85.03 -20.94 29.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.35 -0.844 . . . . 0.0 109.669 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -69.76 -12.34 61.56 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.213 -0.93 . . . . 0.0 109.982 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -88.88 -27.49 20.98 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.211 -0.931 . . . . 0.0 109.829 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.7 pt -117.96 12.21 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.195 -0.94 . . . . 0.0 110.078 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 74.7 m -117.08 175.31 5.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.159 -0.963 . . . . 0.0 109.45 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.484 ' H ' HG12 ' A' ' 40' ' ' VAL . 31.5 mtp -99.78 164.64 11.95 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.368 -0.833 . . . . 0.0 109.522 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.7 -170.83 1.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.324 -0.86 . . . . 0.0 109.745 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.525 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.6 OUTLIER -87.71 -25.97 23.19 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.374 -0.828 . . . . 0.0 109.794 -179.84 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.449 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 1.5 mp0 -82.38 -32.08 29.39 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.525 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -95.0 89.56 5.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.277 -0.889 . . . . 0.0 109.217 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.441 HD12 ' O ' ' A' ' 59' ' ' GLU . 0.1 OUTLIER -115.91 144.74 43.64 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.352 -0.843 . . . . 0.0 109.622 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.669 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.0 mp -86.94 79.44 8.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.415 -0.803 . . . . 0.0 109.155 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.456 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.4 t30 -100.26 -4.64 28.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.304 -0.872 . . . . 0.0 110.01 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.412 ' HA ' ' HD3' ' A' ' 66' ' ' PRO . . . -103.46 143.55 26.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 65' ' ' ALA . 35.3 Cg_endo -77.21 79.94 3.02 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.711 2.274 . . . . 0.0 110.242 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.2 -25.41 0.26 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.669 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.51 149.46 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.371 -1.076 . . . . 0.0 109.403 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 29.6 p -135.91 145.68 46.54 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.925 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 33.5 t80 -108.53 108.55 19.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -99.76 134.22 42.97 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.338 -0.851 . . . . 0.0 109.723 -179.627 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -122.93 113.92 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.38 -0.825 . . . . 0.0 109.319 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -84.63 102.31 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.253 -0.904 . . . . 0.0 109.291 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.64 142.17 31.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.1 p -123.92 -25.66 4.2 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.356 -0.84 . . . . 0.0 109.718 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.0 151.66 46.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.293 -0.879 . . . . 0.0 109.708 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -98.68 120.84 39.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.398 -0.814 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.406 ' H ' HG13 ' A' ' 98' ' ' VAL . . . 168.42 -171.82 42.75 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.4 m -113.56 114.14 26.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.274 -1.133 . . . . 0.0 109.493 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.17 179.02 5.55 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.366 -0.834 . . . . 0.0 109.095 179.753 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.78 101.46 3.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 109.8 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -102.91 163.28 12.3 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.647 ' HB2' HG12 ' A' ' 93' ' ' VAL . 43.7 p90 -155.17 154.32 32.1 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.078 -1.014 . . . . 0.0 110.158 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 35.2 t -66.43 110.08 2.98 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.74 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.686 0 O-C-N 121.451 -0.78 . . . . 0.0 110.247 -179.369 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.844 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.647 HG12 ' HB2' ' A' ' 83' ' ' TYR . 32.8 m -142.74 167.6 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -0.867 . . . . 0.0 109.629 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -147.8 -177.95 22.62 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.1 ptmt -152.36 142.02 21.85 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.122 . . . . 0.0 109.848 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 27.1 t -97.5 112.02 28.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.36 -0.838 . . . . 0.0 109.371 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -95.95 68.89 2.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.203 -0.936 . . . . 0.0 109.175 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 78' ' ' GLY . 4.4 p -81.01 139.52 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.33 -0.856 . . . . 0.0 109.591 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.604 -179.974 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.925 ' NE2' ' O ' ' A' ' 10' ' ' GLY . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.74 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.447 ' HB3' ' OG ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.525 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.171 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.6 108.97 4.61 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.621 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.0 t -104.08 120.37 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.315 -0.866 . . . . 0.0 109.474 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.426 HD23 ' HB2' ' A' ' 30' ' ' LYS . 21.2 mt -107.58 101.68 10.99 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.338 -0.851 . . . . 0.0 109.321 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.881 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -64.44 141.93 58.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.381 -0.824 . . . . 0.0 109.512 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.17 135.16 1.09 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.01 -116.79 0.19 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -130.45 7.64 5.93 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.61 -41.02 0.22 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.334 -1.097 . . . . 0.0 109.586 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.46 48.19 0.04 OUTLIER Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.46 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.8 t -105.67 99.33 8.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.339 -1.095 . . . . 0.0 109.322 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.664 HD11 HG21 ' B' ' 3' ' ' ILE . 11.1 mt -78.32 96.07 5.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.37 -0.831 . . . . 0.0 109.404 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.87 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.23 138.1 3.07 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.342 -0.849 . . . . 0.0 109.728 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.621 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.8 m-85 -66.68 127.71 33.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.357 -0.839 . . . . 0.0 109.031 179.635 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -128.12 103.12 20.94 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.293 -0.879 . . . . 0.0 109.573 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.61 170.43 67.46 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.394 -1.503 . . . . 0.0 110.666 -0.348 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.448 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.22 12.7 48.43 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -167.03 108.6 0.66 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.331 -1.1 . . . . 0.0 109.076 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -130.02 169.49 15.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.393 -0.817 . . . . 0.0 109.666 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 m -121.97 129.65 52.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.332 -0.855 . . . . 0.0 109.438 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.77 -170.17 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.38 -0.825 . . . . 0.0 109.482 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.55 179.11 6.75 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.305 -0.872 . . . . 0.0 109.473 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.09 108.83 5.5 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.27 -17.38 5.62 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -81.8 171.61 14.32 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.345 -1.091 . . . . 0.0 109.468 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -127.97 134.25 49.26 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.285 -0.884 . . . . 0.0 109.665 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.0 149.04 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.437 -0.789 . . . . 0.0 109.042 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 t -132.4 145.71 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.193 -0.942 . . . . 0.0 109.896 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.625 ' HB3' HD11 ' A' ' 5' ' ' LEU . 49.9 m-85 -133.32 80.38 1.88 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.424 -0.797 . . . . 0.0 109.016 179.613 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.426 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.9 mttt -81.55 126.78 32.12 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.223 -0.923 . . . . 0.0 109.729 -179.606 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.496 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 26.9 p-10 -98.07 126.22 43.41 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.333 -0.855 . . . . 0.0 109.484 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.99 -65.72 0.97 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.856 . . . . 0.0 109.522 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.33 146.91 52.49 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.344 -0.848 . . . . 0.0 109.544 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.05 20.95 26.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.546 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.7 p90 -64.24 164.8 16.38 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.363 -1.08 . . . . 0.0 109.634 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.621 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -80.03 153.54 85.99 Favored 'Cis proline' 0 C--N 1.313 -1.338 0 C-N-CA 123.378 -1.509 . . . . 0.0 110.606 -0.246 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.881 ' HB3' HD22 ' A' ' 5' ' ' LEU . 32.2 m-70 -121.1 37.96 4.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.217 179.564 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 15.7 p-10 -65.1 121.64 15.19 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.318 -0.864 . . . . 0.0 109.304 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -94.83 148.43 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.28 -0.888 . . . . 0.0 109.846 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.413 HG21 ' HB3' ' B' ' 63' ' ' ASN . 5.6 m -134.77 117.49 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.482 -0.761 . . . . 0.0 109.01 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -66.38 133.25 50.09 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.322 -0.861 . . . . 0.0 109.82 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -94.96 159.15 15.16 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.389 -0.819 . . . . 0.0 109.361 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.612 ' HA ' HD12 ' A' ' 46' ' ' ILE . 3.9 tp10 -100.55 24.71 8.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 109.591 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.97 -16.69 17.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -131.42 27.21 4.76 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.285 -0.884 . . . . 0.0 109.539 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.735 HG23 ' HD2' ' A' ' 47' ' ' PRO . 28.2 mt -92.15 142.18 25.96 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.301 -0.874 . . . . 0.0 109.055 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.735 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.67 -63.9 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.713 2.276 . . . . 0.0 111.101 -179.545 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.545 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -84.15 -176.85 6.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.162 -0.961 . . . . 0.0 109.563 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.502 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.66 -107.59 0.14 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.41 155.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.494 -1.004 . . . . 0.0 109.841 179.886 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.2 161.55 15.02 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.251 -0.906 . . . . 0.0 109.636 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.12 -22.16 36.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 0.0 109.644 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.78 -13.83 62.2 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.295 -0.878 . . . . 0.0 109.846 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -85.15 -29.86 24.44 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.247 -0.908 . . . . 0.0 109.679 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -114.54 8.2 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.17 -0.956 . . . . 0.0 110.021 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.8 m -113.47 172.93 6.67 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.168 -0.957 . . . . 0.0 109.408 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.8 mtp -92.52 160.91 14.83 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.317 -0.864 . . . . 0.0 109.56 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -95.14 -167.36 1.61 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.42 -0.8 . . . . 0.0 109.545 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.429 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.7 OUTLIER -90.94 -25.67 19.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.288 -0.883 . . . . 0.0 109.785 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.429 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -82.07 -30.41 31.33 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.739 -179.81 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -95.99 93.64 7.12 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.197 -0.94 . . . . 0.0 109.605 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.95 143.1 46.1 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.401 -0.812 . . . . 0.0 109.332 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.711 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.9 mp -89.28 80.52 6.84 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.346 -0.846 . . . . 0.0 109.18 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.483 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.8 t30 -100.09 -21.17 15.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 -179.647 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -88.53 144.82 34.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.175 -0.953 . . . . 0.0 109.864 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.45 81.62 2.6 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.754 2.303 . . . . 0.0 110.276 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.53 -25.6 0.25 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.711 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.58 149.43 50.12 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.419 -1.048 . . . . 0.0 109.408 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.9 p -135.81 145.39 46.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.251 -0.906 . . . . 0.0 109.864 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -108.84 109.22 20.28 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.453 -0.779 . . . . 0.0 109.008 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.29 134.3 43.43 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.343 -0.848 . . . . 0.0 109.726 -179.695 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.94 115.44 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.407 -0.808 . . . . 0.0 109.243 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -86.3 102.21 13.78 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.252 -0.905 . . . . 0.0 109.31 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.3 143.0 30.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.855 . . . . 0.0 109.606 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.3 p -124.63 -26.61 3.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.39 47.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.264 -0.898 . . . . 0.0 109.682 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -98.41 122.43 41.58 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.427 -0.795 . . . . 0.0 109.529 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.48 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.9 -170.92 41.58 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -113.68 114.1 25.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -1.157 . . . . 0.0 109.513 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -92.31 177.87 6.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.419 -0.801 . . . . 0.0 109.118 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.21 93.65 2.12 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.213 -0.93 . . . . 0.0 109.85 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.7 p90 -96.99 154.5 17.26 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 108.791 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.525 ' HB2' HG12 ' A' ' 93' ' ' VAL . 42.1 p90 -144.49 157.05 44.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.134 -0.979 . . . . 0.0 110.174 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 10.1 t -67.83 114.77 6.68 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.767 0 O-C-N 121.348 -0.845 . . . . 0.0 110.036 -179.562 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.87 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 1.3 ptm . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 121.563 0.697 . . . . 0.0 109.325 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.525 HG12 ' HB2' ' A' ' 83' ' ' TYR . 28.0 m -146.8 148.41 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.351 -0.843 . . . . 0.0 109.405 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -129.45 178.69 17.23 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -148.86 138.51 21.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.123 . . . . 0.0 109.636 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.8 t -93.21 110.07 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.08 67.22 3.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.248 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.6 p -79.25 139.59 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.333 -0.854 . . . . 0.0 109.6 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.577 179.936 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.664 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 006 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.644 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.413 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 0.525 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 N--CA 1.503 2.188 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.82 107.97 4.88 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.307 -0.871 . . . . 0.0 109.408 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.63 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.9 t -102.98 124.01 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.363 -0.835 . . . . 0.0 109.451 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.491 HD23 ' HB2' ' A' ' 30' ' ' LYS . 21.8 mt -110.26 101.88 10.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.361 -0.837 . . . . 0.0 109.383 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.822 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.24 133.08 50.7 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.335 -0.853 . . . . 0.0 109.388 -179.99 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.504 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 84.69 133.01 2.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.72 -118.15 0.15 Allowed Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.62 -1.89 6.95 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -132.93 -40.34 0.94 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.129 . . . . 0.0 109.592 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.583 ' HA3' HD11 ' B' ' 3' ' ' ILE . . . 168.31 46.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.504 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.7 t -99.19 94.56 6.56 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.356 -1.085 . . . . 0.0 109.338 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.5 mt -75.18 89.7 2.53 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.343 -0.848 . . . . 0.0 109.471 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.87 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.51 142.03 7.93 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.295 -0.878 . . . . 0.0 109.674 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.63 ' HD2' HG11 ' A' ' 3' ' ' VAL . 38.1 m-85 -68.15 128.26 35.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -0.849 . . . . 0.0 109.159 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.54 102.31 18.33 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 109.604 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.74 171.6 62.44 Favored 'Cis proline' 0 C--N 1.312 -1.351 0 C-N-CA 123.428 -1.488 . . . . 0.0 110.714 -0.269 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.419 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.42 10.77 46.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -165.15 110.46 0.91 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.328 -1.101 . . . . 0.0 109.078 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -131.2 167.75 18.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.639 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.9 m -120.43 129.84 54.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.327 -0.858 . . . . 0.0 109.471 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 98' ' ' VAL . 3.0 m -131.94 -172.85 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.369 -0.832 . . . . 0.0 109.545 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.68 178.55 6.95 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 109.482 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.7 t -72.17 111.47 7.42 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.333 -0.854 . . . . 0.0 109.428 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.77 -16.38 6.94 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -82.57 167.11 18.64 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.395 -1.062 . . . . 0.0 109.488 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -123.92 133.14 53.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.64 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.506 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.3 mp -97.36 151.03 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.438 -0.789 . . . . 0.0 109.042 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.4 t -133.7 145.22 33.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 109.967 -179.618 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.674 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.6 m-85 -130.92 77.43 1.78 Allowed 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.491 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.3 mttt -77.07 132.61 39.0 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.272 -0.892 . . . . 0.0 109.842 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 20.6 p-10 -105.72 122.22 45.62 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.52 -67.18 0.87 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.281 -0.887 . . . . 0.0 109.588 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -125.44 149.99 47.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.326 -0.858 . . . . 0.0 109.525 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.33 11.02 61.55 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.652 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 3.0 p90 -61.76 165.99 6.75 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 121.399 -1.059 . . . . 0.0 109.543 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.57 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.2 Cg_endo -78.84 151.64 88.39 Favored 'Cis proline' 0 C--N 1.313 -1.292 0 C-N-CA 123.329 -1.53 . . . . 0.0 110.506 -0.016 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.822 ' HB3' HD22 ' A' ' 5' ' ' LEU . 50.6 m-70 -122.78 44.78 2.55 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.384 -0.823 . . . . 0.0 109.365 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -68.57 123.15 20.05 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.196 -0.94 . . . . 0.0 109.199 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.07 155.7 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.245 -0.909 . . . . 0.0 109.992 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.478 HG21 ' HB3' ' B' ' 63' ' ' ASN . 3.6 m -141.33 118.8 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.418 -0.801 . . . . 0.0 109.201 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -69.31 130.57 42.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 109.663 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.11 159.39 15.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.355 -0.841 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.603 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.5 tp10 -99.02 34.46 2.11 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.313 -0.867 . . . . 0.0 109.491 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -108.38 -22.09 12.47 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -0.899 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -128.5 32.78 4.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.738 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.717 HG23 ' HD2' ' A' ' 47' ' ' PRO . 49.0 mt -95.35 141.44 23.22 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.24 -0.913 . . . . 0.0 109.188 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.717 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.4 Cg_endo -76.46 -59.6 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.723 2.282 . . . . 0.0 111.038 -179.738 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.527 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.5 t -87.65 -176.26 5.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.932 . . . . 0.0 109.683 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.523 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -78.26 -107.01 0.19 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.45 156.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.513 -0.992 . . . . 0.0 109.773 179.896 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.89 160.75 16.29 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 0.0 109.637 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.26 -18.18 40.02 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.872 . . . . 0.0 109.729 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -77.15 -9.42 58.74 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.222 -0.924 . . . . 0.0 109.851 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.0 tptp -87.75 -27.18 22.51 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.279 -0.888 . . . . 0.0 109.715 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.6 pt -113.68 -5.1 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.212 -0.93 . . . . 0.0 109.976 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.2 m -98.99 175.29 5.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.168 -0.957 . . . . 0.0 109.473 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 16.5 mtp -93.24 157.26 16.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.819 . . . . 0.0 109.563 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -88.35 -160.13 0.61 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.467 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.836 ' OE1' ' HE2' ' B' ' 65' ' ' LYS . 8.8 pm0 -98.24 -29.21 13.32 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.296 -0.877 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.507 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.7 -30.33 36.38 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.302 -0.874 . . . . 0.0 109.737 -179.873 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -92.16 95.42 9.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.335 -0.853 . . . . 0.0 109.48 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.831 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -116.7 141.61 47.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.424 -0.797 . . . . 0.0 109.34 -179.986 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.657 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.0 OUTLIER -90.52 80.14 6.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.338 -0.851 . . . . 0.0 109.14 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -102.7 -41.05 6.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.324 -0.86 . . . . 0.0 109.8 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.49 145.63 98.4 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.326 -0.859 . . . . 0.0 109.979 -179.52 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.75 78.09 3.67 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.771 2.314 . . . . 0.0 110.219 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 165.38 -24.79 0.16 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.657 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.2 tp10 -67.84 148.11 51.62 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.365 -1.08 . . . . 0.0 109.339 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.41 ' HA ' HD21 ' A' ' 63' ' ' LEU . 41.1 p -136.74 143.27 43.2 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 109.899 -179.595 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -105.28 107.15 17.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.348 -0.845 . . . . 0.0 109.094 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.47 131.07 45.02 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 109.62 -179.744 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -121.08 112.44 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.424 -0.798 . . . . 0.0 109.206 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.8 m -83.66 104.04 13.45 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 109.297 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -100.92 141.26 34.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.362 -0.836 . . . . 0.0 109.557 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.9 p -123.14 -24.73 4.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.19 153.42 43.72 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.274 -0.891 . . . . 0.0 109.642 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.8 mttt -100.67 124.07 45.75 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.309 -0.869 . . . . 0.0 109.548 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.427 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 165.71 -168.53 39.64 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.8 m -116.86 110.82 18.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.332 -1.099 . . . . 0.0 109.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -89.35 176.09 7.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.8 92.51 2.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.169 -0.957 . . . . 0.0 109.918 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.423 ' CE2' HG23 ' A' ' 96' ' ' VAL . 47.9 p90 -97.54 154.6 17.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.337 -0.852 . . . . 0.0 108.738 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.675 ' HB2' HG12 ' A' ' 93' ' ' VAL . 41.6 p90 -143.79 154.61 43.6 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 109.987 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 49.6 t -65.9 106.91 1.68 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.502 -0.749 . . . . 0.0 109.024 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.866 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.494 1.725 0 O-C-N 121.49 -0.756 . . . . 0.0 110.089 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.87 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.009 -0.738 . . . . 0.0 109.009 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.675 HG12 ' HB2' ' A' ' 83' ' ' TYR . 35.0 m -144.97 146.79 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.362 -0.836 . . . . 0.0 109.607 -179.487 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.419 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -124.7 176.32 17.04 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.81 136.2 20.29 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.263 -1.139 . . . . 0.0 109.816 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.423 HG23 ' CE2' ' A' ' 82' ' ' PHE . 31.5 t -91.49 109.96 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.344 -0.847 . . . . 0.0 109.476 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -94.79 66.75 3.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.204 -0.935 . . . . 0.0 109.104 179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 7.0 p -79.21 141.24 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.307 -0.87 . . . . 0.0 109.62 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.2 p30 . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.566 179.946 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.583 HD11 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 007 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 61' ' ' LEU . . . . . 0.831 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.866 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.478 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.836 ' HE2' ' OE1' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.4 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.38 107.99 4.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.653 HG11 ' HD2' ' A' ' 14' ' ' PHE . 11.8 t -102.9 125.46 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.364 -0.835 . . . . 0.0 109.504 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.486 HD23 ' HB2' ' A' ' 30' ' ' LYS . 25.0 mt -111.13 100.52 9.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.387 -0.82 . . . . 0.0 109.299 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.836 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.01 128.57 36.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.373 -0.83 . . . . 0.0 109.388 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.492 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 88.71 134.0 4.79 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -77.58 -124.62 0.28 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.26 -13.52 8.25 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -118.74 -37.39 3.27 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.322 -1.104 . . . . 0.0 109.615 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.605 ' HA3' HD11 ' B' ' 3' ' ' ILE . . . 160.61 45.9 0.02 OUTLIER Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.492 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.8 t -94.64 98.47 10.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.288 -1.125 . . . . 0.0 109.301 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.44 HD11 ' CG2' ' B' ' 3' ' ' ILE . 7.6 mt -73.83 91.92 2.0 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.298 -0.876 . . . . 0.0 109.485 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.915 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.2 137.53 5.21 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.358 -0.839 . . . . 0.0 109.617 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.653 ' HD2' HG11 ' A' ' 3' ' ' VAL . 35.4 m-85 -65.71 126.58 28.88 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.383 -0.823 . . . . 0.0 109.054 179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -127.9 102.28 22.29 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.248 -0.907 . . . . 0.0 109.607 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.78 170.47 66.89 Favored 'Cis proline' 0 C--N 1.313 -1.317 0 C-N-CA 123.45 -1.479 . . . . 0.0 110.679 -0.271 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.443 ' HA2' ' HB3' ' A' ' 14' ' ' PHE . . . -105.41 12.45 47.57 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -166.49 105.92 0.64 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.406 -1.055 . . . . 0.0 109.043 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -127.45 167.25 16.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.307 -0.87 . . . . 0.0 109.695 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.64 128.55 53.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 109.404 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 98' ' ' VAL . 3.0 m -130.44 -171.52 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.388 -0.82 . . . . 0.0 109.532 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.31 179.01 6.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.329 -0.857 . . . . 0.0 109.442 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -72.3 110.52 6.78 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.238 -0.914 . . . . 0.0 109.417 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.62 -16.91 6.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -82.1 165.71 20.35 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.34 -1.094 . . . . 0.0 109.472 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -122.61 132.11 54.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.337 -0.852 . . . . 0.0 109.636 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.31 151.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 109.045 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -133.5 146.28 32.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.217 -0.927 . . . . 0.0 109.934 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.675 ' HB3' HD11 ' A' ' 5' ' ' LEU . 52.1 m-85 -132.5 80.05 1.88 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.486 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.3 mttt -80.45 131.79 35.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.333 -0.855 . . . . 0.0 109.716 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.2 p-10 -105.25 119.57 39.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.282 -0.886 . . . . 0.0 109.493 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -98.19 -67.83 0.83 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.343 -0.848 . . . . 0.0 109.573 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -124.68 149.85 46.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.33 -0.856 . . . . 0.0 109.49 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 92.13 12.71 58.51 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.642 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 4.9 p90 -61.5 163.97 10.35 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.405 -1.056 . . . . 0.0 109.542 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.553 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.2 Cg_endo -79.1 157.28 91.4 Favored 'Cis proline' 0 C--N 1.313 -1.322 0 C-N-CA 123.322 -1.532 . . . . 0.0 110.481 -0.138 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.836 ' HB3' HD22 ' A' ' 5' ' ' LEU . 43.9 m-70 -127.97 39.75 3.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.385 -0.822 . . . . 0.0 109.33 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -65.19 120.64 13.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.334 -0.854 . . . . 0.0 109.267 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -93.0 151.45 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.305 -0.872 . . . . 0.0 109.823 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.536 HG12 ' H ' ' A' ' 57' ' ' MET . 10.2 m -137.99 121.71 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.109 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -70.26 132.11 45.22 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.258 -0.901 . . . . 0.0 109.709 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.45 157.86 15.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.294 -0.879 . . . . 0.0 109.53 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.563 ' HA ' HD12 ' A' ' 46' ' ' ILE . 6.0 tp10 -98.02 47.04 1.01 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.294 -0.879 . . . . 0.0 109.45 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.56 -26.77 5.67 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.286 -0.884 . . . . 0.0 109.38 179.727 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -124.25 25.25 7.83 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.342 -0.849 . . . . 0.0 109.61 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.73 HG23 ' HD2' ' A' ' 47' ' ' PRO . 58.0 mt -87.87 141.36 31.54 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.254 -0.904 . . . . 0.0 109.155 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.73 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.0 Cg_endo -76.23 -60.71 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.738 2.292 . . . . 0.0 110.999 -179.595 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.523 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -87.57 -178.3 6.08 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.211 -0.931 . . . . 0.0 109.642 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.536 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.6 -103.39 0.14 Allowed Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.92 157.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.523 -0.987 . . . . 0.0 109.899 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.23 156.42 18.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.263 -0.898 . . . . 0.0 109.624 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.63 -24.41 39.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.321 -0.862 . . . . 0.0 109.677 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -72.82 -15.22 61.63 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 109.777 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -79.43 -31.62 42.63 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.303 -0.873 . . . . 0.0 109.735 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.0 pt -111.07 0.44 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.272 -0.892 . . . . 0.0 109.879 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 62.4 m -104.02 177.93 4.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.536 ' H ' HG12 ' A' ' 40' ' ' VAL . 22.7 mtp -98.67 159.07 15.21 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.289 -0.882 . . . . 0.0 109.523 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.73 -166.43 1.58 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.354 -0.841 . . . . 0.0 109.552 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.53 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -91.43 -28.06 17.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.354 -0.841 . . . . 0.0 109.92 -179.807 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.444 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.5 OUTLIER -80.93 -31.25 35.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.88 . . . . 0.0 109.775 -179.851 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -91.23 97.37 11.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.337 -0.852 . . . . 0.0 109.483 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.656 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -120.15 145.49 46.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.38 -0.825 . . . . 0.0 109.363 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.664 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.0 mp -93.31 75.31 4.56 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.415 -0.803 . . . . 0.0 109.185 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -96.04 -35.45 11.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.292 -0.88 . . . . 0.0 109.749 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -73.21 143.84 83.82 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.308 -0.87 . . . . 0.0 109.808 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.56 80.06 3.03 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.777 2.318 . . . . 0.0 110.215 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 163.84 -24.95 0.19 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.664 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.55 149.33 50.27 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.387 -1.066 . . . . 0.0 109.387 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 36.2 p -136.4 144.22 44.4 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.2 t80 -106.73 108.72 20.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.384 -0.823 . . . . 0.0 109.07 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.452 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.06 132.28 45.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.322 -0.861 . . . . 0.0 109.685 -179.742 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -122.1 112.85 36.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.418 -0.801 . . . . 0.0 109.263 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.6 m -84.2 102.0 12.29 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.291 -0.88 . . . . 0.0 109.326 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -98.46 142.45 30.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.33 -0.856 . . . . 0.0 109.531 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.3 p -123.9 -25.92 4.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.351 -0.843 . . . . 0.0 109.714 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.46 152.27 45.63 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 109.669 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -99.43 123.1 43.41 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.418 -0.801 . . . . 0.0 109.605 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.492 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.68 -171.67 41.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 4.0 m -113.3 111.01 21.3 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.298 -1.119 . . . . 0.0 109.401 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -89.57 175.44 7.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.362 -0.837 . . . . 0.0 109.171 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.7 88.58 1.77 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.223 -0.923 . . . . 0.0 109.861 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.446 ' HE1' ' CE2' ' A' ' 14' ' ' PHE . 48.3 p90 -93.23 146.5 23.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.249 -0.907 . . . . 0.0 108.802 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.545 ' HB2' HG12 ' A' ' 93' ' ' VAL . 50.1 p90 -133.41 153.03 51.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.863 -179.59 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 42.5 t -65.68 109.2 2.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.542 -0.724 . . . . 0.0 109.246 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.823 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.5 OUTLIER . . . . . 0 N--CA 1.495 1.787 0 O-C-N 121.471 -0.768 . . . . 0.0 109.812 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.915 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.359 0.6 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.545 HG12 ' HB2' ' A' ' 83' ' ' TYR . 15.3 m -149.57 134.49 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.299 -0.876 . . . . 0.0 109.31 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -115.17 174.98 15.64 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -147.65 135.3 20.94 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.13 . . . . 0.0 109.614 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.428 HG23 ' CE2' ' A' ' 82' ' ' PHE . 34.9 t -89.33 109.87 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.97 65.87 2.97 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 109.174 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.408 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 4.7 p -78.32 140.47 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.369 -0.832 . . . . 0.0 109.575 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.586 179.982 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.605 HD11 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 008 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 61' ' ' LEU . . . . . 0.656 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.823 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.412 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.53 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.9 p . . . . . 0 N--CA 1.503 2.195 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.56 108.91 5.18 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.235 -0.915 . . . . 0.0 109.46 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.633 HG11 ' HD2' ' A' ' 14' ' ' PHE . 15.8 t -104.35 120.65 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.34 -0.85 . . . . 0.0 109.446 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.433 HD23 ' HB2' ' A' ' 30' ' ' LYS . 19.0 mt -107.63 102.59 11.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.389 -0.82 . . . . 0.0 109.342 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.792 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.09 141.62 58.66 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.326 -0.859 . . . . 0.0 109.415 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.47 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.09 136.48 1.23 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.64 -121.35 0.46 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -125.48 5.12 8.13 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.03 -42.61 0.27 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.315 -1.109 . . . . 0.0 109.601 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.97 42.41 0.05 OUTLIER Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.47 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 1.7 t -97.71 96.91 8.57 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.311 -1.111 . . . . 0.0 109.295 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.1 mt -80.03 90.95 5.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.377 -0.827 . . . . 0.0 109.451 -179.743 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.862 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.61 142.58 6.67 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.338 -0.851 . . . . 0.0 109.781 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.633 ' HD2' HG11 ' A' ' 3' ' ' VAL . 33.5 m-85 -67.62 128.06 35.06 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.418 -0.801 . . . . 0.0 109.082 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.508 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.11 102.76 18.71 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.612 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.75 171.18 64.32 Favored 'Cis proline' 0 C--N 1.312 -1.359 0 C-N-CA 123.43 -1.487 . . . . 0.0 110.648 -0.248 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.463 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -106.17 14.64 43.96 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -169.1 110.54 0.49 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.393 -1.063 . . . . 0.0 109.051 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -132.22 170.19 15.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.34 -0.85 . . . . 0.0 109.67 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.3 m -122.69 130.95 53.54 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 109.443 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -132.96 -169.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.354 -0.841 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.49 178.93 6.86 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.283 -0.885 . . . . 0.0 109.455 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.0 t -71.98 109.42 5.79 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.349 -0.844 . . . . 0.0 109.385 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.43 -17.03 5.9 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -81.91 171.4 14.5 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -1.095 . . . . 0.0 109.479 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.86 133.93 49.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.268 -0.895 . . . . 0.0 109.642 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -95.9 150.72 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.379 -0.825 . . . . 0.0 109.035 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -134.34 146.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 109.949 -179.561 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.637 ' HB3' HD11 ' A' ' 5' ' ' LEU . 56.8 m-85 -133.72 80.21 1.86 Allowed 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.433 ' HB2' HD23 ' A' ' 4' ' ' LEU . 28.6 mttt -81.11 123.86 28.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.229 -0.919 . . . . 0.0 109.825 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -94.46 126.73 39.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.334 -0.854 . . . . 0.0 109.388 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -102.93 -63.7 1.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.847 . . . . 0.0 109.566 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -134.33 148.04 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.344 -0.848 . . . . 0.0 109.561 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 14.96 45.74 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 1.056 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 0.2 OUTLIER -62.86 166.15 8.38 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.44 -1.036 . . . . 0.0 109.542 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.568 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 35.6 Cg_endo -78.06 145.32 78.13 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.679 0.249 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.792 ' HB3' HD22 ' A' ' 5' ' ' LEU . 34.7 m-70 -115.58 32.7 5.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -58.23 119.38 6.78 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.269 -0.894 . . . . 0.0 109.361 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -93.32 157.23 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.358 -0.839 . . . . 0.0 110.026 -179.238 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.5 m -139.79 119.98 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.397 -0.814 . . . . 0.0 109.194 179.708 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -67.19 116.74 8.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.397 -0.814 . . . . 0.0 109.927 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.43 ' O ' HG13 ' A' ' 46' ' ' ILE . 1.3 t70 -81.41 149.62 28.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.29 -0.881 . . . . 0.0 109.523 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 1.279 ' CB ' ' HE2' ' B' ' 187' ' ' LYS . 1.0 OUTLIER -96.79 6.44 48.66 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.267 -0.896 . . . . 0.0 109.918 179.909 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.43 -19.7 57.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.183 -0.948 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -131.49 38.44 3.6 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.384 -0.823 . . . . 0.0 109.515 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.786 HG23 ' HD2' ' A' ' 47' ' ' PRO . 8.1 mt -98.96 143.97 27.35 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.254 -0.904 . . . . 0.0 109.25 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.786 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.9 Cg_endo -76.02 -63.99 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.786 2.324 . . . . 0.0 111.068 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -83.4 -176.45 6.32 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.177 -0.952 . . . . 0.0 109.686 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.564 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -78.37 -105.63 0.2 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.564 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.65 160.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.56 -0.964 . . . . 0.0 109.861 179.811 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -99.45 162.61 12.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.256 -0.903 . . . . 0.0 109.547 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.415 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -81.78 -17.23 48.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.33 -0.856 . . . . 0.0 109.73 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.62 -2.3 28.64 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.217 -0.927 . . . . 0.0 109.898 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -101.5 -25.57 13.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.235 -0.915 . . . . 0.0 109.649 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.3 pt -119.0 6.67 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.198 -0.939 . . . . 0.0 110.114 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 69.0 m -113.05 171.18 7.7 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.108 -0.995 . . . . 0.0 109.366 179.746 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.6 mtp -88.79 152.12 21.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.323 -0.86 . . . . 0.0 109.571 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.2 t -89.82 -154.67 0.33 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.43 -0.794 . . . . 0.0 109.498 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' B' ' 66' ' ' LYS . 3.2 pt-20 -101.83 -33.55 9.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.259 -0.9 . . . . 0.0 109.888 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.86 -29.69 63.4 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.874 . . . . 0.0 109.829 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -96.88 87.26 4.23 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.262 -0.899 . . . . 0.0 109.672 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.05 139.75 43.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.374 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.7 mp -89.75 84.52 6.29 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.587 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 17.5 t-20 -111.44 -4.47 14.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.272 -0.892 . . . . 0.0 109.824 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -101.38 146.71 32.67 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 109.689 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -77.11 78.47 3.44 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.795 2.33 . . . . 0.0 110.225 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.94 -23.88 0.29 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -68.2 147.16 52.64 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.322 -1.105 . . . . 0.0 109.442 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.0 p -136.36 147.32 47.31 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.247 -0.908 . . . . 0.0 109.828 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.6 t80 -110.24 109.27 19.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.81 . . . . 0.0 109.019 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.23 133.86 44.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 -179.673 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -123.05 116.58 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.384 -0.823 . . . . 0.0 109.242 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -87.14 102.48 14.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.287 -0.883 . . . . 0.0 109.355 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.76 142.95 30.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.343 -0.848 . . . . 0.0 109.584 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.7 p -124.46 -27.04 3.8 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.374 -0.829 . . . . 0.0 109.786 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.67 152.08 46.21 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.216 -0.927 . . . . 0.0 109.696 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -99.18 125.13 44.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.375 -0.828 . . . . 0.0 109.557 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.424 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.71 -165.88 37.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.2 m -118.28 120.05 36.5 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.317 -1.108 . . . . 0.0 109.524 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -97.08 178.15 5.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.421 -0.799 . . . . 0.0 109.085 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -147.54 88.36 1.7 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.114 -0.992 . . . . 0.0 109.891 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.435 ' CE2' HG23 ' A' ' 96' ' ' VAL . 42.6 p90 -93.65 161.22 14.43 Favored 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.663 ' HB2' HG12 ' A' ' 93' ' ' VAL . 44.7 p90 -155.15 152.96 30.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.038 -1.039 . . . . 0.0 110.339 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 51.6 t -64.31 114.08 4.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.612 -0.68 . . . . 0.0 109.233 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' SER . . . . . 1.261 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 5.6 t . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.407 -0.808 . . . . 0.0 110.107 -179.419 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.862 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.8 ptm . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.505 0.669 . . . . 0.0 109.26 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.663 HG12 ' HB2' ' A' ' 83' ' ' TYR . 35.1 m -143.88 153.22 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.46 176.45 19.87 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.04 138.11 22.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.316 -1.108 . . . . 0.0 109.74 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.435 HG23 ' CE2' ' A' ' 82' ' ' PHE . 45.7 t -93.25 108.67 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.361 -0.837 . . . . 0.0 109.473 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -92.35 67.3 4.83 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.263 -0.898 . . . . 0.0 109.162 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.405 HG12 ' H ' ' A' ' 98' ' ' VAL . 3.7 p -78.7 139.71 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.378 -0.826 . . . . 0.0 109.607 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.563 179.937 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 009 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 1.261 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.779 HD22 ' HB2' ' B' ' 65' ' ' LYS . 1.7 p-10 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.779 ' HB2' HD22 ' B' ' 63' ' ' ASN . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 66' ' ' LYS . . . . . 0.513 ' O ' ' CB ' ' A' ' 59' ' ' GLU . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 70' ' ' ASN . . . . . 0.522 ' OD1' ' ND2' ' A' ' 64' ' ' ASN . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 1.056 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 187' ' ' LYS . . . . . 1.279 ' HE2' ' CB ' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.141 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.76 108.29 4.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.639 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.9 t -103.55 121.12 54.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.469 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.421 HD23 ' HB2' ' A' ' 30' ' ' LYS . 20.1 mt -108.24 101.87 11.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.355 -0.841 . . . . 0.0 109.275 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.833 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.74 137.11 57.6 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.352 -0.843 . . . . 0.0 109.398 -179.956 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 83.0 135.37 2.42 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.07 -119.13 0.26 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.27 4.17 7.75 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -141.3 -41.28 0.38 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.311 -1.111 . . . . 0.0 109.592 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 171.03 43.66 0.03 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.527 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.3 t -97.4 99.39 10.82 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.344 -1.092 . . . . 0.0 109.273 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.665 HD11 HG21 ' B' ' 3' ' ' ILE . 6.6 mt -79.67 93.35 5.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.914 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -166.59 139.11 3.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 109.792 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.639 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.5 m-85 -65.9 127.05 30.5 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.42 -0.8 . . . . 0.0 108.98 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.423 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -127.86 102.84 21.82 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 109.641 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.73 170.22 67.83 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 123.452 -1.478 . . . . 0.0 110.651 -0.24 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.453 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.47 13.28 47.4 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -167.56 107.62 0.58 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.415 -1.05 . . . . 0.0 108.991 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -129.37 169.13 15.28 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.355 -0.84 . . . . 0.0 109.661 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.8 m -121.77 129.19 52.49 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.417 -0.802 . . . . 0.0 109.434 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.36 -170.11 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.61 179.15 6.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.329 -0.857 . . . . 0.0 109.476 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -71.96 108.39 5.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.7 -17.23 5.53 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -81.97 172.17 13.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.318 -1.107 . . . . 0.0 109.516 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -128.52 134.9 48.79 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.314 -0.866 . . . . 0.0 109.662 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.54 149.3 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.473 -0.767 . . . . 0.0 109.047 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -133.29 145.54 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.913 . . . . 0.0 109.952 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.673 ' HB3' HD11 ' A' ' 5' ' ' LEU . 50.8 m-85 -132.96 80.29 1.88 Allowed 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.421 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.9 mttt -80.88 124.31 29.0 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.165 -0.959 . . . . 0.0 109.767 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.6 p-10 -96.63 116.96 29.98 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.269 -0.894 . . . . 0.0 109.441 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -94.39 -69.21 0.76 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.536 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.11 151.17 49.51 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.358 -0.839 . . . . 0.0 109.473 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 94.1 10.16 58.79 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.824 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 2.1 p90 -57.94 166.18 2.13 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.34 -1.094 . . . . 0.0 109.421 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.57 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.2 Cg_endo -78.95 150.01 85.55 Favored 'Cis proline' 0 C--N 1.312 -1.355 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.536 -0.094 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.833 ' HB3' HD22 ' A' ' 5' ' ' LEU . 45.1 m-70 -121.72 45.24 2.36 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.339 -0.851 . . . . 0.0 109.25 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.9 p-10 -70.48 119.05 14.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.229 -0.919 . . . . 0.0 109.304 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -92.27 152.5 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.392 -0.818 . . . . 0.0 109.964 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.577 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.8 m -140.52 119.27 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 109.033 179.693 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -67.48 132.38 47.49 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.22 -0.925 . . . . 0.0 109.771 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -94.15 159.33 15.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.394 -0.816 . . . . 0.0 109.465 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.614 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.4 tp10 -99.82 24.81 7.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.312 -0.867 . . . . 0.0 109.573 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.02 -17.33 16.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.186 -0.946 . . . . 0.0 109.489 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -131.72 36.72 3.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.268 -0.895 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ILE . . . . . 0.73 HG23 ' HD2' ' A' ' 47' ' ' PRO . 33.4 mt -100.43 141.93 23.64 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.333 -0.855 . . . . 0.0 108.988 179.71 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.73 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.55 -63.6 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.696 2.264 . . . . 0.0 111.151 -179.591 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . 0.528 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.7 t -85.48 -175.14 5.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.169 -0.957 . . . . 0.0 109.641 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.51 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.89 -108.18 0.14 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.44 155.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.494 -1.003 . . . . 0.0 109.796 179.895 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.98 162.21 14.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.297 -0.877 . . . . 0.0 109.583 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.48 -21.88 35.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.387 -0.82 . . . . 0.0 109.671 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -71.27 -12.53 61.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.273 -0.892 . . . . 0.0 109.927 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -86.68 -27.68 23.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.285 -0.884 . . . . 0.0 109.749 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.1 pt -116.72 6.32 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.235 -0.916 . . . . 0.0 110.045 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -110.77 174.55 5.81 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.174 -0.954 . . . . 0.0 109.348 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' MET . . . . . 0.461 ' H ' HG12 ' A' ' 40' ' ' VAL . 27.6 mtp -95.6 160.58 14.43 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.382 -0.824 . . . . 0.0 109.498 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -95.63 -170.86 2.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.358 -0.839 . . . . 0.0 109.563 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.49 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.5 OUTLIER -87.48 -26.19 23.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.301 -0.874 . . . . 0.0 109.865 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.49 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.39 -35.42 35.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.284 -0.885 . . . . 0.0 109.643 -179.865 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.58 92.81 8.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.428 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.764 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -114.82 141.36 48.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 109.462 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.3 mp -89.48 87.45 7.07 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.423 -0.798 . . . . 0.0 109.179 179.783 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.458 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.6 OUTLIER -108.52 -32.8 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.33 -0.856 . . . . 0.0 109.765 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.44 144.83 81.62 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.226 -0.921 . . . . 0.0 109.837 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.39 80.28 2.95 Favored 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.733 2.289 . . . . 0.0 110.25 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.51 -25.15 0.22 Allowed Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -67.36 148.72 51.26 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.364 -1.08 . . . . 0.0 109.448 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 32.0 p -136.36 144.21 44.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.915 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -107.73 109.17 20.69 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.35 -0.844 . . . . 0.0 108.998 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' LYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.49 134.44 43.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.343 -0.848 . . . . 0.0 109.743 -179.729 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -123.25 114.73 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.405 -0.809 . . . . 0.0 109.242 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -85.46 102.35 13.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.301 -0.875 . . . . 0.0 109.301 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.54 142.99 30.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.4 p -124.6 -26.8 3.79 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.372 -0.83 . . . . 0.0 109.818 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.03 47.81 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.272 -0.893 . . . . 0.0 109.683 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -97.99 121.33 39.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.373 -0.829 . . . . 0.0 109.52 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.454 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.93 -171.91 42.49 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -112.93 115.01 27.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.311 -1.111 . . . . 0.0 109.487 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 46.3 m-85 -93.32 178.61 5.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.351 -0.843 . . . . 0.0 109.093 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.59 93.27 2.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.984 . . . . 0.0 109.912 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -97.12 155.62 16.74 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.553 ' HB2' HG12 ' A' ' 93' ' ' VAL . 40.6 p90 -145.0 153.18 41.22 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.041 -1.037 . . . . 0.0 110.272 -179.575 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.0 t -68.65 106.81 2.74 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.821 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.747 0 O-C-N 121.414 -0.804 . . . . 0.0 110.109 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' MET . . . . . 0.914 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.6 ptm . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.473 0.654 . . . . 0.0 109.305 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.553 HG12 ' HB2' ' A' ' 83' ' ' TYR . 27.6 m -145.57 138.4 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.295 -0.878 . . . . 0.0 109.485 -179.666 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -118.79 177.42 16.41 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -148.25 137.43 21.96 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -1.145 . . . . 0.0 109.675 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 30.8 t -91.91 108.13 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.293 -0.879 . . . . 0.0 109.503 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -92.99 66.76 4.21 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.302 -0.874 . . . . 0.0 109.256 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 p -78.96 138.94 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.341 -0.849 . . . . 0.0 109.56 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.592 179.922 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 3' ' ' ILE . . . . . 0.665 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 010 nuclear build core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 61' ' ' LEU . . . . . 0.764 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 62' ' ' ALA . . . . . 0.821 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 63' ' ' ASN . . . . . 0.577 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 117' ' ' PRO . . . . . 0.824 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.503 2.187 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.83 108.21 5.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.276 -0.89 . . . . 0.0 109.469 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.604 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.7 t -103.82 125.91 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.405 -0.809 . . . . 0.0 109.47 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.421 HD23 ' HB2' ' A' ' 30' ' ' LYS . 18.5 mt -113.08 105.4 13.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 109.319 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.832 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.48 140.94 58.04 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.334 -0.854 . . . . 0.0 109.421 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.57 137.72 1.59 Allowed Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.53 -118.79 0.38 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -127.76 7.05 6.95 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -145.69 -41.83 0.22 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.287 -1.125 . . . . 0.0 109.57 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.3 45.59 0.04 OUTLIER Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.458 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -102.72 97.67 7.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.373 -1.075 . . . . 0.0 109.253 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.572 HD13 ' CE1' ' A' ' 87' ' ' HIS . 7.5 mt -77.72 94.19 4.41 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.378 -0.826 . . . . 0.0 109.415 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.869 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.65 139.31 4.49 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.324 -0.86 . . . . 0.0 109.7 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.604 ' HD2' HG11 ' A' ' 3' ' ' VAL . 37.2 m-85 -67.36 127.74 33.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.285 -0.884 . . . . 0.0 109.094 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.529 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.43 103.44 20.02 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.25 -0.906 . . . . 0.0 109.593 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.73 170.91 65.53 Favored 'Cis proline' 0 C--N 1.312 -1.373 0 C-N-CA 123.454 -1.478 . . . . 0.0 110.646 -0.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.452 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.28 12.39 48.09 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -167.11 111.14 0.72 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.371 -1.076 . . . . 0.0 109.125 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.0 p90 -132.2 169.68 16.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.358 -0.839 . . . . 0.0 109.709 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.89 130.24 53.2 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.384 -0.823 . . . . 0.0 109.45 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.48 -170.8 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.314 -0.867 . . . . 0.0 109.456 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.92 179.12 6.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.29 -0.881 . . . . 0.0 109.504 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.7 t -72.09 108.81 5.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.332 -0.855 . . . . 0.0 109.401 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.29 -17.02 5.65 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -82.09 172.55 13.08 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.366 -1.079 . . . . 0.0 109.493 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -129.06 134.96 48.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.633 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.542 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.7 149.52 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 t -133.44 145.72 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 109.939 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.647 ' HB3' HD11 ' A' ' 5' ' ' LEU . 51.3 m-85 -133.09 79.94 1.86 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.456 -0.777 . . . . 0.0 108.927 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.421 ' HB2' HD23 ' A' ' 4' ' ' LEU . 29.6 mttt -81.81 124.23 29.48 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.26 -0.9 . . . . 0.0 109.783 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 26.8 p-10 -95.14 130.23 41.93 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.311 -0.868 . . . . 0.0 109.425 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -104.51 -67.9 0.88 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -0.851 . . . . 0.0 109.593 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.86 152.42 48.53 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.329 -0.857 . . . . 0.0 109.568 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.28 21.45 35.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.526 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 2.8 p90 -64.34 163.03 28.1 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.354 -1.086 . . . . 0.0 109.585 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -79.5 155.49 89.55 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.421 -1.491 . . . . 0.0 110.726 -0.038 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.832 ' HB3' HD22 ' A' ' 5' ' ' LEU . 27.3 m-70 -126.62 40.99 3.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.413 -0.805 . . . . 0.0 109.222 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.477 ' OD1' ' HD3' ' A' ' 86' ' ' PRO . 11.4 p-10 -68.2 128.3 36.05 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.249 -0.907 . . . . 0.0 109.369 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -100.23 153.17 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.33 -0.856 . . . . 0.0 109.841 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.491 HG12 ' H ' ' A' ' 57' ' ' MET . 9.7 m -140.7 123.0 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.418 -0.801 . . . . 0.0 109.217 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.52 133.42 45.8 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.291 -0.88 . . . . 0.0 109.571 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.409 ' HB2' ' HE1' ' A' ' 83' ' ' TYR . 0.7 OUTLIER -96.29 160.15 14.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.36 -0.838 . . . . 0.0 109.571 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.536 ' HA ' HD12 ' A' ' 46' ' ' ILE . 6.7 tp10 -100.39 44.84 1.0 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.37 -0.831 . . . . 0.0 109.429 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.29 -23.8 6.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.304 -0.872 . . . . 0.0 109.373 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -125.59 25.76 6.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 0.0 109.471 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.715 HG23 ' HD2' ' A' ' 47' ' ' PRO . 55.8 mt -90.09 141.15 27.64 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.314 -0.866 . . . . 0.0 108.988 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.715 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.7 Cg_endo -75.62 -62.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.68 2.253 . . . . 0.0 111.023 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.529 ' O ' HG22 ' A' ' 46' ' ' ILE . 2.0 t -87.05 -178.94 6.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.151 -0.968 . . . . 0.0 109.549 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.545 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -75.25 -101.68 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.67 157.56 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.517 -0.99 . . . . 0.0 109.867 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.478 ' HA ' ' NZ ' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -88.83 154.84 19.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.267 -0.896 . . . . 0.0 109.632 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.505 ' H ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.77 -27.27 40.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.419 -0.8 . . . . 0.0 109.532 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.96 -17.02 62.68 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.378 -0.827 . . . . 0.0 109.854 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.0 tptt -77.12 -31.24 55.64 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.299 -0.875 . . . . 0.0 109.699 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -113.02 4.97 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.196 -0.94 . . . . 0.0 109.935 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 66.3 m -108.52 177.81 4.68 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.491 ' H ' HG12 ' A' ' 40' ' ' VAL . 28.3 mtp -98.78 164.07 12.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -98.55 -168.47 1.65 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.395 -0.816 . . . . 0.0 109.563 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.527 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.4 OUTLIER -88.64 -27.58 21.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.383 -0.823 . . . . 0.0 109.816 -179.817 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.479 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.6 OUTLIER -81.12 -33.36 33.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.233 -0.917 . . . . 0.0 109.703 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -91.38 90.63 7.78 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.286 -0.884 . . . . 0.0 109.443 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.639 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -115.98 145.83 42.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.355 -0.841 . . . . 0.0 109.444 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.707 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.1 mp -92.93 80.59 4.61 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.831 . . . . 0.0 109.149 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.517 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.8 OUTLIER -102.09 -17.67 15.93 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.344 -0.847 . . . . 0.0 109.812 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.34 145.46 30.05 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.256 -0.903 . . . . 0.0 109.781 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.33 83.46 2.14 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.736 2.291 . . . . 0.0 110.274 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.5 -26.18 0.3 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.707 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -68.47 148.82 50.06 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.348 -1.09 . . . . 0.0 109.42 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -136.15 146.25 46.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.876 . . . . 0.0 109.85 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -109.18 109.08 19.95 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.35 -0.844 . . . . 0.0 109.011 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.542 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.19 133.87 43.95 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.662 -179.72 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -122.76 115.74 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -0.785 . . . . 0.0 109.243 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.69 102.95 14.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.31 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -100.0 143.07 30.63 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.69 -26.36 3.83 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.347 -0.846 . . . . 0.0 109.744 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.19 152.15 45.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.213 -0.929 . . . . 0.0 109.666 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.7 mttt -99.11 121.61 41.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.369 -0.832 . . . . 0.0 109.556 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.504 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.61 -171.18 42.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -113.26 114.73 27.11 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.328 -1.101 . . . . 0.0 109.512 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -93.1 177.79 5.95 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.376 -0.828 . . . . 0.0 109.176 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.52 97.56 2.65 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.155 -0.966 . . . . 0.0 109.887 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -100.66 159.16 15.4 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.533 ' HB2' HG12 ' A' ' 93' ' ' VAL . 40.0 p90 -149.13 155.65 41.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 110.16 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.407 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 36.9 t -67.82 111.77 4.5 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.654 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.4 OUTLIER -53.19 -52.41 66.12 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.402 -0.811 . . . . 0.0 110.215 -179.42 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.755 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 33.5 Cg_endo -74.98 21.93 0.42 Allowed 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.288 1.992 . . . . 0.0 111.012 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.755 ' CD2' ' O ' ' A' ' 86' ' ' PRO . 8.8 m170 -173.33 49.18 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.382 -0.824 . . . . 0.0 109.413 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.539 ' OE1' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -78.08 -41.54 35.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.085 -1.009 . . . . 0.0 109.137 179.869 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.84 -7.31 84.21 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -67.53 -60.79 2.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.331 -1.099 . . . . 0.0 109.379 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 145.44 1.37 0.76 Allowed Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.872 -1.156 . . . . 0.0 110.373 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.869 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.8 ptm -98.23 103.82 15.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.13 -1.217 . . . . 0.0 109.377 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.533 HG12 ' HB2' ' A' ' 83' ' ' TYR . 27.7 m -145.91 153.12 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.269 -0.894 . . . . 0.0 109.425 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.19 178.79 18.11 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -149.39 139.85 22.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.276 -1.131 . . . . 0.0 109.701 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.3 t -94.63 109.66 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.325 -0.86 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -94.05 68.3 3.74 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.257 -0.902 . . . . 0.0 109.254 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.1 p -80.23 139.77 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.34 -0.85 . . . . 0.0 109.623 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.58 179.948 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.55 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 001 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 61' ' ' LEU . . . . . 0.639 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.654 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.527 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.505 ' HE2' ' H ' ' A' ' 52' ' ' ALA . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.502 2.14 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.28 107.79 5.08 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.305 -0.872 . . . . 0.0 109.506 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.627 HG11 ' HD2' ' A' ' 14' ' ' PHE . 15.2 t -102.65 125.25 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 0.0 109.398 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.479 HD23 ' HB2' ' A' ' 30' ' ' LYS . 22.3 mt -111.36 103.27 11.63 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.399 -0.813 . . . . 0.0 109.347 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.767 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -65.6 139.09 58.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.375 -0.828 . . . . 0.0 109.415 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.71 136.79 1.82 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.01 -118.46 0.33 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -128.74 5.12 6.56 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -143.21 -41.38 0.3 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.366 -1.079 . . . . 0.0 109.62 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.27 46.13 0.04 OUTLIER Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.438 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.5 t -103.83 93.5 4.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.365 -1.079 . . . . 0.0 109.374 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.461 HD13 ' CE1' ' A' ' 87' ' ' HIS . 6.7 mt -75.67 91.79 2.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 109.414 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.879 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.07 141.71 8.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.331 -0.856 . . . . 0.0 109.637 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.627 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.8 m-85 -68.84 128.45 36.71 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.401 -0.812 . . . . 0.0 109.217 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.95 103.02 17.28 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.889 . . . . 0.0 109.637 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.71 171.2 64.36 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.482 . . . . 0.0 110.687 -0.235 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.414 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.97 10.32 47.97 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -164.88 113.26 1.05 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.351 -1.088 . . . . 0.0 109.135 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -133.87 170.58 15.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 109.641 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.4 m -122.58 131.34 53.78 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.352 -0.842 . . . . 0.0 109.474 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -133.25 -171.93 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.384 -0.823 . . . . 0.0 109.468 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.02 178.29 7.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.0 t -72.07 111.93 7.72 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.275 -0.89 . . . . 0.0 109.405 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.32 -17.52 7.0 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -81.42 167.4 19.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.317 -1.108 . . . . 0.0 109.496 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -124.09 131.17 53.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.594 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -95.66 151.08 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 108.986 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 t -133.42 146.74 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.176 -0.953 . . . . 0.0 110.007 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.603 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.7 m-85 -132.65 77.35 1.74 Allowed 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.479 ' HB2' HD23 ' A' ' 4' ' ' LEU . 29.4 mttt -78.92 134.01 36.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.912 . . . . 0.0 109.786 -179.606 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.472 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.4 p-10 -106.04 137.58 43.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.278 -0.889 . . . . 0.0 109.415 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -112.64 -70.46 0.81 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.352 -0.842 . . . . 0.0 109.672 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -121.09 149.97 41.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 109.578 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.91 23.22 36.11 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.469 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 4.0 p90 -67.82 162.45 58.28 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.441 -1.035 . . . . 0.0 109.525 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.526 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 35.9 Cg_endo -79.26 158.19 90.57 Favored 'Cis proline' 0 C--N 1.313 -1.31 0 C-N-CA 123.395 -1.502 . . . . 0.0 110.806 0.052 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.767 ' HB3' HD22 ' A' ' 5' ' ' LEU . 25.1 m-70 -126.17 39.77 3.87 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.43 -0.794 . . . . 0.0 109.269 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.448 ' OD1' ' HG3' ' A' ' 86' ' ' PRO . 10.8 p-10 -66.06 130.47 43.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.159 -0.963 . . . . 0.0 109.273 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -105.17 157.69 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 0.0 109.923 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.698 HG11 ' HB3' ' B' ' 63' ' ' ASN . 4.8 m -141.65 130.87 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.469 -0.77 . . . . 0.0 109.307 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -78.0 136.24 37.92 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.478 ' O ' HG13 ' A' ' 46' ' ' ILE . 0.6 OUTLIER -104.56 157.93 16.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.41 -0.806 . . . . 0.0 109.322 179.734 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.51 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 10.5 tp10 -94.47 17.38 13.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.333 -0.854 . . . . 0.0 109.671 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.6 -19.78 32.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 109.455 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -136.89 36.4 2.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.35 -0.844 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.74 HG23 ' HD2' ' A' ' 47' ' ' PRO . 22.1 mt -99.32 142.47 24.67 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.086 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.74 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.3 Cg_endo -76.03 -66.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 122.665 2.244 . . . . 0.0 111.125 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.521 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.9 t -84.39 -178.77 7.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.213 -0.929 . . . . 0.0 109.679 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.465 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.36 -100.76 0.14 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.465 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.61 152.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.511 -0.993 . . . . 0.0 109.79 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.504 ' HA ' ' NZ ' ' B' ' 187' ' ' LYS . 0.6 OUTLIER -80.68 152.93 28.18 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.211 -0.931 . . . . 0.0 109.597 -179.869 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.524 ' N ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.93 -25.31 40.55 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.349 -0.844 . . . . 0.0 109.593 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -74.89 -16.93 60.65 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.32 -0.862 . . . . 0.0 109.794 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.4 tptt -76.29 -32.48 58.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.334 -0.854 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.1 pt -107.54 -3.32 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.28 -0.887 . . . . 0.0 109.89 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 58.8 m -99.79 177.3 5.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.227 -0.92 . . . . 0.0 109.3 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.617 ' H ' HG12 ' A' ' 40' ' ' VAL . 8.4 mtp -92.48 155.94 17.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.269 -0.894 . . . . 0.0 109.595 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.21 -163.19 0.8 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.352 -0.842 . . . . 0.0 109.512 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.519 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -96.4 -31.35 12.89 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.348 -0.845 . . . . 0.0 110.003 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.403 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.62 -30.78 36.73 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.305 -0.872 . . . . 0.0 109.797 -179.734 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -89.08 100.69 13.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.304 -0.873 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.715 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -124.5 145.21 49.68 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.473 -0.767 . . . . 0.0 109.488 -179.935 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 4.2 mp -91.03 68.57 6.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.392 -0.817 . . . . 0.0 109.16 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -24.69 20.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.351 -0.843 . . . . 0.0 109.949 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.87 146.17 38.24 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.218 -0.926 . . . . 0.0 109.738 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.34 79.25 3.22 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.755 2.303 . . . . 0.0 110.252 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.09 -24.92 0.19 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.1 tp10 -68.31 148.6 50.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.444 -1.033 . . . . 0.0 109.347 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.7 p -136.09 145.81 46.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 109.867 -179.567 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 23.3 t80 -107.06 107.78 18.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.35 -0.844 . . . . 0.0 109.144 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.85 131.25 45.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 109.566 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.98 114.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.363 -0.836 . . . . 0.0 109.3 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.7 m -86.66 101.65 13.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.342 -0.849 . . . . 0.0 109.254 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -98.63 142.15 30.56 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.371 -0.83 . . . . 0.0 109.57 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.5 p -123.3 -24.68 4.6 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.699 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.36 153.99 42.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.288 -0.883 . . . . 0.0 109.622 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.3 mttt -101.16 125.38 47.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.533 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.99 -166.88 37.77 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -117.44 112.65 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.298 -1.119 . . . . 0.0 109.527 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -91.21 176.83 6.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.338 -0.851 . . . . 0.0 109.178 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.4 99.31 3.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.199 -0.938 . . . . 0.0 109.866 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.434 ' CE2' HG23 ' A' ' 96' ' ' VAL . 44.9 p90 -103.48 164.04 11.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.361 -0.837 . . . . 0.0 108.868 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.644 ' HB2' HG12 ' A' ' 93' ' ' VAL . 34.7 p90 -153.02 155.78 37.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.168 -0.957 . . . . 0.0 109.812 -179.649 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.406 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 42.4 t -66.68 108.1 2.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.424 -0.797 . . . . 0.0 109.119 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.842 ' HB3' ' HB3' ' B' ' 62' ' ' ALA . 0.6 OUTLIER -51.44 -53.31 51.06 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.48 -0.763 . . . . 0.0 109.924 -179.89 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.787 ' HA ' ' CGD' ' B' ' 251' ' ' HEC . 32.4 Cg_endo -74.04 34.68 0.37 Allowed 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.209 1.939 . . . . 0.0 110.733 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.708 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 7.9 m170 174.12 34.61 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.59 -0.694 . . . . 0.0 109.187 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.75 -33.21 73.51 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.254 -0.904 . . . . 0.0 109.571 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.42 ' HA3' ' CD2' ' B' ' 160' ' ' TYR . . . -92.22 -10.08 61.31 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -67.65 -72.57 0.17 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.391 -1.064 . . . . 0.0 109.406 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.24 29.53 0.03 OUTLIER Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.838 -1.173 . . . . 0.0 110.426 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.879 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm -126.39 104.69 8.31 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.157 -1.202 . . . . 0.0 109.07 179.494 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.644 HG12 ' HB2' ' A' ' 83' ' ' TYR . 32.4 m -143.06 165.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.271 -0.893 . . . . 0.0 109.615 -179.534 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.414 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -144.14 177.76 22.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -150.14 139.03 20.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.261 -1.141 . . . . 0.0 109.839 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.434 HG23 ' CE2' ' A' ' 82' ' ' PHE . 40.8 t -94.64 115.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.401 -0.812 . . . . 0.0 109.507 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -98.21 67.2 1.85 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.253 -0.905 . . . . 0.0 109.122 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.79 141.85 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.39 -0.819 . . . . 0.0 109.643 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.581 179.939 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 002 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 61' ' ' LEU . . . . . 0.715 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.842 ' HB3' ' HB3' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.698 ' HB3' HG11 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.519 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.524 ' HE2' ' N ' ' A' ' 52' ' ' ALA . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 N--CA 1.502 2.143 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.3 109.86 4.94 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.303 -0.873 . . . . 0.0 109.417 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.645 HG11 ' HD2' ' A' ' 14' ' ' PHE . 11.5 t -104.52 120.53 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.328 -0.858 . . . . 0.0 109.559 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.485 HD23 ' HB2' ' A' ' 30' ' ' LYS . 24.6 mt -106.73 101.36 10.81 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -0.838 . . . . 0.0 109.287 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.829 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.2 mp -64.42 141.21 58.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 109.432 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.18 138.36 1.56 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.74 -115.28 0.33 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -132.12 6.37 5.38 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.6 -41.34 0.22 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.346 -1.091 . . . . 0.0 109.596 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.22 45.45 0.04 OUTLIER Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.403 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.3 t -105.65 98.0 7.76 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.308 -1.113 . . . . 0.0 109.304 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.018 HD11 HG21 ' B' ' 3' ' ' ILE . 9.0 mt -78.79 101.12 7.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.324 -0.86 . . . . 0.0 109.487 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.692 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -169.58 136.24 1.63 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 109.661 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.645 ' HD2' HG11 ' A' ' 3' ' ' VAL . 39.6 m-85 -65.9 126.5 28.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 109.124 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.513 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -126.83 103.14 24.36 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.262 -0.898 . . . . 0.0 109.573 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.513 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.72 169.33 70.86 Favored 'Cis proline' 0 C--N 1.312 -1.356 0 C-N-CA 123.459 -1.475 . . . . 0.0 110.67 -0.224 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.458 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.2 12.28 51.89 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -166.98 105.63 0.58 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.393 -1.063 . . . . 0.0 109.009 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -126.77 167.67 15.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.707 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.5 128.39 53.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.345 -0.847 . . . . 0.0 109.393 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -130.43 -171.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.35 -0.844 . . . . 0.0 109.519 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.15 179.38 6.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.312 -0.868 . . . . 0.0 109.451 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.19 108.78 5.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.297 -0.877 . . . . 0.0 109.385 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.47 -17.26 5.58 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -81.84 171.41 14.53 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.31 -1.112 . . . . 0.0 109.434 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -128.27 133.39 48.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.288 -0.883 . . . . 0.0 109.702 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -94.45 146.56 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.442 -0.786 . . . . 0.0 109.071 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -129.57 145.48 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.19 -0.944 . . . . 0.0 109.818 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.631 ' HB3' HD11 ' A' ' 5' ' ' LEU . 46.5 m-85 -133.01 82.04 1.97 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.469 -0.769 . . . . 0.0 109.03 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.485 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.7 mttt -83.34 126.57 32.84 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.201 -0.937 . . . . 0.0 109.752 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.498 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.9 p-10 -98.85 127.8 44.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.259 -0.901 . . . . 0.0 109.481 179.752 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -104.65 -65.74 1.01 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 109.54 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -129.71 144.1 51.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.338 -0.851 . . . . 0.0 109.517 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.43 22.53 16.46 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.54 ' HB2' ' HA ' ' A' ' 64' ' ' ASN . 3.3 p90 -66.78 163.98 37.94 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.362 -1.081 . . . . 0.0 109.486 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.63 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.4 Cg_endo -80.4 152.14 83.09 Favored 'Cis proline' 0 C--N 1.312 -1.36 0 C-N-CA 123.389 -1.504 . . . . 0.0 110.858 -0.062 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.829 ' HB3' HD22 ' A' ' 5' ' ' LEU . 27.4 m-70 -118.26 40.35 3.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.347 -0.846 . . . . 0.0 109.222 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.402 ' OD1' ' HD3' ' A' ' 86' ' ' PRO . 16.2 p-10 -65.64 120.29 12.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.311 -0.868 . . . . 0.0 109.34 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.7 m -96.35 148.8 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.335 -0.853 . . . . 0.0 109.9 -179.376 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' B' ' 63' ' ' ASN . 7.7 m -134.82 119.79 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.43 -0.794 . . . . 0.0 109.048 179.769 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 15.0 m-85 -67.78 131.92 46.46 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.287 -0.883 . . . . 0.0 109.968 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.44 ' HB2' ' HE2' ' A' ' 83' ' ' TYR . 1.4 t0 -93.79 158.08 15.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.384 -0.822 . . . . 0.0 109.43 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.71 ' OE1' ' HE2' ' B' ' 187' ' ' LYS . 2.8 tp10 -100.55 17.82 20.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.844 . . . . 0.0 109.631 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -92.3 -18.04 23.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.148 -0.97 . . . . 0.0 109.483 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -130.64 26.21 5.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.226 -0.922 . . . . 0.0 109.629 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.738 HG23 ' HD2' ' A' ' 47' ' ' PRO . 19.0 mt -91.06 142.65 27.54 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.258 -0.901 . . . . 0.0 109.182 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.738 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -75.96 -65.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.704 2.27 . . . . 0.0 111.171 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.541 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.7 t -81.84 -177.61 6.64 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.189 -0.944 . . . . 0.0 109.692 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.505 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.9 -107.61 0.14 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.505 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.5 156.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.969 . . . . 0.0 109.856 179.926 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.72 160.8 14.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.401 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -80.55 -24.13 39.46 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.307 -0.871 . . . . 0.0 109.613 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -66.27 -19.16 65.74 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.227 -0.921 . . . . 0.0 109.951 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -80.57 -30.88 36.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.236 -0.915 . . . . 0.0 109.682 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.1 pt -117.17 23.26 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 109.84 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.401 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 45.0 m -127.72 171.28 11.85 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.472 ' H ' HG12 ' A' ' 40' ' ' VAL . 27.0 mtp -96.78 162.86 13.24 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.356 -0.84 . . . . 0.0 109.638 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.1 t -102.0 -171.2 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.349 -0.844 . . . . 0.0 109.746 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -84.64 -24.76 28.92 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.373 -0.829 . . . . 0.0 109.817 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -82.2 -32.42 29.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.254 -0.904 . . . . 0.0 109.705 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -95.23 90.02 5.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.83 146.29 42.11 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.42 -0.8 . . . . 0.0 109.388 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.664 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.6 mp -93.28 76.01 4.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.387 -0.821 . . . . 0.0 109.357 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.54 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.7 OUTLIER -98.04 -0.82 43.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.339 -0.851 . . . . 0.0 109.944 -179.721 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -107.19 143.85 27.97 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.174 -0.954 . . . . 0.0 109.711 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.42 84.7 1.91 Allowed 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.704 2.27 . . . . 0.0 110.296 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.22 -25.43 0.47 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.664 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -69.2 149.72 48.27 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.339 -1.095 . . . . 0.0 109.428 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 37.1 p -136.55 145.44 45.01 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.266 -0.896 . . . . 0.0 109.797 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -108.68 109.67 20.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.352 -0.842 . . . . 0.0 109.034 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.95 134.25 44.22 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.258 -0.901 . . . . 0.0 109.762 -179.722 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -123.14 115.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.374 -0.829 . . . . 0.0 109.211 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.49 104.18 15.71 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.281 -0.887 . . . . 0.0 109.343 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -101.4 142.75 32.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.384 -0.822 . . . . 0.0 109.547 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.8 p -124.66 -25.99 3.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.436 -0.79 . . . . 0.0 109.737 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 152.7 45.1 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.247 -0.908 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -99.61 124.39 44.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 109.514 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.465 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 164.13 -168.55 38.63 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.3 m -115.3 118.72 34.07 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.313 -1.11 . . . . 0.0 109.528 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -96.63 179.13 5.1 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.349 -0.845 . . . . 0.0 109.149 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.79 96.99 2.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.193 -0.942 . . . . 0.0 109.835 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -100.43 153.52 19.28 Favored 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.591 ' CD1' ' HB3' ' A' ' 88' ' ' GLN . 35.5 p90 -143.46 155.97 44.51 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.081 -1.012 . . . . 0.0 110.34 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.443 ' HB3' ' O ' ' A' ' 87' ' ' HIS . 8.6 t -68.55 114.02 6.58 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.459 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.608 ' N ' ' HD2' ' A' ' 86' ' ' PRO . 0.3 OUTLIER -51.28 -50.53 75.42 Favored Pre-proline 0 N--CA 1.495 1.809 0 O-C-N 121.252 -0.905 . . . . 0.0 109.992 -179.481 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.692 ' O ' ' HE2' ' B' ' 1' ' ' TYR . 33.0 Cg_endo -75.16 -19.4 17.54 Favored 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.23 1.953 . . . . 0.0 110.937 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.747 ' NE2' ' CD2' ' B' ' 1' ' ' TYR . 43.7 m170 -137.22 65.37 1.5 Allowed 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.051 -1.03 . . . . 0.0 110.159 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 1.168 ' OE1' ' OH ' ' B' ' 160' ' ' TYR . 0.0 OUTLIER -105.71 -22.06 13.04 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.059 -1.026 . . . . 0.0 109.219 179.502 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.69 -4.23 62.12 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.837 ' HB2' ' HZ ' ' B' ' 4' ' ' PHE . . . -84.47 -55.98 3.86 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.406 -1.055 . . . . 0.0 109.4 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.3 -15.08 0.48 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.758 ' CG ' ' O ' ' A' ' 92' ' ' MET . 0.5 OUTLIER -77.18 94.98 4.18 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.169 -1.195 . . . . 0.0 109.515 -179.781 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.42 HG12 ' HB2' ' A' ' 83' ' ' TYR . 17.4 m -146.63 148.61 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.381 -0.825 . . . . 0.0 109.211 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.32 179.88 16.69 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.3 ptmt -149.44 139.56 22.14 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.444 -1.033 . . . . 0.0 109.6 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.1 t -93.44 109.33 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.374 -0.829 . . . . 0.0 109.536 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -93.88 68.1 3.82 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.275 -0.891 . . . . 0.0 109.169 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.3 p -79.77 141.23 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.309 -0.869 . . . . 0.0 109.535 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.636 -179.998 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.747 ' CD2' ' NE2' ' A' ' 87' ' ' HIS . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 1.018 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.837 ' HZ ' ' HB2' ' A' ' 90' ' ' ALA . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 003 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.523 ' HB2' ' NH1' ' B' ' 156' ' ' ARG . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.537 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 1.168 ' OH ' ' OE1' ' A' ' 88' ' ' GLN . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.71 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.43 108.32 4.8 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 0.0 109.427 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.608 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.7 t -103.73 125.0 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.869 . . . . 0.0 109.497 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.413 HD23 ' HB2' ' A' ' 30' ' ' LYS . 19.8 mt -111.98 104.06 12.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.357 -0.839 . . . . 0.0 109.299 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.873 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.0 OUTLIER -65.62 139.42 58.42 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.834 . . . . 0.0 109.445 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.479 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.57 136.47 1.72 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.01 -117.07 0.23 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -129.86 7.39 6.13 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.38 -41.11 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.332 -1.099 . . . . 0.0 109.59 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.89 47.64 0.04 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.479 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -104.92 97.93 7.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.347 -1.09 . . . . 0.0 109.373 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.554 HD13 ' CE1' ' A' ' 87' ' ' HIS . 8.7 mt -77.42 94.21 4.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.34 -0.85 . . . . 0.0 109.403 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.878 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.86 139.4 4.35 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.366 -0.834 . . . . 0.0 109.744 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.608 ' HD2' HG11 ' A' ' 3' ' ' VAL . 37.2 m-85 -67.51 128.06 35.02 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.406 -0.809 . . . . 0.0 109.072 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.463 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.66 103.17 19.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.234 -0.916 . . . . 0.0 109.572 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.3 Cg_endo -79.74 170.79 65.88 Favored 'Cis proline' 0 C--N 1.313 -1.333 0 C-N-CA 123.41 -1.496 . . . . 0.0 110.646 -0.269 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.443 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.33 12.49 47.92 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -166.9 110.08 0.71 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.338 -1.095 . . . . 0.0 109.086 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -131.3 169.45 15.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.678 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.5 m -121.91 130.35 53.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.345 -0.847 . . . . 0.0 109.498 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.49 -170.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.398 -0.814 . . . . 0.0 109.453 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.08 179.15 6.67 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.8 t -72.12 109.14 5.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.289 -0.882 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.72 -17.04 5.81 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.1 171.22 14.59 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.339 -1.095 . . . . 0.0 109.467 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.69 134.7 49.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.272 -0.892 . . . . 0.0 109.646 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.82 149.91 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.416 -0.803 . . . . 0.0 109.058 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.34 145.95 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.209 -0.932 . . . . 0.0 109.949 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.647 ' HB3' HD11 ' A' ' 5' ' ' LEU . 52.0 m-85 -133.41 79.99 1.86 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 108.95 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.413 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.3 mttt -81.36 125.74 30.75 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.242 -0.911 . . . . 0.0 109.758 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.435 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 26.6 p-10 -97.11 125.99 41.97 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.304 -0.873 . . . . 0.0 109.52 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -101.21 -65.46 0.97 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.33 -0.857 . . . . 0.0 109.544 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.17 148.28 52.7 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.54 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.04 21.1 26.3 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.49 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.9 p90 -64.86 163.23 30.54 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.324 -1.104 . . . . 0.0 109.676 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.564 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -79.75 153.65 87.17 Favored 'Cis proline' 0 C--N 1.312 -1.363 0 C-N-CA 123.367 -1.514 . . . . 0.0 110.68 -0.162 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.873 ' HB3' HD22 ' A' ' 5' ' ' LEU . 34.4 m-70 -123.9 39.0 4.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.405 -0.81 . . . . 0.0 109.269 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -66.0 126.0 27.2 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.272 -0.892 . . . . 0.0 109.367 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -97.89 149.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.884 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.409 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.4 m -136.61 119.88 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.504 -0.747 . . . . 0.0 108.999 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -68.62 133.17 48.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.232 -0.918 . . . . 0.0 109.692 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.21 159.99 14.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.37 -0.831 . . . . 0.0 109.371 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.579 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.9 tp10 -100.78 31.94 3.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.4 -0.812 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.15 -18.66 13.95 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -130.67 24.93 5.07 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.345 -0.847 . . . . 0.0 109.56 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.736 HG23 ' HD2' ' A' ' 47' ' ' PRO . 35.8 mt -89.36 141.82 29.26 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.324 -0.86 . . . . 0.0 109.119 179.683 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.736 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.8 Cg_endo -75.69 -63.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.733 2.289 . . . . 0.0 111.103 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.543 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.9 t -84.81 -177.95 6.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.177 -0.952 . . . . 0.0 109.588 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.517 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.41 -105.47 0.13 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.517 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.24 156.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.53 -0.982 . . . . 0.0 109.835 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.76 158.2 16.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.307 -0.871 . . . . 0.0 109.581 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.46 -24.25 39.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.334 -0.854 . . . . 0.0 109.558 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.31 -15.94 62.94 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.38 -0.825 . . . . 0.0 109.853 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.2 tptt -81.3 -31.17 33.69 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.283 -0.886 . . . . 0.0 109.697 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.5 pt -113.23 7.55 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 67.5 m -111.74 173.92 6.12 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.194 -0.942 . . . . 0.0 109.419 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.4 ' H ' HG12 ' A' ' 40' ' ' VAL . 19.8 mtp -93.63 161.29 14.41 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 109.624 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.8 -167.25 1.56 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.341 -0.849 . . . . 0.0 109.681 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.412 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.8 OUTLIER -90.18 -28.66 18.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.339 -0.851 . . . . 0.0 109.976 -179.666 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.412 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -80.28 -30.38 38.33 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.253 -0.905 . . . . 0.0 109.859 -179.734 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -95.0 91.5 6.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.213 -0.93 . . . . 0.0 109.575 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.403 HD11 HD21 ' B' ' 61' ' ' LEU . 0.2 OUTLIER -115.6 142.98 46.0 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.406 -0.809 . . . . 0.0 109.296 179.914 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.719 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.8 mp -89.14 80.57 6.92 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.3 -0.875 . . . . 0.0 109.133 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.476 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 2.0 t30 -100.4 -22.9 14.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.91 145.46 36.63 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 109.905 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.59 81.6 2.62 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.801 2.334 . . . . 0.0 110.275 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 -25.74 0.24 Allowed Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.719 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.59 149.18 50.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.331 -1.1 . . . . 0.0 109.441 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -135.79 145.98 47.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 109.878 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.7 t80 -109.09 108.94 19.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.343 -0.848 . . . . 0.0 109.045 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.0 133.83 43.81 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.314 -0.866 . . . . 0.0 109.703 -179.697 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.76 115.22 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.42 -0.8 . . . . 0.0 109.239 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.24 102.04 13.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.296 -0.878 . . . . 0.0 109.279 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.1 142.98 29.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.347 -0.845 . . . . 0.0 109.559 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.56 -26.31 3.88 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.335 -0.853 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 151.8 46.47 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.328 -0.858 . . . . 0.0 109.615 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.3 mttt -98.81 122.55 42.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.376 -0.828 . . . . 0.0 109.594 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.5 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.64 -171.42 41.55 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -112.97 114.4 26.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.319 -1.106 . . . . 0.0 109.494 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -92.73 176.89 6.27 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.303 -0.873 . . . . 0.0 109.123 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.43 93.9 2.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.117 -0.99 . . . . 0.0 109.86 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -97.36 155.94 16.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.331 -0.856 . . . . 0.0 108.806 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.542 ' HB2' HG12 ' A' ' 93' ' ' VAL . 41.4 p90 -145.84 155.32 42.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.041 -1.037 . . . . 0.0 110.207 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.415 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 36.7 t -67.69 107.2 2.47 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.587 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -49.48 -52.42 49.99 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.395 -0.816 . . . . 0.0 109.975 -179.674 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.749 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 34.6 Cg_endo -76.25 31.67 0.4 Allowed 'Trans proline' 0 C--N 1.311 -1.413 0 C-N-CA 122.298 1.999 . . . . 0.0 110.761 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.749 ' CD2' ' O ' ' A' ' 86' ' ' PRO . 8.9 m170 175.77 49.79 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.433 -0.792 . . . . 0.0 109.316 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.543 ' OE1' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -81.35 -41.53 21.87 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.019 -1.05 . . . . 0.0 109.281 179.967 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.432 ' O ' ' OD1' ' B' ' 162' ' ' ASP . . . -81.88 -10.53 83.95 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.24 -64.13 0.92 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.277 -1.131 . . . . 0.0 109.425 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 149.53 -1.0 0.49 Allowed Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.915 -1.136 . . . . 0.0 110.337 179.67 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.878 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.4 ptm -94.42 103.79 15.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.087 -1.243 . . . . 0.0 109.481 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.542 HG12 ' HB2' ' A' ' 83' ' ' TYR . 28.9 m -146.72 150.08 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.443 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.0 178.17 17.93 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.7 ptmt -149.03 138.93 22.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.35 -1.088 . . . . 0.0 109.696 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 33.0 t -93.98 110.12 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.343 -0.848 . . . . 0.0 109.533 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.18 67.53 3.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.303 -0.873 . . . . 0.0 109.297 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.0 p -79.46 140.0 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.4 -0.812 . . . . 0.0 109.55 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.549 179.994 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.434 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 004 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 61' ' ' LEU . . . . . 0.403 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.587 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.409 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 162' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 89' ' ' GLY . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.493 ' HD3' ' HG2' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.2 p . . . . . 0 N--CA 1.502 2.162 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.85 106.64 4.87 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.895 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.565 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.9 t -102.33 126.35 56.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 17.8 mt -114.0 106.29 14.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.382 -0.823 . . . . 0.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.829 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.65 136.85 56.18 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.39 -0.819 . . . . 0.0 109.419 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.484 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 81.2 135.44 1.75 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.88 -119.42 0.26 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.88 -0.69 9.03 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -134.82 -41.11 0.76 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.364 -1.08 . . . . 0.0 109.549 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.925 ' O ' ' NE2' ' B' ' 7' ' ' GLN . . . 169.57 42.93 0.03 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.484 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.2 t -94.6 93.47 7.6 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.274 -1.133 . . . . 0.0 109.324 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -73.75 92.26 1.99 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.286 -0.884 . . . . 0.0 109.491 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.844 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.43 141.96 3.77 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.334 -0.854 . . . . 0.0 109.6 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.565 ' HD2' HG11 ' A' ' 3' ' ' VAL . 43.0 m-85 -68.12 127.87 34.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.378 -0.826 . . . . 0.0 109.197 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.4 mp -129.35 104.18 17.9 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 109.591 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.55 170.43 67.65 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.389 -1.505 . . . . 0.0 110.66 -0.272 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.42 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.65 10.47 49.34 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -165.05 111.65 0.97 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.316 -1.108 . . . . 0.0 109.131 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -132.29 169.38 16.55 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.388 -0.82 . . . . 0.0 109.59 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.07 130.16 53.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.344 -0.848 . . . . 0.0 109.423 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.6 m -132.92 -171.58 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.369 -0.832 . . . . 0.0 109.487 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.99 178.52 7.06 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.4 t -71.9 109.94 6.08 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.296 -0.878 . . . . 0.0 109.326 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.54 -17.29 5.85 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.04 173.4 12.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.39 -1.065 . . . . 0.0 109.453 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -129.73 134.67 47.76 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.284 -0.885 . . . . 0.0 109.675 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.546 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.46 149.39 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.407 -0.808 . . . . 0.0 109.046 179.7 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 t -133.25 145.6 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.179 -0.951 . . . . 0.0 109.992 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.635 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.0 m-85 -132.89 77.89 1.76 Allowed 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 mttt -79.38 124.66 28.64 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.191 -0.943 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.429 ' HA ' ' HB2' ' A' ' 5' ' ' LEU . 24.0 p-10 -96.75 120.82 37.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.319 -0.863 . . . . 0.0 109.451 179.69 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -93.99 -65.56 0.98 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 109.677 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.14 150.46 52.14 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.351 -0.843 . . . . 0.0 109.643 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 17.08 37.78 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.512 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 5.1 p90 -63.27 162.93 20.74 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.334 -1.098 . . . . 0.0 109.601 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.59 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.2 Cg_endo -79.11 150.9 86.53 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.483 . . . . 0.0 110.848 0.123 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.829 ' HB3' HD22 ' A' ' 5' ' ' LEU . 37.0 m-70 -124.04 42.39 3.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.39 -0.819 . . . . 0.0 109.41 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.502 ' OD1' ' HD3' ' A' ' 86' ' ' PRO . 8.8 p-10 -66.24 126.4 28.58 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.168 -0.958 . . . . 0.0 109.333 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.5 m -96.53 150.57 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.283 -0.886 . . . . 0.0 109.75 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.484 HG12 ' H ' ' A' ' 57' ' ' MET . 10.2 m -138.99 121.51 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.438 -0.789 . . . . 0.0 109.302 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -71.07 127.8 33.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.24 -0.913 . . . . 0.0 109.41 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.26 163.98 18.32 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.238 -0.914 . . . . 0.0 109.624 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.503 ' HA ' HD12 ' A' ' 46' ' ' ILE . 1.3 tp10 -101.49 25.58 8.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.408 -0.807 . . . . 0.0 109.527 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.46 -18.69 14.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.565 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -130.13 59.64 1.63 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.183 -0.948 . . . . 0.0 109.708 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.679 HG23 ' HD2' ' A' ' 47' ' ' PRO . 76.9 mt -119.82 140.3 29.4 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.267 -0.896 . . . . 0.0 109.089 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.679 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -76.05 -62.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 122.697 2.265 . . . . 0.0 110.968 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.469 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.4 t -88.92 -172.91 3.88 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.185 -0.947 . . . . 0.0 109.581 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.477 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.81 -112.29 0.14 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.477 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.8 154.95 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.495 -1.003 . . . . 0.0 109.792 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -95.35 168.05 10.96 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.28 -0.888 . . . . 0.0 109.661 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -85.03 -20.94 29.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.35 -0.844 . . . . 0.0 109.669 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -69.76 -12.34 61.56 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.213 -0.93 . . . . 0.0 109.982 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -88.88 -27.49 20.98 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.211 -0.931 . . . . 0.0 109.829 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.7 pt -117.96 12.21 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.195 -0.94 . . . . 0.0 110.078 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 74.7 m -117.08 175.31 5.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.159 -0.963 . . . . 0.0 109.45 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.484 ' H ' HG12 ' A' ' 40' ' ' VAL . 31.5 mtp -99.78 164.64 11.95 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.368 -0.833 . . . . 0.0 109.522 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.7 -170.83 1.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.324 -0.86 . . . . 0.0 109.745 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.525 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.6 OUTLIER -87.71 -25.97 23.19 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.374 -0.828 . . . . 0.0 109.794 -179.84 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.449 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 1.5 mp0 -82.38 -32.08 29.39 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.525 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -95.0 89.56 5.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.277 -0.889 . . . . 0.0 109.217 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.441 HD12 ' O ' ' A' ' 59' ' ' GLU . 0.1 OUTLIER -115.91 144.74 43.64 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.352 -0.843 . . . . 0.0 109.622 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.669 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.0 mp -86.94 79.44 8.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.415 -0.803 . . . . 0.0 109.155 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.456 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.4 t30 -100.26 -4.64 28.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.304 -0.872 . . . . 0.0 110.01 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.412 ' HA ' ' HD3' ' A' ' 66' ' ' PRO . . . -103.46 143.55 26.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 65' ' ' ALA . 35.3 Cg_endo -77.21 79.94 3.02 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.711 2.274 . . . . 0.0 110.242 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.2 -25.41 0.26 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.669 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.51 149.46 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.371 -1.076 . . . . 0.0 109.403 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 29.6 p -135.91 145.68 46.54 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.925 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 33.5 t80 -108.53 108.55 19.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -99.76 134.22 42.97 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.338 -0.851 . . . . 0.0 109.723 -179.627 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -122.93 113.92 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.38 -0.825 . . . . 0.0 109.319 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -84.63 102.31 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.253 -0.904 . . . . 0.0 109.291 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.64 142.17 31.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.1 p -123.92 -25.66 4.2 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.356 -0.84 . . . . 0.0 109.718 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.0 151.66 46.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.293 -0.879 . . . . 0.0 109.708 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -98.68 120.84 39.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.398 -0.814 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.406 ' H ' HG13 ' A' ' 98' ' ' VAL . . . 168.42 -171.82 42.75 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.4 m -113.56 114.14 26.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.274 -1.133 . . . . 0.0 109.493 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.17 179.02 5.55 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.366 -0.834 . . . . 0.0 109.095 179.753 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.78 101.46 3.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 109.8 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -102.91 163.28 12.3 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.647 ' HB2' HG12 ' A' ' 93' ' ' VAL . 43.7 p90 -155.17 154.32 32.1 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.078 -1.014 . . . . 0.0 110.158 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 35.2 t -66.43 110.08 2.98 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.74 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER -52.47 -55.52 31.33 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.451 -0.78 . . . . 0.0 110.247 -179.369 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.639 ' O ' ' CG ' ' A' ' 87' ' ' HIS . 35.0 Cg_endo -76.38 41.42 0.87 Allowed 'Trans proline' 0 C--N 1.314 -1.268 0 C-N-CA 122.393 2.062 . . . . 0.0 110.947 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.639 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 3.7 m170 174.67 32.45 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.453 -0.779 . . . . 0.0 109.351 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.481 ' H ' ' HG3' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -71.27 -25.72 62.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.312 -0.867 . . . . 0.0 109.24 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.88 -11.54 57.66 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -71.91 -75.51 0.13 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.358 -1.084 . . . . 0.0 109.319 179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 154.51 41.0 0.02 OUTLIER Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.7 -1.238 . . . . 0.0 110.452 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.844 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm -132.45 102.38 5.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.198 -1.177 . . . . 0.0 108.956 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.647 HG12 ' HB2' ' A' ' 83' ' ' TYR . 32.8 m -142.74 167.6 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -0.867 . . . . 0.0 109.629 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -147.8 -177.95 22.62 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.1 ptmt -152.36 142.02 21.85 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.122 . . . . 0.0 109.848 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 27.1 t -97.5 112.02 28.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.36 -0.838 . . . . 0.0 109.371 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -95.95 68.89 2.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.203 -0.936 . . . . 0.0 109.175 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 78' ' ' GLY . 4.4 p -81.01 139.52 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.33 -0.856 . . . . 0.0 109.591 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.604 -179.974 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.925 ' NE2' ' O ' ' A' ' 10' ' ' GLY . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.74 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.447 ' HB3' ' OG ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.525 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.171 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.6 108.97 4.61 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.621 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.0 t -104.08 120.37 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.315 -0.866 . . . . 0.0 109.474 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.426 HD23 ' HB2' ' A' ' 30' ' ' LYS . 21.2 mt -107.58 101.68 10.99 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.338 -0.851 . . . . 0.0 109.321 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.881 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -64.44 141.93 58.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.381 -0.824 . . . . 0.0 109.512 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.17 135.16 1.09 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.01 -116.79 0.19 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -130.45 7.64 5.93 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.61 -41.02 0.22 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.334 -1.097 . . . . 0.0 109.586 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.46 48.19 0.04 OUTLIER Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.46 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.8 t -105.67 99.33 8.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.339 -1.095 . . . . 0.0 109.322 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.664 HD11 HG21 ' B' ' 3' ' ' ILE . 11.1 mt -78.32 96.07 5.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.37 -0.831 . . . . 0.0 109.404 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.87 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.23 138.1 3.07 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.342 -0.849 . . . . 0.0 109.728 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.621 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.8 m-85 -66.68 127.71 33.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.357 -0.839 . . . . 0.0 109.031 179.635 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -128.12 103.12 20.94 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.293 -0.879 . . . . 0.0 109.573 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.61 170.43 67.46 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.394 -1.503 . . . . 0.0 110.666 -0.348 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.448 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.22 12.7 48.43 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -167.03 108.6 0.66 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.331 -1.1 . . . . 0.0 109.076 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -130.02 169.49 15.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.393 -0.817 . . . . 0.0 109.666 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 m -121.97 129.65 52.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.332 -0.855 . . . . 0.0 109.438 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.77 -170.17 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.38 -0.825 . . . . 0.0 109.482 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.55 179.11 6.75 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.305 -0.872 . . . . 0.0 109.473 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.09 108.83 5.5 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.27 -17.38 5.62 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -81.8 171.61 14.32 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.345 -1.091 . . . . 0.0 109.468 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -127.97 134.25 49.26 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.285 -0.884 . . . . 0.0 109.665 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.0 149.04 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.437 -0.789 . . . . 0.0 109.042 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 t -132.4 145.71 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.193 -0.942 . . . . 0.0 109.896 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.625 ' HB3' HD11 ' A' ' 5' ' ' LEU . 49.9 m-85 -133.32 80.38 1.88 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.424 -0.797 . . . . 0.0 109.016 179.613 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.426 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.9 mttt -81.55 126.78 32.12 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.223 -0.923 . . . . 0.0 109.729 -179.606 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.496 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 26.9 p-10 -98.07 126.22 43.41 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.333 -0.855 . . . . 0.0 109.484 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.99 -65.72 0.97 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.856 . . . . 0.0 109.522 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.33 146.91 52.49 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.344 -0.848 . . . . 0.0 109.544 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.05 20.95 26.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.546 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.7 p90 -64.24 164.8 16.38 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.363 -1.08 . . . . 0.0 109.634 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.621 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -80.03 153.54 85.99 Favored 'Cis proline' 0 C--N 1.313 -1.338 0 C-N-CA 123.378 -1.509 . . . . 0.0 110.606 -0.246 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.881 ' HB3' HD22 ' A' ' 5' ' ' LEU . 32.2 m-70 -121.1 37.96 4.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.217 179.564 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 15.7 p-10 -65.1 121.64 15.19 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.318 -0.864 . . . . 0.0 109.304 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -94.83 148.43 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.28 -0.888 . . . . 0.0 109.846 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.413 HG21 ' HB3' ' B' ' 63' ' ' ASN . 5.6 m -134.77 117.49 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.482 -0.761 . . . . 0.0 109.01 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -66.38 133.25 50.09 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.322 -0.861 . . . . 0.0 109.82 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -94.96 159.15 15.16 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.389 -0.819 . . . . 0.0 109.361 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.612 ' HA ' HD12 ' A' ' 46' ' ' ILE . 3.9 tp10 -100.55 24.71 8.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 109.591 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.97 -16.69 17.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -131.42 27.21 4.76 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.285 -0.884 . . . . 0.0 109.539 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.735 HG23 ' HD2' ' A' ' 47' ' ' PRO . 28.2 mt -92.15 142.18 25.96 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.301 -0.874 . . . . 0.0 109.055 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.735 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.67 -63.9 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.713 2.276 . . . . 0.0 111.101 -179.545 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.545 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -84.15 -176.85 6.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.162 -0.961 . . . . 0.0 109.563 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.502 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.66 -107.59 0.14 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.41 155.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.494 -1.004 . . . . 0.0 109.841 179.886 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.2 161.55 15.02 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.251 -0.906 . . . . 0.0 109.636 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.12 -22.16 36.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 0.0 109.644 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.78 -13.83 62.2 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.295 -0.878 . . . . 0.0 109.846 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -85.15 -29.86 24.44 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.247 -0.908 . . . . 0.0 109.679 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -114.54 8.2 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.17 -0.956 . . . . 0.0 110.021 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.8 m -113.47 172.93 6.67 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.168 -0.957 . . . . 0.0 109.408 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.8 mtp -92.52 160.91 14.83 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.317 -0.864 . . . . 0.0 109.56 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -95.14 -167.36 1.61 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.42 -0.8 . . . . 0.0 109.545 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.429 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.7 OUTLIER -90.94 -25.67 19.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.288 -0.883 . . . . 0.0 109.785 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.429 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -82.07 -30.41 31.33 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.739 -179.81 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -95.99 93.64 7.12 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.197 -0.94 . . . . 0.0 109.605 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.95 143.1 46.1 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.401 -0.812 . . . . 0.0 109.332 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.711 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.9 mp -89.28 80.52 6.84 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.346 -0.846 . . . . 0.0 109.18 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.483 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.8 t30 -100.09 -21.17 15.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 -179.647 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -88.53 144.82 34.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.175 -0.953 . . . . 0.0 109.864 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.45 81.62 2.6 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.754 2.303 . . . . 0.0 110.276 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.53 -25.6 0.25 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.711 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.58 149.43 50.12 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.419 -1.048 . . . . 0.0 109.408 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.9 p -135.81 145.39 46.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.251 -0.906 . . . . 0.0 109.864 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -108.84 109.22 20.28 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.453 -0.779 . . . . 0.0 109.008 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.29 134.3 43.43 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.343 -0.848 . . . . 0.0 109.726 -179.695 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.94 115.44 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.407 -0.808 . . . . 0.0 109.243 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -86.3 102.21 13.78 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.252 -0.905 . . . . 0.0 109.31 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.3 143.0 30.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.855 . . . . 0.0 109.606 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.3 p -124.63 -26.61 3.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.39 47.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.264 -0.898 . . . . 0.0 109.682 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -98.41 122.43 41.58 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.427 -0.795 . . . . 0.0 109.529 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.48 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.9 -170.92 41.58 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -113.68 114.1 25.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -1.157 . . . . 0.0 109.513 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -92.31 177.87 6.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.419 -0.801 . . . . 0.0 109.118 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.21 93.65 2.12 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.213 -0.93 . . . . 0.0 109.85 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.7 p90 -96.99 154.5 17.26 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 108.791 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.525 ' HB2' HG12 ' A' ' 93' ' ' VAL . 42.1 p90 -144.49 157.05 44.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.134 -0.979 . . . . 0.0 110.174 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 10.1 t -67.83 114.77 6.68 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER -54.87 -50.21 87.41 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.348 -0.845 . . . . 0.0 110.036 -179.562 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.629 ' HD2' ' N ' ' A' ' 85' ' ' SER . 32.9 Cg_endo -74.13 -8.28 20.82 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.187 1.925 . . . . 0.0 111.004 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.595 ' NE2' ' CD2' ' B' ' 1' ' ' TYR . 29.4 m170 -146.69 67.62 1.17 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.095 -1.003 . . . . 0.0 109.701 179.568 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.655 ' OE1' ' OH ' ' B' ' 160' ' ' TYR . 0.0 OUTLIER -98.62 -37.0 9.7 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.064 -1.023 . . . . 0.0 109.009 179.581 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.57 -9.88 80.58 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ALA . . . . . 0.479 ' HB2' ' HZ ' ' B' ' 4' ' ' PHE . . . -71.54 -63.4 1.13 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.285 -1.126 . . . . 0.0 109.441 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 153.01 2.47 0.17 Allowed Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.86 -1.162 . . . . 0.0 110.45 179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.87 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 1.3 ptm -96.35 100.87 12.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.13 -1.218 . . . . 0.0 109.325 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.525 HG12 ' HB2' ' A' ' 83' ' ' TYR . 28.0 m -146.8 148.41 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.351 -0.843 . . . . 0.0 109.405 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -129.45 178.69 17.23 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -148.86 138.51 21.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.123 . . . . 0.0 109.636 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.8 t -93.21 110.07 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.08 67.22 3.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.248 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.6 p -79.25 139.59 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.333 -0.854 . . . . 0.0 109.6 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.577 179.936 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.664 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 006 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.644 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.413 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 0.525 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 N--CA 1.503 2.188 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.82 107.97 4.88 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.307 -0.871 . . . . 0.0 109.408 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.63 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.9 t -102.98 124.01 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.363 -0.835 . . . . 0.0 109.451 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.491 HD23 ' HB2' ' A' ' 30' ' ' LYS . 21.8 mt -110.26 101.88 10.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.361 -0.837 . . . . 0.0 109.383 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.822 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.24 133.08 50.7 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.335 -0.853 . . . . 0.0 109.388 -179.99 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.504 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 84.69 133.01 2.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.72 -118.15 0.15 Allowed Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.62 -1.89 6.95 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -132.93 -40.34 0.94 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.129 . . . . 0.0 109.592 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.583 ' HA3' HD11 ' B' ' 3' ' ' ILE . . . 168.31 46.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.504 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.7 t -99.19 94.56 6.56 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.356 -1.085 . . . . 0.0 109.338 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.559 HD13 ' CE1' ' A' ' 87' ' ' HIS . 7.5 mt -75.18 89.7 2.53 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.343 -0.848 . . . . 0.0 109.471 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.87 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.51 142.03 7.93 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.295 -0.878 . . . . 0.0 109.674 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.63 ' HD2' HG11 ' A' ' 3' ' ' VAL . 38.1 m-85 -68.15 128.26 35.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -0.849 . . . . 0.0 109.159 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.54 102.31 18.33 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 109.604 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.74 171.6 62.44 Favored 'Cis proline' 0 C--N 1.312 -1.351 0 C-N-CA 123.428 -1.488 . . . . 0.0 110.714 -0.269 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.419 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.42 10.77 46.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -165.15 110.46 0.91 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.328 -1.101 . . . . 0.0 109.078 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -131.2 167.75 18.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.639 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.9 m -120.43 129.84 54.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.327 -0.858 . . . . 0.0 109.471 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 98' ' ' VAL . 3.0 m -131.94 -172.85 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.369 -0.832 . . . . 0.0 109.545 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.68 178.55 6.95 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 109.482 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.7 t -72.17 111.47 7.42 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.333 -0.854 . . . . 0.0 109.428 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.77 -16.38 6.94 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -82.57 167.11 18.64 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.395 -1.062 . . . . 0.0 109.488 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -123.92 133.14 53.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.64 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.506 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.3 mp -97.36 151.03 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.438 -0.789 . . . . 0.0 109.042 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.4 t -133.7 145.22 33.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 109.967 -179.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.674 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.6 m-85 -130.92 77.43 1.78 Allowed 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.491 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.3 mttt -77.07 132.61 39.0 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.272 -0.892 . . . . 0.0 109.842 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 20.6 p-10 -105.72 122.22 45.62 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.52 -67.18 0.87 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.281 -0.887 . . . . 0.0 109.588 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -125.44 149.99 47.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.326 -0.858 . . . . 0.0 109.525 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.33 11.02 61.55 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.652 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 3.0 p90 -61.76 165.99 6.75 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 121.399 -1.059 . . . . 0.0 109.543 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.57 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.2 Cg_endo -78.84 151.64 88.39 Favored 'Cis proline' 0 C--N 1.313 -1.292 0 C-N-CA 123.329 -1.53 . . . . 0.0 110.506 -0.016 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.822 ' HB3' HD22 ' A' ' 5' ' ' LEU . 50.6 m-70 -122.78 44.78 2.55 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.384 -0.823 . . . . 0.0 109.365 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.498 ' OD1' ' HG3' ' A' ' 86' ' ' PRO . 9.7 p-10 -68.57 123.15 20.05 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.196 -0.94 . . . . 0.0 109.199 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.07 155.7 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.245 -0.909 . . . . 0.0 109.992 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.478 HG21 ' HB3' ' B' ' 63' ' ' ASN . 3.6 m -141.33 118.8 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.418 -0.801 . . . . 0.0 109.201 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -69.31 130.57 42.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 109.663 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.11 159.39 15.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.355 -0.841 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.603 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.5 tp10 -99.02 34.46 2.11 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.313 -0.867 . . . . 0.0 109.491 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -108.38 -22.09 12.47 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -0.899 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -128.5 32.78 4.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.738 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.717 HG23 ' HD2' ' A' ' 47' ' ' PRO . 49.0 mt -95.35 141.44 23.22 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.24 -0.913 . . . . 0.0 109.188 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.717 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.4 Cg_endo -76.46 -59.6 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.723 2.282 . . . . 0.0 111.038 -179.738 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.527 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.5 t -87.65 -176.26 5.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.932 . . . . 0.0 109.683 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.523 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -78.26 -107.01 0.19 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.45 156.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.513 -0.992 . . . . 0.0 109.773 179.896 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.89 160.75 16.29 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 0.0 109.637 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.26 -18.18 40.02 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.872 . . . . 0.0 109.729 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -77.15 -9.42 58.74 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.222 -0.924 . . . . 0.0 109.851 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.0 tptp -87.75 -27.18 22.51 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.279 -0.888 . . . . 0.0 109.715 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.6 pt -113.68 -5.1 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.212 -0.93 . . . . 0.0 109.976 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.2 m -98.99 175.29 5.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.168 -0.957 . . . . 0.0 109.473 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 16.5 mtp -93.24 157.26 16.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.819 . . . . 0.0 109.563 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -88.35 -160.13 0.61 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.467 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.836 ' OE1' ' HE2' ' B' ' 65' ' ' LYS . 8.8 pm0 -98.24 -29.21 13.32 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.296 -0.877 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.507 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.7 -30.33 36.38 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.302 -0.874 . . . . 0.0 109.737 -179.873 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -92.16 95.42 9.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.335 -0.853 . . . . 0.0 109.48 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.831 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -116.7 141.61 47.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.424 -0.797 . . . . 0.0 109.34 -179.986 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.657 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.0 OUTLIER -90.52 80.14 6.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.338 -0.851 . . . . 0.0 109.14 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -102.7 -41.05 6.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.324 -0.86 . . . . 0.0 109.8 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.49 145.63 98.4 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.326 -0.859 . . . . 0.0 109.979 -179.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.75 78.09 3.67 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.771 2.314 . . . . 0.0 110.219 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 165.38 -24.79 0.16 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.657 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.2 tp10 -67.84 148.11 51.62 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.365 -1.08 . . . . 0.0 109.339 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.41 ' HA ' HD21 ' A' ' 63' ' ' LEU . 41.1 p -136.74 143.27 43.2 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 109.899 -179.595 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -105.28 107.15 17.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.348 -0.845 . . . . 0.0 109.094 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.47 131.07 45.02 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 109.62 -179.744 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -121.08 112.44 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.424 -0.798 . . . . 0.0 109.206 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.8 m -83.66 104.04 13.45 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 109.297 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -100.92 141.26 34.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.362 -0.836 . . . . 0.0 109.557 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.9 p -123.14 -24.73 4.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.19 153.42 43.72 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.274 -0.891 . . . . 0.0 109.642 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.8 mttt -100.67 124.07 45.75 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.309 -0.869 . . . . 0.0 109.548 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.427 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 165.71 -168.53 39.64 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.8 m -116.86 110.82 18.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.332 -1.099 . . . . 0.0 109.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -89.35 176.09 7.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.8 92.51 2.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.169 -0.957 . . . . 0.0 109.918 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.423 ' CE2' HG23 ' A' ' 96' ' ' VAL . 47.9 p90 -97.54 154.6 17.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.337 -0.852 . . . . 0.0 108.738 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.675 ' HB2' HG12 ' A' ' 93' ' ' VAL . 41.6 p90 -143.79 154.61 43.6 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 109.987 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.407 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 49.6 t -65.9 106.91 1.68 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.502 -0.749 . . . . 0.0 109.024 179.567 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.866 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -49.33 -55.36 22.24 Favored Pre-proline 0 N--CA 1.494 1.725 0 O-C-N 121.49 -0.756 . . . . 0.0 110.089 -179.553 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.696 ' O ' ' CG ' ' A' ' 87' ' ' HIS . 33.4 Cg_endo -74.08 41.66 0.68 Allowed 'Trans proline' 0 C--N 1.312 -1.346 0 C-N-CA 122.142 1.895 . . . . 0.0 110.783 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.696 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 4.3 m170 170.91 33.91 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.61 -0.681 . . . . 0.0 109.197 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.48 -31.24 70.37 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.269 -0.894 . . . . 0.0 109.391 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -95.72 -4.03 60.66 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.8 -74.42 0.18 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.325 -1.103 . . . . 0.0 109.375 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.2 38.32 0.02 OUTLIER Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.896 -1.145 . . . . 0.0 110.345 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.87 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm -135.47 105.75 6.36 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.224 -1.162 . . . . 0.0 109.009 179.456 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.675 HG12 ' HB2' ' A' ' 83' ' ' TYR . 35.0 m -144.97 146.79 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.362 -0.836 . . . . 0.0 109.607 -179.487 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.419 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -124.7 176.32 17.04 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.81 136.2 20.29 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.263 -1.139 . . . . 0.0 109.816 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.423 HG23 ' CE2' ' A' ' 82' ' ' PHE . 31.5 t -91.49 109.96 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.344 -0.847 . . . . 0.0 109.476 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -94.79 66.75 3.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.204 -0.935 . . . . 0.0 109.104 179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 7.0 p -79.21 141.24 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.307 -0.87 . . . . 0.0 109.62 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.2 p30 . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.566 179.946 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.583 HD11 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 007 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 61' ' ' LEU . . . . . 0.831 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.866 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.478 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.836 ' HE2' ' OE1' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.4 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.38 107.99 4.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.653 HG11 ' HD2' ' A' ' 14' ' ' PHE . 11.8 t -102.9 125.46 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.364 -0.835 . . . . 0.0 109.504 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.486 HD23 ' HB2' ' A' ' 30' ' ' LYS . 25.0 mt -111.13 100.52 9.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.387 -0.82 . . . . 0.0 109.299 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.836 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.01 128.57 36.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.373 -0.83 . . . . 0.0 109.388 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.492 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 88.71 134.0 4.79 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -77.58 -124.62 0.28 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.26 -13.52 8.25 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -118.74 -37.39 3.27 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.322 -1.104 . . . . 0.0 109.615 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.605 ' HA3' HD11 ' B' ' 3' ' ' ILE . . . 160.61 45.9 0.02 OUTLIER Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.492 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.8 t -94.64 98.47 10.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.288 -1.125 . . . . 0.0 109.301 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.616 HD13 ' CE1' ' A' ' 87' ' ' HIS . 7.6 mt -73.83 91.92 2.0 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.298 -0.876 . . . . 0.0 109.485 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.915 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.2 137.53 5.21 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.358 -0.839 . . . . 0.0 109.617 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.653 ' HD2' HG11 ' A' ' 3' ' ' VAL . 35.4 m-85 -65.71 126.58 28.88 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.383 -0.823 . . . . 0.0 109.054 179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -127.9 102.28 22.29 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.248 -0.907 . . . . 0.0 109.607 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.78 170.47 66.89 Favored 'Cis proline' 0 C--N 1.313 -1.317 0 C-N-CA 123.45 -1.479 . . . . 0.0 110.679 -0.271 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.443 ' HA2' ' HB3' ' A' ' 14' ' ' PHE . . . -105.41 12.45 47.57 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -166.49 105.92 0.64 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.406 -1.055 . . . . 0.0 109.043 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -127.45 167.25 16.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.307 -0.87 . . . . 0.0 109.695 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.64 128.55 53.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 109.404 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 98' ' ' VAL . 3.0 m -130.44 -171.52 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.388 -0.82 . . . . 0.0 109.532 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.31 179.01 6.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.329 -0.857 . . . . 0.0 109.442 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -72.3 110.52 6.78 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.238 -0.914 . . . . 0.0 109.417 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.62 -16.91 6.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -82.1 165.71 20.35 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.34 -1.094 . . . . 0.0 109.472 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -122.61 132.11 54.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.337 -0.852 . . . . 0.0 109.636 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.31 151.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 109.045 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -133.5 146.28 32.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.217 -0.927 . . . . 0.0 109.934 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.675 ' HB3' HD11 ' A' ' 5' ' ' LEU . 52.1 m-85 -132.5 80.05 1.88 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.486 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.3 mttt -80.45 131.79 35.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.333 -0.855 . . . . 0.0 109.716 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.2 p-10 -105.25 119.57 39.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.282 -0.886 . . . . 0.0 109.493 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -98.19 -67.83 0.83 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.343 -0.848 . . . . 0.0 109.573 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -124.68 149.85 46.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.33 -0.856 . . . . 0.0 109.49 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 92.13 12.71 58.51 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.642 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 4.9 p90 -61.5 163.97 10.35 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.405 -1.056 . . . . 0.0 109.542 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.553 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.2 Cg_endo -79.1 157.28 91.4 Favored 'Cis proline' 0 C--N 1.313 -1.322 0 C-N-CA 123.322 -1.532 . . . . 0.0 110.481 -0.138 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.836 ' HB3' HD22 ' A' ' 5' ' ' LEU . 43.9 m-70 -127.97 39.75 3.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.385 -0.822 . . . . 0.0 109.33 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -65.19 120.64 13.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.334 -0.854 . . . . 0.0 109.267 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -93.0 151.45 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.305 -0.872 . . . . 0.0 109.823 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.536 HG12 ' H ' ' A' ' 57' ' ' MET . 10.2 m -137.99 121.71 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.109 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -70.26 132.11 45.22 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.258 -0.901 . . . . 0.0 109.709 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.45 157.86 15.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.294 -0.879 . . . . 0.0 109.53 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.563 ' HA ' HD12 ' A' ' 46' ' ' ILE . 6.0 tp10 -98.02 47.04 1.01 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.294 -0.879 . . . . 0.0 109.45 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.56 -26.77 5.67 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.286 -0.884 . . . . 0.0 109.38 179.727 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -124.25 25.25 7.83 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.342 -0.849 . . . . 0.0 109.61 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.73 HG23 ' HD2' ' A' ' 47' ' ' PRO . 58.0 mt -87.87 141.36 31.54 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.254 -0.904 . . . . 0.0 109.155 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.73 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.0 Cg_endo -76.23 -60.71 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.738 2.292 . . . . 0.0 110.999 -179.595 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.523 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -87.57 -178.3 6.08 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.211 -0.931 . . . . 0.0 109.642 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.536 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.6 -103.39 0.14 Allowed Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.92 157.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.523 -0.987 . . . . 0.0 109.899 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.23 156.42 18.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.263 -0.898 . . . . 0.0 109.624 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.63 -24.41 39.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.321 -0.862 . . . . 0.0 109.677 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -72.82 -15.22 61.63 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 109.777 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -79.43 -31.62 42.63 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.303 -0.873 . . . . 0.0 109.735 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.0 pt -111.07 0.44 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.272 -0.892 . . . . 0.0 109.879 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 62.4 m -104.02 177.93 4.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.536 ' H ' HG12 ' A' ' 40' ' ' VAL . 22.7 mtp -98.67 159.07 15.21 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.289 -0.882 . . . . 0.0 109.523 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.73 -166.43 1.58 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.354 -0.841 . . . . 0.0 109.552 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.53 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -91.43 -28.06 17.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.354 -0.841 . . . . 0.0 109.92 -179.807 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.444 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.5 OUTLIER -80.93 -31.25 35.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.88 . . . . 0.0 109.775 -179.851 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -91.23 97.37 11.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.337 -0.852 . . . . 0.0 109.483 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.656 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -120.15 145.49 46.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.38 -0.825 . . . . 0.0 109.363 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.664 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.0 mp -93.31 75.31 4.56 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.415 -0.803 . . . . 0.0 109.185 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -96.04 -35.45 11.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.292 -0.88 . . . . 0.0 109.749 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -73.21 143.84 83.82 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.308 -0.87 . . . . 0.0 109.808 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.56 80.06 3.03 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.777 2.318 . . . . 0.0 110.215 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 163.84 -24.95 0.19 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.664 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.55 149.33 50.27 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.387 -1.066 . . . . 0.0 109.387 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 36.2 p -136.4 144.22 44.4 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.2 t80 -106.73 108.72 20.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.384 -0.823 . . . . 0.0 109.07 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.452 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.06 132.28 45.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.322 -0.861 . . . . 0.0 109.685 -179.742 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -122.1 112.85 36.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.418 -0.801 . . . . 0.0 109.263 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.6 m -84.2 102.0 12.29 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.291 -0.88 . . . . 0.0 109.326 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -98.46 142.45 30.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.33 -0.856 . . . . 0.0 109.531 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.3 p -123.9 -25.92 4.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.351 -0.843 . . . . 0.0 109.714 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.46 152.27 45.63 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 109.669 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -99.43 123.1 43.41 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.418 -0.801 . . . . 0.0 109.605 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.492 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.68 -171.67 41.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 4.0 m -113.3 111.01 21.3 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.298 -1.119 . . . . 0.0 109.401 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -89.57 175.44 7.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.362 -0.837 . . . . 0.0 109.171 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.7 88.58 1.77 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.223 -0.923 . . . . 0.0 109.861 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.446 ' HE1' ' CE2' ' A' ' 14' ' ' PHE . 48.3 p90 -93.23 146.5 23.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.249 -0.907 . . . . 0.0 108.802 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.545 ' HB2' HG12 ' A' ' 93' ' ' VAL . 50.1 p90 -133.41 153.03 51.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.863 -179.59 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.408 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 42.5 t -65.68 109.2 2.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.542 -0.724 . . . . 0.0 109.246 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.823 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.5 OUTLIER -49.49 -54.37 31.31 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.471 -0.768 . . . . 0.0 109.812 -179.8 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.782 ' HA ' ' CGD' ' B' ' 251' ' ' HEC . 32.7 Cg_endo -74.36 33.13 0.35 Allowed 'Trans proline' 0 C--N 1.312 -1.346 0 C-N-CA 122.105 1.87 . . . . 0.0 110.503 179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.74 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 9.9 m170 174.04 49.89 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 179.523 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.482 ' HG3' ' H ' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -74.15 -52.55 12.17 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.202 -0.936 . . . . 0.0 109.161 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.11 1.1 89.27 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -68.4 -61.98 1.59 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.267 -1.137 . . . . 0.0 109.348 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 151.79 -15.61 0.81 Allowed Glycine 0 N--CA 1.493 2.485 0 C-N-CA 119.839 -1.172 . . . . 0.0 110.241 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.915 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm -88.08 109.8 20.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.158 -1.201 . . . . 0.0 109.719 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.545 HG12 ' HB2' ' A' ' 83' ' ' TYR . 15.3 m -149.57 134.49 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.299 -0.876 . . . . 0.0 109.31 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -115.17 174.98 15.64 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -147.65 135.3 20.94 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.13 . . . . 0.0 109.614 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.428 HG23 ' CE2' ' A' ' 82' ' ' PHE . 34.9 t -89.33 109.87 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.97 65.87 2.97 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 109.174 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.408 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 4.7 p -78.32 140.47 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.369 -0.832 . . . . 0.0 109.575 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.586 179.982 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.605 HD11 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 008 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 61' ' ' LEU . . . . . 0.656 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.823 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.412 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.53 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.9 p . . . . . 0 N--CA 1.503 2.195 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.56 108.91 5.18 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.235 -0.915 . . . . 0.0 109.46 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.633 HG11 ' HD2' ' A' ' 14' ' ' PHE . 15.8 t -104.35 120.65 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.34 -0.85 . . . . 0.0 109.446 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.433 HD23 ' HB2' ' A' ' 30' ' ' LYS . 19.0 mt -107.63 102.59 11.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.389 -0.82 . . . . 0.0 109.342 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.792 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.09 141.62 58.66 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.326 -0.859 . . . . 0.0 109.415 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.47 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.09 136.48 1.23 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.64 -121.35 0.46 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -125.48 5.12 8.13 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.03 -42.61 0.27 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.315 -1.109 . . . . 0.0 109.601 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.97 42.41 0.05 OUTLIER Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.47 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 1.7 t -97.71 96.91 8.57 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.311 -1.111 . . . . 0.0 109.295 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.639 HD13 ' CE1' ' A' ' 87' ' ' HIS . 6.1 mt -80.03 90.95 5.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.377 -0.827 . . . . 0.0 109.451 -179.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.862 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.61 142.58 6.67 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.338 -0.851 . . . . 0.0 109.781 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.633 ' HD2' HG11 ' A' ' 3' ' ' VAL . 33.5 m-85 -67.62 128.06 35.06 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.418 -0.801 . . . . 0.0 109.082 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.508 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.11 102.76 18.71 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.612 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.75 171.18 64.32 Favored 'Cis proline' 0 C--N 1.312 -1.359 0 C-N-CA 123.43 -1.487 . . . . 0.0 110.648 -0.248 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.463 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -106.17 14.64 43.96 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -169.1 110.54 0.49 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.393 -1.063 . . . . 0.0 109.051 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -132.22 170.19 15.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.34 -0.85 . . . . 0.0 109.67 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.3 m -122.69 130.95 53.54 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 109.443 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -132.96 -169.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.354 -0.841 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.49 178.93 6.86 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.283 -0.885 . . . . 0.0 109.455 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.0 t -71.98 109.42 5.79 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.349 -0.844 . . . . 0.0 109.385 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.43 -17.03 5.9 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -81.91 171.4 14.5 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -1.095 . . . . 0.0 109.479 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.86 133.93 49.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.268 -0.895 . . . . 0.0 109.642 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -95.9 150.72 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.379 -0.825 . . . . 0.0 109.035 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -134.34 146.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 109.949 -179.561 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.637 ' HB3' HD11 ' A' ' 5' ' ' LEU . 56.8 m-85 -133.72 80.21 1.86 Allowed 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.433 ' HB2' HD23 ' A' ' 4' ' ' LEU . 28.6 mttt -81.11 123.86 28.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.229 -0.919 . . . . 0.0 109.825 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -94.46 126.73 39.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.334 -0.854 . . . . 0.0 109.388 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -102.93 -63.7 1.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.847 . . . . 0.0 109.566 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -134.33 148.04 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.344 -0.848 . . . . 0.0 109.561 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 14.96 45.74 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 1.056 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 0.2 OUTLIER -62.86 166.15 8.38 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.44 -1.036 . . . . 0.0 109.542 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.694 ' O ' ' HG2' ' A' ' 86' ' ' PRO . 35.6 Cg_endo -78.06 145.32 78.13 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.679 0.249 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.792 ' HB3' HD22 ' A' ' 5' ' ' LEU . 34.7 m-70 -115.58 32.7 5.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -58.23 119.38 6.78 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.269 -0.894 . . . . 0.0 109.361 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -93.32 157.23 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.358 -0.839 . . . . 0.0 110.026 -179.238 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.5 m -139.79 119.98 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.397 -0.814 . . . . 0.0 109.194 179.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -67.19 116.74 8.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.397 -0.814 . . . . 0.0 109.927 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.43 ' O ' HG13 ' A' ' 46' ' ' ILE . 1.3 t70 -81.41 149.62 28.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.29 -0.881 . . . . 0.0 109.523 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 1.279 ' CB ' ' HE2' ' B' ' 187' ' ' LYS . 1.0 OUTLIER -96.79 6.44 48.66 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.267 -0.896 . . . . 0.0 109.918 179.909 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.43 -19.7 57.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.183 -0.948 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -131.49 38.44 3.6 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.384 -0.823 . . . . 0.0 109.515 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.786 HG23 ' HD2' ' A' ' 47' ' ' PRO . 8.1 mt -98.96 143.97 27.35 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.254 -0.904 . . . . 0.0 109.25 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.786 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.9 Cg_endo -76.02 -63.99 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.786 2.324 . . . . 0.0 111.068 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -83.4 -176.45 6.32 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.177 -0.952 . . . . 0.0 109.686 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.564 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -78.37 -105.63 0.2 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.564 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.65 160.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.56 -0.964 . . . . 0.0 109.861 179.811 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -99.45 162.61 12.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.256 -0.903 . . . . 0.0 109.547 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.415 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -81.78 -17.23 48.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.33 -0.856 . . . . 0.0 109.73 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.62 -2.3 28.64 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.217 -0.927 . . . . 0.0 109.898 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -101.5 -25.57 13.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.235 -0.915 . . . . 0.0 109.649 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.3 pt -119.0 6.67 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.198 -0.939 . . . . 0.0 110.114 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 69.0 m -113.05 171.18 7.7 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.108 -0.995 . . . . 0.0 109.366 179.746 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.6 mtp -88.79 152.12 21.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.323 -0.86 . . . . 0.0 109.571 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.2 t -89.82 -154.67 0.33 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.43 -0.794 . . . . 0.0 109.498 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' B' ' 66' ' ' LYS . 3.2 pt-20 -101.83 -33.55 9.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.259 -0.9 . . . . 0.0 109.888 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.86 -29.69 63.4 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.874 . . . . 0.0 109.829 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -96.88 87.26 4.23 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.262 -0.899 . . . . 0.0 109.672 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.05 139.75 43.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.374 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.7 mp -89.75 84.52 6.29 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.587 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 17.5 t-20 -111.44 -4.47 14.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.272 -0.892 . . . . 0.0 109.824 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -101.38 146.71 32.67 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 109.689 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -77.11 78.47 3.44 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.795 2.33 . . . . 0.0 110.225 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.94 -23.88 0.29 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -68.2 147.16 52.64 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.322 -1.105 . . . . 0.0 109.442 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.0 p -136.36 147.32 47.31 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.247 -0.908 . . . . 0.0 109.828 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.6 t80 -110.24 109.27 19.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.81 . . . . 0.0 109.019 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.23 133.86 44.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 -179.673 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -123.05 116.58 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.384 -0.823 . . . . 0.0 109.242 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -87.14 102.48 14.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.287 -0.883 . . . . 0.0 109.355 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.76 142.95 30.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.343 -0.848 . . . . 0.0 109.584 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.7 p -124.46 -27.04 3.8 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.374 -0.829 . . . . 0.0 109.786 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.67 152.08 46.21 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.216 -0.927 . . . . 0.0 109.696 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -99.18 125.13 44.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.375 -0.828 . . . . 0.0 109.557 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.424 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.71 -165.88 37.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.2 m -118.28 120.05 36.5 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.317 -1.108 . . . . 0.0 109.524 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -97.08 178.15 5.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.421 -0.799 . . . . 0.0 109.085 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -147.54 88.36 1.7 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.114 -0.992 . . . . 0.0 109.891 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.435 ' CE2' HG23 ' A' ' 96' ' ' VAL . 42.6 p90 -93.65 161.22 14.43 Favored 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.663 ' HB2' HG12 ' A' ' 93' ' ' VAL . 44.7 p90 -155.15 152.96 30.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.038 -1.039 . . . . 0.0 110.339 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 51.6 t -64.31 114.08 4.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.612 -0.68 . . . . 0.0 109.233 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' SER . . . . . 1.261 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 5.6 t -49.99 -63.08 1.96 Allowed Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.407 -0.808 . . . . 0.0 110.107 -179.419 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.897 ' HD3' ' HB3' ' A' ' 85' ' ' SER . 36.1 Cg_endo -76.7 62.16 7.13 Favored 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 122.284 1.989 . . . . 0.0 110.767 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.773 ' NE2' ' CE2' ' B' ' 1' ' ' TYR . 4.4 m170 159.03 25.91 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.537 -0.727 . . . . 0.0 109.531 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.609 ' HG2' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -71.06 -24.42 62.33 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.133 -0.979 . . . . 0.0 108.906 179.529 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.86 -13.14 55.68 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -69.92 -71.27 0.24 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.408 -1.054 . . . . 0.0 109.263 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 152.97 36.24 0.03 OUTLIER Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.82 -1.181 . . . . 0.0 110.491 179.554 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.862 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.8 ptm -127.88 102.51 6.8 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -1.197 . . . . 0.0 109.26 179.473 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.663 HG12 ' HB2' ' A' ' 83' ' ' TYR . 35.1 m -143.88 153.22 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.46 176.45 19.87 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.04 138.11 22.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.316 -1.108 . . . . 0.0 109.74 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.435 HG23 ' CE2' ' A' ' 82' ' ' PHE . 45.7 t -93.25 108.67 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.361 -0.837 . . . . 0.0 109.473 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -92.35 67.3 4.83 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.263 -0.898 . . . . 0.0 109.162 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.405 HG12 ' H ' ' A' ' 98' ' ' VAL . 3.7 p -78.7 139.71 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.378 -0.826 . . . . 0.0 109.607 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.563 179.937 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.773 ' CE2' ' NE2' ' A' ' 87' ' ' HIS . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 009 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 1.261 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.779 HD22 ' HB2' ' B' ' 65' ' ' LYS . 1.7 p-10 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.779 ' HB2' HD22 ' B' ' 63' ' ' ASN . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 66' ' ' LYS . . . . . 0.513 ' O ' ' CB ' ' A' ' 59' ' ' GLU . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 1.056 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 187' ' ' LYS . . . . . 1.279 ' HE2' ' CB ' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.141 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.76 108.29 4.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.639 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.9 t -103.55 121.12 54.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.469 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.421 HD23 ' HB2' ' A' ' 30' ' ' LYS . 20.1 mt -108.24 101.87 11.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.355 -0.841 . . . . 0.0 109.275 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.833 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.74 137.11 57.6 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.352 -0.843 . . . . 0.0 109.398 -179.956 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 83.0 135.37 2.42 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.07 -119.13 0.26 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.27 4.17 7.75 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -141.3 -41.28 0.38 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.311 -1.111 . . . . 0.0 109.592 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 171.03 43.66 0.03 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.527 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.3 t -97.4 99.39 10.82 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.344 -1.092 . . . . 0.0 109.273 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.718 HD13 ' CE1' ' A' ' 87' ' ' HIS . 6.6 mt -79.67 93.35 5.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.914 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -166.59 139.11 3.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 109.792 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.639 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.5 m-85 -65.9 127.05 30.5 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.42 -0.8 . . . . 0.0 108.98 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.423 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -127.86 102.84 21.82 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 109.641 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.73 170.22 67.83 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 123.452 -1.478 . . . . 0.0 110.651 -0.24 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.453 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.47 13.28 47.4 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -167.56 107.62 0.58 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.415 -1.05 . . . . 0.0 108.991 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -129.37 169.13 15.28 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.355 -0.84 . . . . 0.0 109.661 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.8 m -121.77 129.19 52.49 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.417 -0.802 . . . . 0.0 109.434 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.36 -170.11 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.61 179.15 6.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.329 -0.857 . . . . 0.0 109.476 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -71.96 108.39 5.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.7 -17.23 5.53 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -81.97 172.17 13.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.318 -1.107 . . . . 0.0 109.516 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -128.52 134.9 48.79 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.314 -0.866 . . . . 0.0 109.662 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.54 149.3 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.473 -0.767 . . . . 0.0 109.047 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -133.29 145.54 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.913 . . . . 0.0 109.952 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.673 ' HB3' HD11 ' A' ' 5' ' ' LEU . 50.8 m-85 -132.96 80.29 1.88 Allowed 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.421 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.9 mttt -80.88 124.31 29.0 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.165 -0.959 . . . . 0.0 109.767 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.6 p-10 -96.63 116.96 29.98 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.269 -0.894 . . . . 0.0 109.441 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -94.39 -69.21 0.76 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.536 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.11 151.17 49.51 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.358 -0.839 . . . . 0.0 109.473 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 94.1 10.16 58.79 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.824 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 2.1 p90 -57.94 166.18 2.13 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.34 -1.094 . . . . 0.0 109.421 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.61 ' O ' ' HG2' ' A' ' 86' ' ' PRO . 36.2 Cg_endo -78.95 150.01 85.55 Favored 'Cis proline' 0 C--N 1.312 -1.355 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.536 -0.094 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.833 ' HB3' HD22 ' A' ' 5' ' ' LEU . 45.1 m-70 -121.72 45.24 2.36 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.339 -0.851 . . . . 0.0 109.25 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.462 ' OD1' ' HD3' ' A' ' 86' ' ' PRO . 10.9 p-10 -70.48 119.05 14.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.229 -0.919 . . . . 0.0 109.304 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -92.27 152.5 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.392 -0.818 . . . . 0.0 109.964 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.577 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.8 m -140.52 119.27 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 109.033 179.693 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -67.48 132.38 47.49 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.22 -0.925 . . . . 0.0 109.771 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -94.15 159.33 15.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.394 -0.816 . . . . 0.0 109.465 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.614 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.4 tp10 -99.82 24.81 7.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.312 -0.867 . . . . 0.0 109.573 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.02 -17.33 16.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.186 -0.946 . . . . 0.0 109.489 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -131.72 36.72 3.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.268 -0.895 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ILE . . . . . 0.73 HG23 ' HD2' ' A' ' 47' ' ' PRO . 33.4 mt -100.43 141.93 23.64 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.333 -0.855 . . . . 0.0 108.988 179.71 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.73 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.55 -63.6 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.696 2.264 . . . . 0.0 111.151 -179.591 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.528 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.7 t -85.48 -175.14 5.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.169 -0.957 . . . . 0.0 109.641 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.51 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.89 -108.18 0.14 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.44 155.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.494 -1.003 . . . . 0.0 109.796 179.895 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.98 162.21 14.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.297 -0.877 . . . . 0.0 109.583 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.48 -21.88 35.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.387 -0.82 . . . . 0.0 109.671 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -71.27 -12.53 61.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.273 -0.892 . . . . 0.0 109.927 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -86.68 -27.68 23.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.285 -0.884 . . . . 0.0 109.749 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.1 pt -116.72 6.32 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.235 -0.916 . . . . 0.0 110.045 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -110.77 174.55 5.81 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.174 -0.954 . . . . 0.0 109.348 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' MET . . . . . 0.461 ' H ' HG12 ' A' ' 40' ' ' VAL . 27.6 mtp -95.6 160.58 14.43 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.382 -0.824 . . . . 0.0 109.498 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -95.63 -170.86 2.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.358 -0.839 . . . . 0.0 109.563 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.49 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.5 OUTLIER -87.48 -26.19 23.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.301 -0.874 . . . . 0.0 109.865 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.49 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.39 -35.42 35.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.284 -0.885 . . . . 0.0 109.643 -179.865 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.58 92.81 8.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.428 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.764 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -114.82 141.36 48.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 109.462 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.3 mp -89.48 87.45 7.07 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.423 -0.798 . . . . 0.0 109.179 179.783 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.458 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.6 OUTLIER -108.52 -32.8 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.33 -0.856 . . . . 0.0 109.765 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.44 144.83 81.62 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.226 -0.921 . . . . 0.0 109.837 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.39 80.28 2.95 Favored 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.733 2.289 . . . . 0.0 110.25 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.51 -25.15 0.22 Allowed Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -67.36 148.72 51.26 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.364 -1.08 . . . . 0.0 109.448 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 32.0 p -136.36 144.21 44.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.915 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -107.73 109.17 20.69 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.35 -0.844 . . . . 0.0 108.998 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.49 134.44 43.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.343 -0.848 . . . . 0.0 109.743 -179.729 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -123.25 114.73 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.405 -0.809 . . . . 0.0 109.242 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -85.46 102.35 13.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.301 -0.875 . . . . 0.0 109.301 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.54 142.99 30.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.4 p -124.6 -26.8 3.79 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.372 -0.83 . . . . 0.0 109.818 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.03 47.81 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.272 -0.893 . . . . 0.0 109.683 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -97.99 121.33 39.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.373 -0.829 . . . . 0.0 109.52 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.454 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.93 -171.91 42.49 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -112.93 115.01 27.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.311 -1.111 . . . . 0.0 109.487 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 46.3 m-85 -93.32 178.61 5.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.351 -0.843 . . . . 0.0 109.093 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.59 93.27 2.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.984 . . . . 0.0 109.912 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -97.12 155.62 16.74 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.553 ' HB2' HG12 ' A' ' 93' ' ' VAL . 40.6 p90 -145.0 153.18 41.22 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.041 -1.037 . . . . 0.0 110.272 -179.575 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' CYS . . . . . 0.419 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 52.0 t -68.65 106.81 2.74 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.711 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.821 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER -47.55 -55.09 18.02 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.414 -0.804 . . . . 0.0 110.109 -179.599 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.759 ' O ' ' CG ' ' A' ' 87' ' ' HIS . 34.3 Cg_endo -75.46 42.39 0.9 Allowed 'Trans proline' 0 C--N 1.313 -1.318 0 C-N-CA 122.273 1.982 . . . . 0.0 110.643 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.759 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 6.9 m170 168.15 29.98 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.608 -0.683 . . . . 0.0 109.331 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.483 ' HG2' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -69.3 -31.93 70.74 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.235 -0.916 . . . . 0.0 109.225 179.899 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.02 -4.67 64.69 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.294 -1.523 . . . . 0.0 109.294 179.384 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.85 -69.7 0.42 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.43 -1.041 . . . . 0.0 109.273 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.37 21.77 0.03 OUTLIER Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.581 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' MET . . . . . 0.914 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.6 ptm -118.25 104.01 10.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.099 -1.236 . . . . 0.0 109.305 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.553 HG12 ' HB2' ' A' ' 83' ' ' TYR . 27.6 m -145.57 138.4 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.295 -0.878 . . . . 0.0 109.485 -179.666 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -118.79 177.42 16.41 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -148.25 137.43 21.96 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -1.145 . . . . 0.0 109.675 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 30.8 t -91.91 108.13 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.293 -0.879 . . . . 0.0 109.503 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -92.99 66.76 4.21 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.302 -0.874 . . . . 0.0 109.256 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 p -78.96 138.94 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.341 -0.849 . . . . 0.0 109.56 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.592 179.922 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 3' ' ' ILE . . . . . 0.665 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 010 nuclear build full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 61' ' ' LEU . . . . . 0.764 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 62' ' ' ALA . . . . . 0.821 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 63' ' ' ASN . . . . . 0.577 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 117' ' ' PRO . . . . . 0.824 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.503 2.187 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.83 108.21 5.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.276 -0.89 . . . . 0.0 109.469 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.604 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.7 t -103.82 125.91 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.405 -0.809 . . . . 0.0 109.47 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.421 HD23 ' HB2' ' A' ' 30' ' ' LYS . 18.5 mt -113.08 105.4 13.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 109.319 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.832 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.48 140.94 58.04 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.334 -0.854 . . . . 0.0 109.421 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.57 137.72 1.59 Allowed Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.53 -118.79 0.38 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -127.76 7.05 6.95 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -145.69 -41.83 0.22 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.287 -1.125 . . . . 0.0 109.57 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.3 45.59 0.04 OUTLIER Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.458 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -102.72 97.67 7.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.373 -1.075 . . . . 0.0 109.253 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.55 HD11 HG21 ' B' ' 3' ' ' ILE . 7.5 mt -77.72 94.19 4.41 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.378 -0.826 . . . . 0.0 109.415 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.869 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.65 139.31 4.49 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.324 -0.86 . . . . 0.0 109.7 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.604 ' HD2' HG11 ' A' ' 3' ' ' VAL . 37.2 m-85 -67.36 127.74 33.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.285 -0.884 . . . . 0.0 109.094 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.529 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.43 103.44 20.02 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.25 -0.906 . . . . 0.0 109.593 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.73 170.91 65.53 Favored 'Cis proline' 0 C--N 1.312 -1.373 0 C-N-CA 123.454 -1.478 . . . . 0.0 110.646 -0.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.452 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.28 12.39 48.09 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -167.11 111.14 0.72 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.371 -1.076 . . . . 0.0 109.125 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.0 p90 -132.2 169.68 16.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.358 -0.839 . . . . 0.0 109.709 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.89 130.24 53.2 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.384 -0.823 . . . . 0.0 109.45 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.48 -170.8 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.314 -0.867 . . . . 0.0 109.456 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.92 179.12 6.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.29 -0.881 . . . . 0.0 109.504 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.7 t -72.09 108.81 5.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.332 -0.855 . . . . 0.0 109.401 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.29 -17.02 5.65 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -82.09 172.55 13.08 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.366 -1.079 . . . . 0.0 109.493 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -129.06 134.96 48.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.633 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.542 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.7 149.52 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 t -133.44 145.72 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 109.939 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.647 ' HB3' HD11 ' A' ' 5' ' ' LEU . 51.3 m-85 -133.09 79.94 1.86 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.456 -0.777 . . . . 0.0 108.927 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.421 ' HB2' HD23 ' A' ' 4' ' ' LEU . 29.6 mttt -81.81 124.23 29.48 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.26 -0.9 . . . . 0.0 109.783 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 26.8 p-10 -95.14 130.23 41.93 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.311 -0.868 . . . . 0.0 109.425 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -104.51 -67.9 0.88 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -0.851 . . . . 0.0 109.593 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.86 152.42 48.53 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.329 -0.857 . . . . 0.0 109.568 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.28 21.45 35.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.526 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 2.8 p90 -64.34 163.03 28.1 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.354 -1.086 . . . . 0.0 109.585 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -79.5 155.49 89.55 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.421 -1.491 . . . . 0.0 110.726 -0.038 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.832 ' HB3' HD22 ' A' ' 5' ' ' LEU . 27.3 m-70 -126.62 40.99 3.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.413 -0.805 . . . . 0.0 109.222 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 11.4 p-10 -68.2 128.3 36.05 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.249 -0.907 . . . . 0.0 109.369 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -100.23 153.17 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.33 -0.856 . . . . 0.0 109.841 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.491 HG12 ' H ' ' A' ' 57' ' ' MET . 9.7 m -140.7 123.0 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.418 -0.801 . . . . 0.0 109.217 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.52 133.42 45.8 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.291 -0.88 . . . . 0.0 109.571 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.409 ' HB2' ' HE1' ' A' ' 83' ' ' TYR . 0.7 OUTLIER -96.29 160.15 14.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.36 -0.838 . . . . 0.0 109.571 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.536 ' HA ' HD12 ' A' ' 46' ' ' ILE . 6.7 tp10 -100.39 44.84 1.0 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.37 -0.831 . . . . 0.0 109.429 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.29 -23.8 6.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.304 -0.872 . . . . 0.0 109.373 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -125.59 25.76 6.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 0.0 109.471 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.715 HG23 ' HD2' ' A' ' 47' ' ' PRO . 55.8 mt -90.09 141.15 27.64 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.314 -0.866 . . . . 0.0 108.988 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.715 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.7 Cg_endo -75.62 -62.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.68 2.253 . . . . 0.0 111.023 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.529 ' O ' HG22 ' A' ' 46' ' ' ILE . 2.0 t -87.05 -178.94 6.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.151 -0.968 . . . . 0.0 109.549 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.545 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -75.25 -101.68 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.67 157.56 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.517 -0.99 . . . . 0.0 109.867 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.478 ' HA ' ' NZ ' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -88.83 154.84 19.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.267 -0.896 . . . . 0.0 109.632 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.505 ' H ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.77 -27.27 40.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.419 -0.8 . . . . 0.0 109.532 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.96 -17.02 62.68 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.378 -0.827 . . . . 0.0 109.854 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.0 tptt -77.12 -31.24 55.64 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.299 -0.875 . . . . 0.0 109.699 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -113.02 4.97 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.196 -0.94 . . . . 0.0 109.935 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 66.3 m -108.52 177.81 4.68 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.491 ' H ' HG12 ' A' ' 40' ' ' VAL . 28.3 mtp -98.78 164.07 12.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -98.55 -168.47 1.65 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.395 -0.816 . . . . 0.0 109.563 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.527 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.4 OUTLIER -88.64 -27.58 21.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.383 -0.823 . . . . 0.0 109.816 -179.817 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.479 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.6 OUTLIER -81.12 -33.36 33.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.233 -0.917 . . . . 0.0 109.703 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -91.38 90.63 7.78 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.286 -0.884 . . . . 0.0 109.443 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.639 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -115.98 145.83 42.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.355 -0.841 . . . . 0.0 109.444 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.707 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.1 mp -92.93 80.59 4.61 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.831 . . . . 0.0 109.149 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.517 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.8 OUTLIER -102.09 -17.67 15.93 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.344 -0.847 . . . . 0.0 109.812 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.34 145.46 30.05 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.256 -0.903 . . . . 0.0 109.781 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.33 83.46 2.14 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.736 2.291 . . . . 0.0 110.274 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.5 -26.18 0.3 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.707 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -68.47 148.82 50.06 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.348 -1.09 . . . . 0.0 109.42 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -136.15 146.25 46.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.876 . . . . 0.0 109.85 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -109.18 109.08 19.95 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.35 -0.844 . . . . 0.0 109.011 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.542 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.19 133.87 43.95 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.662 -179.72 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -122.76 115.74 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -0.785 . . . . 0.0 109.243 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.69 102.95 14.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.31 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -100.0 143.07 30.63 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.69 -26.36 3.83 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.347 -0.846 . . . . 0.0 109.744 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.19 152.15 45.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.213 -0.929 . . . . 0.0 109.666 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.7 mttt -99.11 121.61 41.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.369 -0.832 . . . . 0.0 109.556 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.504 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.61 -171.18 42.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -113.26 114.73 27.11 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.328 -1.101 . . . . 0.0 109.512 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -93.1 177.79 5.95 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.376 -0.828 . . . . 0.0 109.176 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.52 97.56 2.65 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.155 -0.966 . . . . 0.0 109.887 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -100.66 159.16 15.4 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.533 ' HB2' HG12 ' A' ' 93' ' ' VAL . 40.0 p90 -149.13 155.65 41.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 110.16 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.9 t -67.82 111.77 4.5 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.654 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.718 0 O-C-N 121.402 -0.811 . . . . 0.0 110.215 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.869 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.8 ptm . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.531 0.682 . . . . 0.0 109.377 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.533 HG12 ' HB2' ' A' ' 83' ' ' TYR . 27.7 m -145.91 153.12 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.269 -0.894 . . . . 0.0 109.425 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.19 178.79 18.11 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -149.39 139.85 22.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.276 -1.131 . . . . 0.0 109.701 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.3 t -94.63 109.66 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.325 -0.86 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -94.05 68.3 3.74 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.257 -0.902 . . . . 0.0 109.254 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.1 p -80.23 139.77 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.34 -0.85 . . . . 0.0 109.623 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.58 179.948 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.55 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . 0.639 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.654 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.527 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.505 ' HE2' ' H ' ' A' ' 52' ' ' ALA . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.502 2.14 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.28 107.79 5.08 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.305 -0.872 . . . . 0.0 109.506 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.627 HG11 ' HD2' ' A' ' 14' ' ' PHE . 15.2 t -102.65 125.25 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 0.0 109.398 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.479 HD23 ' HB2' ' A' ' 30' ' ' LYS . 22.3 mt -111.36 103.27 11.63 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.399 -0.813 . . . . 0.0 109.347 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.767 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -65.6 139.09 58.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.375 -0.828 . . . . 0.0 109.415 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.71 136.79 1.82 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.01 -118.46 0.33 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -128.74 5.12 6.56 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -143.21 -41.38 0.3 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.366 -1.079 . . . . 0.0 109.62 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.27 46.13 0.04 OUTLIER Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.438 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.5 t -103.83 93.5 4.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.365 -1.079 . . . . 0.0 109.374 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 mt -75.67 91.79 2.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 109.414 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.879 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.07 141.71 8.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.331 -0.856 . . . . 0.0 109.637 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.627 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.8 m-85 -68.84 128.45 36.71 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.401 -0.812 . . . . 0.0 109.217 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.95 103.02 17.28 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.889 . . . . 0.0 109.637 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.71 171.2 64.36 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.482 . . . . 0.0 110.687 -0.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.414 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.97 10.32 47.97 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -164.88 113.26 1.05 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.351 -1.088 . . . . 0.0 109.135 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -133.87 170.58 15.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 109.641 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.4 m -122.58 131.34 53.78 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.352 -0.842 . . . . 0.0 109.474 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -133.25 -171.93 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.384 -0.823 . . . . 0.0 109.468 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.02 178.29 7.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.0 t -72.07 111.93 7.72 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.275 -0.89 . . . . 0.0 109.405 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.32 -17.52 7.0 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -81.42 167.4 19.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.317 -1.108 . . . . 0.0 109.496 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -124.09 131.17 53.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.594 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -95.66 151.08 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 108.986 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 t -133.42 146.74 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.176 -0.953 . . . . 0.0 110.007 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.603 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.7 m-85 -132.65 77.35 1.74 Allowed 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.479 ' HB2' HD23 ' A' ' 4' ' ' LEU . 29.4 mttt -78.92 134.01 36.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.912 . . . . 0.0 109.786 -179.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.472 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.4 p-10 -106.04 137.58 43.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.278 -0.889 . . . . 0.0 109.415 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -112.64 -70.46 0.81 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.352 -0.842 . . . . 0.0 109.672 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -121.09 149.97 41.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 109.578 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.91 23.22 36.11 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.469 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 4.0 p90 -67.82 162.45 58.28 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.441 -1.035 . . . . 0.0 109.525 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.526 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 35.9 Cg_endo -79.26 158.19 90.57 Favored 'Cis proline' 0 C--N 1.313 -1.31 0 C-N-CA 123.395 -1.502 . . . . 0.0 110.806 0.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.767 ' HB3' HD22 ' A' ' 5' ' ' LEU . 25.1 m-70 -126.17 39.77 3.87 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.43 -0.794 . . . . 0.0 109.269 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.8 p-10 -66.06 130.47 43.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.159 -0.963 . . . . 0.0 109.273 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -105.17 157.69 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 0.0 109.923 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.698 HG11 ' HB3' ' B' ' 63' ' ' ASN . 4.8 m -141.65 130.87 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.469 -0.77 . . . . 0.0 109.307 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -78.0 136.24 37.92 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.478 ' O ' HG13 ' A' ' 46' ' ' ILE . 0.6 OUTLIER -104.56 157.93 16.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.41 -0.806 . . . . 0.0 109.322 179.734 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.51 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 10.5 tp10 -94.47 17.38 13.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.333 -0.854 . . . . 0.0 109.671 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.6 -19.78 32.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 109.455 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -136.89 36.4 2.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.35 -0.844 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.74 HG23 ' HD2' ' A' ' 47' ' ' PRO . 22.1 mt -99.32 142.47 24.67 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.086 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.74 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.3 Cg_endo -76.03 -66.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 122.665 2.244 . . . . 0.0 111.125 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.521 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.9 t -84.39 -178.77 7.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.213 -0.929 . . . . 0.0 109.679 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.465 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.36 -100.76 0.14 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.465 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.61 152.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.511 -0.993 . . . . 0.0 109.79 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.504 ' HA ' ' NZ ' ' B' ' 187' ' ' LYS . 0.6 OUTLIER -80.68 152.93 28.18 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.211 -0.931 . . . . 0.0 109.597 -179.869 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.524 ' N ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.93 -25.31 40.55 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.349 -0.844 . . . . 0.0 109.593 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -74.89 -16.93 60.65 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.32 -0.862 . . . . 0.0 109.794 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.4 tptt -76.29 -32.48 58.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.334 -0.854 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.1 pt -107.54 -3.32 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.28 -0.887 . . . . 0.0 109.89 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 58.8 m -99.79 177.3 5.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.227 -0.92 . . . . 0.0 109.3 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.617 ' H ' HG12 ' A' ' 40' ' ' VAL . 8.4 mtp -92.48 155.94 17.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.269 -0.894 . . . . 0.0 109.595 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.21 -163.19 0.8 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.352 -0.842 . . . . 0.0 109.512 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.519 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -96.4 -31.35 12.89 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.348 -0.845 . . . . 0.0 110.003 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.403 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.62 -30.78 36.73 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.305 -0.872 . . . . 0.0 109.797 -179.734 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -89.08 100.69 13.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.304 -0.873 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.715 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -124.5 145.21 49.68 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.473 -0.767 . . . . 0.0 109.488 -179.935 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 4.2 mp -91.03 68.57 6.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.392 -0.817 . . . . 0.0 109.16 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -24.69 20.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.351 -0.843 . . . . 0.0 109.949 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.87 146.17 38.24 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.218 -0.926 . . . . 0.0 109.738 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.34 79.25 3.22 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.755 2.303 . . . . 0.0 110.252 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.09 -24.92 0.19 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.1 tp10 -68.31 148.6 50.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.444 -1.033 . . . . 0.0 109.347 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.7 p -136.09 145.81 46.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 109.867 -179.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 23.3 t80 -107.06 107.78 18.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.35 -0.844 . . . . 0.0 109.144 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.85 131.25 45.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 109.566 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.98 114.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.363 -0.836 . . . . 0.0 109.3 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.7 m -86.66 101.65 13.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.342 -0.849 . . . . 0.0 109.254 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -98.63 142.15 30.56 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.371 -0.83 . . . . 0.0 109.57 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.5 p -123.3 -24.68 4.6 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.699 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.36 153.99 42.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.288 -0.883 . . . . 0.0 109.622 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.3 mttt -101.16 125.38 47.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.533 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.99 -166.88 37.77 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -117.44 112.65 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.298 -1.119 . . . . 0.0 109.527 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -91.21 176.83 6.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.338 -0.851 . . . . 0.0 109.178 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.4 99.31 3.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.199 -0.938 . . . . 0.0 109.866 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.434 ' CE2' HG23 ' A' ' 96' ' ' VAL . 44.9 p90 -103.48 164.04 11.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.361 -0.837 . . . . 0.0 108.868 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.644 ' HB2' HG12 ' A' ' 93' ' ' VAL . 34.7 p90 -153.02 155.78 37.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.168 -0.957 . . . . 0.0 109.812 -179.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.68 108.1 2.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.424 -0.797 . . . . 0.0 109.119 179.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.842 ' HB3' ' HB3' ' B' ' 62' ' ' ALA . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.48 -0.763 . . . . 0.0 109.924 -179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.879 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.644 HG12 ' HB2' ' A' ' 83' ' ' TYR . 32.4 m -143.06 165.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.271 -0.893 . . . . 0.0 109.615 -179.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.414 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -144.14 177.76 22.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -150.14 139.03 20.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.261 -1.141 . . . . 0.0 109.839 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.434 HG23 ' CE2' ' A' ' 82' ' ' PHE . 40.8 t -94.64 115.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.401 -0.812 . . . . 0.0 109.507 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -98.21 67.2 1.85 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.253 -0.905 . . . . 0.0 109.122 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.79 141.85 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.39 -0.819 . . . . 0.0 109.643 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.581 179.939 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . 0.715 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.842 ' HB3' ' HB3' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.698 ' HB3' HG11 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.519 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.524 ' HE2' ' N ' ' A' ' 52' ' ' ALA . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 N--CA 1.502 2.143 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.3 109.86 4.94 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.303 -0.873 . . . . 0.0 109.417 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.645 HG11 ' HD2' ' A' ' 14' ' ' PHE . 11.5 t -104.52 120.53 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.328 -0.858 . . . . 0.0 109.559 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.485 HD23 ' HB2' ' A' ' 30' ' ' LYS . 24.6 mt -106.73 101.36 10.81 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -0.838 . . . . 0.0 109.287 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.829 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.2 mp -64.42 141.21 58.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 109.432 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.18 138.36 1.56 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.74 -115.28 0.33 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -132.12 6.37 5.38 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.6 -41.34 0.22 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.346 -1.091 . . . . 0.0 109.596 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.22 45.45 0.04 OUTLIER Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.403 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.3 t -105.65 98.0 7.76 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.308 -1.113 . . . . 0.0 109.304 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.018 HD11 HG21 ' B' ' 3' ' ' ILE . 9.0 mt -78.79 101.12 7.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.324 -0.86 . . . . 0.0 109.487 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.692 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -169.58 136.24 1.63 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 109.661 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.645 ' HD2' HG11 ' A' ' 3' ' ' VAL . 39.6 m-85 -65.9 126.5 28.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 109.124 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.513 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -126.83 103.14 24.36 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.262 -0.898 . . . . 0.0 109.573 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.513 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.72 169.33 70.86 Favored 'Cis proline' 0 C--N 1.312 -1.356 0 C-N-CA 123.459 -1.475 . . . . 0.0 110.67 -0.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.458 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.2 12.28 51.89 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -166.98 105.63 0.58 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.393 -1.063 . . . . 0.0 109.009 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -126.77 167.67 15.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.707 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.5 128.39 53.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.345 -0.847 . . . . 0.0 109.393 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -130.43 -171.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.35 -0.844 . . . . 0.0 109.519 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.15 179.38 6.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.312 -0.868 . . . . 0.0 109.451 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.19 108.78 5.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.297 -0.877 . . . . 0.0 109.385 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.47 -17.26 5.58 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -81.84 171.41 14.53 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.31 -1.112 . . . . 0.0 109.434 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -128.27 133.39 48.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.288 -0.883 . . . . 0.0 109.702 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -94.45 146.56 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.442 -0.786 . . . . 0.0 109.071 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -129.57 145.48 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.19 -0.944 . . . . 0.0 109.818 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.631 ' HB3' HD11 ' A' ' 5' ' ' LEU . 46.5 m-85 -133.01 82.04 1.97 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.469 -0.769 . . . . 0.0 109.03 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.485 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.7 mttt -83.34 126.57 32.84 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.201 -0.937 . . . . 0.0 109.752 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.498 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.9 p-10 -98.85 127.8 44.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.259 -0.901 . . . . 0.0 109.481 179.752 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -104.65 -65.74 1.01 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 109.54 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -129.71 144.1 51.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.338 -0.851 . . . . 0.0 109.517 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.43 22.53 16.46 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.54 ' HB2' ' HA ' ' A' ' 64' ' ' ASN . 3.3 p90 -66.78 163.98 37.94 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.362 -1.081 . . . . 0.0 109.486 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.63 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.4 Cg_endo -80.4 152.14 83.09 Favored 'Cis proline' 0 C--N 1.312 -1.36 0 C-N-CA 123.389 -1.504 . . . . 0.0 110.858 -0.062 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.829 ' HB3' HD22 ' A' ' 5' ' ' LEU . 27.4 m-70 -118.26 40.35 3.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.347 -0.846 . . . . 0.0 109.222 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.2 p-10 -65.64 120.29 12.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.311 -0.868 . . . . 0.0 109.34 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.7 m -96.35 148.8 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.335 -0.853 . . . . 0.0 109.9 -179.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' B' ' 63' ' ' ASN . 7.7 m -134.82 119.79 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.43 -0.794 . . . . 0.0 109.048 179.769 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 15.0 m-85 -67.78 131.92 46.46 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.287 -0.883 . . . . 0.0 109.968 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.44 ' HB2' ' HE2' ' A' ' 83' ' ' TYR . 1.4 t0 -93.79 158.08 15.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.384 -0.822 . . . . 0.0 109.43 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.71 ' OE1' ' HE2' ' B' ' 187' ' ' LYS . 2.8 tp10 -100.55 17.82 20.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.844 . . . . 0.0 109.631 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -92.3 -18.04 23.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.148 -0.97 . . . . 0.0 109.483 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -130.64 26.21 5.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.226 -0.922 . . . . 0.0 109.629 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.738 HG23 ' HD2' ' A' ' 47' ' ' PRO . 19.0 mt -91.06 142.65 27.54 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.258 -0.901 . . . . 0.0 109.182 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.738 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -75.96 -65.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.704 2.27 . . . . 0.0 111.171 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.541 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.7 t -81.84 -177.61 6.64 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.189 -0.944 . . . . 0.0 109.692 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.505 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.9 -107.61 0.14 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.505 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.5 156.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.969 . . . . 0.0 109.856 179.926 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.72 160.8 14.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.401 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -80.55 -24.13 39.46 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.307 -0.871 . . . . 0.0 109.613 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -66.27 -19.16 65.74 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.227 -0.921 . . . . 0.0 109.951 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -80.57 -30.88 36.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.236 -0.915 . . . . 0.0 109.682 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.1 pt -117.17 23.26 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 109.84 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.401 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 45.0 m -127.72 171.28 11.85 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.472 ' H ' HG12 ' A' ' 40' ' ' VAL . 27.0 mtp -96.78 162.86 13.24 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.356 -0.84 . . . . 0.0 109.638 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.1 t -102.0 -171.2 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.349 -0.844 . . . . 0.0 109.746 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -84.64 -24.76 28.92 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.373 -0.829 . . . . 0.0 109.817 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -82.2 -32.42 29.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.254 -0.904 . . . . 0.0 109.705 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -95.23 90.02 5.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.83 146.29 42.11 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.42 -0.8 . . . . 0.0 109.388 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.664 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.6 mp -93.28 76.01 4.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.387 -0.821 . . . . 0.0 109.357 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.54 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.7 OUTLIER -98.04 -0.82 43.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.339 -0.851 . . . . 0.0 109.944 -179.721 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -107.19 143.85 27.97 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.174 -0.954 . . . . 0.0 109.711 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.42 84.7 1.91 Allowed 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.704 2.27 . . . . 0.0 110.296 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.22 -25.43 0.47 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.664 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -69.2 149.72 48.27 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.339 -1.095 . . . . 0.0 109.428 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 37.1 p -136.55 145.44 45.01 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.266 -0.896 . . . . 0.0 109.797 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -108.68 109.67 20.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.352 -0.842 . . . . 0.0 109.034 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.95 134.25 44.22 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.258 -0.901 . . . . 0.0 109.762 -179.722 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -123.14 115.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.374 -0.829 . . . . 0.0 109.211 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.49 104.18 15.71 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.281 -0.887 . . . . 0.0 109.343 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -101.4 142.75 32.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.384 -0.822 . . . . 0.0 109.547 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.8 p -124.66 -25.99 3.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.436 -0.79 . . . . 0.0 109.737 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 152.7 45.1 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.247 -0.908 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -99.61 124.39 44.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 109.514 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.465 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 164.13 -168.55 38.63 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.3 m -115.3 118.72 34.07 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.313 -1.11 . . . . 0.0 109.528 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -96.63 179.13 5.1 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.349 -0.845 . . . . 0.0 109.149 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.79 96.99 2.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.193 -0.942 . . . . 0.0 109.835 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -100.43 153.52 19.28 Favored 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.44 ' HE2' ' HB2' ' A' ' 42' ' ' ASP . 35.5 p90 -143.46 155.97 44.51 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.081 -1.012 . . . . 0.0 110.34 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 8.6 t -68.55 114.02 6.58 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.481 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.809 0 O-C-N 121.252 -0.905 . . . . 0.0 109.992 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.758 ' CG ' ' O ' ' A' ' 92' ' ' MET . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 121.576 0.703 . . . . 0.0 109.515 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.42 HG12 ' HB2' ' A' ' 83' ' ' TYR . 17.4 m -146.63 148.61 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.381 -0.825 . . . . 0.0 109.211 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.32 179.88 16.69 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.3 ptmt -149.44 139.56 22.14 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.444 -1.033 . . . . 0.0 109.6 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.1 t -93.44 109.33 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.374 -0.829 . . . . 0.0 109.536 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -93.88 68.1 3.82 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.275 -0.891 . . . . 0.0 109.169 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.3 p -79.77 141.23 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.309 -0.869 . . . . 0.0 109.535 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.636 -179.998 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 1.018 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.523 ' HB2' ' NH1' ' B' ' 156' ' ' ARG . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.537 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.71 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.43 108.32 4.8 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 0.0 109.427 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.608 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.7 t -103.73 125.0 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.869 . . . . 0.0 109.497 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.413 HD23 ' HB2' ' A' ' 30' ' ' LYS . 19.8 mt -111.98 104.06 12.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.357 -0.839 . . . . 0.0 109.299 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.873 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.0 OUTLIER -65.62 139.42 58.42 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.834 . . . . 0.0 109.445 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.479 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.57 136.47 1.72 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.01 -117.07 0.23 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -129.86 7.39 6.13 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.38 -41.11 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.332 -1.099 . . . . 0.0 109.59 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.89 47.64 0.04 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.479 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -104.92 97.93 7.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.347 -1.09 . . . . 0.0 109.373 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.434 HD11 HG21 ' B' ' 3' ' ' ILE . 8.7 mt -77.42 94.21 4.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.34 -0.85 . . . . 0.0 109.403 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.878 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.86 139.4 4.35 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.366 -0.834 . . . . 0.0 109.744 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.608 ' HD2' HG11 ' A' ' 3' ' ' VAL . 37.2 m-85 -67.51 128.06 35.02 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.406 -0.809 . . . . 0.0 109.072 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.463 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.66 103.17 19.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.234 -0.916 . . . . 0.0 109.572 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.3 Cg_endo -79.74 170.79 65.88 Favored 'Cis proline' 0 C--N 1.313 -1.333 0 C-N-CA 123.41 -1.496 . . . . 0.0 110.646 -0.269 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.443 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.33 12.49 47.92 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -166.9 110.08 0.71 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.338 -1.095 . . . . 0.0 109.086 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -131.3 169.45 15.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.678 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.5 m -121.91 130.35 53.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.345 -0.847 . . . . 0.0 109.498 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.49 -170.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.398 -0.814 . . . . 0.0 109.453 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.08 179.15 6.67 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.8 t -72.12 109.14 5.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.289 -0.882 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.72 -17.04 5.81 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.1 171.22 14.59 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.339 -1.095 . . . . 0.0 109.467 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.69 134.7 49.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.272 -0.892 . . . . 0.0 109.646 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.82 149.91 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.416 -0.803 . . . . 0.0 109.058 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.34 145.95 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.209 -0.932 . . . . 0.0 109.949 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.647 ' HB3' HD11 ' A' ' 5' ' ' LEU . 52.0 m-85 -133.41 79.99 1.86 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 108.95 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.413 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.3 mttt -81.36 125.74 30.75 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.242 -0.911 . . . . 0.0 109.758 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.435 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 26.6 p-10 -97.11 125.99 41.97 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.304 -0.873 . . . . 0.0 109.52 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -101.21 -65.46 0.97 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.33 -0.857 . . . . 0.0 109.544 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.17 148.28 52.7 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.54 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.04 21.1 26.3 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.49 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.9 p90 -64.86 163.23 30.54 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.324 -1.104 . . . . 0.0 109.676 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.564 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -79.75 153.65 87.17 Favored 'Cis proline' 0 C--N 1.312 -1.363 0 C-N-CA 123.367 -1.514 . . . . 0.0 110.68 -0.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.873 ' HB3' HD22 ' A' ' 5' ' ' LEU . 34.4 m-70 -123.9 39.0 4.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.405 -0.81 . . . . 0.0 109.269 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -66.0 126.0 27.2 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.272 -0.892 . . . . 0.0 109.367 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -97.89 149.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.884 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.409 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.4 m -136.61 119.88 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.504 -0.747 . . . . 0.0 108.999 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -68.62 133.17 48.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.232 -0.918 . . . . 0.0 109.692 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.21 159.99 14.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.37 -0.831 . . . . 0.0 109.371 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.579 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.9 tp10 -100.78 31.94 3.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.4 -0.812 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.15 -18.66 13.95 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -130.67 24.93 5.07 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.345 -0.847 . . . . 0.0 109.56 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.736 HG23 ' HD2' ' A' ' 47' ' ' PRO . 35.8 mt -89.36 141.82 29.26 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.324 -0.86 . . . . 0.0 109.119 179.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.736 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.8 Cg_endo -75.69 -63.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.733 2.289 . . . . 0.0 111.103 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.543 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.9 t -84.81 -177.95 6.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.177 -0.952 . . . . 0.0 109.588 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.517 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.41 -105.47 0.13 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.517 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.24 156.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.53 -0.982 . . . . 0.0 109.835 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.76 158.2 16.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.307 -0.871 . . . . 0.0 109.581 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.46 -24.25 39.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.334 -0.854 . . . . 0.0 109.558 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.31 -15.94 62.94 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.38 -0.825 . . . . 0.0 109.853 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.2 tptt -81.3 -31.17 33.69 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.283 -0.886 . . . . 0.0 109.697 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.5 pt -113.23 7.55 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 67.5 m -111.74 173.92 6.12 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.194 -0.942 . . . . 0.0 109.419 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.4 ' H ' HG12 ' A' ' 40' ' ' VAL . 19.8 mtp -93.63 161.29 14.41 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 109.624 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.8 -167.25 1.56 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.341 -0.849 . . . . 0.0 109.681 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.412 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.8 OUTLIER -90.18 -28.66 18.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.339 -0.851 . . . . 0.0 109.976 -179.666 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.412 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -80.28 -30.38 38.33 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.253 -0.905 . . . . 0.0 109.859 -179.734 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -95.0 91.5 6.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.213 -0.93 . . . . 0.0 109.575 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.403 HD11 HD21 ' B' ' 61' ' ' LEU . 0.2 OUTLIER -115.6 142.98 46.0 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.406 -0.809 . . . . 0.0 109.296 179.914 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.719 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.8 mp -89.14 80.57 6.92 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.3 -0.875 . . . . 0.0 109.133 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.476 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 2.0 t30 -100.4 -22.9 14.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.91 145.46 36.63 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 109.905 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.59 81.6 2.62 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.801 2.334 . . . . 0.0 110.275 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 -25.74 0.24 Allowed Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.719 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.59 149.18 50.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.331 -1.1 . . . . 0.0 109.441 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -135.79 145.98 47.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 109.878 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.7 t80 -109.09 108.94 19.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.343 -0.848 . . . . 0.0 109.045 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.0 133.83 43.81 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.314 -0.866 . . . . 0.0 109.703 -179.697 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.76 115.22 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.42 -0.8 . . . . 0.0 109.239 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.24 102.04 13.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.296 -0.878 . . . . 0.0 109.279 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.1 142.98 29.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.347 -0.845 . . . . 0.0 109.559 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.56 -26.31 3.88 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.335 -0.853 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 151.8 46.47 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.328 -0.858 . . . . 0.0 109.615 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.3 mttt -98.81 122.55 42.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.376 -0.828 . . . . 0.0 109.594 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.5 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.64 -171.42 41.55 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -112.97 114.4 26.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.319 -1.106 . . . . 0.0 109.494 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -92.73 176.89 6.27 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.303 -0.873 . . . . 0.0 109.123 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.43 93.9 2.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.117 -0.99 . . . . 0.0 109.86 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -97.36 155.94 16.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.331 -0.856 . . . . 0.0 108.806 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.542 ' HB2' HG12 ' A' ' 93' ' ' VAL . 41.4 p90 -145.84 155.32 42.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.041 -1.037 . . . . 0.0 110.207 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 36.7 t -67.69 107.2 2.47 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.587 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.495 1.803 0 O-C-N 121.395 -0.816 . . . . 0.0 109.975 -179.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.878 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.4 ptm . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 121.559 0.695 . . . . 0.0 109.481 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.542 HG12 ' HB2' ' A' ' 83' ' ' TYR . 28.9 m -146.72 150.08 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.443 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.0 178.17 17.93 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.7 ptmt -149.03 138.93 22.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.35 -1.088 . . . . 0.0 109.696 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 33.0 t -93.98 110.12 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.343 -0.848 . . . . 0.0 109.533 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.18 67.53 3.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.303 -0.873 . . . . 0.0 109.297 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.0 p -79.46 140.0 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.4 -0.812 . . . . 0.0 109.55 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.549 179.994 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.434 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . 0.403 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.587 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.409 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.493 ' HD3' ' HG2' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.2 p . . . . . 0 N--CA 1.502 2.162 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.85 106.64 4.87 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.895 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.565 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.9 t -102.33 126.35 56.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 17.8 mt -114.0 106.29 14.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.382 -0.823 . . . . 0.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.829 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.65 136.85 56.18 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.39 -0.819 . . . . 0.0 109.419 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.484 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 81.2 135.44 1.75 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.88 -119.42 0.26 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.88 -0.69 9.03 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -134.82 -41.11 0.76 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.364 -1.08 . . . . 0.0 109.549 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.925 ' O ' ' NE2' ' B' ' 7' ' ' GLN . . . 169.57 42.93 0.03 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.484 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.2 t -94.6 93.47 7.6 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.274 -1.133 . . . . 0.0 109.324 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -73.75 92.26 1.99 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.286 -0.884 . . . . 0.0 109.491 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.844 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.43 141.96 3.77 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.334 -0.854 . . . . 0.0 109.6 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.565 ' HD2' HG11 ' A' ' 3' ' ' VAL . 43.0 m-85 -68.12 127.87 34.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.378 -0.826 . . . . 0.0 109.197 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.4 mp -129.35 104.18 17.9 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 109.591 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.55 170.43 67.65 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.389 -1.505 . . . . 0.0 110.66 -0.272 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.42 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.65 10.47 49.34 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -165.05 111.65 0.97 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.316 -1.108 . . . . 0.0 109.131 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -132.29 169.38 16.55 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.388 -0.82 . . . . 0.0 109.59 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.07 130.16 53.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.344 -0.848 . . . . 0.0 109.423 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.6 m -132.92 -171.58 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.369 -0.832 . . . . 0.0 109.487 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.99 178.52 7.06 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.4 t -71.9 109.94 6.08 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.296 -0.878 . . . . 0.0 109.326 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.54 -17.29 5.85 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.04 173.4 12.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.39 -1.065 . . . . 0.0 109.453 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -129.73 134.67 47.76 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.284 -0.885 . . . . 0.0 109.675 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.546 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.46 149.39 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.407 -0.808 . . . . 0.0 109.046 179.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 t -133.25 145.6 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.179 -0.951 . . . . 0.0 109.992 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.635 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.0 m-85 -132.89 77.89 1.76 Allowed 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 mttt -79.38 124.66 28.64 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.191 -0.943 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.429 ' HA ' ' HB2' ' A' ' 5' ' ' LEU . 24.0 p-10 -96.75 120.82 37.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.319 -0.863 . . . . 0.0 109.451 179.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -93.99 -65.56 0.98 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 109.677 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.14 150.46 52.14 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.351 -0.843 . . . . 0.0 109.643 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 17.08 37.78 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.512 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 5.1 p90 -63.27 162.93 20.74 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.334 -1.098 . . . . 0.0 109.601 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.59 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.2 Cg_endo -79.11 150.9 86.53 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.483 . . . . 0.0 110.848 0.123 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.829 ' HB3' HD22 ' A' ' 5' ' ' LEU . 37.0 m-70 -124.04 42.39 3.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.39 -0.819 . . . . 0.0 109.41 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.8 p-10 -66.24 126.4 28.58 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.168 -0.958 . . . . 0.0 109.333 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.5 m -96.53 150.57 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.283 -0.886 . . . . 0.0 109.75 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.484 HG12 ' H ' ' A' ' 57' ' ' MET . 10.2 m -138.99 121.51 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.438 -0.789 . . . . 0.0 109.302 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -71.07 127.8 33.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.24 -0.913 . . . . 0.0 109.41 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.26 163.98 18.32 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.238 -0.914 . . . . 0.0 109.624 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.503 ' HA ' HD12 ' A' ' 46' ' ' ILE . 1.3 tp10 -101.49 25.58 8.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.408 -0.807 . . . . 0.0 109.527 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.46 -18.69 14.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.565 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -130.13 59.64 1.63 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.183 -0.948 . . . . 0.0 109.708 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.679 HG23 ' HD2' ' A' ' 47' ' ' PRO . 76.9 mt -119.82 140.3 29.4 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.267 -0.896 . . . . 0.0 109.089 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.679 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -76.05 -62.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 122.697 2.265 . . . . 0.0 110.968 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.469 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.4 t -88.92 -172.91 3.88 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.185 -0.947 . . . . 0.0 109.581 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.477 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.81 -112.29 0.14 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.477 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.8 154.95 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.495 -1.003 . . . . 0.0 109.792 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -95.35 168.05 10.96 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.28 -0.888 . . . . 0.0 109.661 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -85.03 -20.94 29.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.35 -0.844 . . . . 0.0 109.669 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -69.76 -12.34 61.56 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.213 -0.93 . . . . 0.0 109.982 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -88.88 -27.49 20.98 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.211 -0.931 . . . . 0.0 109.829 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.7 pt -117.96 12.21 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.195 -0.94 . . . . 0.0 110.078 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 74.7 m -117.08 175.31 5.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.159 -0.963 . . . . 0.0 109.45 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.484 ' H ' HG12 ' A' ' 40' ' ' VAL . 31.5 mtp -99.78 164.64 11.95 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.368 -0.833 . . . . 0.0 109.522 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.7 -170.83 1.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.324 -0.86 . . . . 0.0 109.745 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.525 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.6 OUTLIER -87.71 -25.97 23.19 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.374 -0.828 . . . . 0.0 109.794 -179.84 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.449 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 1.5 mp0 -82.38 -32.08 29.39 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.525 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -95.0 89.56 5.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.277 -0.889 . . . . 0.0 109.217 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.441 HD12 ' O ' ' A' ' 59' ' ' GLU . 0.1 OUTLIER -115.91 144.74 43.64 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.352 -0.843 . . . . 0.0 109.622 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.669 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.0 mp -86.94 79.44 8.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.415 -0.803 . . . . 0.0 109.155 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.456 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.4 t30 -100.26 -4.64 28.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.304 -0.872 . . . . 0.0 110.01 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.412 ' HA ' ' HD3' ' A' ' 66' ' ' PRO . . . -103.46 143.55 26.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 65' ' ' ALA . 35.3 Cg_endo -77.21 79.94 3.02 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.711 2.274 . . . . 0.0 110.242 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.2 -25.41 0.26 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.669 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.51 149.46 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.371 -1.076 . . . . 0.0 109.403 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 29.6 p -135.91 145.68 46.54 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.925 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 33.5 t80 -108.53 108.55 19.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -99.76 134.22 42.97 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.338 -0.851 . . . . 0.0 109.723 -179.627 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -122.93 113.92 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.38 -0.825 . . . . 0.0 109.319 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -84.63 102.31 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.253 -0.904 . . . . 0.0 109.291 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.64 142.17 31.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.1 p -123.92 -25.66 4.2 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.356 -0.84 . . . . 0.0 109.718 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.0 151.66 46.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.293 -0.879 . . . . 0.0 109.708 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -98.68 120.84 39.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.398 -0.814 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.406 ' H ' HG13 ' A' ' 98' ' ' VAL . . . 168.42 -171.82 42.75 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.4 m -113.56 114.14 26.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.274 -1.133 . . . . 0.0 109.493 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.17 179.02 5.55 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.366 -0.834 . . . . 0.0 109.095 179.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.78 101.46 3.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 109.8 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -102.91 163.28 12.3 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.647 ' HB2' HG12 ' A' ' 93' ' ' VAL . 43.7 p90 -155.17 154.32 32.1 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.078 -1.014 . . . . 0.0 110.158 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 35.2 t -66.43 110.08 2.98 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.74 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.686 0 O-C-N 121.451 -0.78 . . . . 0.0 110.247 -179.369 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.844 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.647 HG12 ' HB2' ' A' ' 83' ' ' TYR . 32.8 m -142.74 167.6 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -0.867 . . . . 0.0 109.629 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -147.8 -177.95 22.62 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.1 ptmt -152.36 142.02 21.85 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.122 . . . . 0.0 109.848 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 27.1 t -97.5 112.02 28.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.36 -0.838 . . . . 0.0 109.371 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -95.95 68.89 2.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.203 -0.936 . . . . 0.0 109.175 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 78' ' ' GLY . 4.4 p -81.01 139.52 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.33 -0.856 . . . . 0.0 109.591 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.604 -179.974 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.925 ' NE2' ' O ' ' A' ' 10' ' ' GLY . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.74 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.447 ' HB3' ' OG ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.525 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.171 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.6 108.97 4.61 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.621 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.0 t -104.08 120.37 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.315 -0.866 . . . . 0.0 109.474 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.426 HD23 ' HB2' ' A' ' 30' ' ' LYS . 21.2 mt -107.58 101.68 10.99 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.338 -0.851 . . . . 0.0 109.321 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.881 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -64.44 141.93 58.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.381 -0.824 . . . . 0.0 109.512 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.17 135.16 1.09 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.01 -116.79 0.19 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -130.45 7.64 5.93 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.61 -41.02 0.22 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.334 -1.097 . . . . 0.0 109.586 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.46 48.19 0.04 OUTLIER Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.46 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.8 t -105.67 99.33 8.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.339 -1.095 . . . . 0.0 109.322 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.664 HD11 HG21 ' B' ' 3' ' ' ILE . 11.1 mt -78.32 96.07 5.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.37 -0.831 . . . . 0.0 109.404 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.87 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.23 138.1 3.07 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.342 -0.849 . . . . 0.0 109.728 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.621 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.8 m-85 -66.68 127.71 33.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.357 -0.839 . . . . 0.0 109.031 179.635 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -128.12 103.12 20.94 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.293 -0.879 . . . . 0.0 109.573 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.61 170.43 67.46 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.394 -1.503 . . . . 0.0 110.666 -0.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.448 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.22 12.7 48.43 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -167.03 108.6 0.66 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.331 -1.1 . . . . 0.0 109.076 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -130.02 169.49 15.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.393 -0.817 . . . . 0.0 109.666 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 m -121.97 129.65 52.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.332 -0.855 . . . . 0.0 109.438 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.77 -170.17 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.38 -0.825 . . . . 0.0 109.482 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.55 179.11 6.75 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.305 -0.872 . . . . 0.0 109.473 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.09 108.83 5.5 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.27 -17.38 5.62 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -81.8 171.61 14.32 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.345 -1.091 . . . . 0.0 109.468 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -127.97 134.25 49.26 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.285 -0.884 . . . . 0.0 109.665 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.0 149.04 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.437 -0.789 . . . . 0.0 109.042 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 t -132.4 145.71 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.193 -0.942 . . . . 0.0 109.896 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.625 ' HB3' HD11 ' A' ' 5' ' ' LEU . 49.9 m-85 -133.32 80.38 1.88 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.424 -0.797 . . . . 0.0 109.016 179.613 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.426 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.9 mttt -81.55 126.78 32.12 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.223 -0.923 . . . . 0.0 109.729 -179.606 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.496 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 26.9 p-10 -98.07 126.22 43.41 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.333 -0.855 . . . . 0.0 109.484 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.99 -65.72 0.97 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.856 . . . . 0.0 109.522 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.33 146.91 52.49 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.344 -0.848 . . . . 0.0 109.544 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.05 20.95 26.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.546 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.7 p90 -64.24 164.8 16.38 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.363 -1.08 . . . . 0.0 109.634 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.621 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -80.03 153.54 85.99 Favored 'Cis proline' 0 C--N 1.313 -1.338 0 C-N-CA 123.378 -1.509 . . . . 0.0 110.606 -0.246 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.881 ' HB3' HD22 ' A' ' 5' ' ' LEU . 32.2 m-70 -121.1 37.96 4.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.217 179.564 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 15.7 p-10 -65.1 121.64 15.19 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.318 -0.864 . . . . 0.0 109.304 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -94.83 148.43 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.28 -0.888 . . . . 0.0 109.846 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.413 HG21 ' HB3' ' B' ' 63' ' ' ASN . 5.6 m -134.77 117.49 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.482 -0.761 . . . . 0.0 109.01 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -66.38 133.25 50.09 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.322 -0.861 . . . . 0.0 109.82 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -94.96 159.15 15.16 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.389 -0.819 . . . . 0.0 109.361 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.612 ' HA ' HD12 ' A' ' 46' ' ' ILE . 3.9 tp10 -100.55 24.71 8.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 109.591 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.97 -16.69 17.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -131.42 27.21 4.76 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.285 -0.884 . . . . 0.0 109.539 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.735 HG23 ' HD2' ' A' ' 47' ' ' PRO . 28.2 mt -92.15 142.18 25.96 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.301 -0.874 . . . . 0.0 109.055 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.735 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.67 -63.9 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.713 2.276 . . . . 0.0 111.101 -179.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.545 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -84.15 -176.85 6.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.162 -0.961 . . . . 0.0 109.563 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.502 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.66 -107.59 0.14 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.41 155.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.494 -1.004 . . . . 0.0 109.841 179.886 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.2 161.55 15.02 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.251 -0.906 . . . . 0.0 109.636 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.12 -22.16 36.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 0.0 109.644 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.78 -13.83 62.2 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.295 -0.878 . . . . 0.0 109.846 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -85.15 -29.86 24.44 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.247 -0.908 . . . . 0.0 109.679 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -114.54 8.2 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.17 -0.956 . . . . 0.0 110.021 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.8 m -113.47 172.93 6.67 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.168 -0.957 . . . . 0.0 109.408 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.8 mtp -92.52 160.91 14.83 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.317 -0.864 . . . . 0.0 109.56 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -95.14 -167.36 1.61 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.42 -0.8 . . . . 0.0 109.545 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.429 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.7 OUTLIER -90.94 -25.67 19.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.288 -0.883 . . . . 0.0 109.785 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.429 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -82.07 -30.41 31.33 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.739 -179.81 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -95.99 93.64 7.12 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.197 -0.94 . . . . 0.0 109.605 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.95 143.1 46.1 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.401 -0.812 . . . . 0.0 109.332 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.711 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.9 mp -89.28 80.52 6.84 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.346 -0.846 . . . . 0.0 109.18 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.483 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.8 t30 -100.09 -21.17 15.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 -179.647 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -88.53 144.82 34.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.175 -0.953 . . . . 0.0 109.864 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.45 81.62 2.6 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.754 2.303 . . . . 0.0 110.276 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.53 -25.6 0.25 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.711 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.58 149.43 50.12 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.419 -1.048 . . . . 0.0 109.408 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.9 p -135.81 145.39 46.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.251 -0.906 . . . . 0.0 109.864 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -108.84 109.22 20.28 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.453 -0.779 . . . . 0.0 109.008 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.29 134.3 43.43 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.343 -0.848 . . . . 0.0 109.726 -179.695 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.94 115.44 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.407 -0.808 . . . . 0.0 109.243 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -86.3 102.21 13.78 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.252 -0.905 . . . . 0.0 109.31 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.3 143.0 30.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.855 . . . . 0.0 109.606 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.3 p -124.63 -26.61 3.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.39 47.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.264 -0.898 . . . . 0.0 109.682 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -98.41 122.43 41.58 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.427 -0.795 . . . . 0.0 109.529 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.48 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.9 -170.92 41.58 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -113.68 114.1 25.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -1.157 . . . . 0.0 109.513 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -92.31 177.87 6.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.419 -0.801 . . . . 0.0 109.118 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.21 93.65 2.12 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.213 -0.93 . . . . 0.0 109.85 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.7 p90 -96.99 154.5 17.26 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 108.791 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.525 ' HB2' HG12 ' A' ' 93' ' ' VAL . 42.1 p90 -144.49 157.05 44.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.134 -0.979 . . . . 0.0 110.174 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 10.1 t -67.83 114.77 6.68 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.767 0 O-C-N 121.348 -0.845 . . . . 0.0 110.036 -179.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.87 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 1.3 ptm . . . . . 0 N--CA 1.491 1.609 0 CA-C-O 121.563 0.697 . . . . 0.0 109.325 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.525 HG12 ' HB2' ' A' ' 83' ' ' TYR . 28.0 m -146.8 148.41 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.351 -0.843 . . . . 0.0 109.405 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -129.45 178.69 17.23 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -148.86 138.51 21.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.123 . . . . 0.0 109.636 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.8 t -93.21 110.07 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.08 67.22 3.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.248 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.6 p -79.25 139.59 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.333 -0.854 . . . . 0.0 109.6 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.577 179.936 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.664 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.644 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.413 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 0.525 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 N--CA 1.503 2.188 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.82 107.97 4.88 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.307 -0.871 . . . . 0.0 109.408 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.63 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.9 t -102.98 124.01 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.363 -0.835 . . . . 0.0 109.451 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.491 HD23 ' HB2' ' A' ' 30' ' ' LYS . 21.8 mt -110.26 101.88 10.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.361 -0.837 . . . . 0.0 109.383 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.822 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.24 133.08 50.7 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.335 -0.853 . . . . 0.0 109.388 -179.99 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.504 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 84.69 133.01 2.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.72 -118.15 0.15 Allowed Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.62 -1.89 6.95 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -132.93 -40.34 0.94 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.129 . . . . 0.0 109.592 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.583 ' HA3' HD11 ' B' ' 3' ' ' ILE . . . 168.31 46.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.504 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.7 t -99.19 94.56 6.56 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.356 -1.085 . . . . 0.0 109.338 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.5 mt -75.18 89.7 2.53 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.343 -0.848 . . . . 0.0 109.471 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.87 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.51 142.03 7.93 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.295 -0.878 . . . . 0.0 109.674 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.63 ' HD2' HG11 ' A' ' 3' ' ' VAL . 38.1 m-85 -68.15 128.26 35.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -0.849 . . . . 0.0 109.159 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.54 102.31 18.33 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 109.604 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.74 171.6 62.44 Favored 'Cis proline' 0 C--N 1.312 -1.351 0 C-N-CA 123.428 -1.488 . . . . 0.0 110.714 -0.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.419 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.42 10.77 46.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -165.15 110.46 0.91 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.328 -1.101 . . . . 0.0 109.078 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -131.2 167.75 18.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.639 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.9 m -120.43 129.84 54.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.327 -0.858 . . . . 0.0 109.471 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 98' ' ' VAL . 3.0 m -131.94 -172.85 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.369 -0.832 . . . . 0.0 109.545 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.68 178.55 6.95 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 109.482 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.7 t -72.17 111.47 7.42 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.333 -0.854 . . . . 0.0 109.428 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.77 -16.38 6.94 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -82.57 167.11 18.64 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.395 -1.062 . . . . 0.0 109.488 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -123.92 133.14 53.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.64 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.506 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.3 mp -97.36 151.03 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.438 -0.789 . . . . 0.0 109.042 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.4 t -133.7 145.22 33.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 109.967 -179.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.674 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.6 m-85 -130.92 77.43 1.78 Allowed 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.491 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.3 mttt -77.07 132.61 39.0 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.272 -0.892 . . . . 0.0 109.842 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 20.6 p-10 -105.72 122.22 45.62 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.52 -67.18 0.87 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.281 -0.887 . . . . 0.0 109.588 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -125.44 149.99 47.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.326 -0.858 . . . . 0.0 109.525 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.33 11.02 61.55 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.652 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 3.0 p90 -61.76 165.99 6.75 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 121.399 -1.059 . . . . 0.0 109.543 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.57 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.2 Cg_endo -78.84 151.64 88.39 Favored 'Cis proline' 0 C--N 1.313 -1.292 0 C-N-CA 123.329 -1.53 . . . . 0.0 110.506 -0.016 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.822 ' HB3' HD22 ' A' ' 5' ' ' LEU . 50.6 m-70 -122.78 44.78 2.55 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.384 -0.823 . . . . 0.0 109.365 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 9.7 p-10 -68.57 123.15 20.05 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.196 -0.94 . . . . 0.0 109.199 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.07 155.7 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.245 -0.909 . . . . 0.0 109.992 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.478 HG21 ' HB3' ' B' ' 63' ' ' ASN . 3.6 m -141.33 118.8 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.418 -0.801 . . . . 0.0 109.201 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -69.31 130.57 42.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 109.663 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.11 159.39 15.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.355 -0.841 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.603 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.5 tp10 -99.02 34.46 2.11 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.313 -0.867 . . . . 0.0 109.491 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -108.38 -22.09 12.47 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -0.899 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -128.5 32.78 4.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.738 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.717 HG23 ' HD2' ' A' ' 47' ' ' PRO . 49.0 mt -95.35 141.44 23.22 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.24 -0.913 . . . . 0.0 109.188 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.717 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.4 Cg_endo -76.46 -59.6 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.723 2.282 . . . . 0.0 111.038 -179.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.527 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.5 t -87.65 -176.26 5.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.932 . . . . 0.0 109.683 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.523 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -78.26 -107.01 0.19 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.45 156.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.513 -0.992 . . . . 0.0 109.773 179.896 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.89 160.75 16.29 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 0.0 109.637 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.26 -18.18 40.02 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.872 . . . . 0.0 109.729 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -77.15 -9.42 58.74 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.222 -0.924 . . . . 0.0 109.851 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.0 tptp -87.75 -27.18 22.51 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.279 -0.888 . . . . 0.0 109.715 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.6 pt -113.68 -5.1 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.212 -0.93 . . . . 0.0 109.976 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.2 m -98.99 175.29 5.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.168 -0.957 . . . . 0.0 109.473 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 16.5 mtp -93.24 157.26 16.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.819 . . . . 0.0 109.563 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -88.35 -160.13 0.61 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.467 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.836 ' OE1' ' HE2' ' B' ' 65' ' ' LYS . 8.8 pm0 -98.24 -29.21 13.32 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.296 -0.877 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.507 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.7 -30.33 36.38 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.302 -0.874 . . . . 0.0 109.737 -179.873 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -92.16 95.42 9.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.335 -0.853 . . . . 0.0 109.48 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.831 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -116.7 141.61 47.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.424 -0.797 . . . . 0.0 109.34 -179.986 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.657 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.0 OUTLIER -90.52 80.14 6.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.338 -0.851 . . . . 0.0 109.14 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -102.7 -41.05 6.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.324 -0.86 . . . . 0.0 109.8 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.49 145.63 98.4 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.326 -0.859 . . . . 0.0 109.979 -179.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.75 78.09 3.67 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.771 2.314 . . . . 0.0 110.219 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 165.38 -24.79 0.16 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.657 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.2 tp10 -67.84 148.11 51.62 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.365 -1.08 . . . . 0.0 109.339 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.41 ' HA ' HD21 ' A' ' 63' ' ' LEU . 41.1 p -136.74 143.27 43.2 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 109.899 -179.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -105.28 107.15 17.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.348 -0.845 . . . . 0.0 109.094 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.47 131.07 45.02 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 109.62 -179.744 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -121.08 112.44 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.424 -0.798 . . . . 0.0 109.206 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.8 m -83.66 104.04 13.45 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 109.297 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -100.92 141.26 34.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.362 -0.836 . . . . 0.0 109.557 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.9 p -123.14 -24.73 4.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.19 153.42 43.72 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.274 -0.891 . . . . 0.0 109.642 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.8 mttt -100.67 124.07 45.75 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.309 -0.869 . . . . 0.0 109.548 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.427 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 165.71 -168.53 39.64 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.8 m -116.86 110.82 18.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.332 -1.099 . . . . 0.0 109.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -89.35 176.09 7.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.8 92.51 2.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.169 -0.957 . . . . 0.0 109.918 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.423 ' CE2' HG23 ' A' ' 96' ' ' VAL . 47.9 p90 -97.54 154.6 17.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.337 -0.852 . . . . 0.0 108.738 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.675 ' HB2' HG12 ' A' ' 93' ' ' VAL . 41.6 p90 -143.79 154.61 43.6 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 109.987 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 49.6 t -65.9 106.91 1.68 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.502 -0.749 . . . . 0.0 109.024 179.567 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.866 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.494 1.725 0 O-C-N 121.49 -0.756 . . . . 0.0 110.089 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.87 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.009 -0.738 . . . . 0.0 109.009 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.675 HG12 ' HB2' ' A' ' 83' ' ' TYR . 35.0 m -144.97 146.79 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.362 -0.836 . . . . 0.0 109.607 -179.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.419 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -124.7 176.32 17.04 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.81 136.2 20.29 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.263 -1.139 . . . . 0.0 109.816 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.423 HG23 ' CE2' ' A' ' 82' ' ' PHE . 31.5 t -91.49 109.96 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.344 -0.847 . . . . 0.0 109.476 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -94.79 66.75 3.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.204 -0.935 . . . . 0.0 109.104 179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 7.0 p -79.21 141.24 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.307 -0.87 . . . . 0.0 109.62 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.2 p30 . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.566 179.946 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.583 HD11 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . 0.831 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.866 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.478 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.836 ' HE2' ' OE1' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.4 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.38 107.99 4.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.653 HG11 ' HD2' ' A' ' 14' ' ' PHE . 11.8 t -102.9 125.46 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.364 -0.835 . . . . 0.0 109.504 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.486 HD23 ' HB2' ' A' ' 30' ' ' LYS . 25.0 mt -111.13 100.52 9.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.387 -0.82 . . . . 0.0 109.299 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.836 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.01 128.57 36.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.373 -0.83 . . . . 0.0 109.388 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.492 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 88.71 134.0 4.79 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -77.58 -124.62 0.28 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.26 -13.52 8.25 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -118.74 -37.39 3.27 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.322 -1.104 . . . . 0.0 109.615 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.605 ' HA3' HD11 ' B' ' 3' ' ' ILE . . . 160.61 45.9 0.02 OUTLIER Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.492 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.8 t -94.64 98.47 10.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.288 -1.125 . . . . 0.0 109.301 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.44 HD11 ' CG2' ' B' ' 3' ' ' ILE . 7.6 mt -73.83 91.92 2.0 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.298 -0.876 . . . . 0.0 109.485 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.915 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.2 137.53 5.21 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.358 -0.839 . . . . 0.0 109.617 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.653 ' HD2' HG11 ' A' ' 3' ' ' VAL . 35.4 m-85 -65.71 126.58 28.88 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.383 -0.823 . . . . 0.0 109.054 179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -127.9 102.28 22.29 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.248 -0.907 . . . . 0.0 109.607 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.78 170.47 66.89 Favored 'Cis proline' 0 C--N 1.313 -1.317 0 C-N-CA 123.45 -1.479 . . . . 0.0 110.679 -0.271 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.443 ' HA2' ' HB3' ' A' ' 14' ' ' PHE . . . -105.41 12.45 47.57 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -166.49 105.92 0.64 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.406 -1.055 . . . . 0.0 109.043 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -127.45 167.25 16.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.307 -0.87 . . . . 0.0 109.695 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.64 128.55 53.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 109.404 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 98' ' ' VAL . 3.0 m -130.44 -171.52 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.388 -0.82 . . . . 0.0 109.532 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.31 179.01 6.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.329 -0.857 . . . . 0.0 109.442 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -72.3 110.52 6.78 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.238 -0.914 . . . . 0.0 109.417 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.62 -16.91 6.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -82.1 165.71 20.35 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.34 -1.094 . . . . 0.0 109.472 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -122.61 132.11 54.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.337 -0.852 . . . . 0.0 109.636 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.31 151.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 109.045 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -133.5 146.28 32.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.217 -0.927 . . . . 0.0 109.934 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.675 ' HB3' HD11 ' A' ' 5' ' ' LEU . 52.1 m-85 -132.5 80.05 1.88 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.486 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.3 mttt -80.45 131.79 35.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.333 -0.855 . . . . 0.0 109.716 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.2 p-10 -105.25 119.57 39.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.282 -0.886 . . . . 0.0 109.493 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -98.19 -67.83 0.83 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.343 -0.848 . . . . 0.0 109.573 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -124.68 149.85 46.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.33 -0.856 . . . . 0.0 109.49 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 92.13 12.71 58.51 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.642 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 4.9 p90 -61.5 163.97 10.35 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.405 -1.056 . . . . 0.0 109.542 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.553 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.2 Cg_endo -79.1 157.28 91.4 Favored 'Cis proline' 0 C--N 1.313 -1.322 0 C-N-CA 123.322 -1.532 . . . . 0.0 110.481 -0.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.836 ' HB3' HD22 ' A' ' 5' ' ' LEU . 43.9 m-70 -127.97 39.75 3.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.385 -0.822 . . . . 0.0 109.33 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -65.19 120.64 13.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.334 -0.854 . . . . 0.0 109.267 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -93.0 151.45 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.305 -0.872 . . . . 0.0 109.823 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.536 HG12 ' H ' ' A' ' 57' ' ' MET . 10.2 m -137.99 121.71 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.109 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -70.26 132.11 45.22 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.258 -0.901 . . . . 0.0 109.709 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.45 157.86 15.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.294 -0.879 . . . . 0.0 109.53 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.563 ' HA ' HD12 ' A' ' 46' ' ' ILE . 6.0 tp10 -98.02 47.04 1.01 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.294 -0.879 . . . . 0.0 109.45 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.56 -26.77 5.67 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.286 -0.884 . . . . 0.0 109.38 179.727 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -124.25 25.25 7.83 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.342 -0.849 . . . . 0.0 109.61 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.73 HG23 ' HD2' ' A' ' 47' ' ' PRO . 58.0 mt -87.87 141.36 31.54 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.254 -0.904 . . . . 0.0 109.155 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.73 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.0 Cg_endo -76.23 -60.71 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.738 2.292 . . . . 0.0 110.999 -179.595 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.523 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -87.57 -178.3 6.08 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.211 -0.931 . . . . 0.0 109.642 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.536 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.6 -103.39 0.14 Allowed Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.92 157.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.523 -0.987 . . . . 0.0 109.899 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.23 156.42 18.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.263 -0.898 . . . . 0.0 109.624 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.63 -24.41 39.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.321 -0.862 . . . . 0.0 109.677 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -72.82 -15.22 61.63 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 109.777 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -79.43 -31.62 42.63 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.303 -0.873 . . . . 0.0 109.735 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.0 pt -111.07 0.44 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.272 -0.892 . . . . 0.0 109.879 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 62.4 m -104.02 177.93 4.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.536 ' H ' HG12 ' A' ' 40' ' ' VAL . 22.7 mtp -98.67 159.07 15.21 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.289 -0.882 . . . . 0.0 109.523 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.73 -166.43 1.58 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.354 -0.841 . . . . 0.0 109.552 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.53 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -91.43 -28.06 17.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.354 -0.841 . . . . 0.0 109.92 -179.807 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.444 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.5 OUTLIER -80.93 -31.25 35.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.88 . . . . 0.0 109.775 -179.851 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -91.23 97.37 11.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.337 -0.852 . . . . 0.0 109.483 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.656 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -120.15 145.49 46.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.38 -0.825 . . . . 0.0 109.363 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.664 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.0 mp -93.31 75.31 4.56 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.415 -0.803 . . . . 0.0 109.185 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -96.04 -35.45 11.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.292 -0.88 . . . . 0.0 109.749 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -73.21 143.84 83.82 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.308 -0.87 . . . . 0.0 109.808 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.56 80.06 3.03 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.777 2.318 . . . . 0.0 110.215 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 163.84 -24.95 0.19 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.664 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.55 149.33 50.27 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.387 -1.066 . . . . 0.0 109.387 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 36.2 p -136.4 144.22 44.4 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.2 t80 -106.73 108.72 20.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.384 -0.823 . . . . 0.0 109.07 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.452 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.06 132.28 45.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.322 -0.861 . . . . 0.0 109.685 -179.742 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -122.1 112.85 36.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.418 -0.801 . . . . 0.0 109.263 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.6 m -84.2 102.0 12.29 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.291 -0.88 . . . . 0.0 109.326 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -98.46 142.45 30.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.33 -0.856 . . . . 0.0 109.531 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.3 p -123.9 -25.92 4.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.351 -0.843 . . . . 0.0 109.714 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.46 152.27 45.63 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 109.669 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -99.43 123.1 43.41 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.418 -0.801 . . . . 0.0 109.605 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.492 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.68 -171.67 41.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 4.0 m -113.3 111.01 21.3 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.298 -1.119 . . . . 0.0 109.401 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -89.57 175.44 7.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.362 -0.837 . . . . 0.0 109.171 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.7 88.58 1.77 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.223 -0.923 . . . . 0.0 109.861 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.446 ' HE1' ' CE2' ' A' ' 14' ' ' PHE . 48.3 p90 -93.23 146.5 23.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.249 -0.907 . . . . 0.0 108.802 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.545 ' HB2' HG12 ' A' ' 93' ' ' VAL . 50.1 p90 -133.41 153.03 51.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.863 -179.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 42.5 t -65.68 109.2 2.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.542 -0.724 . . . . 0.0 109.246 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.823 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.5 OUTLIER . . . . . 0 N--CA 1.495 1.787 0 O-C-N 121.471 -0.768 . . . . 0.0 109.812 -179.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.915 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 121.359 0.6 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.545 HG12 ' HB2' ' A' ' 83' ' ' TYR . 15.3 m -149.57 134.49 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.299 -0.876 . . . . 0.0 109.31 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -115.17 174.98 15.64 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -147.65 135.3 20.94 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.13 . . . . 0.0 109.614 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.428 HG23 ' CE2' ' A' ' 82' ' ' PHE . 34.9 t -89.33 109.87 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.97 65.87 2.97 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 109.174 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.408 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 4.7 p -78.32 140.47 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.369 -0.832 . . . . 0.0 109.575 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.586 179.982 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.605 HD11 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.415 ' NE2' ' O ' ' A' ' 10' ' ' GLY . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . 0.656 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.823 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.412 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.53 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.9 p . . . . . 0 N--CA 1.503 2.195 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.56 108.91 5.18 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.235 -0.915 . . . . 0.0 109.46 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.633 HG11 ' HD2' ' A' ' 14' ' ' PHE . 15.8 t -104.35 120.65 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.34 -0.85 . . . . 0.0 109.446 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.433 HD23 ' HB2' ' A' ' 30' ' ' LYS . 19.0 mt -107.63 102.59 11.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.389 -0.82 . . . . 0.0 109.342 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.792 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.09 141.62 58.66 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.326 -0.859 . . . . 0.0 109.415 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.47 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.09 136.48 1.23 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.64 -121.35 0.46 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -125.48 5.12 8.13 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.03 -42.61 0.27 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.315 -1.109 . . . . 0.0 109.601 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.97 42.41 0.05 OUTLIER Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.47 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 1.7 t -97.71 96.91 8.57 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.311 -1.111 . . . . 0.0 109.295 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.1 mt -80.03 90.95 5.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.377 -0.827 . . . . 0.0 109.451 -179.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.862 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.61 142.58 6.67 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.338 -0.851 . . . . 0.0 109.781 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.633 ' HD2' HG11 ' A' ' 3' ' ' VAL . 33.5 m-85 -67.62 128.06 35.06 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.418 -0.801 . . . . 0.0 109.082 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.508 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.11 102.76 18.71 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.612 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.75 171.18 64.32 Favored 'Cis proline' 0 C--N 1.312 -1.359 0 C-N-CA 123.43 -1.487 . . . . 0.0 110.648 -0.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.463 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -106.17 14.64 43.96 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -169.1 110.54 0.49 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.393 -1.063 . . . . 0.0 109.051 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -132.22 170.19 15.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.34 -0.85 . . . . 0.0 109.67 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.3 m -122.69 130.95 53.54 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 109.443 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -132.96 -169.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.354 -0.841 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.49 178.93 6.86 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.283 -0.885 . . . . 0.0 109.455 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.0 t -71.98 109.42 5.79 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.349 -0.844 . . . . 0.0 109.385 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.43 -17.03 5.9 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -81.91 171.4 14.5 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -1.095 . . . . 0.0 109.479 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.86 133.93 49.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.268 -0.895 . . . . 0.0 109.642 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -95.9 150.72 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.379 -0.825 . . . . 0.0 109.035 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -134.34 146.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 109.949 -179.561 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.637 ' HB3' HD11 ' A' ' 5' ' ' LEU . 56.8 m-85 -133.72 80.21 1.86 Allowed 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.433 ' HB2' HD23 ' A' ' 4' ' ' LEU . 28.6 mttt -81.11 123.86 28.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.229 -0.919 . . . . 0.0 109.825 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -94.46 126.73 39.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.334 -0.854 . . . . 0.0 109.388 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -102.93 -63.7 1.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.847 . . . . 0.0 109.566 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -134.33 148.04 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.344 -0.848 . . . . 0.0 109.561 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 14.96 45.74 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 1.056 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 0.2 OUTLIER -62.86 166.15 8.38 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.44 -1.036 . . . . 0.0 109.542 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.568 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 35.6 Cg_endo -78.06 145.32 78.13 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.679 0.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.792 ' HB3' HD22 ' A' ' 5' ' ' LEU . 34.7 m-70 -115.58 32.7 5.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -58.23 119.38 6.78 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.269 -0.894 . . . . 0.0 109.361 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -93.32 157.23 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.358 -0.839 . . . . 0.0 110.026 -179.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.5 m -139.79 119.98 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.397 -0.814 . . . . 0.0 109.194 179.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -67.19 116.74 8.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.397 -0.814 . . . . 0.0 109.927 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.43 ' O ' HG13 ' A' ' 46' ' ' ILE . 1.3 t70 -81.41 149.62 28.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.29 -0.881 . . . . 0.0 109.523 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 1.279 ' CB ' ' HE2' ' B' ' 187' ' ' LYS . 1.0 OUTLIER -96.79 6.44 48.66 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.267 -0.896 . . . . 0.0 109.918 179.909 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.43 -19.7 57.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.183 -0.948 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -131.49 38.44 3.6 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.384 -0.823 . . . . 0.0 109.515 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.786 HG23 ' HD2' ' A' ' 47' ' ' PRO . 8.1 mt -98.96 143.97 27.35 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.254 -0.904 . . . . 0.0 109.25 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.786 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.9 Cg_endo -76.02 -63.99 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.786 2.324 . . . . 0.0 111.068 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -83.4 -176.45 6.32 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.177 -0.952 . . . . 0.0 109.686 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.564 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -78.37 -105.63 0.2 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.564 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.65 160.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.56 -0.964 . . . . 0.0 109.861 179.811 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -99.45 162.61 12.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.256 -0.903 . . . . 0.0 109.547 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.415 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -81.78 -17.23 48.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.33 -0.856 . . . . 0.0 109.73 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.62 -2.3 28.64 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.217 -0.927 . . . . 0.0 109.898 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -101.5 -25.57 13.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.235 -0.915 . . . . 0.0 109.649 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.3 pt -119.0 6.67 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.198 -0.939 . . . . 0.0 110.114 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 69.0 m -113.05 171.18 7.7 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.108 -0.995 . . . . 0.0 109.366 179.746 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.6 mtp -88.79 152.12 21.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.323 -0.86 . . . . 0.0 109.571 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.2 t -89.82 -154.67 0.33 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.43 -0.794 . . . . 0.0 109.498 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' B' ' 66' ' ' LYS . 3.2 pt-20 -101.83 -33.55 9.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.259 -0.9 . . . . 0.0 109.888 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.86 -29.69 63.4 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.874 . . . . 0.0 109.829 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -96.88 87.26 4.23 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.262 -0.899 . . . . 0.0 109.672 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.05 139.75 43.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.374 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.7 mp -89.75 84.52 6.29 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.587 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.4 OUTLIER -111.44 -4.47 14.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.272 -0.892 . . . . 0.0 109.824 -179.763 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -101.38 146.71 32.67 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 109.689 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -77.11 78.47 3.44 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.795 2.33 . . . . 0.0 110.225 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.94 -23.88 0.29 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -68.2 147.16 52.64 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.322 -1.105 . . . . 0.0 109.442 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.0 p -136.36 147.32 47.31 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.247 -0.908 . . . . 0.0 109.828 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.6 t80 -110.24 109.27 19.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.81 . . . . 0.0 109.019 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.23 133.86 44.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 -179.673 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -123.05 116.58 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.384 -0.823 . . . . 0.0 109.242 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -87.14 102.48 14.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.287 -0.883 . . . . 0.0 109.355 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.76 142.95 30.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.343 -0.848 . . . . 0.0 109.584 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.7 p -124.46 -27.04 3.8 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.374 -0.829 . . . . 0.0 109.786 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.67 152.08 46.21 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.216 -0.927 . . . . 0.0 109.696 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -99.18 125.13 44.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.375 -0.828 . . . . 0.0 109.557 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.424 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.71 -165.88 37.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.2 m -118.28 120.05 36.5 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.317 -1.108 . . . . 0.0 109.524 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -97.08 178.15 5.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.421 -0.799 . . . . 0.0 109.085 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -147.54 88.36 1.7 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.114 -0.992 . . . . 0.0 109.891 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.435 ' CE2' HG23 ' A' ' 96' ' ' VAL . 42.6 p90 -93.65 161.22 14.43 Favored 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.663 ' HB2' HG12 ' A' ' 93' ' ' VAL . 44.7 p90 -155.15 152.96 30.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.038 -1.039 . . . . 0.0 110.339 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 51.6 t -64.31 114.08 4.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.612 -0.68 . . . . 0.0 109.233 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 1.261 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 5.6 t . . . . . 0 N--CA 1.493 1.684 0 O-C-N 121.407 -0.808 . . . . 0.0 110.107 -179.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.862 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.8 ptm . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.505 0.669 . . . . 0.0 109.26 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.663 HG12 ' HB2' ' A' ' 83' ' ' TYR . 35.1 m -143.88 153.22 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.46 176.45 19.87 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.04 138.11 22.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.316 -1.108 . . . . 0.0 109.74 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.435 HG23 ' CE2' ' A' ' 82' ' ' PHE . 45.7 t -93.25 108.67 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.361 -0.837 . . . . 0.0 109.473 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -92.35 67.3 4.83 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.263 -0.898 . . . . 0.0 109.162 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.405 HG12 ' H ' ' A' ' 98' ' ' VAL . 3.7 p -78.7 139.71 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.378 -0.826 . . . . 0.0 109.607 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.563 179.937 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 1.261 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 1.014 HD22 ' CB ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . 0.513 ' O ' ' CB ' ' A' ' 59' ' ' GLU . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 1.056 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . 1.279 ' HE2' ' CB ' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.141 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.76 108.29 4.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.639 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.9 t -103.55 121.12 54.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.469 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.421 HD23 ' HB2' ' A' ' 30' ' ' LYS . 20.1 mt -108.24 101.87 11.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.355 -0.841 . . . . 0.0 109.275 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.833 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.74 137.11 57.6 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.352 -0.843 . . . . 0.0 109.398 -179.956 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 83.0 135.37 2.42 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.07 -119.13 0.26 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.27 4.17 7.75 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -141.3 -41.28 0.38 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.311 -1.111 . . . . 0.0 109.592 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 171.03 43.66 0.03 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.527 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.3 t -97.4 99.39 10.82 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.344 -1.092 . . . . 0.0 109.273 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.665 HD11 HG21 ' B' ' 3' ' ' ILE . 6.6 mt -79.67 93.35 5.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.914 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -166.59 139.11 3.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 109.792 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.639 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.5 m-85 -65.9 127.05 30.5 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.42 -0.8 . . . . 0.0 108.98 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.423 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -127.86 102.84 21.82 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 109.641 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.73 170.22 67.83 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 123.452 -1.478 . . . . 0.0 110.651 -0.24 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.453 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.47 13.28 47.4 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -167.56 107.62 0.58 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.415 -1.05 . . . . 0.0 108.991 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -129.37 169.13 15.28 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.355 -0.84 . . . . 0.0 109.661 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.8 m -121.77 129.19 52.49 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.417 -0.802 . . . . 0.0 109.434 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.36 -170.11 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.61 179.15 6.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.329 -0.857 . . . . 0.0 109.476 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -71.96 108.39 5.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.7 -17.23 5.53 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -81.97 172.17 13.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.318 -1.107 . . . . 0.0 109.516 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -128.52 134.9 48.79 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.314 -0.866 . . . . 0.0 109.662 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.54 149.3 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.473 -0.767 . . . . 0.0 109.047 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -133.29 145.54 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.913 . . . . 0.0 109.952 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.673 ' HB3' HD11 ' A' ' 5' ' ' LEU . 50.8 m-85 -132.96 80.29 1.88 Allowed 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.421 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.9 mttt -80.88 124.31 29.0 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.165 -0.959 . . . . 0.0 109.767 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.6 p-10 -96.63 116.96 29.98 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.269 -0.894 . . . . 0.0 109.441 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -94.39 -69.21 0.76 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.536 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.11 151.17 49.51 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.358 -0.839 . . . . 0.0 109.473 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 94.1 10.16 58.79 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.824 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 2.1 p90 -57.94 166.18 2.13 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.34 -1.094 . . . . 0.0 109.421 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.57 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.2 Cg_endo -78.95 150.01 85.55 Favored 'Cis proline' 0 C--N 1.312 -1.355 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.536 -0.094 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.833 ' HB3' HD22 ' A' ' 5' ' ' LEU . 45.1 m-70 -121.72 45.24 2.36 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.339 -0.851 . . . . 0.0 109.25 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.9 p-10 -70.48 119.05 14.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.229 -0.919 . . . . 0.0 109.304 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -92.27 152.5 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.392 -0.818 . . . . 0.0 109.964 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.577 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.8 m -140.52 119.27 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 109.033 179.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -67.48 132.38 47.49 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.22 -0.925 . . . . 0.0 109.771 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -94.15 159.33 15.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.394 -0.816 . . . . 0.0 109.465 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.614 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.4 tp10 -99.82 24.81 7.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.312 -0.867 . . . . 0.0 109.573 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.02 -17.33 16.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.186 -0.946 . . . . 0.0 109.489 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -131.72 36.72 3.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.268 -0.895 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . 0.73 HG23 ' HD2' ' A' ' 47' ' ' PRO . 33.4 mt -100.43 141.93 23.64 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.333 -0.855 . . . . 0.0 108.988 179.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.73 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.55 -63.6 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.696 2.264 . . . . 0.0 111.151 -179.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . 0.528 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.7 t -85.48 -175.14 5.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.169 -0.957 . . . . 0.0 109.641 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.51 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.89 -108.18 0.14 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.44 155.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.494 -1.003 . . . . 0.0 109.796 179.895 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.98 162.21 14.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.297 -0.877 . . . . 0.0 109.583 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.48 -21.88 35.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.387 -0.82 . . . . 0.0 109.671 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -71.27 -12.53 61.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.273 -0.892 . . . . 0.0 109.927 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -86.68 -27.68 23.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.285 -0.884 . . . . 0.0 109.749 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.1 pt -116.72 6.32 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.235 -0.916 . . . . 0.0 110.045 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -110.77 174.55 5.81 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.174 -0.954 . . . . 0.0 109.348 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' MET . . . . . 0.461 ' H ' HG12 ' A' ' 40' ' ' VAL . 27.6 mtp -95.6 160.58 14.43 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.382 -0.824 . . . . 0.0 109.498 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -95.63 -170.86 2.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.358 -0.839 . . . . 0.0 109.563 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.49 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.5 OUTLIER -87.48 -26.19 23.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.301 -0.874 . . . . 0.0 109.865 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.49 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.39 -35.42 35.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.284 -0.885 . . . . 0.0 109.643 -179.865 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.58 92.81 8.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.428 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.764 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -114.82 141.36 48.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 109.462 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.3 mp -89.48 87.45 7.07 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.423 -0.798 . . . . 0.0 109.179 179.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.458 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.6 OUTLIER -108.52 -32.8 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.33 -0.856 . . . . 0.0 109.765 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.44 144.83 81.62 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.226 -0.921 . . . . 0.0 109.837 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.39 80.28 2.95 Favored 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.733 2.289 . . . . 0.0 110.25 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.51 -25.15 0.22 Allowed Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -67.36 148.72 51.26 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.364 -1.08 . . . . 0.0 109.448 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 32.0 p -136.36 144.21 44.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.915 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -107.73 109.17 20.69 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.35 -0.844 . . . . 0.0 108.998 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' LYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.49 134.44 43.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.343 -0.848 . . . . 0.0 109.743 -179.729 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -123.25 114.73 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.405 -0.809 . . . . 0.0 109.242 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -85.46 102.35 13.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.301 -0.875 . . . . 0.0 109.301 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.54 142.99 30.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.4 p -124.6 -26.8 3.79 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.372 -0.83 . . . . 0.0 109.818 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.03 47.81 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.272 -0.893 . . . . 0.0 109.683 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -97.99 121.33 39.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.373 -0.829 . . . . 0.0 109.52 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.454 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.93 -171.91 42.49 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -112.93 115.01 27.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.311 -1.111 . . . . 0.0 109.487 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 46.3 m-85 -93.32 178.61 5.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.351 -0.843 . . . . 0.0 109.093 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.59 93.27 2.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.984 . . . . 0.0 109.912 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -97.12 155.62 16.74 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.553 ' HB2' HG12 ' A' ' 93' ' ' VAL . 40.6 p90 -145.0 153.18 41.22 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.041 -1.037 . . . . 0.0 110.272 -179.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 52.0 t -68.65 106.81 2.74 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.821 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.494 1.747 0 O-C-N 121.414 -0.804 . . . . 0.0 110.109 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' MET . . . . . 0.914 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.6 ptm . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.473 0.654 . . . . 0.0 109.305 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.553 HG12 ' HB2' ' A' ' 83' ' ' TYR . 27.6 m -145.57 138.4 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.295 -0.878 . . . . 0.0 109.485 -179.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -118.79 177.42 16.41 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -148.25 137.43 21.96 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -1.145 . . . . 0.0 109.675 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 30.8 t -91.91 108.13 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.293 -0.879 . . . . 0.0 109.503 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -92.99 66.76 4.21 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.302 -0.874 . . . . 0.0 109.256 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 p -78.96 138.94 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.341 -0.849 . . . . 0.0 109.56 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.592 179.922 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 3' ' ' ILE . . . . . 0.665 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 61' ' ' LEU . . . . . 0.764 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 62' ' ' ALA . . . . . 0.821 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 63' ' ' ASN . . . . . 0.577 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 70' ' ' ASN . . . . . 0.406 ' O ' ' HA ' ' B' ' 154' ' ' ARG . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 117' ' ' PRO . . . . . 0.824 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 156' ' ' ARG . . . . . 0.523 ' NH1' ' HB2' ' B' ' 62' ' ' ALA . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.503 2.187 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.83 108.21 5.0 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.276 -0.89 . . . . 0.0 109.469 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.604 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.7 t -103.82 125.91 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.405 -0.809 . . . . 0.0 109.47 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.421 HD23 ' HB2' ' A' ' 30' ' ' LYS . 18.5 mt -113.08 105.4 13.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.357 -0.839 . . . . 0.0 109.319 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.832 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.48 140.94 58.04 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.334 -0.854 . . . . 0.0 109.421 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.57 137.72 1.59 Allowed Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.53 -118.79 0.38 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -127.76 7.05 6.95 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -145.69 -41.83 0.22 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.287 -1.125 . . . . 0.0 109.57 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.3 45.59 0.04 OUTLIER Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.458 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -102.72 97.67 7.8 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.373 -1.075 . . . . 0.0 109.253 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.572 HD13 ' CE1' ' A' ' 87' ' ' HIS . 7.5 mt -77.72 94.19 4.41 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.378 -0.826 . . . . 0.0 109.415 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.869 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.65 139.31 4.49 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.324 -0.86 . . . . 0.0 109.7 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.604 ' HD2' HG11 ' A' ' 3' ' ' VAL . 37.2 m-85 -67.36 127.74 33.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.285 -0.884 . . . . 0.0 109.094 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.529 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.43 103.44 20.02 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.25 -0.906 . . . . 0.0 109.593 -179.647 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.73 170.91 65.53 Favored 'Cis proline' 0 C--N 1.312 -1.373 0 C-N-CA 123.454 -1.478 . . . . 0.0 110.646 -0.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.452 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.28 12.39 48.09 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -167.11 111.14 0.72 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.371 -1.076 . . . . 0.0 109.125 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.0 p90 -132.2 169.68 16.09 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.358 -0.839 . . . . 0.0 109.709 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.89 130.24 53.2 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.384 -0.823 . . . . 0.0 109.45 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.7 m -132.48 -170.8 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.314 -0.867 . . . . 0.0 109.456 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.92 179.12 6.68 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.29 -0.881 . . . . 0.0 109.504 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.7 t -72.09 108.81 5.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.332 -0.855 . . . . 0.0 109.401 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.29 -17.02 5.65 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -82.09 172.55 13.08 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.366 -1.079 . . . . 0.0 109.493 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -129.06 134.96 48.31 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.311 -0.868 . . . . 0.0 109.633 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.542 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.7 149.52 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.364 -0.835 . . . . 0.0 109.047 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 t -133.44 145.72 33.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.162 -0.961 . . . . 0.0 109.939 -179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.647 ' HB3' HD11 ' A' ' 5' ' ' LEU . 51.3 m-85 -133.09 79.94 1.86 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.456 -0.777 . . . . 0.0 108.927 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.421 ' HB2' HD23 ' A' ' 4' ' ' LEU . 29.6 mttt -81.81 124.23 29.48 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.26 -0.9 . . . . 0.0 109.783 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 26.8 p-10 -95.14 130.23 41.93 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.311 -0.868 . . . . 0.0 109.425 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -104.51 -67.9 0.88 Allowed 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.338 -0.851 . . . . 0.0 109.593 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.86 152.42 48.53 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.329 -0.857 . . . . 0.0 109.568 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.28 21.45 35.13 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.526 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 2.8 p90 -64.34 163.03 28.1 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.354 -1.086 . . . . 0.0 109.585 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -79.5 155.49 89.55 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.421 -1.491 . . . . 0.0 110.726 -0.038 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.832 ' HB3' HD22 ' A' ' 5' ' ' LEU . 27.3 m-70 -126.62 40.99 3.61 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.413 -0.805 . . . . 0.0 109.222 179.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.477 ' OD1' ' HD3' ' A' ' 86' ' ' PRO . 11.4 p-10 -68.2 128.3 36.05 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.249 -0.907 . . . . 0.0 109.369 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -100.23 153.17 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.33 -0.856 . . . . 0.0 109.841 -179.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.491 HG12 ' H ' ' A' ' 57' ' ' MET . 9.7 m -140.7 123.0 15.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.418 -0.801 . . . . 0.0 109.217 179.762 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -71.52 133.42 45.8 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.291 -0.88 . . . . 0.0 109.571 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.409 ' HB2' ' HE1' ' A' ' 83' ' ' TYR . 0.7 OUTLIER -96.29 160.15 14.58 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.36 -0.838 . . . . 0.0 109.571 179.98 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.536 ' HA ' HD12 ' A' ' 46' ' ' ILE . 6.7 tp10 -100.39 44.84 1.0 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.37 -0.831 . . . . 0.0 109.429 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.29 -23.8 6.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.304 -0.872 . . . . 0.0 109.373 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -125.59 25.76 6.91 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 0.0 109.471 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.715 HG23 ' HD2' ' A' ' 47' ' ' PRO . 55.8 mt -90.09 141.15 27.64 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.314 -0.866 . . . . 0.0 108.988 179.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.715 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.7 Cg_endo -75.62 -62.25 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.68 2.253 . . . . 0.0 111.023 -179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.529 ' O ' HG22 ' A' ' 46' ' ' ILE . 2.0 t -87.05 -178.94 6.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.151 -0.968 . . . . 0.0 109.549 -179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.545 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -75.25 -101.68 0.11 Allowed Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.67 157.56 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.517 -0.99 . . . . 0.0 109.867 179.907 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.478 ' HA ' ' NZ ' ' B' ' 187' ' ' LYS . 0.7 OUTLIER -88.83 154.84 19.93 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.267 -0.896 . . . . 0.0 109.632 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.505 ' H ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.77 -27.27 40.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.419 -0.8 . . . . 0.0 109.532 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.96 -17.02 62.68 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.378 -0.827 . . . . 0.0 109.854 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.0 tptt -77.12 -31.24 55.64 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.299 -0.875 . . . . 0.0 109.699 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -113.02 4.97 8.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.196 -0.94 . . . . 0.0 109.935 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 66.3 m -108.52 177.81 4.68 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.172 -0.955 . . . . 0.0 109.403 179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.491 ' H ' HG12 ' A' ' 40' ' ' VAL . 28.3 mtp -98.78 164.07 12.37 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -98.55 -168.47 1.65 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.395 -0.816 . . . . 0.0 109.563 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.527 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.4 OUTLIER -88.64 -27.58 21.2 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.383 -0.823 . . . . 0.0 109.816 -179.817 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.479 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.6 OUTLIER -81.12 -33.36 33.31 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.233 -0.917 . . . . 0.0 109.703 -179.857 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -91.38 90.63 7.78 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.286 -0.884 . . . . 0.0 109.443 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.639 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -115.98 145.83 42.62 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.355 -0.841 . . . . 0.0 109.444 -179.991 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.707 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.1 mp -92.93 80.59 4.61 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.371 -0.831 . . . . 0.0 109.149 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.517 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.8 OUTLIER -102.09 -17.67 15.93 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.344 -0.847 . . . . 0.0 109.812 -179.681 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.34 145.46 30.05 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.256 -0.903 . . . . 0.0 109.781 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.33 83.46 2.14 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 C-N-CA 122.736 2.291 . . . . 0.0 110.274 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 160.5 -26.18 0.3 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.707 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -68.47 148.82 50.06 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.348 -1.09 . . . . 0.0 109.42 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -136.15 146.25 46.7 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.876 . . . . 0.0 109.85 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.8 t80 -109.18 109.08 19.95 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.35 -0.844 . . . . 0.0 109.011 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.542 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.19 133.87 43.95 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.363 -0.836 . . . . 0.0 109.662 -179.72 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -122.76 115.74 46.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.445 -0.785 . . . . 0.0 109.243 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.69 102.95 14.69 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.31 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -100.0 143.07 30.63 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.382 -0.824 . . . . 0.0 109.569 -179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.69 -26.36 3.83 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.347 -0.846 . . . . 0.0 109.744 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.19 152.15 45.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.213 -0.929 . . . . 0.0 109.666 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.7 mttt -99.11 121.61 41.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.369 -0.832 . . . . 0.0 109.556 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.504 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.61 -171.18 42.08 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -113.26 114.73 27.11 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.328 -1.101 . . . . 0.0 109.512 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -93.1 177.79 5.95 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.376 -0.828 . . . . 0.0 109.176 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.52 97.56 2.65 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.155 -0.966 . . . . 0.0 109.887 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -100.66 159.16 15.4 Favored 'General case' 0 N--CA 1.492 1.629 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.533 ' HB2' HG12 ' A' ' 93' ' ' VAL . 40.0 p90 -149.13 155.65 41.01 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 110.16 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.407 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 36.9 t -67.82 111.77 4.5 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.654 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.4 OUTLIER -53.19 -52.41 66.12 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.402 -0.811 . . . . 0.0 110.215 -179.42 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.755 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 33.5 Cg_endo -74.98 21.93 0.42 Allowed 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.288 1.992 . . . . 0.0 111.012 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.755 ' CD2' ' O ' ' A' ' 86' ' ' PRO . 8.8 m170 -173.33 49.18 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.382 -0.824 . . . . 0.0 109.413 179.549 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.539 ' OE1' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -78.08 -41.54 35.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.085 -1.009 . . . . 0.0 109.137 179.869 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.84 -7.31 84.21 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -67.53 -60.79 2.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.331 -1.099 . . . . 0.0 109.379 179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 145.44 1.37 0.76 Allowed Glycine 0 N--CA 1.493 2.457 0 C-N-CA 119.872 -1.156 . . . . 0.0 110.373 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.869 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.8 ptm -98.23 103.82 15.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.13 -1.217 . . . . 0.0 109.377 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.533 HG12 ' HB2' ' A' ' 83' ' ' TYR . 27.7 m -145.91 153.12 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.269 -0.894 . . . . 0.0 109.425 -179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.19 178.79 18.11 Favored Glycine 0 N--CA 1.493 2.48 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -149.39 139.85 22.44 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.276 -1.131 . . . . 0.0 109.701 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.3 t -94.63 109.66 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.325 -0.86 . . . . 0.0 109.492 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -94.05 68.3 3.74 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.257 -0.902 . . . . 0.0 109.254 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.1 p -80.23 139.77 17.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.34 -0.85 . . . . 0.0 109.623 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.694 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.58 179.948 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.55 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . 0.639 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.654 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.527 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.505 ' HE2' ' H ' ' A' ' 52' ' ' ALA . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.0 p . . . . . 0 N--CA 1.502 2.14 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.28 107.79 5.08 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.305 -0.872 . . . . 0.0 109.506 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.627 HG11 ' HD2' ' A' ' 14' ' ' PHE . 15.2 t -102.65 125.25 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.338 -0.851 . . . . 0.0 109.398 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.479 HD23 ' HB2' ' A' ' 30' ' ' LYS . 22.3 mt -111.36 103.27 11.63 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.399 -0.813 . . . . 0.0 109.347 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.767 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -65.6 139.09 58.4 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.375 -0.828 . . . . 0.0 109.415 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.438 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.71 136.79 1.82 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.01 -118.46 0.33 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -128.74 5.12 6.56 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -143.21 -41.38 0.3 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.366 -1.079 . . . . 0.0 109.62 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.27 46.13 0.04 OUTLIER Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.438 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.5 t -103.83 93.5 4.92 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.365 -1.079 . . . . 0.0 109.374 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.461 HD13 ' CE1' ' A' ' 87' ' ' HIS . 6.7 mt -75.67 91.79 2.91 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 109.414 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.879 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.07 141.71 8.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.331 -0.856 . . . . 0.0 109.637 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.627 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.8 m-85 -68.84 128.45 36.71 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.401 -0.812 . . . . 0.0 109.217 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.95 103.02 17.28 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.277 -0.889 . . . . 0.0 109.637 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.71 171.2 64.36 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.482 . . . . 0.0 110.687 -0.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.414 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.97 10.32 47.97 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.879 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -164.88 113.26 1.05 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.351 -1.088 . . . . 0.0 109.135 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -133.87 170.58 15.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.297 -0.877 . . . . 0.0 109.641 -179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.4 m -122.58 131.34 53.78 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.352 -0.842 . . . . 0.0 109.474 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -133.25 -171.93 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.384 -0.823 . . . . 0.0 109.468 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.02 178.29 7.19 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 11.0 t -72.07 111.93 7.72 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.275 -0.89 . . . . 0.0 109.405 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.32 -17.52 7.0 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.0 mm-40 -81.42 167.4 19.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.317 -1.108 . . . . 0.0 109.496 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -124.09 131.17 53.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.594 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -95.66 151.08 4.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.42 -0.8 . . . . 0.0 108.986 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.0 t -133.42 146.74 31.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.176 -0.953 . . . . 0.0 110.007 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.603 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.7 m-85 -132.65 77.35 1.74 Allowed 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.479 ' HB2' HD23 ' A' ' 4' ' ' LEU . 29.4 mttt -78.92 134.01 36.89 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.912 . . . . 0.0 109.786 -179.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.472 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.4 p-10 -106.04 137.58 43.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.278 -0.889 . . . . 0.0 109.415 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -112.64 -70.46 0.81 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.352 -0.842 . . . . 0.0 109.672 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -121.09 149.97 41.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 109.578 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 88.91 23.22 36.11 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.469 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 4.0 p90 -67.82 162.45 58.28 Favored Pre-proline 0 N--CA 1.494 1.77 0 O-C-N 121.441 -1.035 . . . . 0.0 109.525 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.526 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 35.9 Cg_endo -79.26 158.19 90.57 Favored 'Cis proline' 0 C--N 1.313 -1.31 0 C-N-CA 123.395 -1.502 . . . . 0.0 110.806 0.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.767 ' HB3' HD22 ' A' ' 5' ' ' LEU . 25.1 m-70 -126.17 39.77 3.87 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.43 -0.794 . . . . 0.0 109.269 179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.448 ' OD1' ' HG3' ' A' ' 86' ' ' PRO . 10.8 p-10 -66.06 130.47 43.35 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.159 -0.963 . . . . 0.0 109.273 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -105.17 157.69 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.307 -0.871 . . . . 0.0 109.923 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.698 HG11 ' HB3' ' B' ' 63' ' ' ASN . 4.8 m -141.65 130.87 23.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.469 -0.77 . . . . 0.0 109.307 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -78.0 136.24 37.92 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.266 -0.896 . . . . 0.0 109.769 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.478 ' O ' HG13 ' A' ' 46' ' ' ILE . 0.6 OUTLIER -104.56 157.93 16.84 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.41 -0.806 . . . . 0.0 109.322 179.734 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.51 ' O ' ' HG3' ' A' ' 43' ' ' GLU . 10.5 tp10 -94.47 17.38 13.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.333 -0.854 . . . . 0.0 109.671 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -84.6 -19.78 32.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.127 -0.983 . . . . 0.0 109.455 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -136.89 36.4 2.6 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.35 -0.844 . . . . 0.0 109.525 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.74 HG23 ' HD2' ' A' ' 47' ' ' PRO . 22.1 mt -99.32 142.47 24.67 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.217 -0.927 . . . . 0.0 109.086 179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.74 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.3 Cg_endo -76.03 -66.33 0.02 OUTLIER 'Trans proline' 0 C--N 1.313 -1.308 0 C-N-CA 122.665 2.244 . . . . 0.0 111.125 -179.636 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.521 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.9 t -84.39 -178.77 7.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.213 -0.929 . . . . 0.0 109.679 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.465 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.36 -100.76 0.14 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.465 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.61 152.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.511 -0.993 . . . . 0.0 109.79 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.504 ' HA ' ' NZ ' ' B' ' 187' ' ' LYS . 0.6 OUTLIER -80.68 152.93 28.18 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.211 -0.931 . . . . 0.0 109.597 -179.869 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.524 ' N ' ' HE2' ' B' ' 187' ' ' LYS . . . -79.93 -25.31 40.55 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.349 -0.844 . . . . 0.0 109.593 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -74.89 -16.93 60.65 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.32 -0.862 . . . . 0.0 109.794 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.4 tptt -76.29 -32.48 58.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.334 -0.854 . . . . 0.0 109.68 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.1 pt -107.54 -3.32 10.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 O-C-N 121.28 -0.887 . . . . 0.0 109.89 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 58.8 m -99.79 177.3 5.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.227 -0.92 . . . . 0.0 109.3 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.617 ' H ' HG12 ' A' ' 40' ' ' VAL . 8.4 mtp -92.48 155.94 17.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.269 -0.894 . . . . 0.0 109.595 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -85.21 -163.19 0.8 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.352 -0.842 . . . . 0.0 109.512 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.519 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -96.4 -31.35 12.89 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.348 -0.845 . . . . 0.0 110.003 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.403 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.62 -30.78 36.73 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.305 -0.872 . . . . 0.0 109.797 -179.734 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -89.08 100.69 13.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.304 -0.873 . . . . 0.0 109.538 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.715 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -124.5 145.21 49.68 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.473 -0.767 . . . . 0.0 109.488 -179.935 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 4.2 mp -91.03 68.57 6.16 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.392 -0.817 . . . . 0.0 109.16 179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -91.02 -24.69 20.0 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.351 -0.843 . . . . 0.0 109.949 -179.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.87 146.17 38.24 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.218 -0.926 . . . . 0.0 109.738 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -77.34 79.25 3.22 Favored 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.755 2.303 . . . . 0.0 110.252 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.09 -24.92 0.19 Allowed Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.1 tp10 -68.31 148.6 50.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.444 -1.033 . . . . 0.0 109.347 179.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.7 p -136.09 145.81 46.34 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 109.867 -179.567 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 23.3 t80 -107.06 107.78 18.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.35 -0.844 . . . . 0.0 109.144 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.85 131.25 45.1 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.389 -0.819 . . . . 0.0 109.566 -179.736 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -120.98 114.74 44.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.363 -0.836 . . . . 0.0 109.3 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.7 m -86.66 101.65 13.46 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.342 -0.849 . . . . 0.0 109.254 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -98.63 142.15 30.56 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.371 -0.83 . . . . 0.0 109.57 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.5 p -123.3 -24.68 4.6 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.404 -0.81 . . . . 0.0 109.699 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.36 153.99 42.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.288 -0.883 . . . . 0.0 109.622 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.3 mttt -101.16 125.38 47.77 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.329 -0.857 . . . . 0.0 109.576 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.533 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.99 -166.88 37.77 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -117.44 112.65 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.298 -1.119 . . . . 0.0 109.527 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.7 m-85 -91.21 176.83 6.44 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.338 -0.851 . . . . 0.0 109.178 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.4 99.31 3.01 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.199 -0.938 . . . . 0.0 109.866 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.434 ' CE2' HG23 ' A' ' 96' ' ' VAL . 44.9 p90 -103.48 164.04 11.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.361 -0.837 . . . . 0.0 108.868 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.644 ' HB2' HG12 ' A' ' 93' ' ' VAL . 34.7 p90 -153.02 155.78 37.54 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.168 -0.957 . . . . 0.0 109.812 -179.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.406 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 42.4 t -66.68 108.1 2.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.424 -0.797 . . . . 0.0 109.119 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.842 ' HB3' ' HB3' ' B' ' 62' ' ' ALA . 0.6 OUTLIER -51.44 -53.31 51.06 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.48 -0.763 . . . . 0.0 109.924 -179.89 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.787 ' HA ' ' CGD' ' B' ' 251' ' ' HEC . 32.4 Cg_endo -74.04 34.68 0.37 Allowed 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.209 1.939 . . . . 0.0 110.733 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.708 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 7.9 m170 174.12 34.61 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.59 -0.694 . . . . 0.0 109.187 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.75 -33.21 73.51 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.254 -0.904 . . . . 0.0 109.571 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.42 ' HA3' ' CD2' ' B' ' 160' ' ' TYR . . . -92.22 -10.08 61.31 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -67.65 -72.57 0.17 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.391 -1.064 . . . . 0.0 109.406 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.24 29.53 0.03 OUTLIER Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.838 -1.173 . . . . 0.0 110.426 179.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.879 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm -126.39 104.69 8.31 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.157 -1.202 . . . . 0.0 109.07 179.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.644 HG12 ' HB2' ' A' ' 83' ' ' TYR . 32.4 m -143.06 165.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.762 0 O-C-N 121.271 -0.893 . . . . 0.0 109.615 -179.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.414 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -144.14 177.76 22.58 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -150.14 139.03 20.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.261 -1.141 . . . . 0.0 109.839 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.434 HG23 ' CE2' ' A' ' 82' ' ' PHE . 40.8 t -94.64 115.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.401 -0.812 . . . . 0.0 109.507 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -98.21 67.2 1.85 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.253 -0.905 . . . . 0.0 109.122 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.1 p -78.79 141.85 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.39 -0.819 . . . . 0.0 109.643 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.581 179.939 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . 0.715 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.842 ' HB3' ' HB3' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.698 ' HB3' HG11 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.519 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.524 ' HE2' ' N ' ' A' ' 52' ' ' ALA . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 N--CA 1.502 2.143 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.3 109.86 4.94 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.303 -0.873 . . . . 0.0 109.417 179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.645 HG11 ' HD2' ' A' ' 14' ' ' PHE . 11.5 t -104.52 120.53 55.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.328 -0.858 . . . . 0.0 109.559 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.485 HD23 ' HB2' ' A' ' 30' ' ' LYS . 24.6 mt -106.73 101.36 10.81 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.359 -0.838 . . . . 0.0 109.287 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.829 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.2 mp -64.42 141.21 58.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.333 -0.855 . . . . 0.0 109.432 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.18 138.36 1.56 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.74 -115.28 0.33 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -132.12 6.37 5.38 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.6 -41.34 0.22 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.346 -1.091 . . . . 0.0 109.596 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 172.22 45.45 0.04 OUTLIER Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.403 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.3 t -105.65 98.0 7.76 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.308 -1.113 . . . . 0.0 109.304 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.018 HD11 HG21 ' B' ' 3' ' ' ILE . 9.0 mt -78.79 101.12 7.44 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.324 -0.86 . . . . 0.0 109.487 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.692 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -169.58 136.24 1.63 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.302 -0.874 . . . . 0.0 109.661 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.645 ' HD2' HG11 ' A' ' 3' ' ' VAL . 39.6 m-85 -65.9 126.5 28.73 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 109.124 179.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.513 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -126.83 103.14 24.36 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.262 -0.898 . . . . 0.0 109.573 -179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.513 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.72 169.33 70.86 Favored 'Cis proline' 0 C--N 1.312 -1.356 0 C-N-CA 123.459 -1.475 . . . . 0.0 110.67 -0.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.458 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.2 12.28 51.89 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -166.98 105.63 0.58 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.393 -1.063 . . . . 0.0 109.009 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.8 p90 -126.77 167.67 15.45 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.707 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.5 128.39 53.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.345 -0.847 . . . . 0.0 109.393 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -130.43 -171.06 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.35 -0.844 . . . . 0.0 109.519 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -138.15 179.38 6.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.312 -0.868 . . . . 0.0 109.451 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.19 108.78 5.54 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.297 -0.877 . . . . 0.0 109.385 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.47 -17.26 5.58 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -81.84 171.41 14.53 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.31 -1.112 . . . . 0.0 109.434 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -128.27 133.39 48.77 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.288 -0.883 . . . . 0.0 109.702 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -94.45 146.56 6.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.442 -0.786 . . . . 0.0 109.071 179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -129.57 145.48 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.19 -0.944 . . . . 0.0 109.818 -179.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.631 ' HB3' HD11 ' A' ' 5' ' ' LEU . 46.5 m-85 -133.01 82.04 1.97 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.469 -0.769 . . . . 0.0 109.03 179.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.485 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.7 mttt -83.34 126.57 32.84 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.201 -0.937 . . . . 0.0 109.752 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.498 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 25.9 p-10 -98.85 127.8 44.88 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.259 -0.901 . . . . 0.0 109.481 179.752 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.7 t30 -104.65 -65.74 1.01 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.346 -0.846 . . . . 0.0 109.54 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -129.71 144.1 51.13 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.338 -0.851 . . . . 0.0 109.517 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 97.43 22.53 16.46 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.54 ' HB2' ' HA ' ' A' ' 64' ' ' ASN . 3.3 p90 -66.78 163.98 37.94 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.362 -1.081 . . . . 0.0 109.486 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.63 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.4 Cg_endo -80.4 152.14 83.09 Favored 'Cis proline' 0 C--N 1.312 -1.36 0 C-N-CA 123.389 -1.504 . . . . 0.0 110.858 -0.062 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.829 ' HB3' HD22 ' A' ' 5' ' ' LEU . 27.4 m-70 -118.26 40.35 3.2 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.347 -0.846 . . . . 0.0 109.222 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.402 ' OD1' ' HD3' ' A' ' 86' ' ' PRO . 16.2 p-10 -65.64 120.29 12.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.311 -0.868 . . . . 0.0 109.34 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.7 m -96.35 148.8 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.335 -0.853 . . . . 0.0 109.9 -179.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.537 HG21 ' HB3' ' B' ' 63' ' ' ASN . 7.7 m -134.82 119.79 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.43 -0.794 . . . . 0.0 109.048 179.769 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 15.0 m-85 -67.78 131.92 46.46 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.287 -0.883 . . . . 0.0 109.968 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.44 ' HB2' ' HE2' ' A' ' 83' ' ' TYR . 1.4 t0 -93.79 158.08 15.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.384 -0.822 . . . . 0.0 109.43 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.71 ' OE1' ' HE2' ' B' ' 187' ' ' LYS . 2.8 tp10 -100.55 17.82 20.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.844 . . . . 0.0 109.631 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -92.3 -18.04 23.92 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.148 -0.97 . . . . 0.0 109.483 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.6 mt-10 -130.64 26.21 5.04 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.226 -0.922 . . . . 0.0 109.629 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.738 HG23 ' HD2' ' A' ' 47' ' ' PRO . 19.0 mt -91.06 142.65 27.54 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.258 -0.901 . . . . 0.0 109.182 179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.738 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -75.96 -65.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.312 -1.379 0 C-N-CA 122.704 2.27 . . . . 0.0 111.171 -179.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.541 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.7 t -81.84 -177.61 6.64 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.189 -0.944 . . . . 0.0 109.692 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.505 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.9 -107.61 0.14 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.505 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.5 156.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.969 . . . . 0.0 109.856 179.926 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.72 160.8 14.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 0.0 109.57 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.401 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -80.55 -24.13 39.46 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.307 -0.871 . . . . 0.0 109.613 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -66.27 -19.16 65.74 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.227 -0.921 . . . . 0.0 109.951 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -80.57 -30.88 36.96 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.236 -0.915 . . . . 0.0 109.682 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.1 pt -117.17 23.26 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 109.84 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.401 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 45.0 m -127.72 171.28 11.85 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.188 -0.945 . . . . 0.0 109.428 179.729 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.472 ' H ' HG12 ' A' ' 40' ' ' VAL . 27.0 mtp -96.78 162.86 13.24 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.356 -0.84 . . . . 0.0 109.638 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.1 t -102.0 -171.2 1.93 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.349 -0.844 . . . . 0.0 109.746 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -84.64 -24.76 28.92 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.373 -0.829 . . . . 0.0 109.817 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -82.2 -32.42 29.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.254 -0.904 . . . . 0.0 109.705 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -95.23 90.02 5.71 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.506 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -115.83 146.29 42.11 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.42 -0.8 . . . . 0.0 109.388 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.664 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.6 mp -93.28 76.01 4.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.387 -0.821 . . . . 0.0 109.357 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.54 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.7 OUTLIER -98.04 -0.82 43.88 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.339 -0.851 . . . . 0.0 109.944 -179.721 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -107.19 143.85 27.97 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.174 -0.954 . . . . 0.0 109.711 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.42 84.7 1.91 Allowed 'Trans proline' 0 C--N 1.311 -1.395 0 C-N-CA 122.704 2.27 . . . . 0.0 110.296 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 157.22 -25.43 0.47 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.664 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -69.2 149.72 48.27 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.339 -1.095 . . . . 0.0 109.428 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 37.1 p -136.55 145.44 45.01 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.266 -0.896 . . . . 0.0 109.797 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -108.68 109.67 20.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.352 -0.842 . . . . 0.0 109.034 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.95 134.25 44.22 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.258 -0.901 . . . . 0.0 109.762 -179.722 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -123.14 115.77 46.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.374 -0.829 . . . . 0.0 109.211 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.49 104.18 15.71 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.281 -0.887 . . . . 0.0 109.343 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -101.4 142.75 32.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.384 -0.822 . . . . 0.0 109.547 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.8 p -124.66 -25.99 3.9 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.436 -0.79 . . . . 0.0 109.737 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 152.7 45.1 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.247 -0.908 . . . . 0.0 109.689 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.2 mttt -99.61 124.39 44.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.335 -0.853 . . . . 0.0 109.514 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.465 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 164.13 -168.55 38.63 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.3 m -115.3 118.72 34.07 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.313 -1.11 . . . . 0.0 109.528 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -96.63 179.13 5.1 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.349 -0.845 . . . . 0.0 109.149 179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -150.79 96.99 2.43 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.193 -0.942 . . . . 0.0 109.835 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -100.43 153.52 19.28 Favored 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.591 ' CD1' ' HB3' ' A' ' 88' ' ' GLN . 35.5 p90 -143.46 155.97 44.51 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.081 -1.012 . . . . 0.0 110.34 -179.45 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.443 ' HB3' ' O ' ' A' ' 87' ' ' HIS . 8.6 t -68.55 114.02 6.58 Favored 'General case' 0 N--CA 1.492 1.646 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.459 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.608 ' N ' ' HD2' ' A' ' 86' ' ' PRO . 0.3 OUTLIER -51.28 -50.53 75.42 Favored Pre-proline 0 N--CA 1.495 1.809 0 O-C-N 121.252 -0.905 . . . . 0.0 109.992 -179.481 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.692 ' O ' ' HE2' ' B' ' 1' ' ' TYR . 33.0 Cg_endo -75.16 -19.4 17.54 Favored 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.23 1.953 . . . . 0.0 110.937 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.747 ' NE2' ' CD2' ' B' ' 1' ' ' TYR . 43.7 m170 -137.22 65.37 1.5 Allowed 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.051 -1.03 . . . . 0.0 110.159 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 1.168 ' OE1' ' OH ' ' B' ' 160' ' ' TYR . 0.0 OUTLIER -105.71 -22.06 13.04 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.059 -1.026 . . . . 0.0 109.219 179.502 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.69 -4.23 62.12 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.837 ' HB2' ' HZ ' ' B' ' 4' ' ' PHE . . . -84.47 -55.98 3.86 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.406 -1.055 . . . . 0.0 109.4 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 155.3 -15.08 0.48 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 110.179 -1.168 . . . . 0.0 110.179 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.758 ' CG ' ' O ' ' A' ' 92' ' ' MET . 0.5 OUTLIER -77.18 94.98 4.18 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.169 -1.195 . . . . 0.0 109.515 -179.781 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.42 HG12 ' HB2' ' A' ' 83' ' ' TYR . 17.4 m -146.63 148.61 16.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.381 -0.825 . . . . 0.0 109.211 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.32 179.88 16.69 Favored Glycine 0 N--CA 1.494 2.508 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.3 ptmt -149.44 139.56 22.14 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.444 -1.033 . . . . 0.0 109.6 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.1 t -93.44 109.33 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.374 -0.829 . . . . 0.0 109.536 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -93.88 68.1 3.82 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.275 -0.891 . . . . 0.0 109.169 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.3 p -79.77 141.23 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.309 -0.869 . . . . 0.0 109.535 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.3 p30 . . . . . 0 N--CA 1.494 1.754 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.636 -179.998 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.747 ' CD2' ' NE2' ' A' ' 87' ' ' HIS . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 1.018 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.837 ' HZ ' ' HB2' ' A' ' 90' ' ' ALA . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.523 ' HB2' ' NH1' ' B' ' 156' ' ' ARG . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.537 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 1.168 ' OH ' ' OE1' ' A' ' 88' ' ' GLN . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.71 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.43 108.32 4.8 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.217 -0.927 . . . . 0.0 109.427 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.608 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.7 t -103.73 125.0 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.309 -0.869 . . . . 0.0 109.497 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.413 HD23 ' HB2' ' A' ' 30' ' ' LYS . 19.8 mt -111.98 104.06 12.31 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.357 -0.839 . . . . 0.0 109.299 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.873 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.0 OUTLIER -65.62 139.42 58.42 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.365 -0.834 . . . . 0.0 109.445 -179.99 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.479 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 80.57 136.47 1.72 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.01 -117.07 0.23 Allowed Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -129.86 7.39 6.13 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.38 -41.11 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.332 -1.099 . . . . 0.0 109.59 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.89 47.64 0.04 OUTLIER Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.479 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.6 t -104.92 97.93 7.72 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.347 -1.09 . . . . 0.0 109.373 179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.554 HD13 ' CE1' ' A' ' 87' ' ' HIS . 8.7 mt -77.42 94.21 4.21 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.34 -0.85 . . . . 0.0 109.403 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.878 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -165.86 139.4 4.35 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.366 -0.834 . . . . 0.0 109.744 -179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.608 ' HD2' HG11 ' A' ' 3' ' ' VAL . 37.2 m-85 -67.51 128.06 35.02 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.406 -0.809 . . . . 0.0 109.072 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.463 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.7 mp -128.66 103.17 19.53 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.234 -0.916 . . . . 0.0 109.572 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.3 Cg_endo -79.74 170.79 65.88 Favored 'Cis proline' 0 C--N 1.313 -1.333 0 C-N-CA 123.41 -1.496 . . . . 0.0 110.646 -0.269 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.443 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.33 12.49 47.92 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -166.9 110.08 0.71 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.338 -1.095 . . . . 0.0 109.086 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.1 p90 -131.3 169.45 15.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.678 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.5 m -121.91 130.35 53.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.345 -0.847 . . . . 0.0 109.498 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -132.49 -170.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.398 -0.814 . . . . 0.0 109.453 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.08 179.15 6.67 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.315 -0.866 . . . . 0.0 109.495 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.8 t -72.12 109.14 5.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.289 -0.882 . . . . 0.0 109.39 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.72 -17.04 5.81 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.796 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.1 171.22 14.59 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.339 -1.095 . . . . 0.0 109.467 179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.69 134.7 49.59 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.272 -0.892 . . . . 0.0 109.646 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.535 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -96.82 149.91 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.416 -0.803 . . . . 0.0 109.058 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.5 t -133.34 145.95 33.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.209 -0.932 . . . . 0.0 109.949 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.647 ' HB3' HD11 ' A' ' 5' ' ' LEU . 52.0 m-85 -133.41 79.99 1.86 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.471 -0.768 . . . . 0.0 108.95 179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.413 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.3 mttt -81.36 125.74 30.75 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.242 -0.911 . . . . 0.0 109.758 -179.639 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.435 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 26.6 p-10 -97.11 125.99 41.97 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.304 -0.873 . . . . 0.0 109.52 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.5 t30 -101.21 -65.46 0.97 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.33 -0.857 . . . . 0.0 109.544 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.17 148.28 52.7 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.54 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.04 21.1 26.3 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.49 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.9 p90 -64.86 163.23 30.54 Favored Pre-proline 0 N--CA 1.495 1.82 0 O-C-N 121.324 -1.104 . . . . 0.0 109.676 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.564 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -79.75 153.65 87.17 Favored 'Cis proline' 0 C--N 1.312 -1.363 0 C-N-CA 123.367 -1.514 . . . . 0.0 110.68 -0.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.873 ' HB3' HD22 ' A' ' 5' ' ' LEU . 34.4 m-70 -123.9 39.0 4.07 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.405 -0.81 . . . . 0.0 109.269 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.6 p-10 -66.0 126.0 27.2 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.272 -0.892 . . . . 0.0 109.367 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.4 m -97.89 149.87 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.884 -179.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.409 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.4 m -136.61 119.88 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.504 -0.747 . . . . 0.0 108.999 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 22.8 m-85 -68.62 133.17 48.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.232 -0.918 . . . . 0.0 109.692 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.21 159.99 14.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.37 -0.831 . . . . 0.0 109.371 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.579 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.9 tp10 -100.78 31.94 3.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.4 -0.812 . . . . 0.0 109.583 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.15 -18.66 13.95 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.174 -0.954 . . . . 0.0 109.349 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -130.67 24.93 5.07 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.345 -0.847 . . . . 0.0 109.56 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.736 HG23 ' HD2' ' A' ' 47' ' ' PRO . 35.8 mt -89.36 141.82 29.26 Favored Pre-proline 0 N--CA 1.493 1.676 0 O-C-N 121.324 -0.86 . . . . 0.0 109.119 179.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.736 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.8 Cg_endo -75.69 -63.34 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.733 2.289 . . . . 0.0 111.103 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.543 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.9 t -84.81 -177.95 6.72 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.177 -0.952 . . . . 0.0 109.588 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.517 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.41 -105.47 0.13 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.517 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.24 156.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.53 -0.982 . . . . 0.0 109.835 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -90.76 158.2 16.99 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.307 -0.871 . . . . 0.0 109.581 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.46 -24.25 39.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.334 -0.854 . . . . 0.0 109.558 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.31 -15.94 62.94 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.38 -0.825 . . . . 0.0 109.853 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.2 tptt -81.3 -31.17 33.69 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.283 -0.886 . . . . 0.0 109.697 -179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.5 pt -113.23 7.55 7.92 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 -179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 67.5 m -111.74 173.92 6.12 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.194 -0.942 . . . . 0.0 109.419 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.4 ' H ' HG12 ' A' ' 40' ' ' VAL . 19.8 mtp -93.63 161.29 14.41 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.323 -0.861 . . . . 0.0 109.624 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -95.8 -167.25 1.56 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.341 -0.849 . . . . 0.0 109.681 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.412 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.8 OUTLIER -90.18 -28.66 18.76 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.339 -0.851 . . . . 0.0 109.976 -179.666 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.412 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -80.28 -30.38 38.33 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.253 -0.905 . . . . 0.0 109.859 -179.734 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -95.0 91.5 6.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.213 -0.93 . . . . 0.0 109.575 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.403 HD11 HD21 ' B' ' 61' ' ' LEU . 0.2 OUTLIER -115.6 142.98 46.0 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.406 -0.809 . . . . 0.0 109.296 179.914 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.719 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.8 mp -89.14 80.57 6.92 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.3 -0.875 . . . . 0.0 109.133 179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.476 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 2.0 t30 -100.4 -22.9 14.89 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.335 -0.853 . . . . 0.0 109.913 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.91 145.46 36.63 Favored Pre-proline 0 N--CA 1.493 1.69 0 O-C-N 121.223 -0.923 . . . . 0.0 109.905 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.59 81.6 2.62 Favored 'Trans proline' 0 C--N 1.312 -1.386 0 C-N-CA 122.801 2.334 . . . . 0.0 110.275 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.01 -25.74 0.24 Allowed Glycine 0 N--CA 1.492 2.425 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.719 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.59 149.18 50.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.331 -1.1 . . . . 0.0 109.441 179.861 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.4 p -135.79 145.98 47.09 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.284 -0.885 . . . . 0.0 109.878 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.7 t80 -109.09 108.94 19.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.343 -0.848 . . . . 0.0 109.045 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.535 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.0 133.83 43.81 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.314 -0.866 . . . . 0.0 109.703 -179.697 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.76 115.22 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.42 -0.8 . . . . 0.0 109.239 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -86.24 102.04 13.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.296 -0.878 . . . . 0.0 109.279 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.1 142.98 29.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.347 -0.845 . . . . 0.0 109.559 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.5 p -124.56 -26.31 3.88 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.335 -0.853 . . . . 0.0 109.778 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.1 151.8 46.47 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.328 -0.858 . . . . 0.0 109.615 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.3 mttt -98.81 122.55 42.19 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.376 -0.828 . . . . 0.0 109.594 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.5 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.64 -171.42 41.55 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -112.97 114.4 26.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.319 -1.106 . . . . 0.0 109.494 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 42.0 m-85 -92.73 176.89 6.27 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.303 -0.873 . . . . 0.0 109.123 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -148.43 93.9 2.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.117 -0.99 . . . . 0.0 109.86 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 44.1 p90 -97.36 155.94 16.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.331 -0.856 . . . . 0.0 108.806 179.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.542 ' HB2' HG12 ' A' ' 93' ' ' VAL . 41.4 p90 -145.84 155.32 42.82 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.041 -1.037 . . . . 0.0 110.207 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.415 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 36.7 t -67.69 107.2 2.47 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.587 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -49.48 -52.42 49.99 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.395 -0.816 . . . . 0.0 109.975 -179.674 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.749 ' O ' ' CD2' ' A' ' 87' ' ' HIS . 34.6 Cg_endo -76.25 31.67 0.4 Allowed 'Trans proline' 0 C--N 1.311 -1.413 0 C-N-CA 122.298 1.999 . . . . 0.0 110.761 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.749 ' CD2' ' O ' ' A' ' 86' ' ' PRO . 8.9 m170 175.77 49.79 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.433 -0.792 . . . . 0.0 109.316 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.543 ' OE1' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -81.35 -41.53 21.87 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.019 -1.05 . . . . 0.0 109.281 179.967 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.432 ' O ' ' OD1' ' B' ' 162' ' ' ASP . . . -81.88 -10.53 83.95 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -66.24 -64.13 0.92 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.277 -1.131 . . . . 0.0 109.425 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 149.53 -1.0 0.49 Allowed Glycine 0 N--CA 1.493 2.5 0 C-N-CA 119.915 -1.136 . . . . 0.0 110.337 179.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.878 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.4 ptm -94.42 103.79 15.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.087 -1.243 . . . . 0.0 109.481 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.542 HG12 ' HB2' ' A' ' 83' ' ' TYR . 28.9 m -146.72 150.08 15.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.268 -0.895 . . . . 0.0 109.471 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.443 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -131.0 178.17 17.93 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.7 ptmt -149.03 138.93 22.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.35 -1.088 . . . . 0.0 109.696 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 33.0 t -93.98 110.12 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.751 0 O-C-N 121.343 -0.848 . . . . 0.0 109.533 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.18 67.53 3.59 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.303 -0.873 . . . . 0.0 109.297 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 4.0 p -79.46 140.0 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.4 -0.812 . . . . 0.0 109.55 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.549 179.994 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.434 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . 0.403 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.587 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.409 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 89' ' ' GLY . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.493 ' HD3' ' HG2' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.2 p . . . . . 0 N--CA 1.502 2.162 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.85 106.64 4.87 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.269 -0.895 . . . . 0.0 109.446 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.565 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.9 t -102.33 126.35 56.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.357 -0.839 . . . . 0.0 109.414 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 17.8 mt -114.0 106.29 14.24 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.382 -0.823 . . . . 0.0 109.419 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.829 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -66.65 136.85 56.18 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.39 -0.819 . . . . 0.0 109.419 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.484 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 81.2 135.44 1.75 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.88 -119.42 0.26 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.536 -1.425 . . . . 0.0 109.536 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.88 -0.69 9.03 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -134.82 -41.11 0.76 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.364 -1.08 . . . . 0.0 109.549 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.925 ' O ' ' NE2' ' B' ' 7' ' ' GLN . . . 169.57 42.93 0.03 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.484 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.2 t -94.6 93.47 7.6 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.274 -1.133 . . . . 0.0 109.324 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -73.75 92.26 1.99 Allowed 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.286 -0.884 . . . . 0.0 109.491 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.844 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.43 141.96 3.77 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.334 -0.854 . . . . 0.0 109.6 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.565 ' HD2' HG11 ' A' ' 3' ' ' VAL . 43.0 m-85 -68.12 127.87 34.46 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.378 -0.826 . . . . 0.0 109.197 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.431 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.4 mp -129.35 104.18 17.9 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 109.591 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.431 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.55 170.43 67.65 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.389 -1.505 . . . . 0.0 110.66 -0.272 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.42 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -104.65 10.47 49.34 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 47.7 t0 -165.05 111.65 0.97 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.316 -1.108 . . . . 0.0 109.131 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.6 p90 -132.29 169.38 16.55 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.388 -0.82 . . . . 0.0 109.59 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 57.8 m -121.07 130.16 53.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.344 -0.848 . . . . 0.0 109.423 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.6 m -132.92 -171.58 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.369 -0.832 . . . . 0.0 109.487 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.99 178.52 7.06 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.277 -0.889 . . . . 0.0 109.446 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.4 t -71.9 109.94 6.08 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.296 -0.878 . . . . 0.0 109.326 179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.54 -17.29 5.85 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -82.04 173.4 12.22 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.39 -1.065 . . . . 0.0 109.453 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 -129.73 134.67 47.76 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.284 -0.885 . . . . 0.0 109.675 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.546 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.46 149.39 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.407 -0.808 . . . . 0.0 109.046 179.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.0 t -133.25 145.6 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.179 -0.951 . . . . 0.0 109.992 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.635 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.0 m-85 -132.89 77.89 1.76 Allowed 'General case' 0 N--CA 1.493 1.724 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 28.4 mttt -79.38 124.66 28.64 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.191 -0.943 . . . . 0.0 109.771 -179.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.429 ' HA ' ' HB2' ' A' ' 5' ' ' LEU . 24.0 p-10 -96.75 120.82 37.79 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.319 -0.863 . . . . 0.0 109.451 179.69 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -93.99 -65.56 0.98 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.336 -0.852 . . . . 0.0 109.677 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.14 150.46 52.14 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.351 -0.843 . . . . 0.0 109.643 -179.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 17.08 37.78 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.512 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 5.1 p90 -63.27 162.93 20.74 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.334 -1.098 . . . . 0.0 109.601 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.59 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.2 Cg_endo -79.11 150.9 86.53 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.442 -1.483 . . . . 0.0 110.848 0.123 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.829 ' HB3' HD22 ' A' ' 5' ' ' LEU . 37.0 m-70 -124.04 42.39 3.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.39 -0.819 . . . . 0.0 109.41 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.502 ' OD1' ' HD3' ' A' ' 86' ' ' PRO . 8.8 p-10 -66.24 126.4 28.58 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.168 -0.958 . . . . 0.0 109.333 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.5 m -96.53 150.57 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.283 -0.886 . . . . 0.0 109.75 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.484 HG12 ' H ' ' A' ' 57' ' ' MET . 10.2 m -138.99 121.51 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.438 -0.789 . . . . 0.0 109.302 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -71.07 127.8 33.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.24 -0.913 . . . . 0.0 109.41 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.26 163.98 18.32 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.238 -0.914 . . . . 0.0 109.624 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.503 ' HA ' HD12 ' A' ' 46' ' ' ILE . 1.3 tp10 -101.49 25.58 8.23 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.408 -0.807 . . . . 0.0 109.527 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.46 -18.69 14.02 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.19 -0.944 . . . . 0.0 109.565 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -130.13 59.64 1.63 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.183 -0.948 . . . . 0.0 109.708 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.679 HG23 ' HD2' ' A' ' 47' ' ' PRO . 76.9 mt -119.82 140.3 29.4 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.267 -0.896 . . . . 0.0 109.089 179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.679 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.2 Cg_endo -76.05 -62.01 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.324 0 C-N-CA 122.697 2.265 . . . . 0.0 110.968 -179.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.469 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.4 t -88.92 -172.91 3.88 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.185 -0.947 . . . . 0.0 109.581 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.477 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.81 -112.29 0.14 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.477 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.8 154.95 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 121.495 -1.003 . . . . 0.0 109.792 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -95.35 168.05 10.96 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.28 -0.888 . . . . 0.0 109.661 -179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -85.03 -20.94 29.69 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.35 -0.844 . . . . 0.0 109.669 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -69.76 -12.34 61.56 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.213 -0.93 . . . . 0.0 109.982 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -88.88 -27.49 20.98 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.211 -0.931 . . . . 0.0 109.829 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 7.7 pt -117.96 12.21 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.195 -0.94 . . . . 0.0 110.078 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 74.7 m -117.08 175.31 5.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.159 -0.963 . . . . 0.0 109.45 179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.484 ' H ' HG12 ' A' ' 40' ' ' VAL . 31.5 mtp -99.78 164.64 11.95 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.368 -0.833 . . . . 0.0 109.522 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -99.7 -170.83 1.95 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.324 -0.86 . . . . 0.0 109.745 -179.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.525 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.6 OUTLIER -87.71 -25.97 23.19 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.374 -0.828 . . . . 0.0 109.794 -179.84 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.449 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 1.5 mp0 -82.38 -32.08 29.39 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.23 -0.919 . . . . 0.0 109.525 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -95.0 89.56 5.63 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.277 -0.889 . . . . 0.0 109.217 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.441 HD12 ' O ' ' A' ' 59' ' ' GLU . 0.1 OUTLIER -115.91 144.74 43.64 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.352 -0.843 . . . . 0.0 109.622 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.669 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 3.0 mp -86.94 79.44 8.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.415 -0.803 . . . . 0.0 109.155 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.456 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.4 t30 -100.26 -4.64 28.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.304 -0.872 . . . . 0.0 110.01 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.412 ' HA ' ' HD3' ' A' ' 66' ' ' PRO . . . -103.46 143.55 26.86 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.177 -0.952 . . . . 0.0 109.692 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 65' ' ' ALA . 35.3 Cg_endo -77.21 79.94 3.02 Favored 'Trans proline' 0 C--N 1.311 -1.424 0 C-N-CA 122.711 2.274 . . . . 0.0 110.242 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.2 -25.41 0.26 Allowed Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.669 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.51 149.46 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.371 -1.076 . . . . 0.0 109.403 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 29.6 p -135.91 145.68 46.54 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -0.89 . . . . 0.0 109.925 -179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 33.5 t80 -108.53 108.55 19.5 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.415 -0.803 . . . . 0.0 109.022 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -99.76 134.22 42.97 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.338 -0.851 . . . . 0.0 109.723 -179.627 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -122.93 113.92 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.38 -0.825 . . . . 0.0 109.319 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.5 m -84.63 102.31 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.253 -0.904 . . . . 0.0 109.291 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.64 142.17 31.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.281 -0.887 . . . . 0.0 109.493 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.1 p -123.92 -25.66 4.2 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.356 -0.84 . . . . 0.0 109.718 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -69.0 151.66 46.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.293 -0.879 . . . . 0.0 109.708 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.6 mttt -98.68 120.84 39.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.398 -0.814 . . . . 0.0 109.563 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.406 ' H ' HG13 ' A' ' 98' ' ' VAL . . . 168.42 -171.82 42.75 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.4 m -113.56 114.14 26.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.274 -1.133 . . . . 0.0 109.493 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 52.6 m-85 -93.17 179.02 5.55 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.366 -0.834 . . . . 0.0 109.095 179.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.78 101.46 3.06 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.141 -0.974 . . . . 0.0 109.8 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -102.91 163.28 12.3 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.647 ' HB2' HG12 ' A' ' 93' ' ' VAL . 43.7 p90 -155.17 154.32 32.1 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.078 -1.014 . . . . 0.0 110.158 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 35.2 t -66.43 110.08 2.98 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.618 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.74 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER -52.47 -55.52 31.33 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.451 -0.78 . . . . 0.0 110.247 -179.369 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.639 ' O ' ' CG ' ' A' ' 87' ' ' HIS . 35.0 Cg_endo -76.38 41.42 0.87 Allowed 'Trans proline' 0 C--N 1.314 -1.268 0 C-N-CA 122.393 2.062 . . . . 0.0 110.947 -179.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.639 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 3.7 m170 174.67 32.45 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.453 -0.779 . . . . 0.0 109.351 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.481 ' H ' ' HG3' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -71.27 -25.72 62.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.312 -0.867 . . . . 0.0 109.24 179.748 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.88 -11.54 57.66 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -71.91 -75.51 0.13 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.358 -1.084 . . . . 0.0 109.319 179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 154.51 41.0 0.02 OUTLIER Glycine 0 N--CA 1.493 2.495 0 C-N-CA 119.7 -1.238 . . . . 0.0 110.452 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.844 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm -132.45 102.38 5.71 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.198 -1.177 . . . . 0.0 108.956 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.647 HG12 ' HB2' ' A' ' 83' ' ' TYR . 32.8 m -142.74 167.6 14.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.312 -0.867 . . . . 0.0 109.629 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -147.8 -177.95 22.62 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 13.1 ptmt -152.36 142.02 21.85 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.122 . . . . 0.0 109.848 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 27.1 t -97.5 112.02 28.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.36 -0.838 . . . . 0.0 109.371 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.5 m -95.95 68.89 2.79 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.203 -0.936 . . . . 0.0 109.175 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.406 HG13 ' H ' ' A' ' 78' ' ' GLY . 4.4 p -81.01 139.52 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.33 -0.856 . . . . 0.0 109.591 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.604 -179.974 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.925 ' NE2' ' O ' ' A' ' 10' ' ' GLY . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.74 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.447 ' HB3' ' OG ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.525 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.171 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.6 108.97 4.61 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.236 -0.915 . . . . 0.0 109.428 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.621 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.0 t -104.08 120.37 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.315 -0.866 . . . . 0.0 109.474 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.426 HD23 ' HB2' ' A' ' 30' ' ' LYS . 21.2 mt -107.58 101.68 10.99 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.338 -0.851 . . . . 0.0 109.321 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.881 HD22 ' HB3' ' A' ' 37' ' ' HIS . 1.1 mp -64.44 141.93 58.6 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.381 -0.824 . . . . 0.0 109.512 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.17 135.16 1.09 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -78.01 -116.79 0.19 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -130.45 7.64 5.93 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -145.61 -41.02 0.22 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.334 -1.097 . . . . 0.0 109.586 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 170.46 48.19 0.04 OUTLIER Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.46 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.8 t -105.67 99.33 8.93 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.339 -1.095 . . . . 0.0 109.322 179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.664 HD11 HG21 ' B' ' 3' ' ' ILE . 11.1 mt -78.32 96.07 5.2 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.37 -0.831 . . . . 0.0 109.404 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.87 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -167.23 138.1 3.07 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.342 -0.849 . . . . 0.0 109.728 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.621 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.8 m-85 -66.68 127.71 33.47 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.357 -0.839 . . . . 0.0 109.031 179.635 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -128.12 103.12 20.94 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.293 -0.879 . . . . 0.0 109.573 -179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.61 170.43 67.46 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.394 -1.503 . . . . 0.0 110.666 -0.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.448 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.22 12.7 48.43 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -167.03 108.6 0.66 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.331 -1.1 . . . . 0.0 109.076 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -130.02 169.49 15.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.393 -0.817 . . . . 0.0 109.666 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.8 m -121.97 129.65 52.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.332 -0.855 . . . . 0.0 109.438 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.77 -170.17 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.38 -0.825 . . . . 0.0 109.482 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.55 179.11 6.75 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.305 -0.872 . . . . 0.0 109.473 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -72.09 108.83 5.5 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.343 -0.848 . . . . 0.0 109.405 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.27 -17.38 5.62 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -81.8 171.61 14.32 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.345 -1.091 . . . . 0.0 109.468 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -127.97 134.25 49.26 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.285 -0.884 . . . . 0.0 109.665 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.0 149.04 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.437 -0.789 . . . . 0.0 109.042 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 t -132.4 145.71 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.193 -0.942 . . . . 0.0 109.896 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.625 ' HB3' HD11 ' A' ' 5' ' ' LEU . 49.9 m-85 -133.32 80.38 1.88 Allowed 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.424 -0.797 . . . . 0.0 109.016 179.613 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.426 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.9 mttt -81.55 126.78 32.12 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.223 -0.923 . . . . 0.0 109.729 -179.606 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.496 ' HB3' ' HB2' ' A' ' 37' ' ' HIS . 26.9 p-10 -98.07 126.22 43.41 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.333 -0.855 . . . . 0.0 109.484 179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.99 -65.72 0.97 Allowed 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.856 . . . . 0.0 109.522 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -131.33 146.91 52.49 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.344 -0.848 . . . . 0.0 109.544 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.05 20.95 26.68 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.546 ' HB2' ' HA ' ' A' ' 36' ' ' PRO . 2.7 p90 -64.24 164.8 16.38 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.363 -1.08 . . . . 0.0 109.634 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.621 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.3 Cg_endo -80.03 153.54 85.99 Favored 'Cis proline' 0 C--N 1.313 -1.338 0 C-N-CA 123.378 -1.509 . . . . 0.0 110.606 -0.246 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.881 ' HB3' HD22 ' A' ' 5' ' ' LEU . 32.2 m-70 -121.1 37.96 4.19 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.293 -0.879 . . . . 0.0 109.217 179.564 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 15.7 p-10 -65.1 121.64 15.19 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.318 -0.864 . . . . 0.0 109.304 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -94.83 148.43 5.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.28 -0.888 . . . . 0.0 109.846 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.413 HG21 ' HB3' ' B' ' 63' ' ' ASN . 5.6 m -134.77 117.49 23.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.482 -0.761 . . . . 0.0 109.01 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -66.38 133.25 50.09 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.322 -0.861 . . . . 0.0 109.82 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -94.96 159.15 15.16 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.389 -0.819 . . . . 0.0 109.361 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.612 ' HA ' HD12 ' A' ' 46' ' ' ILE . 3.9 tp10 -100.55 24.71 8.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.28 -0.887 . . . . 0.0 109.591 179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.97 -16.69 17.08 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.222 -0.924 . . . . 0.0 109.417 179.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.3 mt-10 -131.42 27.21 4.76 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.285 -0.884 . . . . 0.0 109.539 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.735 HG23 ' HD2' ' A' ' 47' ' ' PRO . 28.2 mt -92.15 142.18 25.96 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.301 -0.874 . . . . 0.0 109.055 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.735 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.67 -63.9 0.03 OUTLIER 'Trans proline' 0 C--N 1.313 -1.333 0 C-N-CA 122.713 2.276 . . . . 0.0 111.101 -179.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.545 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -84.15 -176.85 6.45 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.162 -0.961 . . . . 0.0 109.563 -179.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.502 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.66 -107.59 0.14 Allowed Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.502 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.41 155.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.494 -1.004 . . . . 0.0 109.841 179.886 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.2 161.55 15.02 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.251 -0.906 . . . . 0.0 109.636 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.12 -22.16 36.34 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.337 -0.852 . . . . 0.0 109.644 179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.78 -13.83 62.2 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.295 -0.878 . . . . 0.0 109.846 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -85.15 -29.86 24.44 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.247 -0.908 . . . . 0.0 109.679 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.4 pt -114.54 8.2 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.17 -0.956 . . . . 0.0 110.021 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.8 m -113.47 172.93 6.67 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.168 -0.957 . . . . 0.0 109.408 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 19.8 mtp -92.52 160.91 14.83 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.317 -0.864 . . . . 0.0 109.56 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -95.14 -167.36 1.61 Allowed 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.42 -0.8 . . . . 0.0 109.545 -179.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.429 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.7 OUTLIER -90.94 -25.67 19.66 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.288 -0.883 . . . . 0.0 109.785 -179.83 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.429 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.7 OUTLIER -82.07 -30.41 31.33 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.268 -0.895 . . . . 0.0 109.739 -179.81 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -95.99 93.64 7.12 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.197 -0.94 . . . . 0.0 109.605 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -116.95 143.1 46.1 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.401 -0.812 . . . . 0.0 109.332 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.711 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.9 mp -89.28 80.52 6.84 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.346 -0.846 . . . . 0.0 109.18 179.782 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.483 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 1.8 t30 -100.09 -21.17 15.68 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 109.891 -179.647 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -88.53 144.82 34.21 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.175 -0.953 . . . . 0.0 109.864 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.45 81.62 2.6 Favored 'Trans proline' 0 C--N 1.312 -1.361 0 C-N-CA 122.754 2.303 . . . . 0.0 110.276 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 161.53 -25.6 0.25 Allowed Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.711 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -67.58 149.43 50.12 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.419 -1.048 . . . . 0.0 109.408 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.9 p -135.81 145.39 46.44 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.251 -0.906 . . . . 0.0 109.864 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -108.84 109.22 20.28 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.453 -0.779 . . . . 0.0 109.008 179.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.537 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.29 134.3 43.43 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.343 -0.848 . . . . 0.0 109.726 -179.695 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.94 115.44 45.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.407 -0.808 . . . . 0.0 109.243 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -86.3 102.21 13.78 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.252 -0.905 . . . . 0.0 109.31 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.9 mp -99.3 143.0 30.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.331 -0.855 . . . . 0.0 109.606 -179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.3 p -124.63 -26.61 3.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.39 47.24 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.264 -0.898 . . . . 0.0 109.682 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -98.41 122.43 41.58 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.427 -0.795 . . . . 0.0 109.529 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.48 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.9 -170.92 41.58 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.7 m -113.68 114.1 25.93 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -1.157 . . . . 0.0 109.513 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -92.31 177.87 6.01 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.419 -0.801 . . . . 0.0 109.118 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.21 93.65 2.12 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.213 -0.93 . . . . 0.0 109.85 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.7 p90 -96.99 154.5 17.26 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.382 -0.824 . . . . 0.0 108.791 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.525 ' HB2' HG12 ' A' ' 93' ' ' VAL . 42.1 p90 -144.49 157.05 44.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.134 -0.979 . . . . 0.0 110.174 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 10.1 t -67.83 114.77 6.68 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.644 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER -54.87 -50.21 87.41 Favored Pre-proline 0 N--CA 1.494 1.767 0 O-C-N 121.348 -0.845 . . . . 0.0 110.036 -179.562 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.629 ' HD2' ' N ' ' A' ' 85' ' ' SER . 32.9 Cg_endo -74.13 -8.28 20.82 Favored 'Trans proline' 0 C--N 1.311 -1.41 0 C-N-CA 122.187 1.925 . . . . 0.0 111.004 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.595 ' NE2' ' CD2' ' B' ' 1' ' ' TYR . 29.4 m170 -146.69 67.62 1.17 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.095 -1.003 . . . . 0.0 109.701 179.568 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.655 ' OE1' ' OH ' ' B' ' 160' ' ' TYR . 0.0 OUTLIER -98.62 -37.0 9.7 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.064 -1.023 . . . . 0.0 109.009 179.581 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -84.57 -9.88 80.58 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . 0.479 ' HB2' ' HZ ' ' B' ' 4' ' ' PHE . . . -71.54 -63.4 1.13 Allowed 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.285 -1.126 . . . . 0.0 109.441 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 153.01 2.47 0.17 Allowed Glycine 0 N--CA 1.492 2.419 0 C-N-CA 119.86 -1.162 . . . . 0.0 110.45 179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.87 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 1.3 ptm -96.35 100.87 12.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.13 -1.218 . . . . 0.0 109.325 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.525 HG12 ' HB2' ' A' ' 83' ' ' TYR . 28.0 m -146.8 148.41 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.351 -0.843 . . . . 0.0 109.405 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -129.45 178.69 17.23 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.6 ptmt -148.86 138.51 21.93 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.292 -1.123 . . . . 0.0 109.636 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.8 t -93.21 110.07 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 121.295 -0.878 . . . . 0.0 109.525 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.08 67.22 3.62 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.274 -0.891 . . . . 0.0 109.248 179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.6 p -79.25 139.59 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.333 -0.854 . . . . 0.0 109.6 -179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.767 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.577 179.936 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.664 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.644 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.413 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 0.525 ' HE2' ' OE1' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 N--CA 1.503 2.188 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.82 107.97 4.88 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.307 -0.871 . . . . 0.0 109.408 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.63 HG11 ' HD2' ' A' ' 14' ' ' PHE . 14.9 t -102.98 124.01 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.363 -0.835 . . . . 0.0 109.451 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.491 HD23 ' HB2' ' A' ' 30' ' ' LYS . 21.8 mt -110.26 101.88 10.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.361 -0.837 . . . . 0.0 109.383 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.822 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.24 133.08 50.7 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.335 -0.853 . . . . 0.0 109.388 -179.99 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.504 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 84.69 133.01 2.59 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.72 -118.15 0.15 Allowed Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.62 -1.89 6.95 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -132.93 -40.34 0.94 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.129 . . . . 0.0 109.592 -179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.583 ' HA3' HD11 ' B' ' 3' ' ' ILE . . . 168.31 46.61 0.03 OUTLIER Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.504 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.7 t -99.19 94.56 6.56 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.356 -1.085 . . . . 0.0 109.338 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.559 HD13 ' CE1' ' A' ' 87' ' ' HIS . 7.5 mt -75.18 89.7 2.53 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.343 -0.848 . . . . 0.0 109.471 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.87 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -163.51 142.03 7.93 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.295 -0.878 . . . . 0.0 109.674 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.63 ' HD2' HG11 ' A' ' 3' ' ' VAL . 38.1 m-85 -68.15 128.26 35.91 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.342 -0.849 . . . . 0.0 109.159 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.54 102.31 18.33 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.288 -0.883 . . . . 0.0 109.604 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.74 171.6 62.44 Favored 'Cis proline' 0 C--N 1.312 -1.351 0 C-N-CA 123.428 -1.488 . . . . 0.0 110.714 -0.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.419 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.42 10.77 46.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -165.15 110.46 0.91 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.328 -1.101 . . . . 0.0 109.078 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -131.2 167.75 18.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.639 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.9 m -120.43 129.84 54.07 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.327 -0.858 . . . . 0.0 109.471 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 98' ' ' VAL . 3.0 m -131.94 -172.85 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.369 -0.832 . . . . 0.0 109.545 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -135.68 178.55 6.95 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.336 -0.852 . . . . 0.0 109.482 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 10.7 t -72.17 111.47 7.42 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.333 -0.854 . . . . 0.0 109.428 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 125.77 -16.38 6.94 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -82.57 167.11 18.64 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.395 -1.062 . . . . 0.0 109.488 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -123.92 133.14 53.79 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.64 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.506 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.3 mp -97.36 151.03 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.438 -0.789 . . . . 0.0 109.042 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 10.4 t -133.7 145.22 33.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 109.967 -179.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.674 ' HB3' HD11 ' A' ' 5' ' ' LEU . 54.6 m-85 -130.92 77.43 1.78 Allowed 'General case' 0 N--CA 1.493 1.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.491 ' HB2' HD23 ' A' ' 4' ' ' LEU . 27.3 mttt -77.07 132.61 39.0 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.272 -0.892 . . . . 0.0 109.842 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 20.6 p-10 -105.72 122.22 45.62 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.307 -0.871 . . . . 0.0 109.397 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -101.52 -67.18 0.87 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.281 -0.887 . . . . 0.0 109.588 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -125.44 149.99 47.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.326 -0.858 . . . . 0.0 109.525 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.33 11.02 61.55 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.652 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 3.0 p90 -61.76 165.99 6.75 Favored Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 121.399 -1.059 . . . . 0.0 109.543 -179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.57 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 36.2 Cg_endo -78.84 151.64 88.39 Favored 'Cis proline' 0 C--N 1.313 -1.292 0 C-N-CA 123.329 -1.53 . . . . 0.0 110.506 -0.016 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.822 ' HB3' HD22 ' A' ' 5' ' ' LEU . 50.6 m-70 -122.78 44.78 2.55 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.384 -0.823 . . . . 0.0 109.365 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.498 ' OD1' ' HG3' ' A' ' 86' ' ' PRO . 9.7 p-10 -68.57 123.15 20.05 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.196 -0.94 . . . . 0.0 109.199 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 m -94.07 155.7 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.245 -0.909 . . . . 0.0 109.992 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.478 HG21 ' HB3' ' B' ' 63' ' ' ASN . 3.6 m -141.33 118.8 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.418 -0.801 . . . . 0.0 109.201 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 30.4 m-85 -69.31 130.57 42.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.319 -0.863 . . . . 0.0 109.663 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -95.11 159.39 15.04 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.355 -0.841 . . . . 0.0 109.453 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.603 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.5 tp10 -99.02 34.46 2.11 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.313 -0.867 . . . . 0.0 109.491 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -108.38 -22.09 12.47 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.262 -0.899 . . . . 0.0 109.448 179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -128.5 32.78 4.78 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.356 -0.84 . . . . 0.0 109.738 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.717 HG23 ' HD2' ' A' ' 47' ' ' PRO . 49.0 mt -95.35 141.44 23.22 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.24 -0.913 . . . . 0.0 109.188 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.717 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.4 Cg_endo -76.46 -59.6 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.317 0 C-N-CA 122.723 2.282 . . . . 0.0 111.038 -179.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.527 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.5 t -87.65 -176.26 5.49 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.21 -0.932 . . . . 0.0 109.683 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.523 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -78.26 -107.01 0.19 Allowed Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.45 156.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.513 -0.992 . . . . 0.0 109.773 179.896 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.89 160.75 16.29 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.241 -0.912 . . . . 0.0 109.637 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -83.26 -18.18 40.02 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.872 . . . . 0.0 109.729 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -77.15 -9.42 58.74 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.222 -0.924 . . . . 0.0 109.851 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.0 tptp -87.75 -27.18 22.51 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.279 -0.888 . . . . 0.0 109.715 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.6 pt -113.68 -5.1 11.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.212 -0.93 . . . . 0.0 109.976 -179.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.2 m -98.99 175.29 5.97 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.168 -0.957 . . . . 0.0 109.473 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 16.5 mtp -93.24 157.26 16.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.389 -0.819 . . . . 0.0 109.563 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -88.35 -160.13 0.61 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.362 -0.836 . . . . 0.0 109.467 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.836 ' OE1' ' HE2' ' B' ' 65' ' ' LYS . 8.8 pm0 -98.24 -29.21 13.32 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.296 -0.877 . . . . 0.0 109.893 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.507 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.7 -30.33 36.38 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.302 -0.874 . . . . 0.0 109.737 -179.873 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -92.16 95.42 9.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.335 -0.853 . . . . 0.0 109.48 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.831 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -116.7 141.61 47.98 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.424 -0.797 . . . . 0.0 109.34 -179.986 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.657 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.0 OUTLIER -90.52 80.14 6.08 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.338 -0.851 . . . . 0.0 109.14 179.819 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -102.7 -41.05 6.35 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.324 -0.86 . . . . 0.0 109.8 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -67.49 145.63 98.4 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.326 -0.859 . . . . 0.0 109.979 -179.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.75 78.09 3.67 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 C-N-CA 122.771 2.314 . . . . 0.0 110.219 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 165.38 -24.79 0.16 Allowed Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.657 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.2 tp10 -67.84 148.11 51.62 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.365 -1.08 . . . . 0.0 109.339 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.41 ' HA ' HD21 ' A' ' 63' ' ' LEU . 41.1 p -136.74 143.27 43.2 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.21 -0.931 . . . . 0.0 109.899 -179.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.7 t80 -105.28 107.15 17.99 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.348 -0.845 . . . . 0.0 109.094 179.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.506 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -98.47 131.07 45.02 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 109.62 -179.744 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -121.08 112.44 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.424 -0.798 . . . . 0.0 109.206 179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.8 m -83.66 104.04 13.45 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.278 -0.889 . . . . 0.0 109.297 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 5.0 mp -100.92 141.26 34.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.362 -0.836 . . . . 0.0 109.557 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.9 p -123.14 -24.73 4.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.346 -0.846 . . . . 0.0 109.703 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -69.19 153.42 43.72 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.274 -0.891 . . . . 0.0 109.642 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 71.8 mttt -100.67 124.07 45.75 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.309 -0.869 . . . . 0.0 109.548 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.427 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 165.71 -168.53 39.64 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.8 m -116.86 110.82 18.84 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.332 -1.099 . . . . 0.0 109.455 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 45.4 m-85 -89.35 176.09 7.07 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.8 92.51 2.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.169 -0.957 . . . . 0.0 109.918 -179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.423 ' CE2' HG23 ' A' ' 96' ' ' VAL . 47.9 p90 -97.54 154.6 17.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.337 -0.852 . . . . 0.0 108.738 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.675 ' HB2' HG12 ' A' ' 93' ' ' VAL . 41.6 p90 -143.79 154.61 43.6 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.105 -0.997 . . . . 0.0 109.987 -179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.407 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 49.6 t -65.9 106.91 1.68 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.502 -0.749 . . . . 0.0 109.024 179.567 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.866 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.3 OUTLIER -49.33 -55.36 22.24 Favored Pre-proline 0 N--CA 1.494 1.725 0 O-C-N 121.49 -0.756 . . . . 0.0 110.089 -179.553 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.696 ' O ' ' CG ' ' A' ' 87' ' ' HIS . 33.4 Cg_endo -74.08 41.66 0.68 Allowed 'Trans proline' 0 C--N 1.312 -1.346 0 C-N-CA 122.142 1.895 . . . . 0.0 110.783 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.696 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 4.3 m170 170.91 33.91 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.61 -0.681 . . . . 0.0 109.197 179.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.48 -31.24 70.37 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.269 -0.894 . . . . 0.0 109.391 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -95.72 -4.03 60.66 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.8 -74.42 0.18 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.325 -1.103 . . . . 0.0 109.375 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.2 38.32 0.02 OUTLIER Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.896 -1.145 . . . . 0.0 110.345 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.87 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.0 ptm -135.47 105.75 6.36 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.224 -1.162 . . . . 0.0 109.009 179.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.675 HG12 ' HB2' ' A' ' 83' ' ' TYR . 35.0 m -144.97 146.79 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.362 -0.836 . . . . 0.0 109.607 -179.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.419 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -124.7 176.32 17.04 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.81 136.2 20.29 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.263 -1.139 . . . . 0.0 109.816 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.423 HG23 ' CE2' ' A' ' 82' ' ' PHE . 31.5 t -91.49 109.96 21.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.344 -0.847 . . . . 0.0 109.476 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -94.79 66.75 3.16 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.204 -0.935 . . . . 0.0 109.104 179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 7.0 p -79.21 141.24 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.307 -0.87 . . . . 0.0 109.62 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.2 p30 . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.566 179.946 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.583 HD11 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . 0.831 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.866 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.478 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.836 ' HE2' ' OE1' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 11.4 p . . . . . 0 N--CA 1.502 2.173 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -70.38 107.99 4.04 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 109.44 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.653 HG11 ' HD2' ' A' ' 14' ' ' PHE . 11.8 t -102.9 125.46 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.364 -0.835 . . . . 0.0 109.504 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.486 HD23 ' HB2' ' A' ' 30' ' ' LYS . 25.0 mt -111.13 100.52 9.17 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.387 -0.82 . . . . 0.0 109.299 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.836 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.01 128.57 36.4 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.373 -0.83 . . . . 0.0 109.388 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.492 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 88.71 134.0 4.79 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 -179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -77.58 -124.62 0.28 Allowed Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -116.26 -13.52 8.25 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -118.74 -37.39 3.27 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.322 -1.104 . . . . 0.0 109.615 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.605 ' HA3' HD11 ' B' ' 3' ' ' ILE . . . 160.61 45.9 0.02 OUTLIER Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.492 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 3.8 t -94.64 98.47 10.83 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.288 -1.125 . . . . 0.0 109.301 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.616 HD13 ' CE1' ' A' ' 87' ' ' HIS . 7.6 mt -73.83 91.92 2.0 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.298 -0.876 . . . . 0.0 109.485 -179.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.915 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.2 137.53 5.21 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.358 -0.839 . . . . 0.0 109.617 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.653 ' HD2' HG11 ' A' ' 3' ' ' VAL . 35.4 m-85 -65.71 126.58 28.88 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.383 -0.823 . . . . 0.0 109.054 179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -127.9 102.28 22.29 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.248 -0.907 . . . . 0.0 109.607 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.78 170.47 66.89 Favored 'Cis proline' 0 C--N 1.313 -1.317 0 C-N-CA 123.45 -1.479 . . . . 0.0 110.679 -0.271 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.443 ' HA2' ' HB3' ' A' ' 14' ' ' PHE . . . -105.41 12.45 47.57 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.716 -1.354 . . . . 0.0 109.716 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 46.8 t0 -166.49 105.92 0.64 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.406 -1.055 . . . . 0.0 109.043 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -127.45 167.25 16.51 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.307 -0.87 . . . . 0.0 109.695 -179.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 58.1 m -120.64 128.55 53.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 109.404 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 98' ' ' VAL . 3.0 m -130.44 -171.52 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.388 -0.82 . . . . 0.0 109.532 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -137.31 179.01 6.65 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.329 -0.857 . . . . 0.0 109.442 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.2 t -72.3 110.52 6.78 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.238 -0.914 . . . . 0.0 109.417 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.62 -16.91 6.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -82.1 165.71 20.35 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.34 -1.094 . . . . 0.0 109.472 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -122.61 132.11 54.13 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.337 -0.852 . . . . 0.0 109.636 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.452 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.2 mp -96.31 151.26 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.354 -0.841 . . . . 0.0 109.045 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.6 t -133.5 146.28 32.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.217 -0.927 . . . . 0.0 109.934 -179.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.675 ' HB3' HD11 ' A' ' 5' ' ' LEU . 52.1 m-85 -132.5 80.05 1.88 Allowed 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.486 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.3 mttt -80.45 131.79 35.63 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.333 -0.855 . . . . 0.0 109.716 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 21.2 p-10 -105.25 119.57 39.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.282 -0.886 . . . . 0.0 109.493 179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.6 t30 -98.19 -67.83 0.83 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.343 -0.848 . . . . 0.0 109.573 -179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -124.68 149.85 46.75 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.33 -0.856 . . . . 0.0 109.49 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 92.13 12.71 58.51 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.697 -1.361 . . . . 0.0 109.697 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.642 ' O ' ' CG ' ' B' ' 117' ' ' PRO . 4.9 p90 -61.5 163.97 10.35 Favored Pre-proline 0 N--CA 1.494 1.75 0 O-C-N 121.405 -1.056 . . . . 0.0 109.542 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.553 ' HA ' ' O ' ' A' ' 63' ' ' LEU . 36.2 Cg_endo -79.1 157.28 91.4 Favored 'Cis proline' 0 C--N 1.313 -1.322 0 C-N-CA 123.322 -1.532 . . . . 0.0 110.481 -0.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.836 ' HB3' HD22 ' A' ' 5' ' ' LEU . 43.9 m-70 -127.97 39.75 3.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.385 -0.822 . . . . 0.0 109.33 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.9 p-10 -65.19 120.64 13.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.334 -0.854 . . . . 0.0 109.267 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -93.0 151.45 3.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.305 -0.872 . . . . 0.0 109.823 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.536 HG12 ' H ' ' A' ' 57' ' ' MET . 10.2 m -137.99 121.71 21.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.425 -0.797 . . . . 0.0 109.109 179.757 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -70.26 132.11 45.22 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.258 -0.901 . . . . 0.0 109.709 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.45 157.86 15.7 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.294 -0.879 . . . . 0.0 109.53 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.563 ' HA ' HD12 ' A' ' 46' ' ' ILE . 6.0 tp10 -98.02 47.04 1.01 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.294 -0.879 . . . . 0.0 109.45 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -119.56 -26.77 5.67 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.286 -0.884 . . . . 0.0 109.38 179.727 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -124.25 25.25 7.83 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.342 -0.849 . . . . 0.0 109.61 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.73 HG23 ' HD2' ' A' ' 47' ' ' PRO . 58.0 mt -87.87 141.36 31.54 Favored Pre-proline 0 N--CA 1.493 1.68 0 O-C-N 121.254 -0.904 . . . . 0.0 109.155 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.73 ' HD2' HG23 ' A' ' 46' ' ' ILE . 34.0 Cg_endo -76.23 -60.71 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.738 2.292 . . . . 0.0 110.999 -179.595 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.523 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -87.57 -178.3 6.08 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.211 -0.931 . . . . 0.0 109.642 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.536 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.6 -103.39 0.14 Allowed Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.536 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.92 157.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.523 -0.987 . . . . 0.0 109.899 179.895 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.23 156.42 18.77 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.263 -0.898 . . . . 0.0 109.624 -179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.63 -24.41 39.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.321 -0.862 . . . . 0.0 109.677 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -72.82 -15.22 61.63 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.321 -0.862 . . . . 0.0 109.777 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.8 tptt -79.43 -31.62 42.63 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.303 -0.873 . . . . 0.0 109.735 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 5.0 pt -111.07 0.44 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.272 -0.892 . . . . 0.0 109.879 -179.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 62.4 m -104.02 177.93 4.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.245 -0.909 . . . . 0.0 109.429 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.536 ' H ' HG12 ' A' ' 40' ' ' VAL . 22.7 mtp -98.67 159.07 15.21 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.289 -0.882 . . . . 0.0 109.523 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -90.73 -166.43 1.58 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.354 -0.841 . . . . 0.0 109.552 -179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.53 ' OE2' ' HE2' ' B' ' 65' ' ' LYS . 0.3 OUTLIER -91.43 -28.06 17.9 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.354 -0.841 . . . . 0.0 109.92 -179.807 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.444 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.5 OUTLIER -80.93 -31.25 35.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.88 . . . . 0.0 109.775 -179.851 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -91.23 97.37 11.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.337 -0.852 . . . . 0.0 109.483 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.656 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -120.15 145.49 46.89 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.38 -0.825 . . . . 0.0 109.363 -179.966 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.664 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 2.0 mp -93.31 75.31 4.56 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.415 -0.803 . . . . 0.0 109.185 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -96.04 -35.45 11.38 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.292 -0.88 . . . . 0.0 109.749 -179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -73.21 143.84 83.82 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.308 -0.87 . . . . 0.0 109.808 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.56 80.06 3.03 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.777 2.318 . . . . 0.0 110.215 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 163.84 -24.95 0.19 Allowed Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.664 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.3 tp10 -67.55 149.33 50.27 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.387 -1.066 . . . . 0.0 109.387 179.846 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 36.2 p -136.4 144.22 44.4 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.242 -0.911 . . . . 0.0 109.905 -179.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 28.2 t80 -106.73 108.72 20.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.384 -0.823 . . . . 0.0 109.07 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.452 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.06 132.28 45.51 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.322 -0.861 . . . . 0.0 109.685 -179.742 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -122.1 112.85 36.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.418 -0.801 . . . . 0.0 109.263 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.6 m -84.2 102.0 12.29 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.291 -0.88 . . . . 0.0 109.326 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -98.46 142.45 30.06 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.33 -0.856 . . . . 0.0 109.531 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 21.3 p -123.9 -25.92 4.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.351 -0.843 . . . . 0.0 109.714 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -68.46 152.27 45.63 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.255 -0.903 . . . . 0.0 109.669 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 69.7 mttt -99.43 123.1 43.41 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.418 -0.801 . . . . 0.0 109.605 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.492 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 166.68 -171.67 41.65 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 4.0 m -113.3 111.01 21.3 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.298 -1.119 . . . . 0.0 109.401 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -89.57 175.44 7.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.362 -0.837 . . . . 0.0 109.171 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -146.7 88.58 1.77 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.223 -0.923 . . . . 0.0 109.861 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.446 ' HE1' ' CE2' ' A' ' 14' ' ' PHE . 48.3 p90 -93.23 146.5 23.65 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.249 -0.907 . . . . 0.0 108.802 179.29 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.545 ' HB2' HG12 ' A' ' 93' ' ' VAL . 50.1 p90 -133.41 153.03 51.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.188 -0.945 . . . . 0.0 109.863 -179.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.408 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 42.5 t -65.68 109.2 2.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.542 -0.724 . . . . 0.0 109.246 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.823 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.5 OUTLIER -49.49 -54.37 31.31 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.471 -0.768 . . . . 0.0 109.812 -179.8 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.782 ' HA ' ' CGD' ' B' ' 251' ' ' HEC . 32.7 Cg_endo -74.36 33.13 0.35 Allowed 'Trans proline' 0 C--N 1.312 -1.346 0 C-N-CA 122.105 1.87 . . . . 0.0 110.503 179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.74 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 9.9 m170 174.04 49.89 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.875 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 179.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.482 ' HG3' ' H ' ' A' ' 88' ' ' GLN . 0.0 OUTLIER -74.15 -52.55 12.17 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.202 -0.936 . . . . 0.0 109.161 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -83.11 1.1 89.27 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -68.4 -61.98 1.59 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.267 -1.137 . . . . 0.0 109.348 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 151.79 -15.61 0.81 Allowed Glycine 0 N--CA 1.493 2.485 0 C-N-CA 119.839 -1.172 . . . . 0.0 110.241 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.915 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 2.5 ptm -88.08 109.8 20.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.158 -1.201 . . . . 0.0 109.719 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.545 HG12 ' HB2' ' A' ' 83' ' ' TYR . 15.3 m -149.57 134.49 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.299 -0.876 . . . . 0.0 109.31 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -115.17 174.98 15.64 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -147.65 135.3 20.94 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.28 -1.13 . . . . 0.0 109.614 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.428 HG23 ' CE2' ' A' ' 82' ' ' PHE . 34.9 t -89.33 109.87 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.4 m -94.97 65.87 2.97 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 109.174 179.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.408 ' HA ' ' O ' ' A' ' 21' ' ' VAL . 4.7 p -78.32 140.47 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.369 -0.832 . . . . 0.0 109.575 -179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.586 179.982 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.605 HD11 ' HA3' ' A' ' 10' ' ' GLY . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.415 ' NE2' ' O ' ' A' ' 10' ' ' GLY . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . 0.656 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.823 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.412 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.53 ' HE2' ' OE2' ' A' ' 59' ' ' GLU . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.72 ' HG3' ' CE1' ' B' ' 1' ' ' TYR . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 12.9 p . . . . . 0 N--CA 1.503 2.195 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -71.56 108.91 5.18 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.235 -0.915 . . . . 0.0 109.46 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.633 HG11 ' HD2' ' A' ' 14' ' ' PHE . 15.8 t -104.35 120.65 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.34 -0.85 . . . . 0.0 109.446 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.433 HD23 ' HB2' ' A' ' 30' ' ' LYS . 19.0 mt -107.63 102.59 11.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.389 -0.82 . . . . 0.0 109.342 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.792 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -65.09 141.62 58.66 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.326 -0.859 . . . . 0.0 109.415 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.47 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 79.09 136.48 1.23 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.64 -121.35 0.46 Allowed Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -125.48 5.12 8.13 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -144.03 -42.61 0.27 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.315 -1.109 . . . . 0.0 109.601 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.97 42.41 0.05 OUTLIER Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.47 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 1.7 t -97.71 96.91 8.57 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.311 -1.111 . . . . 0.0 109.295 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.639 HD13 ' CE1' ' A' ' 87' ' ' HIS . 6.1 mt -80.03 90.95 5.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.377 -0.827 . . . . 0.0 109.451 -179.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.862 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -164.61 142.58 6.67 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.338 -0.851 . . . . 0.0 109.781 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.633 ' HD2' HG11 ' A' ' 3' ' ' VAL . 33.5 m-85 -67.62 128.06 35.06 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.418 -0.801 . . . . 0.0 109.082 179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.508 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -129.11 102.76 18.71 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.612 -179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.4 Cg_endo -79.75 171.18 64.32 Favored 'Cis proline' 0 C--N 1.312 -1.359 0 C-N-CA 123.43 -1.487 . . . . 0.0 110.648 -0.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.463 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -106.17 14.64 43.96 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -169.1 110.54 0.49 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.393 -1.063 . . . . 0.0 109.051 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -132.22 170.19 15.37 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.34 -0.85 . . . . 0.0 109.67 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 59.3 m -122.69 130.95 53.54 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 109.443 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.9 m -132.96 -169.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.354 -0.841 . . . . 0.0 109.518 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.49 178.93 6.86 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.283 -0.885 . . . . 0.0 109.455 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 9.0 t -71.98 109.42 5.79 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.349 -0.844 . . . . 0.0 109.385 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 128.43 -17.03 5.9 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -81.91 171.4 14.5 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -1.095 . . . . 0.0 109.479 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -127.86 133.93 49.37 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.268 -0.895 . . . . 0.0 109.642 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.54 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.1 mp -95.9 150.72 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.379 -0.825 . . . . 0.0 109.035 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -134.34 146.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.172 -0.955 . . . . 0.0 109.949 -179.561 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.637 ' HB3' HD11 ' A' ' 5' ' ' LEU . 56.8 m-85 -133.72 80.21 1.86 Allowed 'General case' 0 N--CA 1.494 1.753 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 179.559 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.433 ' HB2' HD23 ' A' ' 4' ' ' LEU . 28.6 mttt -81.11 123.86 28.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.229 -0.919 . . . . 0.0 109.825 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -94.46 126.73 39.92 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.334 -0.854 . . . . 0.0 109.388 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -102.93 -63.7 1.14 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.847 . . . . 0.0 109.566 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -134.33 148.04 50.67 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.344 -0.848 . . . . 0.0 109.561 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 95.41 14.96 45.74 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 1.056 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 0.2 OUTLIER -62.86 166.15 8.38 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.44 -1.036 . . . . 0.0 109.542 179.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.694 ' O ' ' HG2' ' A' ' 86' ' ' PRO . 35.6 Cg_endo -78.06 145.32 78.13 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.679 0.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.792 ' HB3' HD22 ' A' ' 5' ' ' LEU . 34.7 m-70 -115.58 32.7 5.91 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -58.23 119.38 6.78 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.269 -0.894 . . . . 0.0 109.361 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -93.32 157.23 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.358 -0.839 . . . . 0.0 110.026 -179.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.5 m -139.79 119.98 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.397 -0.814 . . . . 0.0 109.194 179.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -67.19 116.74 8.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.397 -0.814 . . . . 0.0 109.927 -179.515 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.43 ' O ' HG13 ' A' ' 46' ' ' ILE . 1.3 t70 -81.41 149.62 28.74 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.29 -0.881 . . . . 0.0 109.523 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 1.279 ' CB ' ' HE2' ' B' ' 187' ' ' LYS . 1.0 OUTLIER -96.79 6.44 48.66 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.267 -0.896 . . . . 0.0 109.918 179.909 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.43 -19.7 57.82 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.183 -0.948 . . . . 0.0 109.374 179.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -131.49 38.44 3.6 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.384 -0.823 . . . . 0.0 109.515 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.786 HG23 ' HD2' ' A' ' 47' ' ' PRO . 8.1 mt -98.96 143.97 27.35 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.254 -0.904 . . . . 0.0 109.25 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.786 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.9 Cg_endo -76.02 -63.99 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.375 0 C-N-CA 122.786 2.324 . . . . 0.0 111.068 -179.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.55 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.8 t -83.4 -176.45 6.32 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.177 -0.952 . . . . 0.0 109.686 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.564 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -78.37 -105.63 0.2 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.564 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 61.65 160.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.56 -0.964 . . . . 0.0 109.861 179.811 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -99.45 162.61 12.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.256 -0.903 . . . . 0.0 109.547 179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.415 ' O ' ' HB2' ' A' ' 56' ' ' SER . . . -81.78 -17.23 48.35 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.33 -0.856 . . . . 0.0 109.73 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.62 -2.3 28.64 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.217 -0.927 . . . . 0.0 109.898 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 9.9 tptt -101.5 -25.57 13.87 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.235 -0.915 . . . . 0.0 109.649 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.3 pt -119.0 6.67 6.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.198 -0.939 . . . . 0.0 110.114 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 52' ' ' ALA . 69.0 m -113.05 171.18 7.7 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.108 -0.995 . . . . 0.0 109.366 179.746 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . . . . . . . . . 14.6 mtp -88.79 152.12 21.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.323 -0.86 . . . . 0.0 109.571 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.2 t -89.82 -154.67 0.33 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.43 -0.794 . . . . 0.0 109.498 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.513 ' CB ' ' O ' ' B' ' 66' ' ' LYS . 3.2 pt-20 -101.83 -33.55 9.76 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.259 -0.9 . . . . 0.0 109.888 -179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -72.86 -29.69 63.4 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.301 -0.874 . . . . 0.0 109.829 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -96.88 87.26 4.23 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.262 -0.899 . . . . 0.0 109.672 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.05 139.75 43.52 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.386 -0.821 . . . . 0.0 109.374 179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.7 mp -89.75 84.52 6.29 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.587 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.4 OUTLIER -111.44 -4.47 14.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.272 -0.892 . . . . 0.0 109.824 -179.763 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -101.38 146.71 32.67 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.195 -0.94 . . . . 0.0 109.689 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -77.11 78.47 3.44 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 122.795 2.33 . . . . 0.0 110.225 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 159.94 -23.88 0.29 Allowed Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.4 tp10 -68.2 147.16 52.64 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.322 -1.105 . . . . 0.0 109.442 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 30.0 p -136.36 147.32 47.31 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.247 -0.908 . . . . 0.0 109.828 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 27.6 t80 -110.24 109.27 19.67 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.81 . . . . 0.0 109.019 179.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.54 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.23 133.86 44.0 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.348 -0.845 . . . . 0.0 109.7 -179.673 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -123.05 116.58 49.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.384 -0.823 . . . . 0.0 109.242 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -87.14 102.48 14.49 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.287 -0.883 . . . . 0.0 109.355 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.76 142.95 30.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.343 -0.848 . . . . 0.0 109.584 -179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.7 p -124.46 -27.04 3.8 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.374 -0.829 . . . . 0.0 109.786 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -67.67 152.08 46.21 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.216 -0.927 . . . . 0.0 109.696 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 68.0 mttt -99.18 125.13 44.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.375 -0.828 . . . . 0.0 109.557 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.424 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 163.71 -165.88 37.1 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.2 m -118.28 120.05 36.5 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.317 -1.108 . . . . 0.0 109.524 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 40.1 m-85 -97.08 178.15 5.36 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.421 -0.799 . . . . 0.0 109.085 179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -147.54 88.36 1.7 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.114 -0.992 . . . . 0.0 109.891 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.435 ' CE2' HG23 ' A' ' 96' ' ' VAL . 42.6 p90 -93.65 161.22 14.43 Favored 'General case' 0 N--CA 1.493 1.714 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.663 ' HB2' HG12 ' A' ' 93' ' ' VAL . 44.7 p90 -155.15 152.96 30.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.038 -1.039 . . . . 0.0 110.339 -179.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . . . . . . . . . 51.6 t -64.31 114.08 4.02 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.612 -0.68 . . . . 0.0 109.233 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 1.261 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 5.6 t -49.99 -63.08 1.96 Allowed Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.407 -0.808 . . . . 0.0 110.107 -179.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.897 ' HD3' ' HB3' ' A' ' 85' ' ' SER . 36.1 Cg_endo -76.7 62.16 7.13 Favored 'Trans proline' 0 C--N 1.314 -1.243 0 C-N-CA 122.284 1.989 . . . . 0.0 110.767 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.773 ' NE2' ' CE2' ' B' ' 1' ' ' TYR . 4.4 m170 159.03 25.91 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.537 -0.727 . . . . 0.0 109.531 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.609 ' HG2' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -71.06 -24.42 62.33 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.133 -0.979 . . . . 0.0 108.906 179.529 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.86 -13.14 55.68 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.077 -1.609 . . . . 0.0 109.077 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -69.92 -71.27 0.24 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.408 -1.054 . . . . 0.0 109.263 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 152.97 36.24 0.03 OUTLIER Glycine 0 N--CA 1.493 2.444 0 C-N-CA 119.82 -1.181 . . . . 0.0 110.491 179.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.862 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.8 ptm -127.88 102.51 6.8 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -1.197 . . . . 0.0 109.26 179.473 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.663 HG12 ' HB2' ' A' ' 83' ' ' TYR . 35.1 m -143.88 153.22 15.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.29 -0.881 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -134.46 176.45 19.87 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.1 ptmt -148.04 138.11 22.67 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.316 -1.108 . . . . 0.0 109.74 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.435 HG23 ' CE2' ' A' ' 82' ' ' PHE . 45.7 t -93.25 108.67 20.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.361 -0.837 . . . . 0.0 109.473 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.2 m -92.35 67.3 4.83 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.263 -0.898 . . . . 0.0 109.162 179.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.405 HG12 ' H ' ' A' ' 98' ' ' VAL . 3.7 p -78.7 139.71 18.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.378 -0.826 . . . . 0.0 109.607 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.4 p30 . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.563 179.937 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.773 ' CE2' ' NE2' ' A' ' 87' ' ' HIS . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . . . . . . . . . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . . . . . . . . . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 1.261 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 1.014 HD22 ' CB ' ' A' ' 85' ' ' SER . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . 0.513 ' O ' ' CB ' ' A' ' 59' ' ' GLU . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 1.056 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . 1.279 ' HE2' ' CB ' ' A' ' 43' ' ' GLU . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.502 2.141 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.76 108.29 4.37 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.238 -0.914 . . . . 0.0 109.426 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.639 HG11 ' HD2' ' A' ' 14' ' ' PHE . 13.9 t -103.55 121.12 54.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.469 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.421 HD23 ' HB2' ' A' ' 30' ' ' LYS . 20.1 mt -108.24 101.87 11.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.355 -0.841 . . . . 0.0 109.275 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.833 HD22 ' HB3' ' A' ' 37' ' ' HIS . 0.8 OUTLIER -64.74 137.11 57.6 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.352 -0.843 . . . . 0.0 109.398 -179.956 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.527 ' HA2' ' O ' ' A' ' 11' ' ' SER . . . 83.0 135.37 2.42 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -79.07 -119.13 0.26 Allowed Glycine 0 N--CA 1.493 2.441 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -126.27 4.17 7.75 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -141.3 -41.28 0.38 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.311 -1.111 . . . . 0.0 109.592 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 171.03 43.66 0.03 OUTLIER Glycine 0 N--CA 1.492 2.424 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.527 ' O ' ' HA2' ' A' ' 6' ' ' GLY . 2.3 t -97.4 99.39 10.82 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.344 -1.092 . . . . 0.0 109.273 179.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.718 HD13 ' CE1' ' A' ' 87' ' ' HIS . 6.6 mt -79.67 93.35 5.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.314 -0.866 . . . . 0.0 109.455 -179.739 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.914 ' HA ' ' HB2' ' A' ' 92' ' ' MET . . . -166.59 139.11 3.71 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 109.792 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.639 ' HD2' HG11 ' A' ' 3' ' ' VAL . 36.5 m-85 -65.9 127.05 30.5 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.42 -0.8 . . . . 0.0 108.98 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.423 ' HA ' ' HA ' ' A' ' 16' ' ' PRO . 1.6 mp -127.86 102.84 21.82 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.302 -0.874 . . . . 0.0 109.641 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 15' ' ' LEU . 36.5 Cg_endo -79.73 170.22 67.83 Favored 'Cis proline' 0 C--N 1.312 -1.372 0 C-N-CA 123.452 -1.478 . . . . 0.0 110.651 -0.24 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.453 ' O ' ' HA2' ' A' ' 94' ' ' GLY . . . -105.47 13.28 47.4 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -167.56 107.62 0.58 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.415 -1.05 . . . . 0.0 108.991 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.7 p90 -129.37 169.13 15.28 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.355 -0.84 . . . . 0.0 109.661 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' SER . . . . . . . . . . . . . 60.8 m -121.77 129.19 52.49 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.417 -0.802 . . . . 0.0 109.434 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 2.8 m -131.36 -170.11 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.385 -0.822 . . . . 0.0 109.469 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -139.61 179.15 6.73 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.329 -0.857 . . . . 0.0 109.476 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t -71.96 108.39 5.18 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 129.7 -17.23 5.53 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -81.97 172.17 13.58 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.318 -1.107 . . . . 0.0 109.516 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -128.52 134.9 48.79 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.314 -0.866 . . . . 0.0 109.662 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 4.0 mp -96.54 149.3 4.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.473 -0.767 . . . . 0.0 109.047 179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.0 t -133.29 145.54 33.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.24 -0.913 . . . . 0.0 109.952 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.673 ' HB3' HD11 ' A' ' 5' ' ' LEU . 50.8 m-85 -132.96 80.29 1.88 Allowed 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 179.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.421 ' HB2' HD23 ' A' ' 4' ' ' LEU . 26.9 mttt -80.88 124.31 29.0 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.165 -0.959 . . . . 0.0 109.767 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.6 p-10 -96.63 116.96 29.98 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.269 -0.894 . . . . 0.0 109.441 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -94.39 -69.21 0.76 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.309 -0.87 . . . . 0.0 109.536 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -128.11 151.17 49.51 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.358 -0.839 . . . . 0.0 109.473 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 94.1 10.16 58.79 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.824 ' O ' ' HG2' ' B' ' 117' ' ' PRO . 2.1 p90 -57.94 166.18 2.13 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.34 -1.094 . . . . 0.0 109.421 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.61 ' O ' ' HG2' ' A' ' 86' ' ' PRO . 36.2 Cg_endo -78.95 150.01 85.55 Favored 'Cis proline' 0 C--N 1.312 -1.355 0 C-N-CA 123.392 -1.503 . . . . 0.0 110.536 -0.094 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.833 ' HB3' HD22 ' A' ' 5' ' ' LEU . 45.1 m-70 -121.72 45.24 2.36 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.339 -0.851 . . . . 0.0 109.25 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.462 ' OD1' ' HD3' ' A' ' 86' ' ' PRO . 10.9 p-10 -70.48 119.05 14.07 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.229 -0.919 . . . . 0.0 109.304 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 m -92.27 152.5 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.392 -0.818 . . . . 0.0 109.964 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.577 HG21 ' HB3' ' B' ' 63' ' ' ASN . 6.8 m -140.52 119.27 11.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.522 -0.736 . . . . 0.0 109.033 179.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.9 m-85 -67.48 132.38 47.49 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.22 -0.925 . . . . 0.0 109.771 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -94.15 159.33 15.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.394 -0.816 . . . . 0.0 109.465 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.614 ' HA ' HD12 ' A' ' 46' ' ' ILE . 4.4 tp10 -99.82 24.81 7.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.312 -0.867 . . . . 0.0 109.573 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.02 -17.33 16.13 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.186 -0.946 . . . . 0.0 109.489 179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -131.72 36.72 3.7 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.268 -0.895 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . 0.73 HG23 ' HD2' ' A' ' 47' ' ' PRO . 33.4 mt -100.43 141.93 23.64 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.333 -0.855 . . . . 0.0 108.988 179.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.73 ' HD2' HG23 ' A' ' 46' ' ' ILE . 33.6 Cg_endo -75.55 -63.6 0.03 OUTLIER 'Trans proline' 0 C--N 1.312 -1.344 0 C-N-CA 122.696 2.264 . . . . 0.0 111.151 -179.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.528 ' O ' HG22 ' A' ' 46' ' ' ILE . 1.7 t -85.48 -175.14 5.54 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.169 -0.957 . . . . 0.0 109.641 -179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.51 ' O ' HG12 ' A' ' 50' ' ' VAL . . . -76.89 -108.18 0.14 Allowed Glycine 0 N--CA 1.493 2.451 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 49' ' ' GLY . 0.4 OUTLIER 62.44 155.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.494 -1.003 . . . . 0.0 109.796 179.895 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -92.98 162.21 14.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.297 -0.877 . . . . 0.0 109.583 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -82.48 -21.88 35.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.387 -0.82 . . . . 0.0 109.671 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -71.27 -12.53 61.5 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.273 -0.892 . . . . 0.0 109.927 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 10.3 tptt -86.68 -27.68 23.59 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.285 -0.884 . . . . 0.0 109.749 -179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.1 pt -116.72 6.32 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.235 -0.916 . . . . 0.0 110.045 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -110.77 174.55 5.81 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.174 -0.954 . . . . 0.0 109.348 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' MET . . . . . 0.461 ' H ' HG12 ' A' ' 40' ' ' VAL . 27.6 mtp -95.6 160.58 14.43 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.382 -0.824 . . . . 0.0 109.498 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -95.63 -170.86 2.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.358 -0.839 . . . . 0.0 109.563 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.49 ' HG2' ' N ' ' A' ' 60' ' ' GLU . 0.5 OUTLIER -87.48 -26.19 23.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.301 -0.874 . . . . 0.0 109.865 -179.84 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.49 ' N ' ' HG2' ' A' ' 59' ' ' GLU . 0.4 OUTLIER -80.39 -35.42 35.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.284 -0.885 . . . . 0.0 109.643 -179.865 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -91.58 92.81 8.65 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.306 -0.871 . . . . 0.0 109.428 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.764 HD11 HD21 ' B' ' 61' ' ' LEU . 0.1 OUTLIER -114.82 141.36 48.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 109.462 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.68 ' HG ' ' HB3' ' A' ' 68' ' ' GLU . 1.3 mp -89.48 87.45 7.07 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.423 -0.798 . . . . 0.0 109.179 179.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.458 ' HA ' ' HB2' ' A' ' 35' ' ' PHE . 0.6 OUTLIER -108.52 -32.8 7.25 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.33 -0.856 . . . . 0.0 109.765 -179.816 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.44 144.83 81.62 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.226 -0.921 . . . . 0.0 109.837 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -77.39 80.28 2.95 Favored 'Trans proline' 0 C--N 1.311 -1.402 0 C-N-CA 122.733 2.289 . . . . 0.0 110.25 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 162.51 -25.15 0.22 Allowed Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.68 ' HB3' ' HG ' ' A' ' 63' ' ' LEU . 1.5 tp10 -67.36 148.72 51.26 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.364 -1.08 . . . . 0.0 109.448 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 32.0 p -136.36 144.21 44.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.256 -0.902 . . . . 0.0 109.915 -179.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -107.73 109.17 20.69 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.35 -0.844 . . . . 0.0 108.998 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.543 ' HA ' ' O ' ' A' ' 27' ' ' ILE . 0.0 OUTLIER -100.49 134.44 43.45 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.343 -0.848 . . . . 0.0 109.743 -179.729 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -123.25 114.73 43.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.405 -0.809 . . . . 0.0 109.242 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 1.4 m -85.46 102.35 13.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.301 -0.875 . . . . 0.0 109.301 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 4.8 mp -99.54 142.99 30.3 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.318 -0.864 . . . . 0.0 109.521 -179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' THR . . . . . . . . . . . . . 20.4 p -124.6 -26.8 3.79 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.372 -0.83 . . . . 0.0 109.818 -179.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -67.86 151.03 47.81 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.272 -0.893 . . . . 0.0 109.683 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -97.99 121.33 39.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.373 -0.829 . . . . 0.0 109.52 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.454 ' HA3' ' HG3' ' A' ' 47' ' ' PRO . . . 167.93 -171.91 42.49 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.6 m -112.93 115.01 27.76 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.311 -1.111 . . . . 0.0 109.487 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' TYR . . . . . . . . . . . . . 46.3 m-85 -93.32 178.61 5.67 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.351 -0.843 . . . . 0.0 109.093 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -149.59 93.27 2.03 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.125 -0.984 . . . . 0.0 109.912 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -97.12 155.62 16.74 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.553 ' HB2' HG12 ' A' ' 93' ' ' VAL . 40.6 p90 -145.0 153.18 41.22 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.041 -1.037 . . . . 0.0 110.272 -179.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' CYS . . . . . 0.419 ' SG ' ' HB2' ' A' ' 87' ' ' HIS . 52.0 t -68.65 106.81 2.74 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.821 ' O ' ' CB ' ' B' ' 62' ' ' ALA . 0.1 OUTLIER -47.55 -55.09 18.02 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.414 -0.804 . . . . 0.0 110.109 -179.599 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.759 ' O ' ' CG ' ' A' ' 87' ' ' HIS . 34.3 Cg_endo -75.46 42.39 0.9 Allowed 'Trans proline' 0 C--N 1.313 -1.318 0 C-N-CA 122.273 1.982 . . . . 0.0 110.643 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.759 ' CG ' ' O ' ' A' ' 86' ' ' PRO . 6.9 m170 168.15 29.98 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.608 -0.683 . . . . 0.0 109.331 179.688 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.483 ' HG2' ' HB1' ' B' ' 62' ' ' ALA . 0.0 OUTLIER -69.3 -31.93 70.74 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.235 -0.916 . . . . 0.0 109.225 179.899 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.02 -4.67 64.69 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.294 -1.523 . . . . 0.0 109.294 179.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -73.85 -69.7 0.42 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.43 -1.041 . . . . 0.0 109.273 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 156.37 21.77 0.03 OUTLIER Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.581 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' MET . . . . . 0.914 ' HB2' ' HA ' ' A' ' 13' ' ' ALA . 3.6 ptm -118.25 104.01 10.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.099 -1.236 . . . . 0.0 109.305 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.553 HG12 ' HB2' ' A' ' 83' ' ' TYR . 27.6 m -145.57 138.4 20.97 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.295 -0.878 . . . . 0.0 109.485 -179.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 17' ' ' GLY . . . -118.79 177.42 16.41 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 12.2 ptmt -148.25 137.43 21.96 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -1.145 . . . . 0.0 109.675 179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 30.8 t -91.91 108.13 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.293 -0.879 . . . . 0.0 109.503 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 3.3 m -92.99 66.76 4.21 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.302 -0.874 . . . . 0.0 109.256 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 3.3 p -78.96 138.94 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.341 -0.849 . . . . 0.0 109.56 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 3.5 p30 . . . . . 0 N--CA 1.494 1.735 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.592 179.922 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' TYR . . . . . 0.72 ' CE1' ' HG3' ' B' ' 117' ' ' PRO . 58.6 m-85 . . . . . 0 C--O 1.215 -0.719 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' PRO . . . . . 0.582 ' HD2' ' HB3' ' B' ' 1' ' ' TYR . 26.9 Cg_endo -64.86 -25.75 60.04 Favored 'Trans proline' 0 C--N 1.29 -2.518 0 N-CA-C 109.589 -0.966 . . . . 0.0 109.589 -178.204 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' ILE . . . . . 0.665 HG21 HD11 ' A' ' 12' ' ' LEU . 4.5 tp -74.03 -24.74 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.277 -0.89 . . . . 0.0 110.483 -179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . 0.657 ' O ' ' OD1' ' B' ' 8' ' ' ASN . 1.3 m-85 -67.45 -41.37 84.84 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.131 -0.98 . . . . 0.0 109.49 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' ALA . . . . . 0.432 ' HB1' HG21 ' B' ' 20' ' ' VAL . . . -73.74 -40.53 63.47 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.473 -0.767 . . . . 0.0 109.418 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -64.07 -44.53 92.11 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.848 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.7 mt-30 -67.41 -26.3 66.36 Favored 'General case' 0 C--N 1.285 -2.212 0 C-N-CA 119.177 -1.009 . . . . 0.0 111.519 -177.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' ASN . . . . . 0.657 ' OD1' ' O ' ' B' ' 4' ' ' PHE . 0.2 OUTLIER -125.29 -0.06 7.71 Favored 'General case' 0 N--CA 1.531 3.618 0 O-C-N 119.805 -1.809 . . . . 0.0 115.731 -175.818 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' TYR . . . . . 0.405 ' HD2' ' HA ' ' B' ' 5' ' ' ALA . 61.3 m-85 -123.11 125.67 45.6 Favored 'General case' 0 C--N 1.282 -2.356 0 N-CA-C 105.269 -2.122 . . . . 0.0 105.269 176.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -66.38 -45.56 79.63 Favored 'General case' 1 N--CA 1.544 4.233 0 O-C-N 119.262 -2.149 . . . . 0.0 111.976 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -127.94 127.01 23.94 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 104.672 -2.344 . . . . 0.0 104.672 176.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -72.44 -2.31 11.55 Favored 'Trans proline' 0 N--CA 1.523 3.249 0 C-N-CA 124.126 3.217 . . . . 0.0 115.761 -174.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' ARG . . . . . . . . . . . . . 28.9 ttt180 -99.55 123.13 43.54 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -83.56 174.65 10.39 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 121.255 -0.903 . . . . 0.0 110.099 -179.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' ALA . . . . . . . . . . . . . . . -73.01 -27.25 61.67 Favored 'General case' 0 N--CA 1.507 2.412 0 O-C-N 120.942 -1.099 . . . . 0.0 110.566 -179.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' THR . . . . . . . . . . . . . 13.4 p -84.17 -0.63 52.87 Favored 'General case' 0 N--CA 1.489 1.514 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.58 64.52 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.114 -1.195 . . . . 0.0 110.114 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.19 135.47 33.55 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.209 -1.171 . . . . 0.0 110.044 -179.324 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' ILE . . . . . 0.47 HD13 ' CA ' ' B' ' 151' ' ' GLY . 8.2 mt -76.45 139.38 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 177.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' VAL . . . . . 0.432 HG21 ' HB1' ' B' ' 5' ' ' ALA . 17.5 m -57.17 -23.78 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.529 3.479 0 N-CA-C 115.197 1.554 . . . . 0.0 115.197 -175.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' CYS . . . . . 0.454 ' O ' ' HB2' ' B' ' 25' ' ' HIS . 2.0 m -64.93 -19.65 66.06 Favored 'General case' 0 N--CA 1.502 2.157 0 O-C-N 120.832 -1.167 . . . . 0.0 110.226 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.04 -2.36 23.94 Favored 'General case' 0 N--CA 1.503 2.216 0 O-C-N 121.124 -0.985 . . . . 0.0 110.547 -179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -80.67 -31.66 36.26 Favored 'General case' 0 N--CA 1.502 2.126 0 O-C-N 121.5 -0.75 . . . . 0.0 109.444 179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 m -116.37 -26.97 6.95 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.515 -0.74 . . . . 0.0 109.07 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' HIS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' CYS . 91.9 m-70 -94.45 80.79 3.91 Favored 'General case' 0 N--CA 1.523 3.186 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 178.346 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 13.1 mt -82.03 -0.18 43.17 Favored 'General case' 0 N--CA 1.518 2.955 0 N-CA-C 117.4 2.37 . . . . 0.0 117.4 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' ALA . . . . . 0.581 ' HB3' ' HA2' ' B' ' 235' ' ' GLY . . . -92.06 142.4 27.56 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 119.271 -2.143 . . . . 0.0 106.813 176.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' SER . . . . . . . . . . . . . 5.4 t -98.15 119.92 37.65 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 119.474 -2.016 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' LYS . . . . . 0.615 ' HB3' ' CZ ' ' B' ' 154' ' ' ARG . 0.0 OUTLIER -128.56 141.13 40.49 Favored Pre-proline 1 N--CA 1.564 5.236 0 O-C-N 119.942 -1.724 . . . . 0.0 108.933 179.493 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' PRO . . . . . 0.534 ' O ' ' HD2' ' B' ' 52' ' ' PRO . 25.9 Cg_endo -60.44 138.3 79.72 Favored 'Trans proline' 0 N--CA 1.509 2.406 0 N-CA-C 116.803 1.809 . . . . 0.0 116.803 -171.168 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' VAL . . . . . 0.448 HG23 ' HA3' ' B' ' 237' ' ' GLY . 14.0 t -122.51 143.17 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 178.271 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ASP . . . . . 0.461 ' HB3' ' HB2' ' B' ' 50' ' ' LYS . 0.8 OUTLIER -127.32 153.22 46.45 Favored 'General case' 0 N--CA 1.507 2.378 0 O-C-N 120.668 -1.27 . . . . 0.0 110.891 -179.068 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.439 HG23 ' O ' ' B' ' 33' ' ' ILE . 3.7 tt -144.45 122.6 5.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.46 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' GLU . . . . . 0.68 ' HB2' HG13 ' B' ' 48' ' ' VAL . 0.1 OUTLIER -111.15 125.9 54.27 Favored 'General case' 0 C--N 1.281 -2.374 0 N-CA-C 107.003 -1.48 . . . . 0.0 107.003 177.606 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' VAL . . . . . 0.627 HG22 ' HD2' ' B' ' 36' ' ' PRO . 0.5 OUTLIER -136.64 155.85 76.54 Favored Pre-proline 0 N--CA 1.504 2.238 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.244 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . 0.627 ' HD2' HG22 ' B' ' 35' ' ' VAL . 27.8 Cg_endo -66.09 149.05 86.01 Favored 'Trans proline' 0 C--N 1.306 -1.709 0 N-CA-C 109.477 -1.009 . . . . 0.0 109.477 -178.246 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -63.22 -35.92 81.93 Favored 'General case' 0 N--CA 1.514 2.725 0 O-C-N 120.094 -1.629 . . . . 0.0 111.139 -178.662 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' ALA . . . . . . . . . . . . . . . -149.68 152.37 35.24 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 121.564 0.697 . . . . 0.0 109.648 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -138.38 155.53 28.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.673 -0.642 . . . . 0.0 109.384 179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.661 ' HB3' ' HD2' ' B' ' 41' ' ' PRO . 3.1 mm? -91.02 168.03 14.67 Favored Pre-proline 0 N--CA 1.505 2.312 0 O-C-N 121.438 -0.789 . . . . 0.0 109.267 179.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 41' ' ' PRO . . . . . 0.661 ' HD2' ' HB3' ' B' ' 40' ' ' LEU . 29.6 Cg_endo -69.47 149.09 68.28 Favored 'Trans proline' 0 C--N 1.288 -2.649 0 O-C-N 123.118 1.062 . . . . 0.0 109.925 -178.53 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 54.64 39.89 31.53 Favored 'General case' 0 N--CA 1.508 2.449 0 O-C-N 121.777 -0.577 . . . . 0.0 112.25 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 43' ' ' THR . . . . . 0.442 HG21 ' HB2' ' B' ' 40' ' ' LEU . 70.4 p -123.1 150.03 43.72 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.946 -1.097 . . . . 0.0 109.664 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 44' ' ' VAL . . . . . . . . . . . . . 23.0 t -90.14 138.5 19.3 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.122 0 C-N-CA 119.017 -1.073 . . . . 0.0 108.426 178.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 45' ' ' PHE . . . . . 0.844 ' CZ ' ' HB ' ' B' ' 130' ' ' ILE . 52.6 p90 -136.5 169.6 17.43 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 177.136 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 46' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -114.84 138.11 51.16 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 118.657 -1.217 . . . . 0.0 110.208 -179.095 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 47' ' ' ALA . . . . . . . . . . . . . . . -109.8 111.46 22.92 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 104.565 -2.383 . . . . 0.0 104.565 175.432 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 48' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' B' ' 34' ' ' GLU . 0.4 OUTLIER -101.04 115.2 42.28 Favored 'Isoleucine or valine' 0 N--CA 1.508 2.46 0 O-C-N 120.645 -1.284 . . . . 0.0 111.361 -178.289 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 49' ' ' VAL . . . . . . . . . . . . . 29.5 t -105.45 131.88 53.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 CA-C-O 121.729 0.776 . . . . 0.0 109.864 -179.526 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.493 ' O ' ' HD3' ' B' ' 52' ' ' PRO . 47.2 mttm -113.6 124.12 51.59 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 121.883 0.849 . . . . 0.0 109.899 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 51' ' ' ILE . . . . . 0.511 HG23 ' NH1' ' B' ' 154' ' ' ARG . 13.5 mt -117.97 83.78 19.75 Favored Pre-proline 0 N--CA 1.491 1.579 0 N-CA-C 105.159 -2.164 . . . . 0.0 105.159 176.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 52' ' ' PRO . . . . . 0.534 ' HD2' ' O ' ' B' ' 30' ' ' PRO . 36.0 Cg_endo -74.77 144.11 30.72 Favored 'Trans proline' 0 N--CA 1.501 1.969 0 C-N-CA 124.457 3.438 . . . . 0.0 115.717 -175.046 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 53' ' ' TYR . . . . . . . . . . . . . 22.2 p90 -164.06 153.77 14.4 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 122.95 1.357 . . . . 0.0 110.271 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 54' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -67.83 116.88 9.0 Favored 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 55' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -66.43 -25.69 66.87 Favored 'General case' 0 N--CA 1.519 3.003 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -174.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 56' ' ' GLN . . . . . 0.414 ' H ' ' HG2' ' B' ' 56' ' ' GLN . 13.5 pt20 -83.68 13.43 4.69 Favored 'General case' 0 N--CA 1.515 2.792 0 O-C-N 120.006 -1.684 . . . . 0.0 109.854 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 57' ' ' LEU . . . . . 0.478 HD22 ' HB ' ' B' ' 233' ' ' VAL . 15.6 mt -77.44 131.05 37.79 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-O 122.313 1.054 . . . . 0.0 111.224 -178.452 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 58' ' ' LYS . . . . . . . . . . . . . 3.6 mttt -118.87 124.02 46.11 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.892 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 59' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' B' ' 66' ' ' LYS . 5.5 pt20 -101.4 171.51 7.54 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-O 122.86 1.314 . . . . 0.0 110.428 -179.041 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 60' ' ' VAL . . . . . 0.531 HG21 ' HB2' ' B' ' 231' ' ' PRO . 19.5 t -87.43 109.65 19.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 114.142 -1.39 . . . . 0.0 108.025 178.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 61' ' ' LEU . . . . . 0.764 HD21 HD11 ' A' ' 62' ' ' LEU . 1.3 mp -70.61 155.08 41.2 Favored 'General case' 0 N--CA 1.502 2.16 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 178.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 62' ' ' ALA . . . . . 0.821 ' CB ' ' O ' ' A' ' 85' ' ' SER . . . -60.79 7.87 0.03 OUTLIER 'General case' 0 N--CA 1.527 3.407 0 O-C-N 120.384 -1.447 . . . . 0.0 114.573 -175.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 63' ' ' ASN . . . . . 0.577 ' HB3' HG21 ' A' ' 40' ' ' VAL . 5.3 p30 -121.88 10.28 10.18 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.07 -1.019 . . . . 0.0 110.2 -179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 64' ' ' GLY . . . . . 0.401 ' HA3' ' HG3' ' B' ' 209' ' ' ARG . . . 95.47 -28.83 10.81 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' B' ' 65' ' ' LYS . 10.0 mmmm -68.81 160.64 30.14 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.744 -1.445 . . . . 0.0 110.667 -178.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 66' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' B' ' 59' ' ' GLN . 37.5 mttm -98.79 140.34 33.12 Favored 'General case' 0 N--CA 1.504 2.236 0 O-C-N 121.397 -0.814 . . . . 0.0 109.139 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -152.16 -170.57 18.9 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.552 -1.785 . . . . 0.0 114.095 -177.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 68' ' ' ALA . . . . . . . . . . . . . . . -80.19 168.19 19.4 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 113.099 -1.55 . . . . 0.0 111.714 -177.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 69' ' ' LEU . . . . . . . . . . . . . 3.8 mp -97.18 152.35 18.9 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-O 123.403 1.573 . . . . 0.0 111.609 -177.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 70' ' ' ASN . . . . . 0.889 ' HB2' ' CGA' ' B' ' 251' ' ' HEC . 15.3 m-80 -116.51 144.12 44.73 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 112.937 -1.938 . . . . 0.0 107.345 177.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 71' ' ' VAL . . . . . 0.495 ' O ' HG22 ' B' ' 118' ' ' VAL . 2.0 t -115.29 148.83 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.159 0 CA-C-O 122.494 1.14 . . . . 0.0 110.772 -178.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 72' ' ' GLY . . . . . . . . . . . . . . . -144.05 164.84 27.48 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 73' ' ' ALA . . . . . . . . . . . . . . . -156.77 155.07 30.97 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.149 -1.206 . . . . 0.0 111.627 -179.017 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 74' ' ' VAL . . . . . 0.561 ' O ' HG13 ' B' ' 74' ' ' VAL . 7.4 p -132.92 114.11 21.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.293 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.597 HD23 HD11 ' B' ' 77' ' ' LEU . 9.2 tp -104.44 120.73 41.9 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.46 -0.775 . . . . 0.0 110.381 -179.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' B' ' 149' ' ' TYR . 16.6 mt -108.83 104.09 16.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 CA-C-O 121.588 0.709 . . . . 0.0 109.369 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 77' ' ' LEU . . . . . 0.824 ' HB3' ' HD2' ' B' ' 78' ' ' PRO . 3.3 mt -103.21 171.38 5.22 Favored Pre-proline 0 N--CA 1.495 1.777 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 78' ' ' PRO . . . . . 0.824 ' HD2' ' HB3' ' B' ' 77' ' ' LEU . 30.5 Cg_endo -71.81 163.69 38.08 Favored 'Trans proline' 0 C--N 1.292 -2.408 0 O-C-N 123.508 1.267 . . . . 0.0 109.913 -179.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 79' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -65.57 134.29 53.01 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 80' ' ' GLY . . . . . . . . . . . . . . . 112.02 -40.68 2.45 Favored Glycine 0 N--CA 1.498 2.783 0 N-CA-C 108.616 -1.793 . . . . 0.0 108.616 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 81' ' ' PHE . . . . . 0.7 ' CD1' ' HG2' ' B' ' 78' ' ' PRO . 33.0 m-85 -74.18 139.07 44.19 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 82' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -149.61 175.38 11.59 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-O 121.897 0.856 . . . . 0.0 110.54 -179.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 83' ' ' LEU . . . . . . . . . . . . . 7.2 tp -68.54 125.84 27.76 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 121.591 0.71 . . . . 0.0 109.43 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.55 134.09 93.54 Favored Pre-proline 0 N--CA 1.501 2.091 0 O-C-N 121.726 -0.609 . . . . 0.0 109.8 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 85' ' ' PRO . . . . . 0.476 ' O ' HG13 ' B' ' 89' ' ' ILE . 29.2 Cg_endo -66.87 155.65 69.7 Favored 'Trans proline' 0 N--CA 1.497 1.713 0 C-N-CA 123.764 2.976 . . . . 0.0 109.034 -178.349 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . 0.76 ' HA ' HD12 ' B' ' 89' ' ' ILE . 25.5 Cg_endo -62.2 -33.04 82.56 Favored 'Trans proline' 0 C--N 1.299 -2.061 0 C-N-CA 121.109 1.206 . . . . 0.0 112.976 -174.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 87' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -68.55 -25.72 65.06 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.339 -0.851 . . . . 0.0 110.773 -178.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 88' ' ' ARG . . . . . . . . . . . . . 23.5 mmm-85 -91.61 -0.09 57.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.292 -0.88 . . . . 0.0 109.06 179.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 89' ' ' ILE . . . . . 0.76 HD12 ' HA ' ' B' ' 86' ' ' PRO . 97.3 mt -88.69 115.56 28.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.791 0 O-C-N 121.116 -0.99 . . . . 0.0 110.188 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 90' ' ' SER . . . . . . . . . . . . . 20.6 p -68.85 156.66 90.77 Favored Pre-proline 0 N--CA 1.499 2.005 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 91' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_endo -71.41 -24.39 22.68 Favored 'Trans proline' 0 C--N 1.314 -1.242 0 C-N-CA 122.422 2.082 . . . . 0.0 110.931 -178.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 92' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -71.86 -24.34 61.67 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 93' ' ' MET . . . . . 0.488 ' HA ' ' HB2' ' B' ' 96' ' ' LYS . 3.7 ttm -101.51 -13.86 17.73 Favored 'General case' 0 N--CA 1.493 1.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 178.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 94' ' ' LYS . . . . . . . . . . . . . 2.1 tppt? -69.56 -38.53 77.46 Favored 'General case' 0 N--CA 1.496 1.837 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 95' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -78.17 -22.55 48.52 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 178.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 96' ' ' LYS . . . . . 0.488 ' HB2' ' HA ' ' B' ' 93' ' ' MET . 0.0 OUTLIER -70.38 -45.34 66.2 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.92 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 97' ' ' ILE . . . . . . . . . . . . . 9.4 pt -73.17 2.28 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 O-C-N 120.897 -1.127 . . . . 0.0 111.148 -178.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 98' ' ' GLY . . . . . . . . . . . . . . . 58.68 -112.51 4.13 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 109.071 -1.612 . . . . 0.0 109.071 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 6.8 p-10 -149.94 39.37 0.77 Allowed 'General case' 0 N--CA 1.5 2.029 0 O-C-N 121.308 -1.113 . . . . 0.0 108.329 179.208 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 100' ' ' LEU . . . . . 0.551 HD22 HG11 ' B' ' 118' ' ' VAL . 8.1 mt -78.43 155.69 29.8 Favored 'General case' 0 C--N 1.292 -1.914 0 CA-C-O 122.689 1.233 . . . . 0.0 111.108 -178.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 101' ' ' SER . . . . . . . . . . . . . 11.6 p -111.18 113.7 26.41 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 176.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 102' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -87.42 133.86 33.67 Favored 'General case' 0 C--N 1.286 -2.163 0 N-CA-C 106.104 -1.813 . . . . 0.0 106.104 176.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 103' ' ' GLN . . . . . . . . . . . . . 7.8 mm-40 -113.07 160.83 17.77 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.118 178.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 104' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 -84.81 146.96 27.07 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 175.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 105' ' ' TYR . . . . . 0.404 ' HB2' ' CG2' ' B' ' 112' ' ' ILE . 33.2 t80 -57.7 -48.25 80.07 Favored 'General case' 0 N--CA 1.521 3.119 0 O-C-N 120.636 -1.29 . . . . 0.0 109.727 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 106' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -136.8 156.89 75.79 Favored Pre-proline 0 N--CA 1.533 3.704 0 N-CA-C 104.148 -2.538 . . . . 0.0 104.148 176.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 107' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -63.67 -26.58 68.76 Favored 'Trans proline' 0 N--CA 1.517 2.888 0 CA-C-N 123.298 2.214 . . . . 0.0 113.681 -174.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 108' ' ' ASN . . . . . . . . . . . . . 9.1 p30 -90.24 -12.12 38.9 Favored 'General case' 0 N--CA 1.502 2.153 0 CA-C-N 113.977 -1.465 . . . . 0.0 110.287 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 109' ' ' LYS . . . . . 0.419 ' HB3' HD12 ' B' ' 112' ' ' ILE . 37.3 mmtt -99.95 83.65 2.75 Favored 'General case' 0 C--N 1.278 -2.54 0 N-CA-C 105.611 -1.996 . . . . 0.0 105.611 176.005 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 110' ' ' LYS . . . . . . . . . . . . . 34.6 mttm -82.95 -1.56 52.75 Favored 'General case' 0 N--CA 1.506 2.352 0 O-C-N 120.221 -1.549 . . . . 0.0 109.906 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 111' ' ' ASN . . . . . . . . . . . . . 5.6 p-10 -101.18 2.94 40.6 Favored 'General case' 0 N--CA 1.511 2.601 0 CA-C-O 121.561 0.696 . . . . 0.0 110.868 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 112' ' ' ILE . . . . . 0.419 HD12 ' HB3' ' B' ' 109' ' ' LYS . 30.0 mt -118.03 117.74 55.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 177.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 113' ' ' LEU . . . . . . . . . . . . . 23.2 mt -115.55 141.75 47.64 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 120.928 -1.108 . . . . 0.0 111.466 -178.052 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 114' ' ' VAL . . . . . . . . . . . . . 14.7 m -127.18 151.05 33.57 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.854 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.484 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 115' ' ' ILE . . . . . 0.4 HD11 HD13 ' B' ' 100' ' ' LEU . 13.5 tt -150.82 145.2 16.82 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.842 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 178.6 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.1 157.24 10.52 Favored Glycine 0 N--CA 1.509 3.556 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 117' ' ' PRO . . . . . 0.824 ' HG2' ' O ' ' A' ' 35' ' ' PHE . 36.7 Cg_endo -76.37 128.73 17.2 Favored 'Cis proline' 0 C--N 1.317 -1.084 0 CA-C-O 122.638 1.016 . . . . 0.0 113.529 2.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 118' ' ' VAL . . . . . 0.551 HG11 HD22 ' B' ' 100' ' ' LEU . 13.4 m -119.58 157.33 52.15 Favored Pre-proline 0 N--CA 1.504 2.27 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 119' ' ' PRO . . . . . 0.472 ' HD2' ' HB ' ' B' ' 118' ' ' VAL . 25.8 Cg_endo -62.62 134.58 48.24 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.201 1.934 . . . . 0.0 111.426 -175.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 120' ' ' GLY . . . . . . . . . . . . . . . -66.92 -55.94 14.71 Favored Glycine 0 N--CA 1.502 3.081 0 O-C-N 121.018 -1.051 . . . . 0.0 112.452 -177.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 121' ' ' GLN . . . . . . . . . . . . . 19.5 mt-30 -58.09 -13.43 4.79 Favored 'General case' 0 N--CA 1.505 2.281 0 O-C-N 121.225 -1.162 . . . . 0.0 111.519 -178.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 122' ' ' LYS . . . . . 0.472 ' HB2' ' HG2' ' B' ' 119' ' ' PRO . 5.9 mmmt -102.07 -51.31 3.42 Favored 'General case' 0 C--N 1.283 -2.284 0 C-N-CA 118.511 -1.276 . . . . 0.0 109.975 -179.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 123' ' ' TYR . . . . . 0.4 ' CD1' HD11 ' B' ' 100' ' ' LEU . 93.9 m-85 -109.25 57.47 0.61 Allowed 'General case' 0 N--CA 1.505 2.295 0 N-CA-C 114.178 1.177 . . . . 0.0 114.178 -175.381 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 124' ' ' SER . . . . . . . . . . . . . 50.6 m -73.43 -29.27 62.46 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 105.331 -2.099 . . . . 0.0 105.331 175.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 125' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -116.01 123.17 47.3 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.216 -1.401 . . . . 0.0 107.216 177.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 126' ' ' ILE . . . . . . . . . . . . . 19.1 mt -114.9 143.68 24.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-O 121.748 0.785 . . . . 0.0 109.998 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 127' ' ' THR . . . . . . . . . . . . . 8.3 m -114.43 116.84 29.53 Favored 'General case' 0 C--N 1.285 -2.208 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 128' ' ' PHE . . . . . . . . . . . . . 61.7 m-85 -101.05 127.21 32.56 Favored Pre-proline 0 C--N 1.281 -2.404 0 N-CA-C 106.147 -1.798 . . . . 0.0 106.147 176.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 129' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -85.37 107.57 1.02 Allowed 'Trans proline' 0 CA--C 1.549 1.252 0 C-N-CA 122.674 2.25 . . . . 0.0 110.309 177.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 130' ' ' ILE . . . . . 0.844 ' HB ' ' CZ ' ' B' ' 45' ' ' PHE . 21.3 mm -107.42 151.07 9.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 C-N-CA 118.048 -1.461 . . . . 0.0 110.723 -178.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 131' ' ' LEU . . . . . . . . . . . . . 11.6 tp -107.86 122.83 47.59 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 132' ' ' ALA . . . . . . . . . . . . . . . -76.36 143.71 73.26 Favored Pre-proline 0 N--CA 1.498 1.945 0 O-C-N 121.157 -0.964 . . . . 0.0 108.435 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 133' ' ' PRO . . . . . 0.554 ' HG2' HG11 ' B' ' 141' ' ' VAL . 34.6 Cg_endo -76.24 174.28 13.09 Favored 'Trans proline' 0 C--N 1.292 -2.395 0 C-N-CA 121.585 1.523 . . . . 0.0 112.034 -178.358 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 134' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -122.34 127.55 25.82 Favored Pre-proline 0 N--CA 1.487 1.387 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 177.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 135' ' ' PRO . . . . . 0.636 ' HG3' ' CZ ' ' B' ' 143' ' ' PHE . 30.1 Cg_endo -69.29 -44.63 2.27 Favored 'Trans proline' 0 C--N 1.302 -1.871 0 C-N-CA 121.903 1.735 . . . . 0.0 110.416 -177.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 136' ' ' ALA . . . . . . . . . . . . . . . -67.99 1.0 2.97 Favored 'General case' 0 N--CA 1.503 2.202 0 O-C-N 120.957 -1.089 . . . . 0.0 109.221 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 137' ' ' THR . . . . . 0.411 ' H ' ' C ' ' B' ' 135' ' ' PRO . 1.9 m -120.32 -6.7 9.84 Favored 'General case' 0 N--CA 1.487 1.397 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.859 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 138' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -149.48 109.02 3.99 Favored 'General case' 0 N--CA 1.512 2.653 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 139' ' ' LYS . . . . . . . . . . . . . 84.9 mttt -67.53 -2.52 6.7 Favored 'General case' 0 N--CA 1.533 3.679 0 N-CA-C 115.312 1.597 . . . . 0.0 115.312 -174.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 140' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -102.75 -15.97 16.12 Favored 'General case' 0 N--CA 1.512 2.647 0 O-C-N 120.953 -1.092 . . . . 0.0 110.059 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 141' ' ' VAL . . . . . 0.554 HG11 ' HG2' ' B' ' 133' ' ' PRO . 39.4 t -93.08 142.64 12.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.409 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 142' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -144.09 165.32 28.15 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 118.38 -1.328 . . . . 0.0 108.987 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 143' ' ' PHE . . . . . 0.636 ' CZ ' ' HG3' ' B' ' 135' ' ' PRO . 56.7 m-85 -71.56 116.84 12.38 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 105.628 -1.989 . . . . 0.0 105.628 176.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 144' ' ' LEU . . . . . 0.597 ' HG ' ' O ' ' B' ' 143' ' ' PHE . 1.0 OUTLIER -176.19 176.27 1.73 Allowed 'General case' 0 C--N 1.278 -2.541 0 CA-C-O 122.383 1.087 . . . . 0.0 108.655 179.747 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 145' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -86.83 128.48 35.04 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 115.118 -0.947 . . . . 0.0 108.458 178.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 146' ' ' TYR . . . . . 0.48 ' HA ' ' HD3' ' B' ' 147' ' ' PRO . 76.6 m-85 -125.03 147.74 57.87 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.775 -0.578 . . . . 0.0 110.542 -179.135 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 147' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' B' ' 146' ' ' TYR . 37.5 Cg_endo -82.73 146.44 13.26 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.282 2.655 . . . . 0.0 112.137 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 148' ' ' ILE . . . . . . . . . . . . . 72.7 mt -131.02 126.56 59.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 177.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 149' ' ' TYR . . . . . 0.426 ' HB2' ' HB ' ' B' ' 76' ' ' ILE . 92.2 m-85 -117.71 141.27 48.59 Favored 'General case' 0 N--CA 1.507 2.388 0 O-C-N 120.845 -1.159 . . . . 0.0 111.208 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 150' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.89 146.31 30.83 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.391 0 C-N-CA 118.538 -1.265 . . . . 0.0 109.855 -179.671 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 151' ' ' GLY . . . . . 0.47 ' CA ' HD13 ' B' ' 19' ' ' ILE . . . -123.01 132.69 8.73 Favored Glycine 0 C--N 1.288 -2.106 0 N-CA-C 104.974 -3.25 . . . . 0.0 104.974 176.216 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 152' ' ' GLY . . . . . . . . . . . . . . . -129.89 132.87 7.2 Favored Glycine 0 N--CA 1.513 3.768 0 O-C-N 120.462 -1.611 . . . . 0.0 110.849 -179.044 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 153' ' ' ASN . . . . . 0.484 ' HB2' ' HD1' ' B' ' 236' ' ' PHE . 19.4 t-20 -131.33 150.3 52.2 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.14 -1.212 . . . . 0.0 111.129 -178.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 154' ' ' ARG . . . . . 0.839 ' HG2' ' O ' ' B' ' 154' ' ' ARG . 0.3 OUTLIER -146.0 119.83 9.29 Favored 'General case' 0 C--N 1.27 -2.848 0 N-CA-C 105.275 -2.121 . . . . 0.0 105.275 177.389 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 155' ' ' GLY . . . . . . . . . . . . . . . 118.32 162.01 12.09 Favored Glycine 0 N--CA 1.488 2.105 0 C-N-CA 118.876 -1.631 . . . . 0.0 111.092 179.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 156' ' ' ARG . . . . . 0.681 ' HD2' ' O2D' ' B' ' 251' ' ' HEC . 1.8 mtm105 -77.13 143.9 38.83 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.529 0.68 . . . . 0.0 109.743 -179.701 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 157' ' ' GLY . . . . . 0.433 ' H ' ' C3D' ' B' ' 251' ' ' HEC . . . -77.78 167.73 53.86 Favored Glycine 0 N--CA 1.498 2.787 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -178.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 158' ' ' GLN . . . . . 0.492 ' HG3' ' O ' ' B' ' 168' ' ' ASN . 4.7 mp0 -101.3 -28.3 12.7 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.767 -0.843 . . . . 0.0 110.376 -179.004 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 159' ' ' ILE . . . . . . . . . . . . . 48.7 mt -112.89 142.52 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.991 0 O-C-N 120.699 -1.251 . . . . 0.0 110.69 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 160' ' ' TYR . . . . . 0.945 ' HB3' ' HD2' ' B' ' 161' ' ' PRO . 30.9 m-85 -93.78 179.16 1.32 Allowed Pre-proline 0 N--CA 1.524 3.27 0 O-C-N 121.392 -0.818 . . . . 0.0 108.852 179.407 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 161' ' ' PRO . . . . . 0.945 ' HD2' ' HB3' ' B' ' 160' ' ' TYR . 30.9 Cg_endo -70.45 -21.24 30.53 Favored 'Trans proline' 0 C--N 1.308 -1.563 0 C-N-CA 120.997 1.131 . . . . 0.0 112.0 -177.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 162' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -93.7 -2.68 53.55 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.966 -0.459 . . . . 0.0 110.665 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 163' ' ' GLY . . . . . . . . . . . . . . . 98.67 2.91 57.37 Favored Glycine 0 N--CA 1.506 3.356 0 O-C-N 120.449 -1.407 . . . . 0.0 110.621 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 164' ' ' SER . . . . . . . . . . . . . 43.0 m -81.25 143.48 32.26 Favored 'General case' 0 C--N 1.29 -1.994 0 C-N-CA 119.352 -0.939 . . . . 0.0 109.159 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 165' ' ' LYS . . . . . . . . . . . . . 63.4 mttt -81.94 157.21 24.38 Favored 'General case' 0 C--N 1.277 -2.548 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 177.166 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 166' ' ' SER . . . . . . . . . . . . . 62.2 p -100.73 -174.58 2.67 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 106.164 -1.791 . . . . 0.0 106.164 176.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 167' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -88.02 10.59 18.52 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.15 -0.969 . . . . 0.0 109.162 179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 168' ' ' ASN . . . . . 0.513 ' HB2' ' NH2' ' B' ' 156' ' ' ARG . 2.9 t-20 -104.4 41.35 1.33 Allowed 'General case' 0 N--CA 1.512 2.663 0 CA-C-O 122.156 0.979 . . . . 0.0 110.232 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 169' ' ' THR . . . . . . . . . . . . . 9.6 t -151.63 173.47 14.62 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.355 1.074 . . . . 0.0 109.98 -179.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 170' ' ' VAL . . . . . 0.469 HG22 ' CB ' ' B' ' 230' ' ' ASN . 3.4 t -76.6 146.9 8.1 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 CA-C-O 122.432 1.11 . . . . 0.0 109.187 179.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 171' ' ' TYR . . . . . 0.424 ' CZ ' ' HD3' ' B' ' 208' ' ' PRO . 0.8 OUTLIER -107.19 119.94 40.75 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 106.668 -1.604 . . . . 0.0 106.668 177.06 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 172' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -106.47 144.41 33.19 Favored 'General case' 0 N--CA 1.505 2.278 0 CA-C-O 122.203 1.001 . . . . 0.0 112.364 -177.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 173' ' ' ALA . . . . . 0.521 ' HA ' HD11 ' B' ' 227' ' ' LEU . . . -62.27 130.16 44.05 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.448 -179.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 174' ' ' THR . . . . . . . . . . . . . 18.4 p -79.13 -2.8 42.41 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.187 -0.605 . . . . 0.0 109.474 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 175' ' ' ALA . . . . . 0.555 ' HB3' HG21 ' B' ' 203' ' ' VAL . . . -164.18 148.43 9.87 Favored 'General case' 0 C--N 1.293 -1.872 0 O-C-N 120.572 -1.33 . . . . 0.0 109.874 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 176' ' ' GLY . . . . . . . . . . . . . . . -78.69 175.92 54.71 Favored Glycine 0 C--N 1.296 -1.679 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 178.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 177' ' ' GLY . . . . . . . . . . . . . . . 131.46 -160.8 23.56 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 178' ' ' ILE . . . . . . . . . . . . . 8.5 tt -112.0 139.62 35.59 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.774 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 179' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' B' ' 219' ' ' GLU . 37.9 mt -72.69 119.1 18.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 N-CA-C 107.521 -1.288 . . . . 0.0 107.521 178.291 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 180' ' ' SER . . . . . . . . . . . . . 12.0 p -90.46 -31.69 16.7 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.437 -0.789 . . . . 0.0 110.056 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 181' ' ' LYS . . . . . . . . . . . . . 7.1 ttmt -155.73 150.94 26.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.874 -1.141 . . . . 0.0 111.333 -179.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 182' ' ' ILE . . . . . 0.558 HD12 ' HG3' ' B' ' 217' ' ' GLU . 91.0 mt -128.87 101.22 6.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 178.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 183' ' ' LEU . . . . . . . . . . . . . 7.9 tp -86.38 103.96 15.43 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.534 -0.729 . . . . 0.0 111.275 -178.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 184' ' ' ARG . . . . . 0.415 ' HG2' ' HE1' ' B' ' 190' ' ' TYR . 60.1 mtt85 -69.61 121.59 17.4 Favored 'General case' 0 N--CA 1.498 1.943 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 185' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -72.41 146.32 47.07 Favored 'General case' 0 N--CA 1.525 3.284 0 O-C-N 121.047 -1.033 . . . . 0.0 113.736 -176.122 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 186' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -59.6 -52.0 67.4 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.818 -0.551 . . . . 0.0 110.776 -178.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 187' ' ' LYS . . . . . . . . . . . . . 12.8 tptt -94.23 17.03 13.44 Favored 'General case' 0 N--CA 1.5 2.052 0 O-C-N 120.873 -1.142 . . . . 0.0 111.005 -178.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 188' ' ' GLY . . . . . . . . . . . . . . . 110.53 154.75 14.15 Favored Glycine 0 N--CA 1.498 2.802 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 189' ' ' GLY . . . . . . . . . . . . . . . 101.93 173.55 27.82 Favored Glycine 0 C--N 1.29 -1.978 0 C-N-CA 119.045 -1.55 . . . . 0.0 109.754 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 190' ' ' TYR . . . . . 0.753 ' CD2' HD21 ' B' ' 213' ' ' LEU . 59.3 m-85 -148.28 156.13 42.16 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-O 123.712 1.72 . . . . 0.0 111.395 -178.687 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 191' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -121.89 114.22 20.72 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 192' ' ' ILE . . . . . . . . . . . . . 45.5 mt -107.85 123.85 63.57 Favored 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 CA-C-O 121.968 0.89 . . . . 0.0 111.081 -178.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 193' ' ' THR . . . . . . . . . . . . . 3.7 m -96.18 121.22 37.73 Favored 'General case' 0 N--CA 1.496 1.826 0 CA-C-O 121.803 0.811 . . . . 0.0 109.952 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 194' ' ' ILE . . . . . 0.731 ' HB ' HG23 ' B' ' 203' ' ' VAL . 55.7 mt -111.49 127.34 68.7 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 122.262 1.03 . . . . 0.0 110.098 -179.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 195' ' ' VAL . . . . . . . . . . . . . 96.5 t -97.32 98.37 7.36 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 196' ' ' ASP . . . . . . . . . . . . . 4.1 t70 -76.3 82.55 3.07 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 106.147 -1.797 . . . . 0.0 106.147 176.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 197' ' ' ALA . . . . . . . . . . . . . . . -59.76 -21.14 60.34 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 120.984 -1.072 . . . . 0.0 110.704 -178.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 198' ' ' SER . . . . . . . . . . . . . 54.4 m -71.29 -42.16 69.07 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.261 -0.899 . . . . 0.0 110.455 -179.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 199' ' ' ASN . . . . . . . . . . . . . 53.1 m-80 -104.81 8.99 35.02 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.253 -0.904 . . . . 0.0 109.81 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 200' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 53.6 45.45 28.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.028 -1.045 . . . . 0.0 109.123 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 201' ' ' ARG . . . . . . . . . . . . . 25.6 ttp-105 -131.67 146.96 52.46 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.535 -0.866 . . . . 0.0 109.507 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 202' ' ' GLN . . . . . . . . . . . . . 31.2 tt0 -111.33 134.92 52.57 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 203' ' ' VAL . . . . . 0.731 HG23 ' HB ' ' B' ' 194' ' ' ILE . 13.5 m -129.34 148.06 33.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.092 -1.005 . . . . 0.0 109.753 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 204' ' ' ILE . . . . . . . . . . . . . 49.5 mt -114.08 110.75 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.461 -0.774 . . . . 0.0 109.905 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 205' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -92.85 123.11 35.88 Favored 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 206' ' ' ILE . . . . . . . . . . . . . 33.2 mt -97.56 126.98 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.039 0 O-C-N 121.377 -0.827 . . . . 0.0 110.716 -178.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 207' ' ' ILE . . . . . 0.786 HD13 HD22 ' B' ' 213' ' ' LEU . 12.9 mt -113.48 132.79 22.35 Favored Pre-proline 0 N--CA 1.504 2.226 0 O-C-N 121.724 -0.61 . . . . 0.0 109.666 -179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 208' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 207' ' ' ILE . 34.4 Cg_endo -75.43 167.52 26.46 Favored 'Trans proline' 0 C--N 1.313 -1.337 0 C-N-CA 123.019 2.48 . . . . 0.0 112.638 -177.643 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 209' ' ' ARG . . . . . 0.401 ' HG3' ' HA3' ' B' ' 64' ' ' GLY . 2.9 ptm180 -79.19 149.9 31.82 Favored 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.884 0.849 . . . . 0.0 109.841 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 210' ' ' GLY . . . . . . . . . . . . . . . 103.45 -9.55 53.23 Favored Glycine 0 N--CA 1.513 3.802 0 N-CA-C 109.029 -1.628 . . . . 0.0 109.029 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 211' ' ' LEU . . . . . 0.421 ' CD2' ' HG3' ' B' ' 231' ' ' PRO . 0.4 OUTLIER -114.02 139.98 48.82 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-O 123.008 1.385 . . . . 0.0 111.718 -177.868 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 212' ' ' GLU . . . . . 0.406 ' O ' ' HB ' ' B' ' 228' ' ' THR . 6.2 pt-20 -109.45 128.52 55.21 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 113.796 -1.547 . . . . 0.0 107.683 178.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 213' ' ' LEU . . . . . 0.786 HD22 HD13 ' B' ' 207' ' ' ILE . 0.0 OUTLIER -85.07 152.59 23.3 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 122.403 1.097 . . . . 0.0 110.166 -179.226 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 214' ' ' LEU . . . . . 0.583 HD11 ' OG ' ' B' ' 229' ' ' SER . 11.6 mt -112.61 39.82 2.4 Favored 'General case' 0 C--N 1.29 -1.985 0 N-CA-C 105.769 -1.938 . . . . 0.0 105.769 176.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 215' ' ' VAL . . . . . 0.429 HG11 HD23 ' B' ' 227' ' ' LEU . 3.5 m -129.26 147.88 33.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.004 -1.06 . . . . 0.0 110.621 -179.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 216' ' ' SER . . . . . . . . . . . . . 58.7 m -123.86 154.94 38.92 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 121.703 0.763 . . . . 0.0 109.715 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 217' ' ' GLU . . . . . 0.558 ' HG3' HD12 ' B' ' 182' ' ' ILE . 32.6 mt-10 -60.22 141.88 55.34 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 218' ' ' GLY . . . . . . . . . . . . . . . 83.76 9.02 83.6 Favored Glycine 0 N--CA 1.499 2.85 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 179.158 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 219' ' ' GLU . . . . . 0.438 ' HB3' HD12 ' B' ' 179' ' ' ILE . 16.3 tt0 -93.44 145.38 24.54 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.33 -1.1 . . . . 0.0 110.348 -179.053 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 220' ' ' SER . . . . . . . . . . . . . 36.3 m -87.1 123.69 32.43 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 178.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 221' ' ' ILE . . . . . 0.458 HG13 ' HB3' ' B' ' 225' ' ' GLN . 0.5 OUTLIER -116.69 148.53 19.35 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.051 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 222' ' ' LYS . . . . . . . . . . . . . 23.4 mttp -101.64 167.6 10.01 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 178.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 223' ' ' LEU . . . . . 0.526 ' O ' ' CB ' ' B' ' 224' ' ' ASP . 13.5 tp -65.82 137.85 57.5 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 120.495 -1.378 . . . . 0.0 109.159 179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 224' ' ' ASP . . . . . 0.526 ' CB ' ' O ' ' B' ' 223' ' ' LEU . 0.6 OUTLIER 79.13 -3.93 2.12 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.879 -1.138 . . . . 0.0 110.879 179.081 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 225' ' ' GLN . . . . . 0.622 ' CG ' ' HD2' ' B' ' 226' ' ' PRO . 8.8 tt0 -61.91 140.64 95.64 Favored Pre-proline 0 N--CA 1.487 1.376 0 N-CA-C 108.228 -1.026 . . . . 0.0 108.228 179.041 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 226' ' ' PRO . . . . . 0.622 ' HD2' ' CG ' ' B' ' 225' ' ' GLN . 28.0 Cg_endo -66.94 128.25 18.41 Favored 'Trans proline' 0 C--N 1.302 -1.882 0 O-C-N 123.894 1.47 . . . . 0.0 108.301 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 227' ' ' LEU . . . . . 0.521 HD11 ' HA ' ' B' ' 173' ' ' ALA . 58.5 mt -93.85 -29.27 15.4 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.529 -0.732 . . . . 0.0 110.719 -178.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 228' ' ' THR . . . . . 0.686 ' HA ' ' HA ' ' B' ' 213' ' ' LEU . 52.2 p -135.77 173.88 11.23 Favored 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.851 -1.155 . . . . 0.0 109.168 -179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 229' ' ' SER . . . . . 0.583 ' OG ' HD11 ' B' ' 214' ' ' LEU . 46.1 m -75.31 165.65 24.84 Favored 'General case' 0 C--N 1.287 -2.143 0 C-N-CA 118.152 -1.419 . . . . 0.0 108.75 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 230' ' ' ASN . . . . . 0.469 ' CB ' HG22 ' B' ' 170' ' ' VAL . 60.8 t-20 -90.07 112.71 53.93 Favored Pre-proline 0 C--N 1.297 -1.678 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 176.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 231' ' ' PRO . . . . . 0.533 ' HD3' ' O ' ' B' ' 229' ' ' SER . 38.9 Cg_endo -86.58 20.8 1.16 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.853 2.369 . . . . 0.0 112.97 -179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 232' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -87.74 117.41 26.55 Favored 'General case' 0 N--CA 1.505 2.319 0 O-C-N 120.315 -1.491 . . . . 0.0 110.866 -178.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 233' ' ' VAL . . . . . 0.478 ' HB ' HD22 ' B' ' 57' ' ' LEU . 16.0 m -111.96 5.77 8.32 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 118.824 -1.151 . . . . 0.0 109.199 179.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 234' ' ' GLY . . . . . . . . . . . . . . . -107.01 -167.04 22.29 Favored Glycine 0 N--CA 1.501 3.009 0 O-C-N 120.72 -1.238 . . . . 0.0 111.251 -178.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 235' ' ' GLY . . . . . 0.591 ' HA3' ' HB2' ' B' ' 29' ' ' LYS . . . -179.65 165.22 33.7 Favored Glycine 0 N--CA 1.481 1.646 0 C-N-CA 119.142 -1.504 . . . . 0.0 112.38 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 236' ' ' PHE . . . . . 0.484 ' HD1' ' HB2' ' B' ' 153' ' ' ASN . 74.9 t80 -114.64 140.95 48.41 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 113.601 -1.3 . . . . 0.0 107.971 178.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 237' ' ' GLY . . . . . 0.448 ' HA3' HG23 ' B' ' 31' ' ' VAL . . . -132.79 162.46 24.16 Favored Glycine 0 C--N 1.3 -1.428 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 238' ' ' GLN . . . . . 0.432 ' HB3' HD12 ' B' ' 19' ' ' ILE . 8.1 pt20 -130.79 144.36 51.4 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 179.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 239' ' ' GLY . . . . . . . . . . . . . . . -137.89 170.12 23.88 Favored Glycine 0 N--CA 1.497 2.724 0 C-N-CA 120.182 -1.008 . . . . 0.0 111.049 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 240' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -148.22 149.0 31.14 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 122.136 0.97 . . . . 0.0 110.65 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 241' ' ' ALA . . . . . . . . . . . . . . . -148.43 161.51 41.45 Favored 'General case' 0 C--N 1.274 -2.675 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 178.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 242' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -125.2 136.49 53.63 Favored 'General case' 0 C--N 1.294 -1.821 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 243' ' ' ILE . . . . . . . . . . . . . 6.0 tt -121.08 149.29 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.958 -1.088 . . . . 0.0 109.31 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 244' ' ' VAL . . . . . . . . . . . . . 42.5 t -108.75 111.05 34.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.697 0 C-N-CA 117.941 -1.504 . . . . 0.0 108.959 179.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 245' ' ' LEU . . . . . . . . . . . . . 8.4 tp -75.27 107.78 7.6 Favored 'General case' 0 N--CA 1.498 1.934 0 N-CA-C 104.362 -2.458 . . . . 0.0 104.362 175.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 246' ' ' GLN . . . . . . . . . . . . . 15.6 tt0 -97.17 141.91 29.73 Favored 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -173.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 247' ' ' ASP . . . . . 0.429 ' HA ' ' CE1' ' B' ' 143' ' ' PHE . 22.3 t70 -73.63 137.84 77.29 Favored Pre-proline 0 C--N 1.309 -1.172 0 N-CA-C 104.479 -2.415 . . . . 0.0 104.479 175.312 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 248' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' B' ' 247' ' ' ASP . 30.8 Cg_endo -69.26 -5.18 15.27 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 123.527 2.818 . . . . 0.0 111.901 -177.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 249' ' ' LEU . . . . . . . . . . . . . 18.5 mt -109.14 -132.7 0.33 Allowed 'General case' 0 C--N 1.288 -2.071 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 177.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 250' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.7 0 CA-C-O 117.963 -1.017 . . . . 0.0 109.306 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 251' ' ' HEC . . . . . 0.889 ' CGA' ' HB2' ' B' ' 70' ' ' ASN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_